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Summary 
 
Background: Endothelial dysfunction (ED) often occurs secondary to metabolic 
pathologies associated with nutrient excess, such as hyperglycaemia and dyslipidaemia. 
ED, characterised by reduced nitric oxide (NO) bioavailability and activity, and 
inflammation, is associated with cardiovascular diseases, stroke, and 
neurodegeneration. 
Nutrient excess increases amyloid beta peptides (Aβ), which are produced in varying 
lengths by beta-site APP cleaving enzyme 1 (BACE1). Increased circulating Aβ42 levels is 
reported to promote ED, by reducing NO bioavailability, suggesting a role for Aβ in the 
pathogenesis of ED, but the underlying mechanism is unclear.  
One potential mechanism involves mitochondrial dysfunction, whereby mitochondria 
exhibit impaired bioenergetics, increased reactive oxygen species (ROS) production, and 
dysregulated mitochondrial dynamics. Functional mitochondria are key to endothelial 
cell health and impairments may lead to reduced ATP production and increased ROS 
generation, resulting in a decrease in NO bioavailability and activity. Furthermore, 
nutrient excess and Aβ peptides are reported to induce mitochondrial dysfunction.  
Therefore, the work described herein sought to determine whether the early 
pathogenesis of ED, promoted by nutrient excess, is in part due to raised BACE1 activity 
and circulating Aβ levels. Further, it aimed to investigate the potential mechanistic role 
of mitochondrial dysfunction in this process. 
Methods: Microvascular endothelial function was measured in vivo using laser Doppler 
imaging in several mouse models of nutrient excess and varying circulating Aβ levels. A 
6-month old 10-week high-fat diet (HFD)-fed mouse (45% HFD) and an 8-week old db/db 
mouse were used as models of nutrient excess. A 10-12-week old, 10-week HFD-fed 
BACE1 knockout (BACE1KO) mouse was used to investigate the role of BACE1 and Aβ in 
the pathogenesis of ED. Two 10-12 week old, 10-week HFD-fed cohorts of mice, infused 
either centrally or peripherally with Aβ42 peptides (3.36mg/kg/day) for 4 weeks were 
investigated as models of raised circulating Aβ levels. Finally, the APP23 mouse, a 
genetically engineered model of increased Aβ, was infused peripherally with a BACE1 
inhibitor (10mg/kg/day) for 4 weeks to investigate the effects of reducing Aβ peptides 
on endothelial function.  
 xxiii 
Following in vivo investigation, proteins involved in mitochondrial dynamics were 
analysed using Western blot in tissues of interest (vessel enriched brain fraction, aorta) 
as a measure of mitochondrial function. 
Results: Impaired endothelial function was observed in vivo in db/db mice, but not in 
the HFD-fed model. BACE1KO mice had improved endothelial function compared to 
wild-type and heterozygous littermates. Both cohorts infused with Aβ, as well as the 
APP23 mouse, exhibited reduced endothelial function, whilst treating the APP23 mouse 
with a BACE1 inhibitor and thereby reducing Aβ levels rescued the endothelial 
dysfunction phenotype. No significant findings were observed in relation to 
mitochondrial dynamics proteins in any of the models studied. 
Conclusion: The data presented herein suggest a role for increased BACE1 activity and 
circulating Aβ, due to nutrient excess, in the early pathogenesis of ED. However, it is 
unlikely that this process involves altered mitochondrial dynamics processes. These 
studies highlight the possibility of repurposing BACE1 inhibitors for the treatment of ED 
and subsequent vascular diseases. 
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Introduction 
  
 2 
1.1 Nutrient excess and disease 
 
The transition of global diet towards highly refined foods, carbohydrates with high 
glycaemic load (GL; how much a carbohydrate will increase plasma glucose levels), and 
foods rich in saturated fat, termed the ‘nutrition transition’ is becoming increasingly 
evident in the 21st century1. Nutrient excess and unhealthy diet composition can exert 
both immediate and/or long-term adverse implications on health2. The role of this 
‘Western diet’ in the etiology of non-communicable diseases, that is diseases that 
cannot be transmitted, is well accepted. Indeed, excessive nutrient consumption, 
together with sedentary lifestyles and tobacco smoking, plays a major role in the 
development of obesity, diabetes, cardiovascular diseases, and neurodegenerative 
disorders3,4 (Fig. 1.1).  
 
1.2 Obesity 
 
Obesity is described as having an excess of fat accumulation, which could potentially 
pose a risk to an individual’s health. It occurs when an individual has a total energy intake 
that exceeds total energy output. It is clear therefore that dietary patterns are 
inextricably linked to the onset of obesity5. Obesity is associated with a number of 
pathologies, such as but not confined to inflammation6, hypertension7, dyslipidaemia, 
including hypercholesterolaemia8, hyperglycaemia9, insulin resistance9, and poor 
cognitive function10,11. The standard method of measuring obesity is through body mass 
index (BMI), by which the person’s weight (kg) is divided by the square of their height 
(metres). Those who have a BMI of between 25-30 kg/m2 are overweight, whereas those 
with a BMI of over 30 kg/m2 are considered obese. Some studies report variances in 
obesity prevalence across sex, socioeconomic class, ethnicity, and age12,13. However, it 
is clear that obesity is a growing epidemic worldwide. Particularly in developed regions, 
such as North America and Europe where the consumption of Western diet gained 
momentum in the 1970s, the prevalence of overweight and obese people has risen 
unmitigated over the last 50 years. Prevalence of obesity in the USA is reported as ~35% 
of all adults and ~30% of children between the ages of 2-1914. Scotland is not far behind, 
with ~29% of adults and ~13% of children being classed as obese15. As the prevalence of 
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obesity increases, so does the burden of its co-morbidities. Obesity poses a major risk 
to health and is an independent risk factor for many other diseases, including metabolic 
disorders (insulin resistance, type 2 diabetes [T2D]), liver disease, respiratory diseases, 
cardiovascular diseases (CVD), cancer, and as previously mentioned, neurodegenerative 
diseases16,17. Management of obesity focuses on weight loss, which is achieved by a 
negative energy balance – i.e. eating less and exercising more. Management options 
include, but are not limited to, diet therapy and physical activity, bariatric surgery and 
anti-obesity pharmacotherapy18.  Despite these widely available treatment options, the 
prevalence of obesity still grows and places a massive strain on healthcare economy. 
Indeed, people with obesity struggle to adhere to diet/physical activity regimes and find 
it difficult to retain their weight loss, likely ending up heavier than they were before. 
This highlights the need for new treatment options.  
 
1.3 Insulin resistance and type 2 diabetes 
 
Type 2 diabetes mellitus (T2D) is characterised by deficiency in insulin action caused by 
pancreatic beta cell dysfunction and insulin resistance, resulting in hyperglycaemia.  The 
aforementioned increase in obesity, due to physical inactivity and calorie-dense 
Western diets, has resulted in an unprecedented increase in the number of people 
presenting with T2D. Around 4.7 million people in the UK have diabetes, 90% of which 
have T2D19. T2D can commonly lead to amputation due to diabetic foot, CVD, stroke, 
kidney failure, and heart attack19, and is associated with inflammation20,21, 
dyslipidaemia22, oxidative stress23, and hypertension24. Front line therapies for T2D are 
lifestyle changes, insulin therapy, metformin, or sulphonylureas25. 
 
Insulin, a peptide hormone synthesised and secreted from pancreatic beta cells, is 
considered one of the main anabolic hormones and controls many aspects of 
metabolism and growth. Insulin action is heavily linked to diet, as its secretion from beta 
cells is triggered by an increase in plasma glucose (i.e. after eating). Insulin is then 
transported via the circulatory system to target insulin receptors (IR), present on many 
tissues. There are two major pathways in insulin signalling; the phosphoinositide 3-
kinase (PI3K) pathway and Ras/extracellular signal-related kinase (ERK) pathway, a 
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schematic representation of which is shown in Figure 1.226. Insulin plays many different 
roles depending on cell type. A very important role for insulin is regulating blood glucose 
homeostasis. For example, particularly in skeletal muscle, insulin is responsible for 
glucose uptake via GLUT4 translocation27 as well as inhibiting hepatic glucose 
production by inducing the phosphorylation of forkhead box (FOXO) transcription 
factors28. Furthermore, insulin is known to act on the endothelium to cause 
vasodilation29, in the hypothalamus anorexigenically30, as well as the hippocampus to 
promote learning and memory31. Under certain conditions, peripheral insulin resistance 
can occur, and can be described as the continual release of insulin from pancreatic beta 
cells in response to increasing blood glucose levels, but a dampened cellular response 
upon insulin-IR binding in comparison to normal. The dampened cellular response 
results in continual high blood glucose levels (hyperglycaemia) coupled with increased 
pancreatic insulin release from pancreatic beta cells (hyperinsulinaemia) Eventually, 
pancreatic beta cells become exhausted, leading to a decline in insulin release, resulting 
in T2D. The mechanisms behind insulin resistance and type 2 diabetes are currently 
unknown, but it has been suggested that the impairment may be due to inflammation 
due to obesity21, oxidative stress23, mitochondrial dysfunction32, a defective IR or a loss 
of affinity to insulin, or chronic dysregulation of normally adaptive feedback and feed-
forward mechanisms that results in the attenuation of insulin signalling33.  
 
 
 5 
   
Figure 1.1 Nutrient excess and disease 
Nutrient excess due to over consumption of highly processed foods, carbohydrates with high glycaemic 
load (GL), and foods containing high levels of saturated fats are a root cause of many non-communicable 
diseases, such CVD, obesity, T2D, and neurodegenerative disorders. These diseases are inextricably linked 
to one another. Indeed, there are parallels between their pathologies, some of which are associated with 
nutrient excess and are shown above. These are as follows; hyperglycaemia -  high blood glucose levels; 
hypercholesterolaemia - high blood cholesterol levels (low-density lipoprotein, LDL); oxidative stress - 
imbalance in oxidants vs. antioxidants, resulting in increased reactive oxygen species; inflammation - 
physiological reaction presenting as increased immune cell recruitment, and increased cytokine, 
chemokine and chemoattractant expression; dyslipidaemia - dysregulation in blood lipid content, e.g. 
increased triglyceride levels, increased LDL and decreased high-density lipoprotein (HDL); insulin 
resistance - impaired cellular insulin signalling ; hypertension - high blood pressure; cognitive impairment 
- umbrella term describing a range of neurological deficits, including memory loss, behavioural changes, 
and problems with everyday decision making; mitochondrial dysfunction - mitochondria that are 
functioning inadequately resulting in loss of mitochondrial homeostasis and bioenergetic dysfunction. 
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Figure 1.2 Cellular insulin signalling 
Insulin binds the insulin receptor (IR) inducing autophosphorylation and recruitment and subsequent 
phosphorylation of substrates (mainly insulin receptor substrate 1 or 2 [IRS1/2]) required for further 
downstream signalling. Upon IRS phosphorylation, it associates regulatory subunits of PI3K, stimulating 
the transformation of membrane-bound lipoprotein PIP2 in to PIP3. PIP3 recruits PDK1 to the plasma 
membrane, resulting in phosphorylation of PKB by PDK-1 at Thr308, which facilitates a second 
phosphorylation at Ser473 by mTOR. These phosphorylation events potentiate PKB activity seven-fold 
and induce full activation. PKB activation can produce a number of effects dependent on cell type. For 
example, PKB activation facilitates glucose uptake and nitric oxide synthesis. It also inhibits hepatic 
glucose production by phosphorylating FOXO transcription factors and is involved in regulating 
glycogen and protein synthesis, as well as cell growth and survival. IRS, as well as another secondary 
protein Shc, can facilitate the binding of Grb2 and SOS. This then induces the transformation of Ras 
GDP to Ras GTP, which activates the Raf/MEK/Erk pathway. This pathway is known to activate 
transcription factors involved in mitosis and survival. 
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1.4 Cardiovascular disease 
 
The leading cause of death in Western countries is cardiovascular disease (CVD)34, a 
term used to describe a range of disorders affecting the circulatory system including 
hypertension, atherosclerosis, and stroke. It is clear that poor nutrition is a root cause 
of CVD, with excessive intake of processed sugars and saturated fats, together with 
obesity, T2D, and tobacco smoking, being associated with the development of CVD35,36. 
Due to the large body of evidence that suggests that nutrition is one of the most 
preventative factors in CVD death37 and alongside the fact that diet plays an important 
role in the management of CVD-associated pathologies such as hyperglycaemia, 
hypercholesterolaemia, and T2D, it is clear that the role of nutrient excess in the onset 
of CVD needs to be further investigated. 
 
1.5 Dementia 
 
‘Dementia’ is an umbrella term, which describes a range of cognitive symptoms such as 
memory loss, behavior and personality changes, issues with problem solving, and 
language impairments. There are many dementia-causing diseases, including 
Alzheimer’s disease, vascular dementia, Parkinson’s disease, and Huntington’s disease. 
Dementia affects an estimated 47 million people worldwide; 850,000 of which reside in 
the UK. This number is rapidly growing due to the ageing population and the lack of 
disease therapeutics and is expected to reach more than 131 million worldwide and 2 
million in the UK by 205038,39. Despite scientific advances and an increase in research 
funding (£75 million in 2014 compared to £45 million in 200939), the fact remains that 
there are no effective pharmacotherapeutic treatments for dementia-causing 
diseases40. Current treatment options focus on symptomatic improvements and mainly 
consist of neurotransmitter-balancing drugs such as cholinesterase inhibitors41,42, the N-
methyl-D-aspartate (NMDA) receptor antagonist memantine43,44, and several 
antidepressants45,46. Many disease-modifying therapies have made it to clinical trials, 
but these are met with little to no success. Mehta and colleagues offer a concise 
perspective of dementia clinical trials active from 2010 to 2015, with suggestions as to 
why these trials may have failed47. With the increasing prevalence of dementia-causing 
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diseases, it is clear that further investigation into the pathophysiology of these diseases 
is required. 
 
1.5.1 Alzheimer’s disease 
 
Alzheimer’s disease (AD) is the most common form of dementia48, accounting for 
approximately 80% of cases49. The majority of AD cases occur after the age of 65, 
constituting late-onset AD (LOAD), whilst cases that appear before the age of 65, early-
onset AD (EOAD) are considerably rarer, constituting 5% of all AD cases50. There are two 
pathologies that were first described by Alois Alzheimer51,52 that are associated with AD; 
amyloid plaques, extracellular deposits consisting of aggregates of the small peptide 
amyloid beta (A) and neurofibrillary tangles (NFT), intracellular aggregates of 
hyperphosphorylated tau protein. The confirmation of the presence of these two 
abnormalities is still required for post-mortem diagnosis of the disease and it is often 
said these are the hallmark pathologies of the disease53. 
 
1.5.2 Vascular dementia 
 
Vascular cognitive impairment (VCI) is an umbrella term used to describe a range of 
symptoms associated with decline in mental cognition caused by an abnormality of 
vascular origin. This might include ischaemic attacks or stroke54, cerebral amyloid 
angiopathy (CAA)55, microbleeds56, or a reduction in global cerebral perfusion due to 
cardiac arrest57. The most severe form of VCI is vascular dementia, which is responsible 
for around 20% of dementia cases58.  It is hard to pin down exactly how these 
pathologies then lead to VD, but at the heart of them all is the reduction in cerebral 
blood flow (CBF), be that acute yet severe (stroke) or chronic, discrete, and reoccurring 
(multi-infarct). A reduction in CBF to brain tissue results in a hypoxic and nutrient-
deprived environment within the brain area affected, stressors which may lead to 
oxidative stress, cellular metabolic dysfunction, inflammation, and lasting tissue 
damage. Indeed, there is a general consensus that cognitive impairment results from 
brain dysfunction caused by multifactorial and cumulative tissue damage58.  
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The development of dementia can be the result of both Alzheimer-pathology as well as 
a vascular contribution. Patients with VD may also present with amyloid accumulation55, 
and likewise AD patients present with vascular abnormalities59,60, meaning there is 
overlap between these diseases. It is likely that individuals living with dementia may 
experience varying levels of AD-related and vascular pathologies and no two cases will 
be the same. It is important that we do not look at these diseases in pure isolation if we 
are to better understand what is at the core of their development.  
 
1.5.3 Metabolic risk factors for dementia 
 
Interestingly, both VD and AD share common risk factors, largely related to poor 
nutrition, metabolic disorders, and vascular diseases. The biggest risk factor in 
developing dementia is age, with cardiometabolic disturbances such obesity, T2D, and 
hypertension also being implicated. The existing literature on the relationship between 
obesity and dementia is conflicting and contradictory. Most studies report an 
association between obesity in mid-life and increased dementia risk, as well as greater 
burden of Alzheimer’s pathology61–64. It remains unclear whether obesity increases the 
risk of dementia independently or due to its co-pathologies. The pathophysiology of T2D 
and insulin resistance has been likened to the pathophysiology of AD, some reporting 
AD is a brain specific form of diabetes65. The connection between the two pathologies 
gained significant interest after the publishing of the Rotterdam Study, which found that 
those suffering from diabetes had an increased risk of developing dementia66,67. Since 
then, many epidemiological studies have further confirmed this68–72. Although precise 
mechanisms are unclear, there are known parallels between the two diseases that are 
heavily associated with poor diet. As previously stated, those with T2D suffer from a 
chronic low-grade inflammation as well as oxidative and metabolic stress, and these 
cellular impairments are also seen in AD and present as metabolic stress and 
neuroinflammation, as well as insulin resistance73. Both pathologies also present with 
amyloid aggregation, neurodegeneration, and cognitive decline74,75. 
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1.5.4 Vascular risk factors for dementia 
 
Systemic and cerebral atherosclerosis has been suggested to play a role in the 
development of dementia in the elderly76. Atherosclerosis is preceded by endothelial 
cell dysfunction, which kick-starts a cycle of inflammatory events. This disease, the 
development of which is summarised in Fig. 1.3, is characterised by fatty plaque 
deposition in the sub-endothelial space of arteries, often resulting in hardening of the 
vessels. Atherosclerosis can occur in both peripheral and cerebral arteries, but is 
especially common in ilio-femoral arteries in the leg, carotid arteries in the necks, and 
the basilar, posterior, and middle cerebral arteries in the brain77,78. Atherosclerotic 
plaques can remain stable for some time, but if the plaque suddenly ruptures, it may 
trigger platelet aggregation and thrombosis (blood clots) may occur. This can lead to 
ischaemic stroke, or further embolisms as the plaque may detach and travel through the 
blood stream to other vessels. Classical risk factors for developing atherosclerosis 
include poor nutrition79, the presence of a metabolic disorder (obesity, insulin 
resistance, T2D)80, tobacco smoking81, hypertension82, and genetic predisposition83. One 
of the main triggers for developing the disease is the presence of 
hypercholesterolaemia79, usually stemming from an increased consumption of 
cholesterol in the diet or an inherited condition83. Hypercholesteraemia may influence 
disease development through cellular pathologies including inflammation, oxidative 
stress and mitochondrial dysfunction80. Several studies indicate a direct relationship 
between atherosclerosis and Alzheimer’s pathology, thus implying Alzheimer’s 
pathology is potentially rectifiable with the treatment of atherosclerosis. The effect of 
atherosclerosis on dementia may be attributable to its strong relation to cerebral 
infarcts and ischaemic stroke, or a common pathology such as ApoE variants83. However, 
Dolan and colleagues found that the risk of developing dementia greatly increased in 
the presence of intracranial atherosclerosis, independent of the incidence of cerebral 
infarcts76.  Atherosclerosis and dementia are clearly linked, but the foundations of this 
relationship are presently unclear and need to be further investigated.  
 
Hypertension, also known as high blood pressure (BP), is another known vascular risk 
factor for developing dementia. Blood pressure consists of both systolic blood pressure, 
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which is the pressure the blood exerts on the artery walls during a heartbeat, and 
diastolic, which is the pressure the blood exerts on the artery walls when the heart is at 
relaxed. The reading is given as systolic blood pressure/diastolic blood pressure in 
millimeters of mercury (mm Hg). Normal blood pressure is anything below or equal to 
120/80 mmHg. Hypertension stage one is a blood pressure reading of 130-139/80-89 
mmHg and stage 2 is >140/>90 mmHg. Several studies have established a link between 
elevated BP in mid-life and the development of dementia in later life. Chronically 
elevated BP exerting pressure on vessels82, leading to vessel wall thickening and reduced 
microvessel diameter, is likely the cause of this increased risk84. Chronic hypertension is 
also associated with thickening of larger cerebral arteries and atherosclerotic plaque 
formation, which as previously stated can rupture and occlude blood flow. Of note is 
that although several studies have addressed the issue, only two studies have identified 
an association between late-life hypertension and dementia85. Interestingly, two clinical 
trials reported a positive effect of lowering blood pressure on the incidence of dementia, 
again suggesting dementia may be remediable with the treatment of hypertension85.  
 
1.6 Endothelial cells 
 
Endothelial cells (ECs) exist as a monolayer, making up the inner lining of all blood 
vessels in the body. The vessels’ job is to retrieve nutrients and oxygen from their site 
of uptake or production and deliver them around the body where they can be 
metabolised. They are also responsible for removal of waste products from these 
tissues. ECs play a key role in not only regulating blood flow and therefore nutrient and 
oxygen supply, but also transport of numerous molecules across their monolayer 
barrier.  
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Figure 1.3 The development of atherosclerosis 
(A) Cross sectional image of both a healthy and atherosclerotic artery. (B) Development of 
atherosclerosis. The first trigger is the increased expression of cell-surface adhesion molecules (shown in 
purple) on the endothelium such as VCAM, ICAM, and P-selectin, caused by various effectors, for 
example, chronic hypercholesterolaemia, hyperglycaemia, and dyslipidaemia. Monocytes adhere to the 
cell-surface adhesion molecules and begin to migrate through the endothelium (diapedesis). Once in the 
sub-endothelial space, they will differentiate into macrophages. Macrophages respond to this 
proinflammatory environment by secreting chemokines and chemoattractants, recruiting more 
monocytes to the lesion. The high levels of LDL become oxidised by free radicals, forming oxLDL, further 
activating the macrophages and exacerbating the proinflammatory environment. Macrophages develop 
into foam cells as they attempt to engulf the lipid present in the lesion. These processes are cyclical and 
eventually the lesion results in a fatty plaque in the sub-endothelial space.  Smooth muscle cells migrate 
and begin to exhibit lipid deposits, which only acts to exacerbate the lesion. This plaque has the potential 
to impair blood flow at the lesion site, but also it may rupture, triggering platelet aggregation and 
thrombosis.  
 13 
1.6.1 Nitric oxide signalling 
 
One aspect of EC function is to control haemodynamics by releasing nitric oxide (NO). A 
schematic of NO signalling is shown in Fig. 1.4. Briefly, vasoactive agents (acetylcholine, 
insulin, bradykinin) that are present in the blood will act on their respective receptors 
on the luminal surface of ECs to induce a change in endothelial nitric oxide synthase 
(eNOS) activity. eNOS is an important enzyme that is involved in the oxidation of L-
arginine (L-arg) to L-citrulline and NO. When eNOS is active, high concentrations of NO 
are produced, which can then diffuse into neighbouring vascular smooth muscle cells 
(VSMCs) and induce relaxation, ultimately causing vasodilation.  If eNOS activity 
decreases, NO concentrations are reduced, which ultimately will cause 
vasoconstriction86. Therefore, NO bioavailability is a key regulator of haemodynamics. 
The production of NO from L-arg by eNOS requires the presence of 5 co-factors; 
tetrahydrobiopterin (BH4), flavin adenine dinucleotide, flavin mononucleotide, 
calmodulin, and iron protoporphyrin IX (haem). eNOS is synthesised as a monomer but 
is required to exist as a dimer to bind BH4 and L-arg and catalyse NO production. The 
monomers instead produce super oxide (O2-), referred to as eNOS uncoupling. The 
activity and the coupling of eNOS are far more important than its expression in terms of 
NO production. Some vasoactive agonists such as acetylcholine and bradykinin increase 
eNOS activity through a calcium-dependent mechanism. They bind to their respective 
cell surface receptors, which activate downstream signalling pathways to increase 
intracellular calcium ion (Ca2+) concentrations. Ca2+ then binds calmodulin, leading to 
the activation of the calmodulin-binding domain of eNOS and an electron flux from the 
reductase to the oxygenase domains of eNOS facilitating oxidation of L-arg and 
production of NO87.  Although independent of Ca2+, phosphorylation of eNOS on certain 
sites results in a similar electron flux from the reductase to the oxygenase domains, 
therefore increasing NO production. Phosphorylation at serine 1177 increases eNOS 
activity, whereas phosphorylation at threonine 495 reduces eNOS activity. Serine 1177 
phosphorylation is also downstream of protein kinase B (PKB) signalling and AMPK 
signalling86.  
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Figure 1.4 Nitric oxide signalling in healthy vasculature 
Vasoactive agents from the blood act on the luminal surface of endothelial cells (pink) and stimulate 
downstream signalling pathways, resulting in an increase in NO bioavailability.  Examples of 
vasomodulators are acetylcholine/bradykinin (yellow), histamine (green), insulin (purple), and fluid 
shear stress (red), which activate a range of signalling molecules including Ca2+, AMPK and PKB. These 
signals can then go on to increase eNOS activity, either by phosphorylation or promoting coupling, 
resulting in enhanced NO production from L-arg. NO can diffuse into the neighbouring vascular smooth 
muscle cells (brown), and activates sGC, which in turn converts GTP to cGMP. cGMP induces activated 
of PKG, which is known to decrease cytosolic Ca2+, resulting in muscle relaxation and vasodilation. In 
the event of reduced NO bioavailability, either as an adaptive response or in cases of endothelial 
dysfunction, PKG is no longer active and thus unable to minimise cytosolic Ca2+, resulting in muscle 
contraction and vasoconstriction. 
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It is important to mention that ECs also respond to physical forces exerted upon them 
by blood flow. There are two main forces that the EC will experience; a frictional force 
of the blood moving parallel to the ECs called fluid shear stress (FSS) or wall shear stress 
(WSS), and the force of pulsatile blood pressure, which stretches the vessel wall. 
Mechanical stress on the vessel wall can influence NO signalling as well as increase the 
expression of Krüppel-like factor 2 (KLF2), a transcription factor with anti-inflammatory 
and antithrombotic downstream effects. A coherent model of how mechanostimulation 
initiates EC signalling is still to emerge. In vitro studies have implicated an array of shear-
responsive kinases, GTPases, ion channels, and cilia. An excellent review of this topic is 
provided by Zhou and colleagues88.  
 
Once produced, NO diffuses into VSMCs and stimulates soluble guanylyl cyclase (sGC), 
resulting in the formation of cyclic guanosine monophosphate (cGMP) from guanosine 
triphosphate (GTP). cGMP activates protein kinase G, which promotes the uptake of 
cytosolic Ca2+ into the sarcoplasmic reticulum, the discharge of Ca2+ out of the cell, and 
the opening of Ca2+ dependent potassium channels. Intracellular Ca2+ concentration 
decreases and due to this, myosin phosphorylation is attenuated and VSMCs relax89.  
 
1.6.2 Endothelial cell dysfunction 
 
Endothelial dysfunction (ED) can be described as the shift in EC phenotype toward that 
of one which exhibits a blunted response to vasodilatory agents and is generally 
proinflammatory and prothrombotic. As a general rule, if ED is present, NO 
bioavailability will be decreased, usually by a reduced response in the signalling that 
precedes NO production (reduced eNOS activity/coupling, reduced PKB or AMPK 
activity, reduced Ca2+ signalling)90, or NO activity will be reduced. 
 
ED is strongly associated with increased reactive oxygen species (ROS) production and 
there is a growing body of evidence to suggest that oxidative stress plays a causal role 
in the development of ED. NADPH oxidases (NOX) are the main contributor of ROS 
production in endothelial cells, although other sources such as the mitochondria do exist 
(see section mitochondrial ROS). Indeed, Doerries and colleagues showed that deletion 
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of the NOX subunit p47phox protected mice against ED91. Wenzel and colleagues 
described a role for mitochondrial ROS (mROS), when they reported that mice lacking 
one copy of the MnSOD gene, and that therefore exhibit increased mROS, presented 
with worsened age-related ED92. It is well established that one of the most abundant 
ROS, superoxide (O2-) can react with NO to inactivate it and form peroxynitrite (ONOO-
), contributing to ED93. eNOS uncoupling is also associated with ED, potentially due to 
increased NOXs and ROS, leading to oxidation of BH4. In more detail, the product of the 
superoxide O2- and NO, ONOO- oxidises BH4 into the BH3- radical94. As previously 
mentioned, BH4 is a cofactor in the production of NO from L-arginine, thus a reduction 
in its availability will uncouple eNOS from NO production and instead eNOS will produce 
O2-. ONOO and H2O2 have also been shown to increase arginase activity and expression 
in ECs 95,96, resulting in less L-arginine to react with eNOS and lowering NO 
bioavailability. 
 
Aside from NO bioavailabiliy/activity, NOXs can contribute to the development of ED in 
other ways. For example, NOX-derived ROS are involved in NF-kB activation and 
expression of adhesion molecules such as ICAM-1, thus facilitating an inflammatory 
state within the EC97 (see section 1.6.3). Additionally, NOXs are potent activators of 
protein tyrosine phosphatases, such as protein tyrosine phosphatase 1B (PTP1B), which 
is an inhibitor of growth factor signaling98, particularly insulin action. Activation of this 
phosphatase by NOXs may contribute to ED by blocking the vasodilatory action of insulin 
at the ECs. 
 
Interestingly, ED has been associated with an increase in total eNOS expression, likely 
due to high concentrations of hydrogen peroxide (H2O2), the dismutation product of O2- 
(produced by uncoupled eNOS). H2O2 can increase the production and extend the half-
life of eNOS mRNA94. Indeed, H2O2 effects endothelial function in both positive and 
negative ways. H2O2 can induce vasorelaxation through increasing eNOS activity via PI3K 
and ERK1/2 but has also been reported to have vasoconstrictor capabilities99. H2O2 is 
also a hyperpolarising factor which can have a direct effect on potassium (K+) channels 
on ECs, acting to decrease intracellular K+ concentration and promote hyperpolarisation. 
Hyperpolarisation of ECs and release of K+ into the subendothelial space allows for VSMC 
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K+ channels which will further result in hyperpolarisation of VSMCs, promoting VSMC 
relaxation and thus vasodilation. Additionally, H2O2 can promote endothelial activation 
(see section 1.6.3), mediate vascular remodeling and angiogenesis100, and induce 
apoptosis.  
 
Another marker of ED is the powerful vasomodulator endothelin-1 (ET-1). ET-1 is 
produced in ECs and secreted preferentially to the basolateral side of the endothelium, 
acting on endothelin receptor ETA on neighbouring VSMCs to induce constriction. 
Secreted ET-1 can also act in a paracrine manner on ETB, which is present on 
neighbouring ECs and results in an increase in NO, suggesting that ET-1 is a complex 
modulator of haemodynamics, capable of inducing both vasodilation and 
vasoconstriction.  However, since the discovery of ET-1, several studies have suggested 
a link between high circulating levels of ET-1 and CVDs such as atherosclerosis and 
hypertension. Raised ET-1 has also been associated with metabolic disorders (obesity 
and T2D) and neurodegenerative disorders, including AD101. Therefore, ET-1 remains a 
well-utilised marker of ED. 
 
1.6.3 Endothelial cell activation 
 
Another pathology that arises in metabolic and vascular diseases is endothelial 
activation (EA, Fig. 1.5). EA is defined as the increased expression of cell surface 
adhesion molecules on the luminal surface of ECs, typically caused by a proinflammatory 
response from the EC itself. As mentioned in 1.5.4, proinflammatory signalling 
molecules such as TNFα and IL-6 will induce an increase in the expression of cell-surface 
adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1), inducible cell 
adhesion molecule-1 (ICAM-1), endothelial leukocyte adhesion molecule (E-selectin), 
and P-selectin. EA facilitates the recruitment of circulating leukocytes, particularly 
monocytes, which can then migrate into the subendothelial space and begin 
differentiating to macrophages, which will secrete further proinflammatory chemokines 
and chemoattractants102.  
 
 18 
EA and ED are undeniably linked, but it is unclear which pathology arises first. 
Proinflammatory signalling molecules such as TNFα are known to be able to inhibit eNOS 
expression by reducing eNOS mRNA half-life, as well as reduce NO bioavailability 
through induction of ROS through mechanisms described earlier102. It has been shown 
that in the presence of hypercholesterolaemia (through giving atherogenic diet to 
rabbits), VCAM expression is rapid and possibly the first response in the endothelium103. 
However, when cytokines are absent, reduced NO bioavailability (through NO inhibition 
via L-NG-arginine methylester; L-NAME) can also rapidly induce VCAM expression and 
monocyte recruitment, indicating NO can protect against EA104,105. This is further 
supported by the fact that atherosclerotic lesions are more prevalent in areas of vascular 
branching that are exposed to turbulent rather than laminar flow and have reduced NO 
bioavailability106, as well as the fact that genetically modified eNOS-deficient mice 
develop increased atherosclerosis and inflammation107. 
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Figure 1.5 Schematic representation of endothelial activation 
Endothelial activation is a proinflammatory state that the endothelial cell is experiencing due to a cyclical 
series of proinflammatory events. A proinflammatory stimulus (chronic dyslipidaemia, 
hypercholesterolaemia, hyperglycaemia) will induce an increase in the expression of cell-surface adhesion 
molecules such as VCAM, ICAM, E-selectin and P-selectin. This facilitates the recruitment of circulating 
leukocytes, particularly monocytes, which can then migrate into the subendothelial space and begin 
differentiating to macrophages, which will secrete further proinflammatory cytokines such as TNFα, IL-6 
and IL-1β and chemoattractants such as MCP-1 and MIP. 
 
Figure 1.6 Schematic of the blood-brain barrier 
The blood-brain barrier (BBB) is a barrier interface between the blood and the interstitial fluid of the brain. 
The physical barrier compromises of endothelial cells of cerebral vessels, and supporting cells such as 
pericytes, astrocytes, microglia, and neurons play a metabolic regulatory role in maintaining the integrity 
of the BBB. 
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1.7 The blood-brain barrier 
 
The blood-brain barrier (BBB) is an “interface” barrier between the blood and the 
interstitial fluid of the brain. It is not a rigid structure, but rather a dynamic unit 
comprising several cell types, often referred to as the VE fraction unit (NVU; Fig. 1.6). 
ECs joined together by cell-cell junctions including tight junctions (TJs) and adherens 
junctions form the basic structure of the BBB108,  whilst pericytes and astrocytes may 
perform supporting and regulatory functions109. The BBB plays the important role of 
delivering essential nutrients to the brain and removing waste products. Indeed, entry 
of potentially damaging particles is severely restricted by the endothelium of the BBB 
and movement of molecules across the BBB depends on specialised transporters or 
carriers. Aside from barrier function, the endothelium of the BBB is also heavily involved 
in haemodynamics and regulation of cerebral blood flow (CBF). The integrity of the BBB 
is crucial to proper brain function, and when it is compromised, the damage that 
succeeds this may lead to neurodegenerative disorders such as dementia. EC 
dysfunction in the brain is linked to impaired cerebral blood flow and BBB opening110. 
BBB opening will allow entry of toxic blood-derived molecules into the brain and has 
been largely linked to neuroinflammation111. A pro-inflammatory environment at the 
BBB will act to exacerbate the damage; further impairing barrier integrity and 
dysregulating haemodynamics. 
 
There is a growing list of pathologies that exhibit BBB dysfunction, including metabolic 
disorders such as obesity and T2D, as well as cardiovascular disorders such as 
hypertension. Furthermore, cerebrovascular integrity is altered during aging112–114; 
changes that can be accelerated by vascular pathologies such as cerebral amyloid 
angiopathy. Indeed, high-fat diet (HFD)-fed rats exhibit BBB dysfunction as early as 24-
days post diet induction115. T2D-induced changes at the BBB include downregulation of 
TJ proteins including claudin-5 and occludin, and the TJ-associated protein ZO-1116–120, 
promoting BBB opening121,122. Endothelial activation is also promoted, with upregulated 
protein expression of ICAM and VCAM123. Another aspect of BBB damage is basement 
membrane (BM) thickening, and this is seen in T2D124–126, and can result in cell 
detachment from the BM as well as BBB opening. Systemic inflammation observed in 
 21 
multiple metabolic disorders has also been shown to induce BBB opening and 
dysfunctional brain ECs. Indeed, lipopolysaccharide (LPS) challenge in mice induces BBB 
opening, a pathology that is dependent on reduced mitochondrial function127. 
Consequently, there is strong evidence to link nutrient excess, cerebral EC dysfunction, 
and loss of BBB integrity. 
 
1.8 Effects of nutrient excess on endothelial cells 
 
ED and EA are found in multiple diseases, including obesity90,128–131, T2D132–134, type 1 
diabetes (T1D)135, and dementias84,136,137, and are indeed a main driver in the 
development of atherosclerosis and other CVDs. It is believed that pathologies 
succeeding nutrient excess, such as hyperglycaemia and dyslipidaemia, may drive ED 
and EA, contributing to the development of these diseases. 
 
1.8.1 Animal dietary studies investigating endothelial cell function 
 
EC function in relation to nutrient excess has been extensively studied in animal models. 
Noronha and colleagues found that HFD feeding (8 weeks duration) has the capacity to 
reduce insulin-mediated vasodilation in ex vivo murine aortae myograph studies, 
suggesting ED138. Interestingly, the authors observed no change in acetylcholine (ACh)-
mediated aortic vasodilation in HFD-fed mice. This was attributed to the hyperpolarising 
capacity of increased ROS H2O2 levels, as in the presence of catalase (degrades H2O2) the 
response to ACh was indeed blunted in HFD-fed mice. The hyperpolarising effects of 
H2O2 in early ED may act as a compensatory mechanism. NO levels, measured by plasma 
nitrite concentration, were increased in HFD-fed mice138, but this was attributed to 
increased inducible NOS (iNOS) expression, a potential inflammatory response to the 
nutrient excess. Other HFD rodent models (6-24 weeks on HFD) suggest similar findings 
in that HFD induces a blunted vasodilatory response in ex vivo aortae, indicating 
endothelial dysfunction139–141. We have reported that mice fed HFD (20 weeks) exhibit 
significantly reduced in vivo ACh-induced vasodilation when undergoing microvascular 
assessment using laser Doppler flowmetry (see section 2.5), as well as decreased aortic  
phospho-eNOS (S1177), and increased plasma ET-1 levels, increased aortic ICAM protein 
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expression, and reduced plasma nitrite142. These data suggest nutrient excess caused by 
HFD consumption compromises endothelial response through reduced NO 
bioavailability, perhaps caused by blunted upstream signalling and/or a 
proinflammatory environment. It is unclear whether this dysfunction develops prior to 
the onset of obesity and T2D in the mouse. Indeed, we have previously observed marked 
reductions in in vivo vasodilatory response to ACh in HFD-fed mice as soon as 5 weeks 
on when blood glucose levels are likely higher than normal142, but perhaps prior to the 
onset of a complete whole-body insulin resistance143. We did not observe any changes 
at 1 week of HFD and unfortunately do not possess data at this time investigating the 
effects of 2-4 weeks of HFD on ACh-induced vasodilation. It is certainly of interest 
whether endothelial function is compromised after a short duration of nutrient excess, 
or whether it is secondary to the onset of obesity and T2D. Da Silva Rocha and colleagues 
also investigated the effects of HFD-induced obesity on endothelial dysfunction via ex 
vivo aortic myograph experiments144. Interestingly, their model of obesity (HFD-
induced, 20% of calories from fat, 27 weeks), whilst significantly heavier than regular 
chow controls, did not exhibit many classical pathologies of obesity including reduced 
glucose tolerance, hypercholesterolaemia, dyslipidaemia, or hyperinsulinaemia. 
Additionally, they observed no reduction in aortic dilatory response to ACh in obese 
mice, which is contradictory to previous studies. This suggests that HFD-induced 
endothelial dysfunction is dependent on obesity-related pathologies, including 
hyperglycaemia, dyslipidaemia and hypercholesterolaemia. In line with the notion that 
hypercholesterolaemia is a strong contributor to ED, Belch and colleagues reported that 
4 weeks of high-cholesterol diet induced a potent reduction in in vivo skin perfusion 
response to ACh145. 
 
Studies focusing on nutrient excess and brain vasculature are contradictory. Zuloaga and 
colleagues reported that 6 months of HFD feeding in mice did not reduce CBF146, whilst 
Bracko and colleagues observed no worsening of CBF in the Alzheimer’s model APP/PS1 
when they challenged the mice with a 15 month HFD147. However, acute HFD feeding 
has been reported to exacerbate brain ischaemic damage in middle cerebral artery 
occlusion stroke model148, and chronic HFD (12 months) results in a reduction in CBF in 
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mice149. Furthermore, high cholesterol diet reduced ex vivo responsiveness of murine 
posterior cerebral artery to ACh150. 
 
1.8.2 Effects of hyperglycaemia on endothelial cell function 
 
To further investigate how hyperglycaemia may affect EC function, we can look to both 
rodent and human studies on type 1 diabetes mellitus (T1D). Hyperglycaemia alone has 
been linked to atherosclerosis in people with T1D, which we can assume is an indicator 
of reduced EC function. Postmortem studies in T1Ds with favourable lipid profiles 
indicate that hyperglycaemia is an independent risk factor for atherosclerotic plaque 
development151, whilst T1Ds also exhibit reduced CBF152. Genetic and streptozotocin 
(STZ)-induced T1 diabetic mouse models have also shed light on this topic. STZ mice 
exhibit reduced ACh-induced vasodilation in ex vivo aortic myograph studies153,154, 
increased aortic superoxide expression154, and increased serum TNFα153. Furthermore, 
when administered to a mouse model of atherosclerosis (ApoE KO mouse), STZ-induced 
chronic hyperglycaemia acted to further exacerbate the already-blunted ACh-mediated 
vasodilation (ex vivo myography) and increased eNOS mRNA155. Furthermore, on 
crossing a genetic model of T1D (Ins2 Akita mouse) with a genetic model of 
atherosclerosis (LDL receptor KO), Zhou and colleagues found that chronic 
hyperglycaemia exacerbated aortic atherosclerotic lesion area156. In these studies, 
inducing T1D in mouse models of atherosclerosis acted to further increase plasma very 
low-density lipoprotein (VLDL) LDL, HDL, and triglyceride levels, potentially due to 
impaired hepatic function and increased hepatic inflammation156. Therefore, it is 
presently unclear whether hyperglycaemia in these models is directly affecting EC 
function, or whether it is indirectly doing so via enhancing dyslipidaemia. In terms of 
brain vasculature, STZ mice exhibit profound reductions in CBF, which is associated with 
cognitive impairment and worsened performance in memory tasks157. Clinically, 
implementing tight glycaemic control in young T1Ds reduced microvascular 
complications in the initial follow-up period, and also reduced the number of CVD events 
(e.g. ischaemic attacks) in the 10-year follow-up158. Similarly, a similar trial undertaken 
in newly diagnosed T2 diabetics found that tight glycaemic control reduced the number 
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of CVD events in the 10-year follow-up159. However, glycaemic control in persons who 
are already high CVD risk did not exhibit any benefit160,161. These clinical trials data 
suggest that implementation of glycaemic control early following a diabetes diagnoses 
could be a protective measure in reducing CVD risk, but it is unclear whether it would 
be a beneficial course of action in those already at high risk. In 
 
Some in vitro studies corroborate the role of hyperglycaemia in the development of ED. 
Exposing cells to high glucose (HG) concentrations is a tool for measuring the effect of 
HG on cellular function in the absence of other factors. Exposure to HG has been 
reported to reduce phospho-AMPK expression154, reduce phospho-PKB expression162–
164, reduce phospho-eNOS expression154,163, reduce NO levels154,163, impair ERK 
activation164, reduce mitochondrial bioenergetics165,166 increase superoxide levels154, 
induce apoptosis162,167,168, increase cell permeability169, increase ICAM/VCAM 
expression162, enhance cell senescence162,170, and impairs angiogenesis163,164 in a 
number of endothelial cell line models including HUVECs, BAECs, and HMECs.  
 
Studies investigating the effects of hyperglycaemia on brain ECs in vitro are limited. Most 
brain EC studies investigate BBB function and measure outcomes such as transepithelial 
resistance (TEER) as well as expression of tight junction proteins. In brain endothelial 
cell lines (hCMEC/d3, BMEC), acute and chronic exposure to HG both reduced 
TEER171,172, increased permeability118, elevated glycation of tight junction proteins172, 
reduced expression of tight junction proteins118, induced apoptosis171,173, increased 
oxidative stress markers171,173, increased VCAM expression118, increased mitochondrial 
permeability transition pore (mPTP) expression173, decreased mitochondrial membrane 
potential173, increased Ca2+ levels173, increased mitochondrial Drp1 (see 1.12.1) 
expression173, reduced mitochondrial mass173 and reduced mitochondrial biogenesis173. 
 
There are several hypotheses as to how hyperglycaemia impairs NO bioavailability in 
endothelium. A model was proposed by Michael Brownlee (summarised in Fig. 1.7), 
which suggests that hyperglycaemia increases ROS production, which then through 
activation of poly-ADP ribose polymerase (PARP) and subsequent inhibition of the 
glycolysis enzyme D-glyceraldehyde-3-phoshae dehydrogenase (GAPDH), results in an 
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accumulation of glycolysis intermediates (glucose, fructose-6-phosphate [F6P], 
glyceraldehyde [G6P]. Accumulation of G6P may lead to increased de novo synthesis of 
diacylglycerol (DAG)174. DAG is a known activator of PKC, which has been implicated 
previously in the development of ED due to its role in activating ET-1175. G6P can be 
converted into methylglyoxal, which is known to increase formation of intracellular 
advanced glycated end products (AGEs)176, thus increasing inflammatory activation of 
ECs177, promoting further oxidative stress178, and inducing ED179.  F6P can enter the 
hexosamine pathway to produce uridine 5’diphosphate N-acetylglucosamine (UDP- 
GlcNac). UDP-GlcNAc is a precursor for proteoglycans and O-linked GlcNac addition to 
proteins. O-GlcNAcylation of eNOS has been shown to compromise activity180 and is 
associated with enhanced VCAM and ICAM expression181. Increased flux of glucose 
through the hexosamine pathway is also associated with insulin resistance182. The 
sorbitol pathway, by which glucose is converted to sorbitol by aldose reductase, is 
enhanced during hyperglycaemia. Aldose reductase inhibitors have been shown to 
improve endothelial responsiveness to ACh in vivo183, and in vitro by reducing uric acid 
accumulation184. The model thus suggests that hyperglycaemia-induced ED may develop 
due to enhanced accumulation of glycolysis intermediates through oxidative stress-
induced GAPDH inhibition. Indeed, pharmacological shunting of glycolysis intermediates 
down the pentose-phosphate pathway has been demonstrated to  improve endothelial 
function185.  This model depends on the ability of hyperglycaemia to induce ROS 
production, which is covered in section 1.12.4.  
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Figure 1.7 Mechanism of hyperglycaemia-induced ROS-dependent development of endothelial 
dysfunction 
Blue hexagons represent glucose molecules. Hyperglycaemia increases intracellular ROS, which then 
through activation of PARP and subsequent inhibition of the glycolysis enzyme GAPDH results in an 
accumulation of glycolysis intermediates G6P and F6P. Accumulation of G6P leads to increased DAG 
levels and thus PKC activation, which has been implicated in the development of ED due to its role in 
promoting ET-1. G6P can be converted into methylglyoxal, which promotes formation of AGEs, known 
to increase inflammatory activation of ECs, promote further oxidative stress, and induce ED.  F6P can 
enter the hexosamine pathway to produce UDP-GlcNAc, a precursor for proteoglycans and O-linked 
GlcNACylation. O-GlcNAcylation of eNOS has been shown to compromise activity and is associated with 
enhanced VCAM and ICAM expression. Increased flux of glucose through the hexosamine pathway is 
also associated with insulin resistance. Glucose flux through the sorbitol pathway (via aldose reductase) 
is enhanced during hyperglycaemia. Aldose reductase inhibitors have been shown to improve 
endothelial function in vivo and in vitro by reducing uric acid accumulation. The model thus suggests 
that hyperglycaemia-induced ED develops due to accumulation of glycolysis intermediates caused by 
oxidative stress-induced GAPDH inhibition.  
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1.8.3 Effects of dyslipidaemia on endothelial cell function 
 
Dyslipidaemia is also associated with overnutrition and encompasses both 
hyperlipidaemia of saturated free fatty acids (FFA) and LDL due to a diet rich in animal 
products and saturated fats, as well as reduced unsaturated fatty acids (omega-3/-6) 
and HDL.  It has long been accepted that FFA, from dietary intake or produced via the 
breakdown of stored triglycerides, are increased in subjects with obesity and T2D186–188, 
and are a known risk factor in the development of CVD188. Elevation of FFA has been 
reported to induce insulin resistance, impair glucose uptake, and reduce the inhibition 
of hepatic gluconeogenesis. These findings are further corroborated by the finding that 
acipimox, a niacin derivative which inhibits lipolysis and thus reduces plasma FFA, can 
improve whole body glucose tolerance and insulin sensitivity in T2D humans189. 
Numerous animal and cell models of elevated FFAs have been associated with various 
EC pathologies including increased oxidative stress, reduced EC function, inflammation, 
and mitochondrial dysfunction.  
 
Two of the most common FFAs found in human plasma are the long-chain saturated FFA 
palmitate (C16:0) and the monounsaturated oleate (C18:1). Palmitate is often used in 
vitro to simulate elevated FFA in cell culture models190. In peripheral EC lines including 
HUVEC, BAE, HMEC and EA.hy926, palmitate has been shown to induce oxidative 
stress191–196, activate proinflammatory signalling pathways195 (including Toll-like 
receptor [TLR2]/NF-κB191,197, IL-6191,197, IL-8197), induce apoptosis191–193,196,198, increase 
ICAM expression191,192,194,197,198, increase monocyte adhesion194,197, increase receptor 
for AGE (RAGE) expression196, promote endoplasmic reticulum stress192, reduce insulin 
transcytosis197, reduce insulin sensitivity195, and dysregulate mitochondrial 
bioenergetics194,198. It has also been proposed that the detrimental effects of palmitate 
in ECs can be alleviated by oleate192, highlighting the complex relationship between 
saturated and unsaturated lipids and how dyslipidaemia may lead to cellular 
dysfunction.  
 
It is important to note that, similarly to studies into HG, the available literature on 
palmitate exposure in brain ECs is limited. Zhou and colleagues report that palmitate 
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exposure in human BMECs indeed, similarly to peripheral EC models, reduces cell 
viability through increased apoptosis and furthermore impairs mitochondrial membrane 
potential (MMP)199. 
 
Dyslipidaemia also encompasses hypercholesterolaemia (that is an increase in VLDL and 
LDL). The association between high LDL and reduced vascular function is well 
established, with LDL catabolism being significantly reduced in diseases with high CVD 
risk such as T2D. Treatment with statins (to increase LDL metabolism and thus lower 
plasma LDL) shows marked improvements in EC function in humans. Oxidised LDL 
(oxLDL) is a proinflammatory molecule that is produced when LDL reacts with free 
oxygen radicals and it is heavily associated with ED and EA. OxLDL is reported to impair 
eNOS activity and promote foam cell formation, thus exacerbating vascular lesions. 
Interestingly, another type of cholesterol HDL can reverse oxLDL-mediated eNOS 
inhibition.  Decreased HDL levels are associated with diseases of overnutrition such as 
obesity and T2D. Furthermore, the two most widely used animal models of 
atherosclerosis are genetically manipulated to exhibit dysregulated cholesterol 
metabolism; LDL receptor KO mice (LDLR-/-) have delayed clearance of VLDL and LDL, 
therefore have elevated plasma levels of these lipids, whilst Apolipoprotein E KO mice 
(ApoE-/-) have impaired lipid uptake. This is because ApoE binds to lipids in the blood 
and transports them throughout the circulatory system. Without ApoE this process is 
dysfunctional, leading to dyslipidaemia and hypercholesterolaemia. 
 
Native LDL has been shown to reduce endothelial cell viability200, increase 
permeability201, enhance monocyte adhesion202, induce senescence203,204, and promote 
oxidative stress204 whereas glycated forms of LDL induce apoptosis, induce senescence, 
and reduce eNOS expression205. OxLDL has been reported to induce apoptosis206–208, 
increase ICAM206,209, VCAM209, E-selectin209 expression, decrease eNOS expression206, 
induce inflammation (TLR4/NF-κB207, TNFα208,209, IL-1β208–210, IL-8209), promote oxidative 
stress208–210, enhance monocyte adherence209,210, reduce ATP production211, and reduce 
MMP208.  
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More recent studies have investigated the effects of oxLDL on brain ECs and have 
reported that exposure to oxLDL can induce apoptosis212–214, promote senescence213, 
upregulate ICAM213, VCAM213,215, and E-selectin expression215, enhance monocyte 
adherence215, promote oxidative stress213,214, and reduce NO production213,214. 
 
These results strongly indicate that nutrient excess-associated pathologies such as 
hyperglycaemia, dyslipidaemia, and hypercholesterolaemia, can alter healthy EC 
function. Of note is the strong link between nutrient excess and impairments in 
endothelial cellular respiration. However, in comparison to peripheral ECs, little is 
known about brain ECs and how they fare under nutrient excess. The current in vivo 
literature is contradictory, and the in vitro studies are few and far between, especially 
regarding nutrient excess. Considering the absolute importance of healthy brain EC 
function to multiple processes (including cerebral haemodynamics, BBB integrity, 
nutrient transport) and furthermore that neurological complications are secondary to 
many metabolic diseases, it is imperative that further research into nutrient excess and 
brain ECs is undertaken. 
 
1.9 Endothelial cell metabolism 
 
For a long time, EC metabolism was largely overlooked, as they were thought of only as 
an inert blood vessel lining material. However, study of EC function and metabolism has 
gained significant interest over the past 20 years, as researchers begin to realise the 
absolute importance of EC function in health and disease. Most research into EC 
metabolism and fuel utilisation has been in the field of angiogenesis and tumor 
vascularisation. Therefore, relatively little is known about the preferred metabolic 
pathways in cerebral ECs.  
It has been reported extensively by Peter Carmeliet’s lab that ECs prefer not to maximize 
ATP production by shunting all of their glucose into oxidative phosphorylation (OXPHOS, 
1.10.4), but rely instead on glycolysis (1.10.1) for the vast majority of their ATP216. It was 
reported that coronary ECs anaerobically metabolise 99% of their available glucose (to 
produce lactate) and only 0.04% of their glucose was oxidized in the TCA cycle. Glucose 
shunting to aerobic respiration was increased only in glucose concentration lower than 
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1mM, a phenomenon known as the Crabtree/Warburg effect. Of note is that palmitate 
and lactate (substrates preferred by cardiac muscle) oxidation by coronary ECs are 
inhibited in the presence of glucose216. It is likely that FAs (1.10.3), as well as lactate 
(1.10.1), are transported through the coronary ECs to be used by cardiac muscle for 
fuel217. In HUVECs, others also found that glycolytic flux was estimated to be >200-fold 
higher than glucose oxidation flux218. These findings compliment studies that show 
mitochondrial content is significantly lower in ECs than other cell types; 5% in liver-
derived ECs vs. 28% in hepatocytes219, and that OXPHOS is not the main driver of ATP 
production in HUVECs220. 
 
The glycolytic nature of these peripheral ECs may be surprising, as one might assume 
ECs would make use of their close vicinity to oxygen in the blood. However, there are 
several benefits that ECs reap by using glycolysis over OXPHOS.  Firstly, ROS production 
(often generated by OXPHOS) is kept to a minimum221. Secondly, the lactate produced 
by the anaerobic glycolysis can function as a pro-angiogenic signalling molecule222,223. 
Third, the oxygen that is not consumed by ECs can diffuse into perivascular oxygen-
hungry tissues such as cardiac muscle. Furthermore, although glucose oxidation 
produces 10 times more ATP per molecule than glycolysis, ATP generation through 
glycolysis is far more rapid (when glucose is a nonlimiting factor)224, which would enable 
sprouting vessels to proliferate during angiogenesis.  
 
Fuel preference in cerebral endothelial cells has not been as extensively studied. 
Evidence suggests that brain endothelial cells harbor more mitochondria, indicating a 
higher capacity for OXPHOS225,226. Oldendorf and colleagues reported that 
mitochondrial volume accounted for 8-11% of total cytoplasmic volume in rat brain 
capillary ECs, which is 2-4 times the mitochondrial volume of peripheral ECs227. A study 
by Doll and colleagues investigated the role of mitochondria in brain EC function, 
particularly BBB permeability and effects on stroke127. The authors reported that 
inhibiting various parts of the electron transport chain (ETC, section 1.10.4) rapidly 
increased cell permeability in bEnd.3 cells, but did not induce cell death, indicating that 
mitochondrial respiration is key to healthy EC function. Wang and colleagues, who 
reported that rotenone (ETC inhibitor) exposure induced cell damage including 
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increased oxidative stress and increased lipid peroxidation, corroborated this data228. 
However, contrary to Doll and colleagues, the authors also reported increased 
apoptosis. Nevertheless, these studies give an insight into the importance of 
mitochondrial function in EC health, however it remains unclear what brain EC fuel 
preference is, in both health and disease, due to the lack of studies that directly compare 
them.  
 
1.10 The hypothalamus 
 
The hypothalamus can be thought of as the control centre of systemic metabolism, but 
is also involved in mediating circadian rhythm, cognition, hormonal regulation, and 
reproduction. In the hypothalamus, several groups of neurons communicate with one 
another to maintain metabolic homeostasis largely through appetite regulation and 
control of energy expenditure. Among them are the arcuate nucleus, (ARC), dorsomedial 
hypothalamus (DMH), ventromedial hypothalamus (VMH), paraventricular nucleus 
(PVN), and lateral hypothalamus (LH). In the ARC, an antagonistic interaction between 
neurons expressing agouti-related peptide (AgRP) and neuropeptide Y (NPY), and 
neurons expressing proopiomelanocortin (POMC) constitute the metabolic control 
centre (Fig. 1.8). Simply put, the AgRP/NPY neurons promote orexigenic behaviour 
through projections to the LH and PVN229. In addition, the Argp/NPY neurons participate 
in the control of energy expenditure by inhibiting thermogenesis of the brown adipose 
tissue230. The POMC neurons exert anorexigenic behaviour through connections to the 
PVN, LH, and VMH, and by releasing α-melanocyte-stimulating hormone (α-MSH), a 
processed protein product of POMC, to activate melanocortin receptors (MC4R) in the 
target neurons231. These processes are sensitive to hormonal signals from the periphery, 
including leptin, ghrelin, and insulin, as well as availability of nutrients like glucose and 
FAs. Due to its important role in regulating feeding behaviour and metabolic 
homeostasis, the ARC must be in close contact with the blood. For this reason, the 
capillaries comprising the BBB at the ARC are fenestrated, and evidence suggests that 
there are fewer cell-cell junctions between endothelial cells232,233. This allows for rapid 
diffusion of molecules that would not normally be able to pass through, meaning they 
can be detected by first order neurons in the hypothalamus that will then act 
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accordingly. The leakiness of the BBB at this site is obviously an advantage in terms of 
regulating metabolic homeostasis. However, it poses as a potential disadvantage as the 
hypothalamus is then vulnerable to the effects of pathologies associated with metabolic 
syndrome such as chronic hyperglycaemia, dyslipidaemia, and systemic inflammation. 
Therefore, the hypothalamus is an area of interest regarding nutrient excess and BBB 
leakiness.  
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Figure 1.8 Schematic representation of the antagonistic actions of AgRP/NPY neurons and POMC 
neurons in the hypothalamus 
AgRP/NPY neurons originating in the ARC promote feeding and reduce energy expenditure through 
projections to the LH and PVN. The POMC neurons decreased appetite and increase energy expenditure 
through connections to the PVN and LH by releasing α-melanocyte-stimulating hormone (α-MSH). These 
processes are sensitive to hormonal signals from the periphery, including leptin, ghrelin, and insulin, as 
well as nutrients such as glucose, amino acids (AAs), FAs. 
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1.11 Cellular respiration 
 
Cells require energy in the form of adenine triphosphate (ATP). This energy is produced 
through respiration, where the cell utilises fuel (glucose, amino acids, fatty acids) to 
generate ATP. Healthy cellular respiration is key to the cell’s functionality, and when 
respiration fails, cell stress and dysfunction is likely to occur. 
 
1.11.1 Glycolysis 
 
For a cell to use glucose as fuel, glucose must be converted to pyruvate via a process 
termed glycolysis (Fig. 1.9), which takes place in the cytosol. This process is anaerobic, 
meaning it does not require oxygen. Glycolysis produces a relatively low yield of ATP, 
with each 6-carbon molecule of glucose providing 2 molecules of pyruvate and 2 
molecules of ATP. Pyruvate may be metabolised (1.11.2) in order to provide substrate 
for OXPHOS (1.11.4), or it may be reduced to lactate by lactate dehydrogenase (LDH).  
 
1.11.2 Tricarboxylic acid cycle  
 
Before pyruvate can be further metabolised, it must enter the mitochondria via the 
mitochondrial pyruvate carrier (MPC), where it is transformed to acetyl coenzyme A 
(acetyl-CoA) by pyruvate dehydrogenase (PDH). Acetyl-CoA then enters the tricarboxylic 
acid (TCA) cycle. The TCA cycle (Fig. 1.10) is an important mitochondrial process that 
generates reducing equivalents to supply the ETC (section 1.10.4). 
 
1.11.3 Fatty acid oxidation 
 
Glucose is not the only source of fuel, and in many cells is not the preferred substrate. 
FAs found in the plasma, or stored triglycerides (TG), can be broken down and used for 
fuel via a process known as fatty acid oxidation (FAO; Fig. 1.11). For stored TGs to be 
used for fuel, they must first be hydrolysed by hormone sensitive lipase (HSL) to become 
FAs, which can then enter the mitochondria of the same cell for FAO or can then enter 
the blood to be transported elsewhere for FAO. As FAs are transported across the 
plasma membrane, it is possible that they are rapidly converted to acyl-coA, due to the 
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known acyl-CoA synthetase activity of FA transport proteins (FATP) or can be converted 
by long-chain acyl-coA synthetases (ACSL). The mitochondrial membrane is 
impermeable to acyl-CoA; therefore, it must use the carnitine shuttle to gain entry. 
Carnitine palmitoyltransferase I (CPT1) converts acyl-CoA to acylcarnitine. Membrane-
bound carnitine acylcarnitine translocase (CACT) exchanges acylcarnitiine for a carnitine 
molecule from inside the mitochondria, allowing acylcarnitine entry. Once inside, 
acylcarnitine is reconverted to acyl-CoA by CPT2 ready for FAO. During FAO, acyl-CoA is 
degraded to acetyl-coA by the process depicted in figure 1.5. Each cycle yields an acyl-
CoA that is shortened by two carbons, an acetyl-CoA, one NADH, and one FADH2. The 
shortened acyl-CoA will enter another round of FAO, acetyl-CoA will enter the TCA, and 
the electron carriers will deliver electrons to the ETC (see 1.10.4 Oxidative 
phosphorylation).  
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Figure 1.9 Anaerobic glycolysis 
To produce ATP from glucose, glucose must undergo conversion into pyruvate via glycolysis in the cytosol. 
Hexokinase (HK) catalyses the transfer of ATP-derived Pi to glucose, which produces glucose 6-phosphate 
(G6P). Phosphoglucomutase (PGM) isomerises G6P into fructose 6-phosphate (F6P) before 
phosphofructokinase (PFK) transfers Pi from an ATP molecule to F6P, producing fructose 1,6-bisphosphate 
(FBP). FBP is split by aldolase (ALDA) into dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-
phosphate (GAP), which are isomers of one another. DHAP is rapidly converted to GAP by the enzyme 
triose-phosphate isomerase (TPI). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) dehydrogenases 
GAP by transferring a hydrogen molecule to the oxidising agent nicotinamide adenine dinucleotide (NAD+) 
to form NADH + H+ and phosphorylates GAP to form 1,3-bisphosphoglycerate (BPG). BPG is 
dephosphorylated to 3-phosphoglycerate (3-PGA) by phosphoglycerokinase (PGK), producing an ATP 
molecule. Phosphoglyceromutase (PGlyM) move Pi to the second carbon to form 2-phosphoglycerate (2-
PGA). 2-PGA is dehydrated to form phosphoenolpyruvate (PEP) by enolase (ENO), which is then 
dephosphorylated by pyruvate kinase (PK) to produce pyruvate and ATP. 
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Figure 1.10 The TCA cycle 
For pyruvate to be further metabolised for energy, it enters the mitochondria via the pyruvate transporter 
(PyT) and is transformed to acetyl-CoA by pyruvate dehydrogenase (PDH). Acetyl-CoA then enters the 
tricarboxylic acid (TCA) cycle. The TCA cycle is an important mitochondrial process that generates reducing 
equivalents to supply the ETC (see Fig. 1.11). The first step in the TCA cycle is the transfer of an acetate group 
from acetyl-CoA to oxaloacetate, producing citrate. This step is catalysed by citrate synthase (CS). Aconitase 
(AH) catalyses the isomerisation of citrate to isocitrate. Isocitrate is converted to alpha-ketoglutarate by 
isocitrate dehydrogenase (IDH), simultaneously releasing CO2 a hydrogen molecule and transforming NAD+ 
to NADH and H+. Alpha-ketoglutarate dehydrogenase (OGDC) converts alpha-ketoglutarate to succinyl Co-A 
and produces CO2 and NADH and H+. Following this, succinyl Co-A releases its Co-A group to form succinate. 
Succinate dehydrogenase (SDH) is a unique enzyme that plays both an oxidation role in both the TCA cycle 
and OXPHOS. In the TCA cycle, SDH converts succinate to fumarate and reduces FADH to FADH2. Fumarate 
is converted to malate, which is then oxidized by malate dehydrogenase, forming oxaloacetate alongside 
NADH and H+. At the end of each TCA cycle, oxaloacetate is regenerated in order to begin the cycle again. 
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Figure 1.11 Fatty acid oxidation 
FAs are converted to acyl-CoA by long-chain acyl-CoA synthetases (ACSL). The mitochondrial membrane 
is impermeable to acyl-CoA; therefore it must use the carnitine shuttle to gain entry. Carnitine 
palmitoyltransferase I (CPT1) converts acyl-CoA to acylcarnitine. Membrane-bound carnitine acylcarnitine 
translocase (CACT) exchanges acylcarnitine for a carnitine molecule from inside the mitochondria, 
allowing acylcarnitine entry. Once inside, acylcarnitine is reconverted to acyl-CoA by CTP2 ready for FAO. 
During FAO, acyl-CoA is dehydrogenated to enoyl-CoA by acyl-CoA dehydrogenase (ACAD), which is then 
hydrated to 3-L-hydroxyacyl-CoA by enoyl-CoA hydratase (ECH). This is then dehydrogenated to β-
ketoacyl-coA by short chain 3-hydroxyacyl-CoA dehydrogenase (HADH), which undergoes cleavage by 
acyl-CoA:cholesterol acyltransferase (ACAT) to form another acyl-CoA molecule 2 carbons shorter than 
the original acyl-CoA, and acetyl-CoA, which can join the TCA cycle (see Fig. 1.10). The acyl-CoA (-2C) can 
continue undergoing FAO. Each cycle yields an acyl-CoA that is shortened by two carbons, an acetyl-CoA, 
one NADH molecule, and one FADH2 molecule. 
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1.10.4 Oxidative phosphorylation 
 
Oxidative phosphorylation (OXPHOS) is a highly utilised process that cells use to produce 
ATP as a result of the transfer of electrons from NADH or FADH2 to O2 by a series of 
electron carriers named the electron transport chain (ETC). The ETC (Fig. 1.12) consists 
of respiratory complexes I (NADH–ubiquinone oxidoreductase), II (succinate-ubiquinone 
oxidoreductase), III (ubiquinol-ferricytochrome c oxidoreductase) and IV (cytochrome c 
oxidoreductase; COX). The energy liberated during the oxidation of NADH and FADH2 
results in the movement of protons from the matrix to inter membrane space, forming 
an electrochemical proton gradient across the inner mitochondrial membrane (IMM). 
This membrane potential is utilised by ATP synthase (otherwise known as complex V) to 
produce ATP from ADP and one inorganic phosphate (Pi). Therefore OXPHOS can be 
thought of as an energy transduction system, which is coupled to (i) the substrate 
oxidation-driven electron transfer, (ii) the mitochondrial membrane potential (MMP), 
and (iii) ATP production234. However, not all energy generated by the ETC is used for ATP 
production. There exists an unavoidable diffusion of protons back across the IMM 
(referred to as proton leak) from the inter membrane space to the matrix, due to defects 
in the integrity of the IMM235. The extent of this proton leak indeed determines the 
coupling efficiency of OXPHOS to ATP production. In addition to proton leak, cells may 
induce proton leak through expression of uncoupling proteins (UCPs), which are proton 
ionophores and can pump protons across the IMM236.  
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Figure 1.12 Oxidative phosphorylation 
Oxidative phosphorylation (OXPHOS) takes place on the inner mitochondrial membrane (IMM). Reducing 
equivalents from the TCA cycle and FAO are oxidised by the respiratory complexes I and II. The produced 
electrons are transferred through the ETC. They enter at complexes I and II and are transferred to 
ubiquinone (UQ) then to complex III then to cytochrome c (Cyt c). They finally reach complex IV, where 
the electrons react with the final electron acceptor, O2 to form H2O. During the electron transferals, 
protons are pumped from the matrix into the inter membrane space through complex I, III, and IV. This 
results in an electrochemical gradient across the IMM, where the inter membrane space is more positively 
charged than the matrix. This is referred to as mitochondrial membrane potential (MMP). This 
electrochemical potential is used by complex V, ATP synthase, which pumps protons back to the matrix 
and with the energy acquired from that, undergoes a conformation change which facilitates the 
production of ATP from ADP + Pi. OXPHOS is incompletely coupled to ATP synthesis; protons can bypass 
ATP synthase and leak back into the matrix.  
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1.12 Mitochondria 
 
Mitochondria are membrane bound organelles present in almost all eukaryotic cells 
with the exception of red blood cells. They are thought to have originated when 
primitive prokaryotic bacteria were engulfed by anaerobic eukaryotes, and then 
permanently integrated into their structure. This is supported by the fact they carry their 
own residual genome known as mitochondrial DNA (mtDNA) encoding 13 proteins 
involved in the ETC237. They comprise an inner and outer membrane that separate and 
maintain regions known as the intermembrane space and the matrix. Mitochondria 
contribute to many cellular processes such as contributing to providing energy as ATP 
for the cell (1.10.4 Oxidative phosphorylation), Ca2+ signalling, ROS production and 
signalling, biosynthesis of amino acids, nucleotides, and cholesterol, and cell cycle and 
apoptotic control238. Furthermore, mitochondria are dynamic organelles, and are 
capable of shifting their shape (dynamics) and positioning (motility) within the cell239. 
They undergo processes known as fission and fusion (mitochondrial dynamics), where 
mitochondria will separate into 2 or more daughter mitochondria, or 2 or more 
mitochondria will fuse to create one elongated mitochondrion respectively239. 
Mitochondria number is tightly controlled through this dynamic process, as well as by 
mitochondrial biogenesis and mitophagy, ensuring a relatively constant mitochondrial 
population under homeostasis240. In certain pathologies, mitochondria can become 
dysfunctional. This dysfunction may encompass respirational failure, dysregulated 
mitochondrial dynamics, imbalances in biogenesis/mitophagy, excessive ROS 
production, or altered Ca2+ signalling. Mitochondrial dysfunction has been associated 
with a number of diseases, especially age-related disorders and diseases of nutrient 
excess, such as obesity, T2D, CVD, and dementia241.  
 
1.12.1 Regulation of mitochondrial dynamics  
 
As previously stated, mitochondria are dynamic organelles and the shape is largely 
dependent on a balance between fission and fusion. It is believed that mitochondrial 
bioenergetics (i.e. OXPHOS) is strongly dependent on mitochondrial morphology239. A 
number of different proteins have been proposed to contribute to mitochondrial 
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dynamics, including dynamin related protein 1 (Drp1), mitofusin 1/2 (Mfn1/2) and OPA1 
(Fig. 1.13). 
 
Drp1 is a GTPase that resides in the cytoplasm, which attaches and detaches 
mitochondria in cycles dependent on GTP availability, where high GTP induces 
recruitment of Drp1 to the outer mitochondrial membrane. Its assembly involves 
wrapping around the outer membrane of the mitochondria in a ring-like structure to 
facilitate fragmentation of the double membrane242. Some proteins have been 
suggested as docking receptors for Drp1, including Fis1 and mitochondrial fission factor 
(Mff), but the involvement of these proteins remains unclear. The role of Drp1 is 
absolute, however, in both mitochondrial morphology and in overall health; a study 
testing 4 different non-function mutations of Drp1 found that mitochondrial 
connectivity was greatly increased243, with the mitochondria appearing highly 
hypertubulated. Additionally, a person born with a dominant-negative Drp1 allele 
presented with extensive metabolic defects as well as abnormal neural development 
and died 37 days after birth244. Furthermore, Drp1 knockout mice have severe 
developmental abnormalities and are embryonic lethal245. Interestingly, the assembly 
of Drp1 involves formation of helices that are smaller than the diameter of the average 
mitochondria, suggesting that additional factors are indeed required to constrict the 
organelle and perform the scission action246. 
Figure 1.13 Mitochondrial dynamics 
Mitochondria can undergo fusion or fission events to form hypertubulated or fragmented mitochondria 
respectively. OPA1 and Mfn1/2 are the primary modulators of fusion, whereas fission is regulated by 
Drp1. 
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Mitochondrial fusion requires fusion of both the inner and outer mitochondrial 
membranes in a two-step process. IMM fusion is controlled by Optic atrophy 1 (OPA1), 
a dynamin-like protein that resides in the inner mitochondrial membrane. A total of 8 
isoforms of OPA1 are known, and it has been reported that homeostatic morphology of 
mitochondria is greatly dependent upon OPA1 cleavage and the balance of the long and 
short isoforms of OPA1247. Outer mitochondrial membrane (OMM) fusion is controlled 
by GTPases Mfn1 and 2. Genetic deletion experiments reveal that both Mfn1 and 2 are 
required for mitochondrial fusion248, although tissues do show differing expression 
patterns. For example, Mfn2 is expressed more than Mfn1 in the brain, but the opposite 
is true for the heart248. It is thought that Mfn1/2 have a role in tethering mitochondrial 
membranes249, but the exact mechanism as to how they control OMM fusion are 
unknown.  
 
1.12.2 Functionality of mitochondrial dynamics 
 
It has become apparent from numerous studies that the purpose of this tightly regulated 
fission/fusion process goes beyond the mere appearance of mitochondria and likely 
there is a functional role. Fission and fusion could be proposed as an inherent adaptive 
response that the mitochondria utilise to respond to cellular demand or stress. Healthy, 
normal cells respond to acute cellular stressors, partly by regulating mitochondrial 
dynamics, to restore cellular homeostasis. Issues arise when stress becomes chronic, 
leading to abnormal control of mitochondrial dynamics, resulting in mitochondria being 
‘stuck’ in the fused state, or rendering them incapable of undergoing fusion at all. If 
fission is left unregulated, it may lead to a heterogeneous population of organelles with 
differing mtDNA distribution, as well as a reduced ability to produce ATP, increased 
mitochondrial ROS (mROS) production and increased apoptosis. If fusion is left 
unregulated, fused mitochondria can no longer expel their damaged parts, potentially 
leading to a reduced ability to produce ATP, as well as increased mROS production. It is 
clear, therefore, that fission and fusion work in concert to maintain the shape, size, 
number and overall health status of mitochondria. 
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One of the most important consequences of fusion is the mixing of mitochondrial 
content. The mixing of content of the inner matrix seems critical, as the mitochondrial 
defects studied in OPA1-null cells are as severe as Mfn-null cells. Thus even when some 
outer membrane fusion is preserved, this is not sufficient to preserve mitochondrial 
function, suggesting inner matrix fusion is crucial250. Interestingly, fusion assays have 
shown that content mixing can occur between mitochondria even when the duration of 
their fusion event is extremely short-lived; this has been termed ‘kiss-and-run’251. This 
event has been observed to occur very frequently, highlighting its potential functional 
importance. Further studies need to be undertaken to elucidate this process; however, 
the model described below has been proposed by David Chan. Mitochondria have 
proteins that are encoded by their own mtDNA, but other important proteins that are 
required for mitochondrial function are imported from the cytosol. This means that 
individual mitochondria have the potential to act autonomously and have their own 
unique biochemical and functional profile, separate from other mitochondria. This 
would cause mitochondria to diverge. However, during fusion events contents of the 
mitochondria involved are briefly mixed and this may lead to more homogeneity 
between mitochondria, allowing them to function as a unit. Indeed, OPA-1-null and Mfn-
null cells exhibit greater mitochondrial heterogeneity252. Content mixing may also allow 
dispersing of mutant mtDNA, meaning that mitochondria can share the load, and harbor 
mtDNA mutations without any functional consequence. When mitochondrial fusion is 
disrupted the reduction in content mixing may be partly responsible for functional 
defects, such as reduced respiratory capacity. A mouse model carrying an error-prone 
mtDNA polymerase cannot tolerate dysfunctional fusion, corroborating this 
hypothesis253. An alternative view is that fusion events in this setting may in fact be 
detrimental, allowing persistence and spread of mutant mtDNA254. OPA1-null and Mfn-
null cells also exhibit reduced mtDNA nucleoid content, as well as defects in the 
distribution of mtDNA nucleoids throughout the mitochondrial population253,255. As 
mtDNA genome codes for crucial subunits of the ETC, nucleoid-lacking mitochondria are 
respiratory deficient. Indeed, reduced respiratory capacity has been observed in mouse 
embryonic fibroblasts252, Purkinje cells255, and skeletal253 and cardiac myocytes256 that 
lack either OPA1 or Mfn1/2. OPA1-null embryonic fibroblasts also exhibit severely 
abnormal cristae structure, which could potentially play a part in the respiratory defects.  
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Mitochondrial dynamics has also been implicated in mitochondrial-dependent 
apoptosis. For apoptosis to commence, mitochondria must release cytochrome c, 
amongst other pro-apoptotic factors, into the cytoplasm. Frank and colleagues have 
reported that mitochondria undergo increased fission and fragmentation close to the 
time of cytochrome c release and, interestingly, when Drp1 is inhibited, thus preventing 
mitochondrial fission, this prevents cytochrome c release, inhibiting cell death257. Other 
studies confirm this258,259, whilst fusion has been reported to be anti-apoptotic260,261. 
The role for Drp1 in regulating apoptosis has however been disputed by studies involving 
the Drp1 KO mouse262, amongst others263,264. Clearly, further investigation into the 
connection between fusion/fission and apoptosis needs to be performed. 
 
1.12.3 Mitochondrial dysfunction due to nutrient excess 
 
Mitochondrial dysfunction is associated with many metabolic and cardiovascular 
disorders. The capacity of an organism to adapt to different fuel availabilities is known 
as metabolic flexibility265 . For example, a healthy cell should have the ability to switch 
from TG breakdown and FA metabolism in a fasted state, to suppression of FA oxidation 
and enhanced glucose oxidation and upon stimulation with insulin (post-prandial)266. 
Healthy mitochondria can adapt to acute nutrient overload and increase their function 
to burn excess metabolites, usually with a subsequent physiological increase in ROS267. 
However, when nutrient excess becomes chronic and persistent, the oxidative capacity 
of mitochondria may be unable to efficiently burn the excess nutrients, resulting in 
nutrient overload in the cell (Fig. 1.14). This may lead to impaired respiratory capacity 
and ATP production, increased mROS, dysregulated Ca2+ signalling, and potentially 
apoptosis.  
 
Nutrient excess may cause mitochondrial dysfunction by saturating the TCA cycle and 
ETC, which would in turn reduce the capacity of the mitochondria to recycle electron 
acceptor molecules, highlighted in multiple HFD animal studies in varying tissues268–271. 
Furthermore, HFD has been shown to reduce MMP, thus affecting the rate of ATP 
generation272. Increased mROS production has been suggested as a major consequence 
of over-nutrition, with HFD and high-sucrose diet animal studies reporting increased 
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mitochondrial-derived H2O2 levels compared to controls273. Exposure to lard oil induced 
mitochondrial swelling in primary rabbit hepatocytes274, whilst high saturated fat-
feeding in mice decreased PPAR-γ coactivator 1-α (PGC1α) expression (potentially 
reducing mitochondrial biogenesis) and decreased enzymes associated with fatty acid 
oxidation and with the TCA cycle in epididymal white adipose tissue, indicating impaired 
mitochondrial function275. A study investigating high-saturated fat diet (HSD) on hepatic 
mitochondrial function in rats reported that HSD reduced mitochondrial respiratory 
capacity and increased ROS production276. In vitro studies have also furthered the 
understanding of how nutrient excess may lead to mitochondrial dysfunction. Palmitate 
exposure in both rat and human myoblasts impaired ATP production and furthermore 
altered how this ATP was used to fuel ATP-consuming processes, such as de novo protein 
synthesis, sodium pump activity, and DNA/RNA synthesis277. In a similar study, palmitate 
exposure in differentiated rat and human myotubes enhanced proinflammatory 
signalling pathways, promoted ROS generation, reduced mitochondrial respiratory 
capacity, reduced protein and mRNA expression of proteins key to mitochondrial 
function (e.g. PGC1α), and an increase in mitophagic particles278. Interestingly, however, 
palmitate was only able to induce these effects when glucose was present. When 
glucose was absent (either absent from the media or by using 2-deoxyglucose [2-DG]), 
it seemed that the cells were metabolically flexible enough to switch to using palmitate 
as fuel. These data suggest that the nutrient oversupply with both glucose and palmitate 
together poses a major substrate burden on mitochondria. It has been previously 
suggested that FAs not undergoing oxidation will accumulate as FA derivatives such as 
diacylglycerols and ceramide. These substances have been shown to further suppress 
mitochondrial activity.  
 
Indeed, mitochondrial exhaustion due to nutrient burden has been reported in many 
cell types and tissues, ranging from hepatocytes274, to neurons279, to skeletal muscle 
cells277. Some researchers report similar findings in ECs. Cultured peripheral ECs grown 
in HG (25mM) exhibited reduced basal mitochondrial respiration compared to ECs 
grown in LG (5mM), which further decreased as duration exposed to HG conditions 
increased280. Interestingly, chronic HG exposure seems to reduce carbohydrate 
oxidation (pyruvate, glucose), but enhance lipid and amino acid oxidation (glutamine, 
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palmitate), suggesting a switch in metabolic preference in HG conditions. Indeed, the 
authors report that they observed a shuttling of glucose toward anaerobic glycolysis 
rather than oxidation. Switching oxygen usage toward glutamine and fatty acid 
oxidation may be a mechanism to increase anaplerosis and replenish TCA intermediates. 
The chronic HG exposure in these cells also induced oxidative stress. Peripheral ECs 
cultured for 6 days in physiologically normal palmitate concentrations (100-150μM) 
exhibited reduced mitochondrial capacity compared to control, as well as increased 
ICAM expression and increased superoxide production198 
 
Mitochondrial dynamics is also vulnerable to nutrient excess. Cells exposed to nutrient 
rich environments tend to exhibit more fragmented mitochondria, and nutrient-starved 
cells tend to remain in their fused state for longer281,282. HSD feeding in rats also 
promoted fission over fusion by reducing Mfn2 and OPA1, and increasing Drp1 protein 
expression276. Nisr and colleagues also reported that exposure to nutrient overload 
(glucose and palmitate together) in rat myotubes resulted in a higher percentage of 
fragmented mitochondria, measured via confocal microscopy, which was accompanied 
by a modest increase in Drp1 and a modest decrease in Mfn2 protein expression278. 
These data, suggesting nutrient excess leads to mitochondrial fission, has been 
corroborated by others283,284.  
 
1.12.4 ROS production  
 
Mitochondria are an important site for ROS production. The main species produced by 
mitochondria is the superoxide anion (O2-), which is formed when O2 undergoes a one-
electron reduction. This reduction usually takes place at a redox-active center of a 
contributing protein (flavin mononucleotide, FeS center), or when electron donors (such 
as reduced coenzyme Q CoQH2) are bound to proteins, such as mitochondrial respiratory 
complexes285. Complex I is thought to contribute significantly to superoxide 
production286, but only under conditions which result in reverse electron transport (RET, 
Fig. 1.15). This occurs when electrons are transferred backwards from complex II to 
complex I through coenzyme Q, reducing NAD+ to NADH. It has been shown that this 
backwards movement of electrons produces high levels of O2-, due to coenzyme Q 
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(ubiquinone) becoming oversaturated in its reduction ability287. Electrons will then be 
transferred to O2. An oversupply of substrates to the ETC (hyperglycaemia, 
hyperlipidaemia), coupled with no complimentary increase in cellular ATP demand, may 
result in increased movement of electrons through the ETC, a high electrochemical 
mitochondrial membrane potential, increased RET, and therefore increased O2- 
production287.  
 
Interestingly, induction of uncoupling of mitochondria (by UCPs for example), which will 
dissipate the high membrane potential, is protective against O2- production286,288. 
Additionally, Dikalov and colleagues have shown that endothelial mitochondrial O2 - 
production may be dependent on NOX (Nox2 isoform in endothelial cells) activation, 
leading to the activation of RET289. Nutrient excess has also been linked to increased 
Nox2 activity290. 
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Figure 1.14 Regulation of cellular bioenergetics – supply and demand model 
In a balanced/healthy state, the ‘supply’ of nutrients is generally sufficient to sustain cellular ‘demand’. 
Nutrient excess characterised here as ‘excess supply’ in the absence of an increased cellular ‘demand’ 
results in a fuel-associated burden on the cell. The mitochondria can adapt to begin with, upregulating 
uncoupled mitochondrial respiration, i.e. inefficient waste of fuel in the form of heat. However, if the 
nutrient excess is chronic, the mitochondria will eventually become overwhelmed. Fuel that is not being 
used (to create ATP for cellular ‘demand’ or to waste energy as heat) may accumulate, leading to ROS 
production, mitochondrial dysfunction, and eventually cellular dysfunction and apoptosis.  
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Figure 1.15 Mechanism of reverse electron transport and superoxide production 
RET occurs when electrons are transferred backwards from complex II to complex I through ubiquinone, 
reducing NAD+ to NADH. Ubiquinone can become overwhelmed in its reduction ability, meaning 
electrons will then be transferred to O2, producing high levels of O2-. An oversupply of substrates to the 
ETC, accompanied by no increase in cellular energy demand, may result in increased movement of 
electrons through the ETC, a high electrochemical mitochondrial membrane potential, increased RET, and 
therefore increased O2- production. 
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1.13 BACE1 
  
Beta-site APP cleaving enzyme 1 (BACE1) is a membrane-associated aspartic protease, 
recognised as the β-secretase responsible for cleaving amyloid precursor protein (APP) 
in the amyloidogenic pathway291. BACE1 activity is thought to be highest in neurons, 
however BACE1 is expressed in multiple other tissues, including adipose tissue, 
endothelium, and muscle. BACE1 structurally consists of an N-terminal signal peptide 
sequence, a propeptide, a catalytic domain, a transmembrane domain and a cytoplasmic 
carboxy-terminal291. Importantly, BACE1 is subject to various post-translational 
modifications including cleavage to become mature BACE1, as well as palmitoylation 
and glycosylation. Indeed, an immature form of BACE1; pro-BACE1, with a molecular 
weight of approximately 58kDa is synthesised in the endoplasmic reticulum ER, which 
rapidly undergoes maturation in the golgi apparatus292. This stable and mature form of 
BACE1 runs during gel electrophoresis at approximately 70kDa, which is a greater mass 
than predicted for the protein suggesting BACE1 undergoes glycosylation293. BACE1 is 
most widely known for its role in cleaving APP but it is a promiscuous enzyme, which has 
been suggested to have at least 68 substrates294. Validated BACE1 substrates include 
the transmembrane proteins LDL receptor-related protein (LRP)295, neuregulins 1 and 
3296, P-selectin glycoprotein ligand-1 (PSGL-1)297, voltage-gated sodium channel 1-4 
(Nav1-4)298, and IL-1 type II receptor (IL1R2)299. These proteins have been implicated in 
lipid metabolism, myelination, leukocyte recruitment, neuronal excitability, and 
inflammatory responses respectively. We have also identified the insulin receptor as a 
potential substrate for BACE1300. These data suggest a role for BACE1, independent of 
amyloid, in both general regulatory physiology as well as pathophysiology of a range of 
neurological and metabolic disorders.  
 
1.13.1 APP processing 
 
The Alzheimer’s-related protein Aβ is produced by the cleavage of its parental amyloid 
precursor protein (APP), carried out by the enzyme complexes β- and γ-secretase. There 
is another secretase, denoted α-secretase, that can also cleave APP. ADAM10 is likely to 
be the main α-secretase in the brain. BACE1 has been identified as the primary β-
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secretase19, and the γ-secretase is a protein complex consisting of presenilin 1 and 2 
(PS1/PS2), nicastrin, anterior-pharynx defective1 (aph1) and presenlin enhancer 2 (Pen-
2). 
 
APP processing can be either non-amyloidogenic or amyloidogenic (Fig. 1.16), existing 
in a ratio of approximately 9:1 non-amyloidogenic:amyloidogenic. In the preferred non-
amyloidogenic pathway, α-secretase cleaves APP at a site 83 amino acids from the C-
terminus. It is important to recognise that at this step the α-secretase cleaves APP in 
such a way that the production of toxic Aβ from APP is not possible. This cleavage results 
in the release of the ectodomain termed soluble-APP α (sAPPα) into the extracellular 
space and the retention of membrane-bound C83, which is subsequently cleaved by γ-
secretase to produce the short p3 fragment. During amyloidogenic processing, APP is 
cleaved by β-secretase (i.e. BACE1) at a site 99 amino acids away from the C-terminus. 
This releases soluble-APP β (sAPPβ) and a peptide termed C99 is retained in the 
membrane. γ-secretase then cleaves C99 at varying sites, resulting in the production of 
Aβ peptides of different lengths, most notably A1-40 or Aβ1-42301. Indeed, C-terminal 
truncation of Aβ is determined by where the γ-secretase cleaves. A number of different 
forms of Aβ can be produced at this step. For example, a significant proportion of the 
Aβ found in the human AD brain consists of Aβx-40, where x is anything from 2-11302. N-
terminal truncated Aβ is thought to be produced as degraded product but emerging 
evidence suggests BACE1 may cleave APP at different sites depending on its location in 
the cell (ER, golgi body). Furthermore,  Aβ species can be pyroglutamated (AβpE3) at the 
N-terminus303 and this form of Aβ has been reported to be present in high abundance 
in AD brains302. However, the fact remains that Aβ1-40 and 1-42 are considered the most 
relevant; although only approximately 10% of Aβ produced consists of Aβ1-42, it is more 
prone to fibril formation and is the predominant form found in senile plaques.  
 
Amyloidogenic processing can be considered a stress response. Under certain stressors 
and disease states, there is a shift in APP processing toward the amyloidogenic pathway. 
Amyloidogenic processing of APP has been reported to increase during ageing304 and in 
the presence of metabolic disorders305–311. Indeed, BACE1 expression and activity 
increase in response to oxidative stress312, hypoxia313,  nutrient excess,306,308, and 
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inflammation314, pathologies that are known to be associated with not only metabolic 
disorders, but also neurodegenerative diseases. This concept is further elaborated on in 
section 1.13.2.  
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Figure 1.16 APP processing 
APP can follow either an amyloidogenic pathway or a non-amyloidogenic pathway. In the non-amyloidogenic 
pathway, APP is cleaved by an α-secretase to form sAPPα and a membrane bound fragment C83. C83 is 
cleaved by γ-secretase to form a membrane bound fragment AICD, and an extracellular fragment p3. In the 
amyloidogenic pathway, APP is cleaved by BACE1 (at a different site than α-secretase) to form sAPPβ and the 
membrane bound fragment C99. C99 is cleaved by γ-secretase at varying sites to form the membrane bound 
fragment AICD and Aβ peptides of varying length. Of note is that α-secretase cleave APP at a site (shown in 
red) that makes it impossible for Aβ peptides to be produce, hence ‘non-amyloidogenic’. 
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1.13.2 APP, BACE1, Aβ, and nutrient excess 
 
Numerous studies have indicated that nutrient excess can influence BACE1 expression 
and activity. We have shown that BACE1 protein expression is increased by exposure to 
palmitate, and its derivative ceramide in differentiated C2C12 myotubes306, and that HFD-
feeding in mice significantly increases hypothalamic BACE1 mRNA and protein308, as well 
as BACE1 protein in adipose tissue315. HFD-feeding in these mice also increased 
hypothalamic sAPPβ and Aβ42 protein levels, indicating increased BACE1 activity. Our 
collaborators corroborate these data, showing a HFD-dependent increase in BACE1 
protein and mRNA in murine muscle tissue307. BACE1 levels are also increased in the 
livers of the diabetic mouse model db/db300. Most recently, we reported that HFD 
feeding increases aorta and plasma Aβ42 in mice316. We also observed that in humans, 
BACE1 mRNA is increased in mammary arteries and adipose tissue of obese individuals, 
and Aβ42 is increased in plasma from people with T2D, and this increase correlates with 
HbA1c. (Botteri and colleagues further report increased BACE1 levels in adipose tissue 
and increased sAPPβ in plasma from people with T2D307. 
 
In terms of animal models of metabolic disorders, APP, BACE1, and Aβ have all been 
proposed as potential mechanisms of disease progression. We first reported in 2012 
that mice genetically void of BACE1 (BACE KO) are protected against HFD-induced 
obesity, have improved glucose tolerance, and improved insulin sensitivity317, which is 
partly dependent upon adipocyte-BACE1 (unpublished data). The APP(SWE)/PSEN1 
mouse model of AD, which presents with increased Aβ deposits in brain tissue, exhibits 
impaired glucose tolerance even when fed a normal chow diet310. Short-term HFD (8 
weeks duration) led to hypervulnerability to diet-induced weight gain, fasting 
hyperglycaemia, and reduced glucose tolerance in APP(SWE)/PSEN1 mice compared to 
controls310. Neuronal knock-in of BACE1 induces systemic diabetes, in that it causes 
impaired glucose tolerance and increased adiposity, alongside a fatty liver 
phenotype309,311. We reported in 2018 a role for BACE1 and Aβ in the development of 
obesity. We found that BACE1 KO mice are protected against diet-induced leptin 
resistance, in that the leptin-induced reduction in food intake is retained in these mice, 
with reduced hypothalamic NPY and AgRP expression, and increased POMC and CART 
 56 
expression308. Furthermore, pharmacological inhibition of BACE1 rescued diet-induced 
leptin resistance. Due to our findings that Aβ42 was increased in hypothalamic tissue, we 
intracerebroventricularly (icv) infused HFD-fed mice (6 weeks on diet) with Aβ42 versus 
scrambled peptide (ScrP) control and showed that Aβ42 infusion caused 
hypervulnerability to HFD-induce leptin resistance, with mice gaining more weight and 
being hyperphagic308. Our collaborators have also shown that injecting mice with sAPPβ 
intraperitoneally reduces insulin sensitivity307. Additionally, Franck Peiretti’s group 
exhibited a role for BACE1 in cleaving the insulin receptor, resulting in blunted insulin 
signalling300. Indeed, both BACE1 expression and plasma concentrations of cleaved 
insulin receptor (IRsol) are increased in db/db mice, whilst BACE1 KO mice exhibited 
reduced levels of IRsol.  
 
Aside from metabolic dysfunction, APP, BACE1, and Aβ have been implicated in the 
development of vascular disorders. BACE1 is expressed in both peripheral318, and brain 
endothelium319, and its expression and activity is susceptible to stress such as 
endothelial cell senescence318. As previously mentioned, we have also confirmed the 
expression of BACE1 in mouse aortic and human temporal arterial ECs316 and have 
further exhibited that BACE1 expression is increased by HFD-feeding (mice) and in 
obesity305,307,317. When we investigated endothelial function in our BACE1-/- mouse, we 
found that HFD-induced reductions in in vivo endothelial function were not as 
pronounced in BACE1-/- mice and furthermore mice lacking BACE1 exhibited increased 
aortic phospho-eNOS and phospho-PKB protein expression, and decreased ICAM 
expression316. Others report that overexpression of APP in mice resulted in a profound 
defect in neurovascular coupling, with a reduction in response of CBF to a 
somatosensory stimulus (whisker stimulation)320. In vivo CBF studies report that Aβ1-40, 
but not Aβ1-42 can impair neurovascular coupling (induced by whisker stimulation)320 and 
induce vasoconstriction in cerebral arteries independently, an effect that can be partly 
rescued by superoxide scavenging agents SOD and MnTBAP321 and NADPH-oxidase 
inhibition322. Further studies reported that the Aβ-dependent reduction in CBF was 
associated with reduced glucose utilisation323. This study was completed in a mouse 
model of cerebral amyloid pathology, but at a time point prior to plaque formation, 
suggesting that impairments to CBF and glucose metabolism due to smaller Aβ species 
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may be an early event in dementia progression. Park and colleagues corroborated this 
using the Tg-SwDI mouse model of amyloid. At 3 months of age when no amyloid 
deposition is present, mice still exhibited marked reductions in endothelium-dependent 
CBF regulation, a pathology that worsened with age324. These data highlight that 
endothelial dysfunction, due to increases in small Aβ species, may precede multiple 
dementia-causing diseases. However, it is important to note that many studies involving 
Aβ use knock-in animal models with extremely high levels of Aβ peptides that are not 
seen in human disease, or they use very high supraphysiological concentrations of Aβ 
(up to 10μM) that are topically applied directly to the cortex 30 minutes before CBF 
measurement, which is not physiological. A more useful study would be a chronic 
infusion of a physiological concentration of Aβ peptides and investigate in vivo how this 
may affect endothelial function. We undertook this investigation, and found that 
chronic peripheral Aβ42 infusion at physiological concentrations on a HFD-fed 
background (1 week diet, 4 weeks further infusion and diet) reduced endothelial-
dependent vasodilation in vivo, and reduced aortic phospho-eNOS and phospho-PKB 
expression and promoted ICAM expression when compared to ScrP control mice316. The 
physiological concentration of Aβ for these infusion studies was determined by the level 
that is found in murine plasma after 20 weeks HFD316. 
Perhaps paradoxically, Austin and colleagues reported that it is in fact the ED that 
precedes increased Aβ325. eNOS KO mice displayed increased brain APP and BACE1 
expression, and Aβ40 and Aβ42 production compared to control. This is unsurprising, 
considered APP and BACE1 protein levels are reported to increase under many cellular 
stresses, including oxidative stress326. Indeed, lack of eNOS or eNOS function is 
associated with increased oxidative stress327,328, and it may be that the elevated brain 
APP and BACE1 expression, and Aβ40 and Aβ42 production compared is due to the 
oxidative stress phenotype. However, it must be considered that there may exist a feed-
forward mechanism, in that raised BACE1 activity and Aβ production due to nutrient 
excess reduced eNOS activity, which can in turn further induce BACE1 activity.  
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1.13.3 APP, BACE1, Aβ, and mitochondria 
 
APP processing has been implicated in regulating mitochondrial function. APP is 
localised to the mitochondrial outer membrane in AD human brains329, and 
mitochondrial Aβ accumulation is seen in AD human and transgenic AD mouse model 
brain tissue245,330. Of interest, mitochondrial Aβ accumulation in AD mouse models was 
seen prior to Aβ plaque deposits, again suggesting that Aβ-dependent metabolic 
dysfunction might precede disease onset331.  
 
Multiple animal APP transgenic studies have demonstrated a role for APP processing in 
mitochondria dysfunction. Hauptmann and colleagues reported reduced mitochondrial 
capacity, reduced MMP, and reduced ATP production in isolated brain mitochondria 
from Thy-1 APP mice, a double Swedish and London mutant APP transgenic mouse332. 
This data was corroborated by Keil and colleagues, who used the same mouse model 
and demonstrated reduced ATP levels and MMP in brain tissue333. In addition, 
Caspersen and colleagues observed, in a human mutant APP mouse, reduced oxygen 
consumption and reduced enzymatic activity of proteins involved in OXPHOS331. In vitro, 
APPswe overexpression in a neuronal cell line increased ROS production, decreased 
MMP, and reduced ATP production334. Aside from respiratory function, APPswe 
overexpression has been observed to impair mitochondrial morphology and 
distribution. Indeed, Wang and colleagues demonstrated a higher percentage of 
fragmented mitochondria via electron microscopy in cells overexpressing APPswe, as 
well as a reduction in OPA1, Mfn1/2, and an increase in Fis1 protein expression334. These 
defects were rescued through BACE1 inhibition, indicating the detrimental effects 
caused by APP overexpression may be dependent on sAPPβ or Aβ. The authors also 
report a positive correlation between the concentration of Aβ in cellular media and the 
percentage of cells that exhibited extensive fragmented mitochondria. It has been 
demonstrated that BACE1 overexpression in cultured skeletal muscle myotubes impairs 
glucose metabolism and reduced mitochondrial oxygen consumption, an effect that can 
be rescued by BACE1 inhibition306. BACE1 overexpression in neuronal SH-SY5Y cells also 
altered glucose metabolism, by inhibiting glucose oxidation, and compensating by 
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increasing glycolysis335. BACE1 overexpression also reduces alpha-ketoglutarate 
dehydrogenase and isocitrate dehydrogenase, indicating BACE1-dependent lesions in 
TCA cycle activity. Furthermore, BACE1 overexpression lead to a reduction in PDH, thus 
uncoupling glycolysis from OXPHOS. In our BACE1-/- model, we also observed increases 
in UCP2 and UCP3, indicating reduced metabolic efficiency317. These data suggest that 
in the present of raised BACE1, mitochondria have a reduced capacity to cope with 
metabolic stressors, resulting in mitochondrial dysfunction. 
 
The literature is lacking in terms of amyloid and endothelial mitochondrial function. 
Vessels exhibiting CAA exhibit reduced haemodynamics and integrity, however it is 
unclear the extent to which mitochondria contribute to this. One study investigated the 
effects of Aβ40-Q22 (form of Aβ peptide produced with the Dutch mutation) on cultured 
ECs. Aβ40-Q22 incubation at 50μM induced apoptosis, reduced MMP, promoted 
oxidative stress, and reduced mitochondrial Ca2+ concentrations336. However, the study 
does not report any real-time mitochondrial physiological data, and utilises extremely 
supraphysiological concentrations of Aβ, and thus the effect of Aβ on this aspect of 
mitochondrial function remains unknown. 
 
1.14 Project aims and hypotheses 
 
Taken together, there is a potential role for nutrient excess-induced mitochondrial 
dysfunction in the development of ED. ED is a common pathology for non-
communicable diseases such as obesity, T2D, CVDs and dementias. Specifically, nutrient 
excess may induce impairments in mitochondrial dynamics, leading to reduced 
mitochondrial function and thus ED. Nutrient excess is associated with increases BACE1 
activity and increased Aβ levels. We have shown previously that increased Aβ42 can 
induce dysfunction in peripheral ECs, but it is unknown whether this is also true of brain 
ECs. 
 
Therefore, the main objective of this project was to investigate the contribution of 
nutrient-excess induce raised BACE1 activity, and thus Aβ42 production on the onset of 
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endothelial dysfunction. Furthermore, the project sought to investigate the underlying 
molecular mechanism of this process by investigating endothelial mitochondrial 
dysfunction. 
 
The knowledge gained from this research project may provide potential mitochondrial-
related therapeutic targets in the treatment of EC dysfunction, perhaps slowing the 
progress of multiple diseases associated with this pathology, including dementia-
causing diseases. 
 
1.15 Objectives 
 
1) To investigate whether endothelial function is impaired in animal models of nutrient 
excess and determine whether any effects seen are associated with impaired 
mitochondrial dynamics. 
• Using two models of nutrient excess (6-month old short-term HFD-fed and db/db 
mice), in vivo endothelial function will be measured. 
• Tissues of interest (aorta, VE fraction unit, hypothalamus) will be examined to 
investigate whether mitochondrial dynamics are altered in these models of 
nutrient excess. 
 
2) To investigate the role of BACE1 and Aβ42 in endothelial function in vivo and 
determine whether any effects seen are associated with impaired mitochondrial 
dynamics. 
• Using models of varied BACE1 activity (BACE1KO, APP23, and HFD-fed Aβ42 icvly-
infused), in vivo endothelial function will be measure in these models. 
• Tissues of interest (aorta, VE fraction unit, hypothalamus) will again be examined 
to investigate whether mitochondrial dynamics is altered in these models. 
 
3) To investigate the effects of both nutrient excess and increased Aβ42 levels on 
mitochondrial function in a brain endothelial cell line. 
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• A brain endothelial cell line cultured in a high glucose and high palmitate 
environment will be examined to investigate how nutrient excess affects 
mitochondrial function using extracellular flux analysis. 
• The effects of chronic exposure of cells to Aβ42 will be examined to help 
determine whether any changes in mitochondrial function due to high 
glucose/high palmitate are exacerbated by the presence of Aβ42.
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Chapter 2 
Materials and methods 
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2.1 General 
2.1.1 Chemicals, reagents, and materials 
 
All chemicals and commonly used lab reagents were purchased from Sigma Aldrich or 
Invitrogen (ThermoFisher) unless otherwise stated. Chloroform, methanol, ethanol and 
Moxi cell counting strips were purchased from VWR. Isopropanol was purchased from 
ThermoFisher. Cell culture plastic-ware were purchased from Nunc (ThermoFisher), as 
were all Taqman probes. Acrylamide solution was purchased from National Diagnostics. 
EDTA-coated tubes were purchased from Sai Infusion Technologies. Minipumps were 
purchased from Alzet. Amyloid beta 1-42 (Aβ42) and scrambled peptide were purchased 
from Bachem. Anti-body manufacturers are given in Table 2.7. 
 
2.1.2 Statistical analysis 
 
All data are expressed as mean ± standard error of the mean. Statistical analysis was 
carried out using GraphPad Prism 8. Statistical tests are stated in figure legends. A p 
value ≤0.05 was considered statistically significant, with levels of significance denoted 
at * = p≤0.05, **, = p≤0.01, *** = p≤0.001. In some instances, # and $ are also used to 
denote significance. Data were proved to follow normal distribution by using the Shapiro 
Wilk’s test. Unpaired t-tests with Welch’s correction were used for data sets with only 
two groups, Welch’s ANOVA was used for data sets with 3 or more groups (post hoc 
Dunnett’s), and for two factorial analysis, two-way ANOVA was used. Post-hoc tests 
(Bonferroni) were conducted when Welch’s or two-way ANOVAs were significant (p < 
0.05) to compared differences between groups. It should be noted that the non-
parametric tests Kruskal Wallis and Mann Whitney were considered for the data herein 
due to the small sample sizes as well as the fact some data is normalised as fold change. 
However, these tests assume equal variances between groups and thus utilise a pooled 
standard deviation. For the data sets herein, the sample size is too small for the 
variances between groups to be equal. Thus, Welch’s corrections need to be performed 
hence the use of the afore-mentioned tests.  
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2.1.3 Power calculations 
 
Power calculations are performed in order to estimate the required sample size for an 
experiment, given a desired significance level (usually 0.05), effect size (difference between 
group means), and statistical power (usually 0.8). The sample sizes used here were based on 
previous power calculations performed by Dr. Paul Meakin. However, it became clear that the 
studies performed for this PhD project were underpowered and thus post-hoc power 
calculations were performed. Herein, post-hoc power calculations were mostly used to estimate 
sample size required to test significance sufficiently for the studies herein that exhibited a trend 
(estimated by graph appearance or by p < 0.1)337. Further, for pilot studies such as the in 
vitro real-time mitochondrial respiration studies found in Chapter 5, power calculations were 
performed on these data to estimate sample size for follow-up studies. The following formula 
was used to calculate sample size: 
 
  
where  
μA is the mean of one group and μB is the mean of the second group 
κ=nA/nB is the matching ratio 
σ is standard deviation 
Φ is the standard normal distribution function 
Φ-1 is the standard normal quantile function 
α is the Type I error 
β is Type II error 
thus 1 – β is power 
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2.2 Animals studies 
 
Animal procedures were performed in accordance with Home Office guidelines with 
project licences PPL 70/9068 (September 2016 – February 2018) and PLL P0A1F4C5 
(February 2018 onwards) held by Professor Michael LJ Ashford, personal license PIL 
ID046E63B held by Bethany Mae Coull and personal license PIL I6174C440 held by Dr 
Paul Meakin. All procedures were approved by the local ethics board and the Dundee 
University Named Veterinary Surgeon, Ngaire Dennison. 
 
2.2.1 Maintenance of animal lines 
 
All animals were maintained on a 12-hr light/dark cycle at constant temperature and 
provided with ad libitum access to food (normal chow [NC]: 7.5% fat, 17.5% protein and 
75% carbohydrate by energy) and water. For mice on high fat diet (HFD) studies, mice 
were initially provided with a 50/50 NC/HFD for 1 week before switching to 100% HFD 
(45% fat, 20% protein, 35% carbohydrate by energy) for the remainder of the study. 
Details of animal studies are given in introduction sections of the individual results 
chapters. 
 
2.2.2 Tissue harvest 
 
At the end of studies, mice were sacrificed by cervical dislocation and subsequent 
severance of a major artery. Tissues were excised and dissected as necessary. Tissue for 
mRNA and protein analysis were snap frozen in liquid nitrogen. Hemi-brains for vessel 
enriched fractions were processed using the procedure described in Methods 2.6.1. 
Blood was collected in an EDTA-coated tube (Sai Infusion Technologies, PMTP-E-1.3) and 
centrifuged at 2500g for 10 minutes at 4°C to separate plasma. Plasma supernatant was 
removed and snap frozen in liquid nitrogen in a 1.5ml Eppendorf™™. 
 
2.2.3 Creation of the BACE1 knockout mouse 
 
BACE1 KO mice were generated by GlaxoSmithKline on a C57BL6/J background and 
maintained in-house at the Medical Science Resource Unit (MSRU), Ninewells Hospital 
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& Medical School, University of Dundee. Mice were produced by the insertion of the 
LacZ reporter gene in place of exon 1 of BACE1 gene338. Mice were bred in-house het x 
het in order to produce WT, heterozygous, and BACE1 KO mice. 
2.2.4 Diabetic (db/db) mouse model  
 
The db/db mouse was first described by Hummel et al.339. Mice homozygous for a 
spontaneous single point mutation (G → T, intron 18) in the leptin receptor gene exhibit 
morbid obesity, hyperglycaemia and pancreatic β cell dysfunction. Obesity starts at 3-4 
weeks of age, with elevated plasma insulin appearing at around 10-14 days and elevated 
blood sugar at 4-8 weeks. The point mutation produces a Gly to Thr mutation in the 
leptin receptor gene on chromosome 4, resulting in abnormal mRNA splicing and the 
subsequent production of a non-functioning Ob-Rb (LepR long-form) protein and thus, 
dysfunctional Ob-Rb signalling. 4 male and 4 female mice heterozygous for the mutation 
were purchased from Jackson Laboratories (BKS.Cg-Dock7m +/+ Leprdb/J; #00062) to 
initiate a breeding colony. Mice were bred het x het in order to obtain wt/wt, wt/db, 
and db/db mice. 
 
2.2.3 DNA extraction from ear notches 
 
Ear notches were taken from mice and placed into a 1.5ml Eppendorf™ tube. A master 
mix containing 100μl extraction buffer (Sigma Aldrich; E7526) and 25μl tissue 
preparation solution (Sigma Aldrich; T3073) per sample was made and 125μl added to 
each notch. The samples were incubated at room temperature for 10 minutes and then 
heated for 3 minutes at 95°c in a bench-top heat block, after which 100μl neutralization 
buffer (Sigma Aldrich; N3910) was added to each sample. Samples were kept at -20°c 
until required. 
 
2.2.4 Genotyping the BACE1 knockout mouse 
BACE1-/- mice were genotyped using PCR amplification of both BACE1 and LacZ genes 
using KOD hot start DNA polymerase in two separate reactions. BACE1 was detected 
using the forward primer 5’-CGC TGC ACT GGC TCC TGC TAT GGG-3’ and the reverse 
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primer 5’-TCT CCA CAT AGT CCT GGC CGG-3’. LacZ was detected using the forward 
primer 5’-GAC CAG CCC TTC CCG GCT GTG CCG-3’ and the reverse primer 5’-GCC GAC 
CAC GGG TTG CCG TTT TCA-3’. Contents of the PCR reactions contained 1x KOD buffer, 
1.5mM MgSO4, 0.2mM dNTPs, 0.02U/μl KOD hot start DNA polymerase and 0.15μM 
forward and reverse primers. Reactions used 2.5μl of DNA template from ear notches 
and were made up to 25μl total reaction volume using sterile nuclease-free H20. PCR 
was completed using a Veriti Thermal Cycler (Applied Biosystems, 4375786) in the 
thermocycler conditions listed in Table 2.1. 
Once the PCR amplification was completed, 5μl of 6X Blue/Orange loading dye 
(Promega, G2101) was added; final concentration 1X. 10μl of PCR product was loaded 
on to a 1% w/v agarose/1X TAE buffer gel containing 0.01% v/v SYBR Safe DNA Gel Stain 
(Invitrogen, SS33102). One well contained 5μl of 100bp DNA ladder (Promega, G2101). 
Gels were subjected to 110V for 35-40 minutes in 1X TAE buffer (Sigma, T9650) and 
visualised with UV light using a Bio-Rad ChemiDoc MP Imaging System. BACE1 and LacZ 
bands are present at 200bp and 299bp respectively. WT mice exhibit the BACE1 band. 
Heterozygous mice exhibit a band for both genes. BACE1-/- mice lack the band for BACE1 
but express the LacZ band. Fig. 2.1 shows an example gel of BACE1 genotyping. 
 
2.2.5 Genotyping the db/db mouse 
 
All db/db genotyping was optimised and performed by Dr Fiona McLean using a 
modified protocol from Peng and colleagues340. Single point mutations are historically 
difficult to genotype for. The technique the authors developed for db/db genotyping is 
referred to as tetra-primer amplification refractory mutation system-polymerase chain 
reaction (ARMS-PCR). Tetra-primer amplification exploits the use of four primers. There 
are two outer primers (forward and reverse, FO and RO) that bind a site outside the 
target DNA and act as an internal control. There are also two inner primers (a forward 
WT primer and reverse mutant primer) that bind the target DNA site, which is the site 
of the single point mutation herein.  The primer sequences are as follows: 
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FO:      TTGTTCCCTTGTTCTTATACCTATTCTGA 
RO:      CTGTAACAAAATAGGTTCTGACAGCAAC 
WT:      ATTAGAAGATGTTTACATTTTGATGGAAGG 
mutant:   GTCATTCAAACCATAGTTTAGGTTTGTCTA 
 
 
Table 2.1 Thermocycler conditions for BACE1 genotyping 
  
  
Step Temperature (°C) Duration 
1. Polymerase activation 95 2 minutes 
2. Denaturation 95 20 seconds 
3. Annealing 62 15 seconds 
4. Extension 70 7 seconds 
Repeat steps 2-4 x 35 cycles 
Hold at 4°C 
WT HET KO
BACE1	primer
LacZ primer
200	b.p.
300	b.p.
Figure 2.1 Genotyping of BACE1 knockout mice
An ear notch was taken from each mouse and the DNA was extracted as
described in section 2.2.3. Genotyping was performed as described in section
2.2.4. The figure shows an agarose gel ran with PCR products. BACE1 primers
and LacZ primers were used to identify the genotype of each mouse. WT mice
will express the BACE1 gene and no LacZ gene, HET mice will express a copy of
each, and BACE1KO mice will express no BACE1 gene, but will express the LacZ
gene.
200	b.p.
300	b.p.
Figure 2.1 Representative genotyping gel for BACE1 KO mouse line 
An ear notch was taken from each mouse and the DNA was extracted as described in section 2.2.3. 
Genotyping was performed as described in section 2.2.4. The figure shows an agarose gel exhibiting the 
relevant PCR products. BACE1 primers and LacZ primers were used to identify the genotype of each mouse. 
WT mice will express the BACE1 gene and no LacZ gene, HET mice will express a copy of each, and BACE1KO 
mice will express no BACE1 gene, but will express the LacZ gene.  
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The forward WT primer matches the WT target gene, whereas the reverse mutant 
primer sequence does not. Taq polymerase lacks proofreading activity and therefore 
cannot correct this mismatch. This means that when the Taq polymerase is amplifying 
the WT target DNA using the forward WT primer template in combination with the 
reverse outer primer, the DNA is amplified. However, when it tries to amplify the WT 
target sequence using the reverse mutant primer in combination with the forward outer 
primer, it gives up when it reaches the single point mutation. The opposite is true when 
the Taq polymerase attempts to amplify the mutant primer sequence. The PCR thus 
results in 3 potential products: the common amplicon targeted by the outer primers 
(610 b.p.), the WT amplicon targeted by the forward WT and reverse outer primers (264 
b.p.), and the mutant amplicon targeted by the reverse mutant and the forward outer 
primers (406 b.p.). Contents of the PCR reactions contained 12.5μl of Promega PCR 
Master Mix (Promega, M75020, 0.5μl of 10mM FO-1, 0.5μl of 10mM RO-1, 0.5μl of 
10mM FI-1, 0.5μl of 10mM RI-1, 9.5μl nuclease-free water, and 1μl extracted template 
DNA. PCR was completed using a Veriti Thermal Cycler in the thermocycler conditions 
listed in table 2.2. Once the PCR amplification was completed, 5μl of 6X Blue/Orange 
loading dye to produce a final concentration of 1X. 10μl of PCR product was loaded on 
to a 1% w/v agarose/1X TAE buffer gel containing 0.01% v/v SYBR Safe DNA Gel Stain, 
with one well containing 5μl of 100bp DNA ladder. Gels were subjected to 120V for 50 
minutes in 1X TAE buffer and visualised with UV light using a Bio-Rad ChemiDoc MP 
Imaging System. A representative genotyping gel is shown in Fig. 2.2. 
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Table 2.2 Thermocycler conditions for db/db genotyping 
 
 
  
Step Temperature (°C) Duration 
1. Polymerase activation 94 5 minutes 
2. Denaturation 95 30 seconds 
3. Annealing 55 30 seconds 
4. Extension 68 1 minute 
Repeat steps 2-4 x 40 cycles 
Hold at 4°C 
WT HET DB/DBWT
200 b.p.
300 b.p.
400 b.p.
600 b.p.
Figure 2.1 Representative db/db genotyping gel 
An ear notch was taken from each mouse and the DNA was extracted as described in section 2.2.3. 
Genotyping was performed as described in section 2.2.5. The figure shows an agarose gel exhibiting the 
relevant PCR products. All mice will express the common amplicon at 610 b.p, wt mice will express the 
WT amplicon at 264 b.p., db/db mice will express the mutant amplicon at 406 b.p., and heterozygous 
wt/db mice will express both. 
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2.2.6 APP23 mice 
 
APP23 mice are a genetic model normally used for studying AD. Indeed, mutations in 
the App gene are linked to familial AD and APP23 mice in particular express, under the 
Thy1 promoter, the human isoform 751 of APP harbouring the Swedish double mutation 
(APP751*K670N/M671). These mice exhibit extensive β-amyloid pathology at 3-6 months 
of age341. 16 10-week old male hemizygote APP23 mice were purchased from Jackson 
Laboratories (Jax#030504) and were allowed two weeks to habituate to their new 
environment. Within this time, 4 APP23 mice were found dead, leaving 12 to undergo 
peripheral minipump surgery (2.4.2). Post-surgery, a further 4 APP23 mice were found 
dead/had to be euthanised, leaving a total of 8 (4 per treatment). 
 
2.3 Metabolic phenotyping 
2.3.1 Glucose tolerance test 
 
Glucose tolerance tests are used to study the physiological ability of the mouse to 
dispose of a bolus of glucose. Mice were fasted for 16 hours prior to glucose tolerance 
testing. Blood was extracted via a small tail nick at the tip of the tail. Blood glucose 
(whole blood) measurements were made using a glucometer (Contour, Bayer, 
83785579) and glucose test strips (Contour, Bayer, 85723154). Mice were injected 
intraperitoneally (i.p.) with 2mg/kg D-glucose (dissolved in PBS) with blood glucose 
levels assessed pre-injection and then 15, 30, 45, 60, and 120 minutes post-injection. 
 
2.3.2 Insulin tolerance test 
 
Insulin tolerance tests are used to study the insulin sensitivity (measured by 
disappearance of glucose from the blood) of the mouse. Mice were fasted for 4 hours 
prior to insulin tolerance testing. Blood was extracted via a small nick at the tip of the 
tail. Blood glucose (whole blood) measurements were made using a glucometer 
(Contour, Bayer, 83785579) and glucose test strips (Contour, Bayer, 85723154). Mice 
were injected i.p. with 0.75U/kg insulin (Actrapid) diluted in PBS with blood glucose 
levels assessed pre-injection and then 15, 30, 60, 90, and 120 minutes post-injection. 
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2.4 Surgery 
 
All surgeries were performed using aseptic technique. All subcutaneous mini-pump and 
icv mini-pump surgeries were performed by Bethany Mae Coull. Surgical assistance was 
given by Dr Fiona McLean (subcutaneous) and Christie Hancock (icv).  
 
2.4.1 Anaesthesia 
 
Using anaesthetic apparatus (Vettech, AN002A) mice were anaesthetised by a mix of 
3.5% isoflurane (Covetrus, 1169567761) and oxygen (compressed oxygen cylinder size 
E, BOC Medical) delivered at a flow rate of 1-1.5 litres per minute. Mice were maintained 
at a steady depth of anaesthesia, detected by a toe pinch reflex test and observation of 
breathing (optimal = ~55-60 breaths per minute), using a mix of 1-1.5% isoflurane and 
oxygen delivered at 1-1.5 litres per minute.  
 
2.4.2 Peripheral mini-pump surgery 
 
Under anaesthesia, mice were shaved with an electric razor (Wella Contura) to remove 
the fur from the base of the neck and across the upper back. Mice were placed on a heat 
mat for the duration of the surgery in order to help maintain body temperature. Mice 
were injected subcutaneously with 1ml/kg of the analgesic agent Rimadyl (Covetrus, 
6451506845), which had previously been diluted 1:10 with sterile medical saline. The 
skin was sterilised using 1% betadine and 70% ethanol. An incision of around 4 cm was 
made across the upper back. Using blunt dissection, a small pocket was made under the 
skin on the left flank. A subcutaneous minipump (Alzet, 0000298), containing either a 
solution of 3.36µg/kg Aβ42 (Bachem, 4035885.05) or ScrP (Bachem, 4064835.05) was 
placed into the pocket. This Aβ42 concentration was chosen as when it is infused for the 
stated length (4 weeks) of time it results in similar circulating Aβ42 concentrations to 
DIO-induced circulating amyloid concentrations316. For APP23 inhibitor studies, BACE1 
inhibitor M-3 was delivered at 10 mg/kg/day, or vehicle control (50:50 DMSO:PBS). We 
have previously reported that this concentration of M-3 is sufficient to reduce BACE1 
activity and produce a functional output in BACE1-regulated processes, such as 
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hypothalamic leptin action and food intake305. Skin was then glued using the veterinary 
topical adhesive GLUture (ThermoFisher, NC0632797). Mice were placed in baby 
incubators at 37°c to recover for around 30-60 minutes and were monitored closely the 
following week post-surgery. Mouse welfare was monitored using conventional body 
condition scores as well as food/water intake and weight measurements342.   
 
 2.4.3 Intracerebroventricular mini pump surgery 
 
Under anaesthesia, mice were shaved with an electric razor to remove the fur from their 
heads and necks. Mice were placed on a heat mat for the duration of the surgery and 
were placed in a stereotaxic frame, secured via a tooth bar and ear bars. Mice were 
injected subcutaneously with 1ml/kg of the analgesic agent Rimadyl which had 
previously been diluted 1:10 with sterile PBS. The skin was sterilised using 1% betadine 
and 70% ethanol. An incision of around 5cm was made from between the eyes to the 
base of the neck to expose the skull. The skin was pulled to either side and clipped back 
to ensure the skull would stay exposed. Using blunt dissection, a small pocket was made 
under the skin on the left flank. A subcutaneous minipump containing either a solution 
of Aβ42 or ScrP (3.36ug/kg) was placed into the pocket. This concentration was chosen 
as, when infused for the stated length of time (4 weeks), it results in similar 
hypothalamic Aβ42 concentrations to DIO-induced hypothalamic amyloid 
concentrations305. The intracerebroventricular (icv) catheter was placed in the 
stereotaxic frame and was inserted through the skull into the right lateral ventricle using 
stereotaxic coordinates: -0.46 anterior/posterior, +1 lateral. The cap was adhered to the 
skull using super glue and the wound then glued using the veterinary topical adhesive 
GLUture. Mice were placed in baby incubators at 37°c to recover for around 2 hours and 
were monitored closely the following week post-surgery. Mouse welfare was monitored 
using conventional body condition scores as well as food/water intake and weight 
measurements.   
 
2.5 Laser Doppler flowmetry 
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Cutaneous microvasculature is an easily accessible vascular bed for the assessment of 
vascular function in vivo in both humans and rodents. Dysfunctional microvasculature 
has been associated with the development of CVD343–345, and has been reported to be a 
good predictor of cerebrovascular dysfunction346, and white matter lesions and 
cognitive impairment347. Therefore, assessing the microvasculature to measure vascular 
dysfunction is a good method for studying animal models of CVD, and may be a useful 
tool in researching the link between peripheral vascular disturbances and 
cerebrovascular impairments. However, it should be noted that peripheral ECs and brain 
ECs do differ from one another in terms of structure and function, and the peripheral 
microvasculature is not an absolute measure of cerebral microvasculature. 
 
Since the commercialisation of the technique in the 1980s, laser Doppler flowmetry 
(LDF) has become one of the most widely used methods to study microcirculation in 
vivo. LDF adopts the use of a light source (in our case a helium-neon [HeNE] laser beam) 
that is directed at the area of interest on the skin. Consistent with the Doppler theory, 
the laser beam will undergo scattering when reflected off  moving red blood cells (RBCs) 
in the microvasculature. The magnitude of this scattering can then be related to the 
number and the velocity of the RBCs providing a measure of blood flow. Scattered light 
from RBCs beam is received by a photodetector and converted into an electrical signal 
proportional to the Doppler shift. LDF only allows for single-point perfusion analysis, but 
laser Doppler imaging (LDI) measures blood flow over a larger area, thus helping 
dampen the heterogenous and variable signals obtains from blood flow measurements.  
 
The method used herein is LDI, which adopts the use of a scanning HeNe laser beam and 
produces a measurement of skin perfusion over a given area. Using this technique, a 
colour-coded skin perfusion map relating to Doppler shift and therefore blood flow is 
produced (Fig. 2.3). Each pixel on the skin perfusion map corresponds to a ‘flux’ value, 
ranging from 0-1000 (AU). Low flow is represented by blue/purple colours on the skin 
perfusion map, corresponding to a lower flux value (0-250 AU). Larger flow is 
represented by green, yellow and red and corresponds to a higher flux value (300-1000 
AU).  
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2.5.1 Iontophoresis 
 
Assessment of endothelium-dependent vasodilation and non-endothelium dependent 
vasoresponsiveness can be assessed by coupling laser Doppler imaging (LDI) technology 
with iontophoresis of vasoactive agents, such as phenylephrine (PE), ACh, or sodium 
nitroprusside (SNP). Section 1.6.1 provides a detailed response of endothelial cell 
signalling in regard to vasoresponsiveness. Iontophoresis is the unidirectional transport 
of ions in a solution across the epidermal layer by a continuous applied current (Fig. 2.4). 
Ion movement is determined by polarity. The negatively charged electrode (cathode) 
repels negatively charged ions and attracts positively charged ions. A positively charged 
electrode (anode) repels positively charged ions and attracts negatively charged ions. 
By utilising iontophoresis technology in vivo, polarised vasoactive agents can migrate 
across the epidermis into the microvasculature and exert effects, which can be detected 
by laser Doppler imaging.  
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Figure 2.3 Example laser Doppler scan  
LDI scan of an 8-week old WT NC-fed female mouse. Scans 1-3: baseline (dH20), scans 4-9: PE-induced 
scans, scans 10-22: ACh-induced scans. Purple-blue: constricted microvasculature, green-red: dilated 
microvasculature.  
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Figure 2.4 Schematic representation of the principles of iontophoresis in laser Doppler imaging 
The iontophoresis ring is attached to the skin and, in its chamber, it houses the vasoactive agent 
dissolved in dH20. The reference electrode is placed on another area of skin. Through the iontophoresis 
controller, which is connected both to the iontophoresis ring and the reference electrode, a current is 
applied to the skin. Due to this current, the iontophoresis ring becomes positively charged, and the 
electrode becomes negatively charged. Positively charged molecules (PE, ACh) are repulsed by the ring 
and attracted to the electrode, and thus move toward the electrode through the skin and into the 
microvasculature where they can take effect on endothelial cell signalling.  
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2.5.2 Anaesthesia 
 
Using anaesthetic apparatus mice were anaesthetised by a mix of 3.5% isoflurane and 
oxygen (compressed oxygen cylinder size E, BOC Medical) delivered at a flow rate of 1-
1.5 litres per minute. Mice were maintained at a steady depth of anaesthesia using a 
mix of 1-1.5% isoflurane and oxygen delivered at 1-1.5 litres per minute.  
 
2.5.3 Animal preparation 
 
An electric razor was used to shave both flanks of the animal (Fig. 2.5A, B). Gentle 
application of depilatory cream (Veet) was used to entirely remove the fur from one 
flank of the animal, followed by a thorough cleaning with warm H20 to ensure removal 
of any residual cream (Fig. 2.5A). Skin must be exposed as the laser beam cannot 
penetrate through fur. A reference electrode (Moor Instruments Ltd, MIC2) was placed 
underneath the animal on the patch of shaved skin (Fig. 2.5C). The iontophoresis 
electrode ring (Moor Instruments Ltd, MIC2) was attached to the Veeted skin via double-
sided adhesive tape (Fig. 2.5C). The ring was filled with approximately 2ml of dH20 and 
a lid was placed on the ring to ensure there was no spillage of the liquid. There must be 
no air bubbles present in the liquid, as this will result in a false signal. The ring was placed 
at a 35° angle from the laser beam to allow accurate measurement and minimise direct 
reflection of the laser beam (Fig. 2.5C). 
 
2.5.4 Experimental set-up 
 
The laser (Moor Instruments Ltd, MLDI 5082) was positioned 50cm above the animal, 
with the bottom of laser hood being 32cm above tissue (Fig. 2.7A, B). Using Moor 
propriety software (Moor Instruments Ltd, Version 5.3), laser acquisition parameters 
were set as below: 
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Scan resolution: X=60, Y=60 
Scan speed: 10ms/pixel  
Average scan time: 49 seconds  
Time between scans: 5 seconds   
Total scan time: 55 seconds  
 
To investigate endothelium-dependent vasodilation, iontophoresis of both 
phenylephrine (PE) and acetylcholine (ACh) was used. Since PE and ACh are positively 
charged molecules, they migrate toward the reference electrode when it is negatively 
charged and will be repelled from the iontophoresis ring when it is positively charged. 
Three ‘baseline’ scans were first completed with dH20 before iontophoresis of 
vasoactive agents.  To standardise baseline perfusion, vessels were preconstricted with 
1% (w/v) phenylephrine (current = 100μA) and 6 scans were performed. To measure 
endothelium-dependent vasodilation, 2% (w/v) ACh was applied for 13 scans. To 
measure endothelium-independent vasodilation, vessels were preconstricted with 1% 
(w/v) phenylephrine, and then stimulated with 2% (w/v) sodium nitroprusside (SNP), an 
NO donor that can induce smooth muscle cell relaxation independently of endothelium-
derived NO. SNP is negatively charged, therefore the charges on the reference electrode 
and iontophoresis ring must be swapped, making the reference electrode an anode, and 
the iontophoresis ring a cathode. 
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A B
C
35°
iontophoresis ring
reference electrode
Figure 2.5 Animal preparation for laser Doppler imaging 
Under anaesthesia, both flanks of the mouse were shaved using an electric razor. (A) The fur on one 
side was completely removed using depilatory cream (Veeted) and cleaned with warm H20. (B) The 
fur on the other side was shaved, but depilatory cream was not applied. (C) On the flank that no fur 
was present, the iontophoresis ring was attached using double-sided adhesive ring-tape. The 
reference electrode was placed underneath the mouse on the shaved flank. The ring was placed at 
a 35° angle so as not to directly reflect the beam. Prior to the start of the scanning period, H20 was 
placed in the iontophoresis chamber and the lid placed on top to assess whether any leaks were 
present  
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Figure 2.6 Laser Doppler imaging set-up 
(A) Photographs of the laser Doppler imaging set-up, where 1 = laser, 2 = iontophoresis controller, 
3 = reference electrode, and 4 = iontophoresis electrode ring. (B) Representative schematic of the 
laser Doppler imaging set up.  
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2.5.6 Perfusion analysis 
 
Perfusion images (Fig. 2.3) were analyzed using propriety software (Moor Instruments, 
Version 5.3). Each coloured pixel on the image corresponds to a numerical value of flux, 
ranging from 0-1000 (AU). The median of these values is taken for further analysis (Fig. 
2.7). Data are expressed in four ways: (1) baseline flux (AU) which is an average of the 3 
baseline values (green circles in Fig. 2.7A), (2) peak flux in response to ACh (AU) which is 
an average of the top 3 values in response to ACh (red circles in Fig. 2.7A), (3) an XY 
graph denoting percentage change (%∆) over time normalised to the first baseline scan 
(presented in Fig. 2.7B), or (4) a column graph denoting %∆ in response to ACh, 
calculated as maximum ACh-induced vasodilation compared to maximum PE-induced 
vasoconstriction. The latter is calculated by subtracting the bottom 3 PE-induced value 
(blue circles Fig 2.7A) from the average of the top 3 ACh-induced values (red circles Fig 
2.7A), and then converting this difference into % change from the PE-induced value. 
 
The baseline flux is not normalised and is therefore likely to be variable between mice. 
It will be sensitive to factors such as temperature, hormone levels, when the mouse last 
ate, blood pressure, and isoflurane administration. To account for this, the 
microcirculation is normalised across animals by preconstricting the vessels with 
PE145,348. The baseline measurement is still analysed herein, as it may contain interesting 
information about the animal models. However, the data must be interpreted carefully 
and with full awareness of possible confounding factors. 
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Figure 2.7 Prototypical traces of cutaneous skin perfusion in response to PE and ACh/SNP 
(A) Skin perfusion values (AU) against time at baseline (green circle), after PE application (blue circle), and 
after ACh/SNP application (red circle). (B) Typical % skin perfusion trace (% of first baseline reading) at 
baseline, after PE application, and after application of a vasodilatory agent. 
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2.6 Tissue biochemistry 
2.6.1 Vessel enriched fractionation 
 
Vessel enriched fractions were obtained using a modified protocol from Yousif and 
colleagues349. Mice were culled via cervical dislocation and major artery laceration. The 
brain was dissected from the skull and, after removal of the hypothalamus, cerebellum 
and olfactory bulbs, was separated into two hemi-brains. Hemi-brains were 
homogenised in 1ml ice-cold PBS each using a loose-fit 1ml glass Dounce homogeniser. 
Once minced, the homogenate was placed in a 15ml falcon tube and spun at 250g for 
10 minutes at 4°C. The supernatant was removed, and the pellet was resuspended in 
3ml 17.5% Ficoll-400 (Sigma, F9378-25G). Ficoll preparations work on the principle that 
higher density cells will accumulate in a pellet at the bottom of the centrifuge tube, 
whereas lower density cells will not be able to migrate through the Ficoll mixture and 
will remain at the top of the solution. The suspension was then centrifuged at 3200g for 
25 minutes at 4°c. This spin results in a pellet referred to as the vessel-enriched (VE) 
fraction, which is thought to contain ECs, pericytes, and potentially astrocytic end-feet, 
and two layers on top which contain the brain parenchyma, deemed the S0 fraction. The 
S0 fraction was removed and placed in a fresh 15ml Falcon tube. 3ml of ice-cold PBS was 
added and the resulting mixture was centrifuged at 3200g for 10 minutes at 4°C. The 
supernatant was poured off and the pellet was resuspended in 1ml ice-cold PBS and 
spun at 6000g for 10 minutes at 4°C. The two VE fraction pellets are pooled together in 
1ml ice-cold PBS and centrifuged at 6000g for 10 minutes at 4°C. A schematic of this 
process is shown in Fig. 2.8. Both VE and S0 fractions were stored at -80°C until required 
for further processing.  
 
To validate that the VE fraction did indeed contain enriched vessels, ICAM (a protein 
that is highly expressed on endothelium350,554) expression was measured in both the VE 
fraction and the S0 (or parenchymal) fraction (Fig. 2.9). Indeed, the VE fraction expressed 
high levels of ICAM whereas the S0 fraction only possessed very low, residual levels 
(likely due to a small amount of contamination of endothelial cells).  
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Figure 2.8 Schematic of vessel enrichment protocol  
Homogenised hemi-brain is pelleted and then resuspended in Ficoll (brown). Centrifugation of this 
suspension results in the separation of the brain suspension and formation of a pellet which contains 
a vessel enriched fraction (red), termed the VE fraction. The supernatant containing the parenchyma 
is removed (termed S0 frac, white) and is centrifuged a second time, resulting in a second VE fraction 
pellet. The two VE fraction pellets are pooled together. From each hemi-brain, the protocol produces 
one pellet containing the VE fraction and one pellet containing the S0 fraction.  
 
Figure 2.9 Validation of vessel enrichment protocol using ICAM protein expression 
 
Protein was isolated (2.6.5) from VE fractions and S0 fractions. 20μg of sample was loaded onto an 
acrylamide gel and separated using SDS-PAGE (2.6.7). ICAM protein expression was probed for using 
conventional western blotting (2.6.7). Actin was used as a loading control.  
ICAM
ac' n
VE	frac' on S₀	frac' on
120kD
42kD
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Table 2.3 Real-time PCR cycle protocol for Taqman® analysis 
 
 
 
 
 
Table 2.4 Summary of Taqman® probes used herein 
 
 
 
 
 
 
Table 2.5 Components of lower gel (makes 2 gels) 
 
 
 
 
 
 
 
 
Table 2.6 Components of upper gel (makes 2 gels) 
  
Step Temperature (°C) Duration 
1. Polymerase activation 95 10 minutes 
2. Denaturation 95 15 seconds 
3. Annealing 60 1 minute 
4. Extension 60 1 minute 
Repeat steps 2-4 x 40 cycles 
Probe name Specificity Code 
Actin Mouse Mm02619580_g1 
APP Mouse Mm01344172_m1 
BACE1 Mouse Mm00478664_m1 
ICAM Mouse Mm00516023_m1 
Constituent Volume 
dH20 4.15ml 
Lower buffer 3.15ml 
30% acrylamide 3.75ml 
10% SDS 100μl 
TEMED 11μl 
20% APS 55.35μl 
Constituent Volume 
dH20 2.8ml 
Upper buffer 1.25ml 
30% acrylamide 0.85ml 
10% SDS 50μl 
TEMED 5.35μl 
20% APS 50μl 
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2.6.2 RNA extraction 
 
Cells were lysed in 500μl of TRIzol Reagent (Thermo-Fisher Scientific; 155906018). 100μl 
chloroform was added and the sample was shaken vigorously for 15 seconds. Samples 
were allowed to stand at room temperature for 15 minutes before being centrifuged at 
12000 x g for 15 minutes. The clear aqueous phase containing RNA was removed and 
placed in a fresh Eppendorf™ and 250μl of isopropanol was added. The isopropanol, 
when centrifuged, gathers the RNA at the bottom of the tube. Samples were again 
allowed to stand at room temperature for 10 minutes before being spun at 12000 x g 
for 10 minutes to form a visible RNA pellet. The supernatant was removed, and the 
pellet was washed with 1ml 75% ethanol. The samples were spun again at 12000 x g for 
5 minutes and the supernatant was removed. The RNA pellets were allowed to air dry  
for 7.5 minutes in a fume hood before being dissolved in 15-30μl PCR grade RNase free 
water by heating at 60°C for 15 minutes. RNA was stored at -80°C until required for cDNA 
synthesis. 
 
2.6.3 cDNA synthesis 
 
RNA concentration was measured using the Nanodrop ND-8000 Spectrophotometer. 
Purity was also assessed at this stage with a 260/280 ratio ≥ 1.8 used as a lower limit. 
cDNA was produced according to the Invitrogen protocol and reagents for Superscript II 
reverse transcriptase (Invitrogen, 18064022). Briefly, a mix containing 1μl random 
primers (Invitrogen, 48190011), 1μl 10mM dNTP mix (Invitrogen, 18427013), 1μg of RNA 
sample made up to a total volume of 13μl with PCR grade, RNase free water was made 
in a 1.5ml Eppendorf™ tube and heated to 65°C for 5 minutes and then chilled on ice. 
4μl 5x first strand buffer (Invitrogen, 18064022) and 1μl 0.1M DTT (Invitrogen, 
18064022) was added, gently mixed and left at room temperature for 1 minute before 
adding 1μl Superscript II RT and mixing gently again. The samples were then allowed to 
stand at room temperature for a further 10 minutes before being incubated at 42°C for 
50 minutes, after which the reaction was inactivated by heating at 70°C for 15 minutes. 
cDNA was diluted 1:10 with 180μl PCR grade, RNase free water and stored at -20°C until 
required for TaqMan® qPCR. 
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2.6.4 Gene expression analysis using TaqMan® analysis 
 
TaqMan® technology uses a primer/probe mix consisting of a normal PCR primer 
targeted toward the gene of interest in addition to a probe molecule, which has a FAM 
dye label on the 5’ end and a quencher on the 3’ end. When the target gene is amplified 
by the exogenously added DNA polymerase, the exonuclease activity of the enzyme 
separates the FAM dye from the quencher. With each cycle of PCR, more dye molecules 
are released, and this results in increased fluorescence which is proportional to the 
amount of amplified product. This information can then be used to quantify gene 
expression. 
 
To perform TaqMan® analysis, 2.5μl of synthesised cDNA sample was loaded into a 96-
well MicroAmp Fast 96-Well Reaction Plate (Applied Biosystems, 4346907). 17.5μl of a 
pre-made master mix consisting of 6.5μl of PCR grade water, 1μl of the appropriate 
TaqMan® probe (Applied Biosystem, Table 2.4) and 10μl TaqMan® 2X Mastermix 
(Applied Biosystems, 4324020) was then added to each sample. Once loaded, the plate 
was covered with a film lid and spun in a centrifuge to ensure the collection of the 
sample at the bottom of the wells. The plate was then run in a real-time PCR machine 
(Applied Biosystems, 7900HT) according to the protocol in Table 2.3. Steps 2-4 were 
repeated for a total of 40 cycles. 
 
2.6.5 Protein extraction  
 
Tissues, VE/S0 pellets, and cells were lysed in an appropriate volume of lysis buffer (2.9 
Commonly used lab solutions). Aorta and muscle tissues were dissociated using the 
Fisherbrand Bead Mill 24 Homogenizer (ThermoFisher, 15515799) with 0.9-2mm 
stainless steel beads (Next Advance, SSB14B) with the settings speed = 5, time = 20s, 
cycles = 5, dwell = 4s. This homogenate was then sonicated (130 Watt ultrasonic 
processor, Sonics, VCX 130) at 25% amplitude for 20s (5 pulses of 4 seconds on 1 second 
off). Sonication at this amplitude is known to rupture organelle membranes. The 
homogenate was then spun down at 13000 x g for 15 minutes to remove cell debris. The 
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supernatant was removed and placed in a fresh Eppendorf™ and stored at -80°C until 
required. 
 
2.6.6 Bradford assay 
 
Protein concentration was determined using the Bradford assay (Bradford, 1976). 
Briefly, standard wells of known protein concentration were loaded in triplicate into a 
96-well plate using 2mg/ml BSA (Thermo Fisher Scientific; 23209) to create a standard 
curve. 1μl of sample was loaded in triplicate followed by 9μL of ddH20 per well. 250μl 
Bradford reagent was added to each well and the plate was allowed to stand at room 
temperature for 5-10 minutes to ensure colour development. The absorbance of the 
wells was read at 595nm using an EnVision 2104 Multilabel Plate Reader. The standard 
curve was then created using the mean absorbance of wells against known protein 
concentration. The protein concentration of unknown samples can then be extrapolated 
from the standard curve using the mean absorbance values. Equal amounts of protein 
were mixed with 4X sample buffer (2.9 Commonly used lab solutions) and boiled at 95°C 
for 5 minutes. Samples were stored at -20°C until required. 
 
2.5.7 SDS-PAGE and western blotting 
 
Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) is a widely used 
method allowing for the separation of proteins. SDS is a detergent that gives proteins a 
net negative charge. During SDS-PAGE, charges proteins migrate relative to their size, 
thus allowing accurate separation of proteins by size. Typical SDS-PAGE consists of 
loading protein samples from tissue and cell lysates onto a polyacrylamide gel. The gel 
contains pores of differing size (determined by the acrylamide percentage used to make 
the gel) that act to impede the paths of proteins that have been loaded on to the gel. 
Smaller proteins will move through the gel faster than larger proteins, resulting in a 
separation of proteins with low kD-proteins at the bottom of the gel and high kD 
proteins at the top of the gel. A protein ladder consisting of known proteins of known 
sizes is also loaded onto the gel to allow for identification of proteins of interest during 
western blotting. 
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Gels were hand casted using BioRad casting equipment (BioRad, 1658001FC). Separating 
(lower) gels and stacking (upper) gels were made as per Tables 2.5 and 2.6 respectively. 
Samples of known protein concentration were loaded on to gels against the protein 
ladder SeeBlue Pre-stained Protein Standard (ThermoFisher, LC5925). The gel was then 
run at 150V for around 1.5 hours to allow protein separation. The running tank applies 
a current in a vertical plane to attract proteins to the bottom of the gel from the top. 
Once the gel had ran sufficiently, proteins were transferred onto a nitrocellulose 
membrane (SIGMA, GE10600002) at 80V for 1.5 hours. The transfer tank applies a 
current in a horizontal plane to attract proteins onto the nitrocellulose membrane. 
Following transfer, membranes were incubated in Ponceau S solution to ensure efficient 
protein transfer. Ponceau was washed off with TBST (2.9 Commonly used lab solutions) 
and blocked (to reduce non-specific anti-body binding) for 1 hour in 5% w/v milk/TBST 
or 5% w/v BSA/TBST depending on the primary antibody used for protein detection 
(Table 2.7). Following blocking, membranes were washed in TBST to remove milk and 
then incubated at 4°c overnight in a primary antibody directed toward the protein of 
interest (see antibodies table for details). The following day, antibody was removed, and 
the membrane was washed 5 x 5 minutes in TBST. The membrane was then incubated 
for 1 hour at room temperature in a secondary antibody directed toward the species 
that the primary antibody was reared in. Secondary antibodies were conjugated to 
either horseradish peroxidase or a fluorophore. Following this, membranes were 
washed 5 x 5 minutes and imaged using the LI-COR Odyssey CLx Imaging System at 
685nm or 785nm, dependent on the conjugated fluorophore (Table 2.7). Blots were 
analysed by densitometry using Image Studio Lite (LI-COR) and the numerical outputs 
were normalised as fold change compared to the control group. 
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Table 2.7 Summary of anti-bodies used herein  
Antibody Blocking 
agent 
Dilution Species Secondary 
antibody 
Provider Product 
code 
Beta actin 5% 
milk/TBST 
1:1000 Rabbit Goat anti-
rabbit 
800CW 
Abcam ab14128 
BACE1 5% 
milk/TBST 
1:1000 Rabbit Goat anti-
rabbit 
800CW 
Sigma SAB2100200 
Phospho-
Drp1 
serine 616 
5% 
BSA/TBST 
1:1000 Rabbit Goat anti-
rabbit 
800CW 
CST 4494S 
Phospho-
Drp1 
serine 657 
5% 
BSA/TBST 
1:1000 Rabbit Goat anti-
rabbit 
800CW 
CST 6319S 
Total Drp1 5% 
milk/TBST 
1:1000 Rabbit Goat anti-
rabbit 
800CW 
CST 8570 
Phospho-
eNOS 
5% 
milk/TBST 
1:1000 Mouse Donkey anti-
mouse 
680RD 
BD 
Transductions 
612393 
ICAM 5% 
milk/TBST 
1:10000 Goat Donkey anti-
goat 680RD 
R&D Systems AF796 
Mitofusin 
1 
5% 
milk/TBST 
1:200 Mouse Donkey anti-
mouse 
680RD 
Abcam ab126575 
Mitofusin 
2 
5% 
milk/TBST 
1:200 Mouse Donkey anti-
mouse 
680RD 
Abcam ab56889 
OPA1 5% 
milk/TBST 
1:1000 Rabbit Goat anti-
rabbit 
800CW 
Rabbit 80471S 
Phospho-
PKB 
serine473 
5% 
BSA/TBST 
1:1000 Rabbit Goat anti-
rabbit 
800CW 
CST 9271S 
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2.5.8 Nitrite concentration 
 
Investigating NO levels can be difficult, due to it being a small, diffusible radical molecule 
with a short half-life. Therefore, alternative methods to indirectly measure NO have 
been developed. One such method is measuring nitrite (NO2-), which is a stable, non-
volatile metabolite of NO. The assay was first developed by Peter Griess (1879) and 
utilises a diazotisation reaction that occurs when sulfanilamide is added to a biological 
sample containing NO2-. The diazonium salt that is formed in this reaction can then react 
with the azo dye agent (N-1-napthylethylenediamine dihydrochloride; NED) to form an 
azo compound, which is pink in colour. The samples can be measured using an 
absorbance reader, where absorbance and NO2- concentration are positively correlated.  
 
NO2- concentration was determined in both plasma and cellular media using the Griess 
Reagent System (Promega, G2930). Standard wells of known nitrite concentration were 
loaded in triplicate into 96-well plate using the 0.1M Nitrite Standard supplied in the 
assay kit to create a standard curve ranging from 0-100μM. 50μl of sample (plasma 
diluted 1:10 in dH20) was loaded in duplicate. 50μl of the Sulfanilamide Solution was 
added on all experimental samples and the wells containing the Nitrite Standard. After 
5-10 minutes incubating at room temperature, 50μl of the NED Solution was added. The 
plate was incubated again at room temperature for 5-10 minutes, whilst being protected 
from light, and the sample absorbance measured at 540nm using the EnVision 2104 
Multilabel Plate Reader. The standard curve was then created using the mean 
absorbance of wells against known NO2- concentration, thus the NO2-concentration of 
unknown samples could be extrapolated from the standard curve using the mean 
absorbance values. 
 
2.5.9 Endothelin-1 ELISA 
 
Since the discovery of ET-1, several studies have suggested a link between high 
circulating levels of ET-1 and CVDs such as atherosclerosis and hypertension. Raised ET-
1 has also been associated with metabolic disorders (obesity and T2D) and 
neurodegenerative disorders, including AD. Therefore, ET-1 is measured herein.  
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The ET-1 ELISA was completed by Dr Alison McNeilly in a shared plate in order to reduce 
waste. ET-1 was measured using an assay which employs the quantitative sandwich 
enzyme immunoassay technique (R&D Systems, DET100). The assay contains a 
microplate that has been pre-coated with a monoclonal antibody specific for ET-1. 
Standards and samples are loaded into the plate and ET-1 present in the samples will be 
bound by the antibody. After wash steps, a horseradish peroxidase-linked antibody, also 
specific for ET-1 (ET-1 conjugate) is added to the wells. Following wash steps, substrate 
solution is added, which reacts with horseradish peroxidase to induce a colour change. 
The colour development is directly proportional to the amount of ET-1 bound.  
 
In brief, 150μl of Assay Diluent RD1-105 was added to each well. Standard wells of 
known ET-1 concentration (75μl) were loaded in duplicate, whilst 75μl of sample 
(plasma) was added to experimental wells before the plate was covered incubated for 1 
hour at room temperature on an orbital shaker to allow antibody binding. Solutions 
were decanted and wells were washed four times with 400μl Wash Buffer. 200μl of ET-
1 conjugate was added to each well using a multichannel and the plate was covered and 
incubated for 3 hours at room temperature on the shaker. Once again, solutions were 
decanted and wells were washed four times with 400μl Wash Buffer. 200μl substrate 
solution was added to each well and the plate was incubated for 30 minutes at room 
temperature, protected from light. Following this incubation, 50μl stop solution was 
added to each well and the plate was read at 450nm using the EnVision 2104 Multilabel 
Plate Reader. The standard curve was then created using the mean absorbance of wells 
against known ET-1 concentration. Therefore, ET-1 concentration of unknown samples 
can be calculated. 
 
2.6 Cell culture 
 
All cell culture was done under sterile conditions. All cell lines were maintained at 37°C 
in an incubator with an atmospheric O2:CO2 ratio of 95:5%. 
 
2.6.1 Palmitate  
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100mM palmitate was dissolved in a 15ml Falcon tube in 5ml 0.2M NaOH at 70°c (water 
bath) for 15 minutes. Once dissolved, palmitate was conjugated to 2% BSA by adding 
0.5ml of dissolved palmitate to 4.5ml of 2% fatty acid free BSA (Sigma, A8806-5G)/dH20 
and placing the Falcon tube at 55°c (water bath) for a further 15 minutes. The vehicle 
control was made by adding 0.5mL of 0.2M NaOH to 4.5ml of 2% BSA/dH20 and placing 
the Falcon tube at 55°c (water bath) for a further 15 minutes. These solutions were filter 
sterilised before being aliquoted and stored at -20°C. Prior to a palmitate incubation, 
palmitate aliquots were defrosted then heated (heat block) at 55°c for 15 minutes. The 
solution was only used if it remained clear (cloudy solutions are indicative that the 
palmitate is not conjugated to the BSA). 
 
2.6.2 RBE4 cell culture 
 
The rat brain endothelial cell line RBE4 was a kind gift from Michael Aschner (Albert 
Einstein College of Medicine, New York, USA).  To create the cell line, cells were isolated 
from rat brains, cultured and subsequently transfected after two passages with the 
plasmid pE1A/neo351. The plasmid pE1A/neo carries the E1A region of Adenovirus 2 and 
the neomycin-resistance gene for selection by resistance to G418.  
 
Cells were maintained in T-75 cell culture flasks in 1:1 Alpha MEM (Gibco, 12571089) to 
Ham’s F10 (Gibco, 11550043), supplemented with 10% foetal bovine serum (SeraLab, 
discontinued), 1% penicillin/streptomycin (p/s; Gibco, 15140122), 2 mM L-glutamine 
(Gibco, 25030081) and 300 μg/ml G418 (Gibco, 10131027). RBE4 cells were passaged 2-
3 times per week. 
 
2.6.3 bEnd.3 cell culture 
 
The mouse brain endothelial cell line bend.3 was a generous gift from Brenda Kwak 
(University of Geneva, Switzerland). The cell line was originally transformed by infecting 
isolated cerebral endothelial cells (BALB/c mice) with a middle T antigen expressing N-
TKmT retrovirus and the endothelial nature of these cells was confirmed by the 
expression of von Willebrand factor352.  
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bEnd.3 cells were maintained in 1% gelatin (Sigma, G1393) coated flasks in Dulbecco’s 
modified Eagle’s medium (DMEM) diluted 1:5 with Hank’s Buffered Saline Solution 
(HBSSl Invitrogen, 14060073), to reduce the concentration of amino acids (AA), 
especially L-glutamine (L-glut), to physiological levels. The reason for using this reduced-
AA method is because L-glut levels are 8x higher in cellular media than they are in the 
blood (culture media = ~4mM, blood – ~0.5mM353). Other AAs are also present at higher 
concentrations in cellular media compared to blood, such as leucine, iso-leucine, valine, 
and methionine353. The reason for such high concentrations, particularly L-glut, is to give 
the cells extra fuel in times of glucose scarcity, meaning cultured cells are easy and 
flexible model systems for researchers. However, 25mM glucose and high AA 
concentration together could act as a nutrient overload, stressing cells and inducing 
dysfunction. This reduced-AA DMEM was then supplemented with either 5mM or 
25mM sterile D-glucose (Sigma, G8270) 5% foetal bovine serum and 1% p/s. Therefore, 
bEnd.3 cells were cultured at either 5mM glucose (normal glucose) or 25mM glucose 
(high glucose). bEnd.3 cells were passaged 2-3 times per week. 
 
2.6.4 Insulin stimulations 
 
Cells (bEnd.3 or RBE4) were seeded at 2.5x105 cells per well (6-well plate) in 2ml growth 
media and left to adhere overnight. Prior to insulin stimulations, cells were starved of 
serum for 2 hours (RBE4s) or 0, 2, 8, or 16 hours (bEnd.3). Insulin was applied to the cells 
at concentrations ranging from 0-100nM for 5, 10, or 30 minutes. Details of serum starve 
length and insulin concentrations can be found in the figure legends. After insulin 
incubations, media was removed and cells were washed with ice-cold PBS before being 
lysed in 100μl lysis buffer (2.9 Commonly used lab solutions). The cell suspension was 
then centrifuged at 13000g for 15 minutes to pellet cellular debris. Supernatant was 
retained for protein concentration determination. 
 
2.6.5 Glucose and palmitate experiments 
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bEnd.3 cells were plated at a seeding density of 2.5x105 cells per well (6-well plate) in 
2ml media (5mM glucose or 25mM glucose) and allowed to adhere overnight. The next 
day media was removed and replaced with fresh media, before the cells were exposed 
to varying concentrations of palmitate (in 2% fatty acid free BSA/0.02M NaOh) or vehicle 
(2% BSA/0.02M NaOH) for varying incubation times. Details of incubation time and 
concentration are stated in figure legends. Post-incubation, media was removed and 
retained for further analysis. Cells were washed in PBS and then lysed in 100μl lysis 
buffer (2.9 Commonly used lab solutions) or 500μl TRIzol. The cell suspension was then 
sonicated at 25% amplitude for 20s (5 pulses of 4 seconds on 1 second off) to lyse 
mitochondrial membranes and centrifuged at 13000g for 15 minutes to pellet cellular 
debris. Supernatant was retained for protein concentration determination (section 
2.6.5). Cells lysed in TRIzol were subjected to RNA extraction, cDNA synthesis, and gene 
expression analysis protocols (sections 2.6.2 – 2.6.4) 
 
2.7 Measuring mitochondrial bioenergetics 
2.7.1 Seahorse XF24 Analyser 
 
The Seahorse XF24 Analyser allows continuous direct measurements of the 
bioenergetics of cultured cells. The analyser uses a sensor cartridge in a 24-well plate 
format. Each sensor has two fluorophore-embedded probes, one of which is sensitive 
to oxygen (O2) and the other is sensitive to changes in pH. During a measurement, the 
sensor cartridge moves to approximately 200μm away from the cell monolayer, creating 
a microenvironment of around 7μl. The Seahorse instrument uses fibre optic light that, 
when emitted, excites the fluorophores embedded in the sensors. The fluorophores 
emit light of a different wavelength (Stoke’s shift), which is then detected by the 
instrument. The extent by which the wavelength changes is sensitive to the presence of 
O2 and varying pH levels. The instrument can therefore automatically calculate the 
oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR). This is 
useful for measuring the capacity of cellular respiration. Actively respiring mitochondria 
consume O2, allowing for the OCR to be taken as a direct measure of OXPHOS. ECAR 
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reflects the release of lactic acid into the media as a result of its conversion from 
pyruvate during glycolysis.   
 
2.7.2 Mito Stress Test Kit  
 
The Mito Stress Test Kit measures key parameters of mitochondrial function by directly 
measuring changes in OCR in real time. The assay makes use of pharmacological 
inhibitors toward key parts of the respiratory chain to underpin the mitochondrial 
function of cells of interest. The OCR read out can then be used to extrapolate 
information regarding respiratory status such as the rate of oxygen used by the cell for 
basal respiration, ATP-linked respiration, respiratory capacity, maximal respiration, 
proton leak and non-mitochondrial oxygen consumption (Fig. 2.10). 
 
Oligomycin is a potent inhibitor of ATP synthase (complex V) and its addition via the 
injection ports acts to decrease electron flow through the ETC. It is used to investigate 
the extent of oxygen used for mitochondrial-dependent ATP production. The second 
injection is carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP), an 
uncoupler that collapses the proton gradient and disrupts mitochondrial membrane 
potential. This allows for the maximum respiratory ability of the mitochondria to be 
measured, as the ETC works at maximum to maintain the dissipated proton gradient. 
 
The third and final injection is a mixture of rotenone and antimycin A, a complex I 
inhibitor and complex III inhibitor respectively. These inhibitors cause the respiratory 
chain in the mitochondria to shut down completely and allows calculation of non-
mitochondrial respiration.  
 
2.7.3 Mito Stress Test Optimisation 
 
To optimise cell density, cells were plated in a normal 96-well plated at various densities 
ranging from 1x104 – 1x105 cells and left to settle and grow for two days. Optimum 
density was identified by visualising cells; bEnd.3 cells should be utilised when they are 
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a confluent monolayer. 3x104 cells/well was chosen as the optimum cell density. Two 
days before performing the Seahorse protocol, bEnd.3 cells were seeded at 3x104 
cells/well into a Seahorse XF24 Microplate (Agilent, 100777-004) in 200μl normal 
growth media (20/80 DMEM/HBSS, 5mM glucose). The day previous to performing 
Seahorse, a sensor cartridge was hydrated in 1ml of Seahorse XF calibrant (Agilent, 
100840-000) per well and left to incubate overnight at 37°C in the absence of CO2. The 
day of the Seahorse assay, cells were retrieved from the incubator and 150μl of media 
was removed, leaving 50μl behind so as not to let the cells ‘dry out’. 950μl of assay 
media was added to the cells and then removed. Assay media is composed of Seahorse 
XF DMEM Medium (Agilent, 103575), 0.8mM L-glut (Agilent, 103579-100), and 5mM 
glucose (Agilent, 103577-100). 450μl of assay media was then added to the cells (500μl 
final volume assay media) and they were allowed to incubate in the absence of CO2 for 
45 minutes to an hour. Using the Mito Stress Test Kit (Agilent, 103015-100) optimisation 
of oligomycin was performed first. Oligomycin concentrations of 20μM, 15μM, 10μM 
and 5μM were made up in assay media. FCCP was made up at a concentration of 10μM, 
whilst rotenone and antimycin A were made up at a concentration of 5μM. The sensor 
cartridge was retrieved from the incubator and 56μl of the differing oligomycin 
concentrations (Fig. 2.11A), 62μl of 10μM FCCP and 69μl of 5μM rotenone/antimycin A 
was added to port A, B, and C respectively. When these compounds are injected during 
the assay, they are diluted 1:10 into the Seahorse media, resulting in working 
concentrations of 2μM, 1.5μM, 1μM, and 0.5μM oligomycin, 1μM FCCP and 0.5μM 
rotenone/antimycin A. Once loaded, the sensor cartridge was calibrated in the Seahorse 
machine before the cells were loaded into the machine and the Mito Stress Test protocol 
was started. The protocol is a modifiable algorithm embedded in the Seahorse software, 
that dictates to the machine when to inject compounds, mix the media, and take 
OCR/ECAR measurements.  From the results seen in Fig. 2.11B, it was decided that for 
future experiments 1.5μM oligomycin would be used. 
 
Following the oligomycin optimisation, FCCP concentration was optimised in the same 
manner from the following concentrations: 2μM, 1μM, 0.5μM, and 0.25μM (2.12A). 
From the results seen in fig 2.12B, a concentration of 1μM was taken forward for future 
experiments. 
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Figure 2.10 Prototypical representation of a Mito Stress Test profile 
Schematic showing representative oxygen consumption rate (OCR) per μg of protein of cells in response 
to varying mitochondrial modulators (oligomycin, FCCP, and rotenone/antimycin A). The numerical key 
indicates the different parameters of mitochondrial respiration that can be extrapolated from these data.  
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Figure 2.11 Oligomycin optimization 
(A) Seahorse microculture plate layout depicting final oligomycin concentrations used for optimisation. 
(B) % OCR values (baseline = 100%) during a Mito Stress Test with differing concentrations of oligomycin 
ranging from 0.5-2μM. Wells A1, B5, C3, and D6 were used as background wells, in which no cells were 
plated. 
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Fig. 2.12 FCCP optimisation 
(A) Seahorse microculture plate layout depicting final FCCP concentrations used for optimisation. (B) 
% OCR values (baseline = 100%) during a Mito Stress Test with differing concentrations of FCCP 
ranging from 0.25-2μM. Wells A1, B5, C3, and D6 were used as background wells, in which no cells 
were plated. 
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2.7.4 Glucose and palmitate experiments 
 
Two days before performing the Seahorse assay, bEnd.3 cells were seeded at 3x104 
cells/well into a Seahorse XF24 Microplate in 200μl normal growth media (20/80 
DMEM/HBSS, 25mM glucose). The day previous to performing Seahorse, a sensor 
cartridge was hydrated in 1ml of Seahorse XF calibrant (Agilent, 100840-000) per well 
and left to incubate overnight at 37°C in the absence of CO2. For 24-hour palmitate 
exposures, 25 hours prior to the assay 100μl media was removed and 100μl of fresh 
media containing 200μM palmitate or control was added. This produce a final 
concentration of 100μM palmitate. For 6-hour palmitate exposures, 7 hours prior to the 
assay 100μl media was removed and 100μl of fresh media containing 800μM palmitate 
or control was added. This produced a final concentration of 400μM. Following 
palmitate exposures, cells were retrieved from the incubator and 150μl of media was 
removed, leaving 50μl behind so as not to let the cells ‘dry out’. 950μl of assay media 
was added to the cells and then removed. Assay media is composed of Seahorse XF 
DMEM Medium, 0.8mM L-glutamine, and 5mM glucose. 450μl of assay media was then 
added to the cells and they were allowed to incubate in the absence of CO2 for 45 
minutes to an hour.  During this degassing period, the cartridge plate was loaded with 
56μl of 15μM oligomycin in port A, 62μl of 10μM FCCP in port B, and 69μl of 5μM 
rotenone/antimycin in port C. Once loaded, the sensor cartridge was calibrated in the 
Seahorse machine before the cells were loaded into the machine and the Mito Stress 
Test protocol was started. Plates were retained for calculating protein content for 
further analysis. 
 
2.7.5 Aβ42 Mito Stress Test experiments 
 
2nM Aβ42 or ScrP was ‘aged’ in experimental media (20/80 DMEM/HBSS, 25mM glucose) 
in a 37°C cell culture incubator for 5 days prior to cell exposure to allow the peptide to 
aggregate slightly. A previous PhD project in the lab completed by Dr Jennie Gabriel 
optimised this ‘ageing’ time period and observed via Western blot that Aβ42 is present 
mostly in dimers, with some oligomerisation, after 5 days354. Purified Aβ from human 
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CSF has revealed that dimers are indeed associated with neurodegeneration355. Two 
days before performing the Seahorse assay, bEnd.3 cells were seeded at 3x104 cells/well 
into a Seahorse XF24 Microplate in 200μl media (20/80 DMEM/HBSS, 25mM glucose). 
The day previous to performing Seahorse experiment, a sensor cartridge was hydrated 
in 1ml of Seahorse XF calibrant per well and left to incubate overnight at 37°C in the 
absence of CO2. 25 hours prior to the assay 100μl media was removed and 100μl of ScrP 
or Aβ42 media containing 200μM palmitate or control was added. This produced a final 
concentration of 1nM ScrP or Aβ42 and 100μM palmitate (or control). Following a 24-
hour exposure, the same steps as in the glucose/palmitate experiments were 
performed. 
 
2.7.4 Mito Stress Test analysis 
 
Extrapolated data obtained from Mito Stress Tests is indicated in Fig. 2.10. Data are 
expressed as OCR (pmol/min), which is usually normalised to protein or DNA content. 
Four readings are taken prior to and after each injection. These values are then averaged 
and used to deduce the parameters exhibited in Fig. 2.10. A description of these 
parameters and what the measurements may be sensitive to are given in Table 2.8356. 
Data can also be expressed as %OCR over time in order to obtain internally normalised 
data. The reason for expressing OCR as an internally normalised % is to identify changes 
in individual mitochondrial parameters or whether mitochondrial function is changed 
due to substrate availability (changes to TCA cycle or glycolysis).  
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Table 2.8 Mito Stress Test analysis
Parameter Definition What sets the rate 
Basal respiration Resting mitochondrial respiration performed by the cell to meet the 
endogenous ATP demand and drive proton leak. 
Rate of basal respiration is set by ATP demand, substrate 
availability/oxidation, and proton leak. 
ATP-linked respiration The rate of mitochondrial respiration that is sensitive to oligomycin 
(ATP-synthase inhibitor), and therefore the rate that is used to drive 
ATP synthesis. 
The rate of ATP-linked respiration is set by ATP demand. High ATP 
demand = high ATP-linked respiration values. 
Proton leak OXPHOS is not completely coupled to ATP synthesis, and protons will 
leak across the IMM. Proton leak is the rate of mitochondrial 
respiration that remains in the presence of oligomycin. 
Oligomycin-insensitive respiration is set by proton leak. Rate of 
respiration can be set by basal proton leak (membrane leakiness, ADP 
translocase) or inducible proton leak (UCPs). High proton leak could be 
indicative of mitochondrial dysfunction, or a normal adaptation. 
Spare respiratory 
capacity 
The difference between maximum respiratory capacity and basal 
respiration. The ability of a cell to meet an increased energy demand. 
Also indicates how the cell is working basally 
Spare respiratory capacity is dependent on factors affecting basal 
respiration, as well as factors affecting maximal respiration. 
Maximum respiratory 
capacity 
FCCP is a mitochondrial uncoupler that dissipates mitochondrial 
membrane potential. In response to uncoupling, mitochondria will 
maximise substrate oxidation and ETC activity to maintain 
mitochondrial membrane potential. 
Maximal respiration is set by substrate availability and the capacity of 
mitochondria to oxidise them (substrate transport, metabolic enzymes, 
ETC complexes). A reduced maximum respiratory capacity may be 
indicative of impaired function or may be due to reduced substrate 
availability. 
Non-mitochondrial 
oxygen consumption 
Mitochondrial respiration can be inhibited upon inhibiting ETC 
complexes I and III using rotenone and antimycin A respectively. 
Therefore, respiration remaining after the injection of these 
compounds is dependent on oxygen utilised by the cell for other 
processes. 
May be sensitive to cytoplasmic oxidases and cytoplasmic ROS 
production. 
Coupling efficiency The fraction of basal respiration used to drive ATP-synthesis. 
Calculated by dividing ATP-linked respiration by basal respiration.  
Coupling efficiency is sensitive to ATP demand, substrate availability, 
and proton leak. A high coupling efficiency may be due to a high ATP 
demand. Reductions in coupling efficiency may be due to increased 
proton leak, or reduced substrate availability or transport. 
Respiratory control ratio The fraction of maximal respiration used for proton leak. A measure 
of mitochondrial metabolic flexibility and ability to respond to cellular 
demand.  
The respiratory control ratio is sensitive to substrate oxidation and 
proton leak, but not to ATP turnover. Reduced respiratory control ratio 
may be due to increased proton leak or reduced maximum capacity and 
is therefore sensitive to factors affecting both of these parameters. 
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2.7.6 Glycolysis Stress Test 
 
The Glycolysis Stress Test, by measuring pH of the culture media, gives a direct measure 
of glycolytic function. During glycolysis, glucose is converted to pyruvate, which is then 
converted to lactate in the cytoplasm or CO2 and water in the mitochondria. The 
conversion of glucose to pyruvate to lactate results in the production and extrusion of 
protons out of the cell, therefore acidifying the surrounding culture media. Thus, 
changes in ECAR, which is positively correlated with the rate of lactate production, is a 
good measure of glycolytic function. The Glycolysis Stress Test exploits the use of 3 
compounds that are modulators of glycolytic function: glucose, oligomycin, and 2-
deoxyglycose (2-DG). Cells are initially incubated in assay medium without substrate 
(glucose and pyruvate) and basal ECAR is measured. 10mM glucose is then injected in 
order to record glycolytic rate for a given concentration of glucose. The ATP-synthase 
inhibitor oligomycin is added next to measure the glycolytic capacity of the cells as they 
are forced to maintain their ATP production via glycolysis instead of OXPHOS. The final 
injection is 2-DG, a glucose analogue that inhibits glycolysis through competitive binding 
to hexokinase, the first enzyme in the glycolytic pathway. This final injection can be used 
as a confirmation that the changes in ECAR measured throughout were due to glycolytic 
rate and not OXPHOS, which does have acidification capacity. A prototypical Glycolysis 
Stress Test can be observed in Fig. 2.13. 
 
2.7.7 Glycolysis Stress Test experiments 
 
Two days before performing the Seahorse assay, bEnd.3 cells were seeded at 3x104 
cells/well into a Seahorse XF24 Microplate in 200μl media (20/80 DMEM/HBSS, 5mM 
glucose). Sensor cartridges were hydrated overnight in 1ml of Seahorse XF calibrant per 
well at 37°C in the absence of CO2. On the day of the assay, cells were retrieved from 
the incubator and 150μl of media was removed, leaving 50μl behind so as not to let the 
cells ‘dry out’. 950μl of assay media was added to the cells and then removed. Assay 
media for Glycolysis Stress Tests is composed of Seahorse XF DMEM Medium, 
supplemented 0.8mM L-glutamine. No glucose or pyruvate can be present. 450μl of 
assay media was then added to the cells and they were incubated in a non-CO2 incubator 
 106 
for 45 minutes to an hour. During this degassing period, the cartridge plate was loaded 
with 56μl of 100mM glucose, 62μl of 15μM oligomycin in port B, and 500mM 2-DG in 
port C. Once loaded, the sensor cartridge was calibrated in the Seahorse machine before 
the cells were loaded into the machine and the Glycolysis Stress Test protocol was 
started. Plates were retained for calculating protein content for further analysis. 
 
2.7.8 Glycolysis Stress Test analysis 
 
Typical data obtained from Glycolysis Stress Tests can be observed in Fig. 2.13. Data are 
expressed as ECAR (mpH/min), which is usually normalised to protein or DNA content. 
Similar to Mito Stress Tests, four basal readings are taken as well as four measurements after 
each injection. Averages of these four readings are then made in order to work out different 
parameters of glycolysis (Fig. 2.10). Description of the varying parameters regarding 
glycolytic function that can be obtained from these tests are given in Table 2.9. 
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Figure 2.13 Prototypical representation of a Glycolysis Stress Test profile 
Schematic showing representative extracellular acidification rate (OCR) per μg of protein of cells in response 
to varying glycolytic modulators (glucose, oligomycin, 2-DG). The numerical key indicates the different 
parameters of glycolytic function that can be extrapolated from these data.  
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Table 2.9 Glycolysis Stress Test analysis.
Parameter Definition What sets the rate 
Basal acidification rate The cells contribution to acidification of the media at rest. Should be 
relatively low and constant without available substrate 
(glucose/pyruvate).  
Any metabolic pathways that expel protons (H+) as a by-product, or 
CO2, which is hydrated to carbonic acid and released as bicarbonate 
with H+. In assay medium, the only available substrate is L-glutamine. 
Glutaminolysis leads to production of alpha-ketoglutarate, thus basal 
acidification may come from CO2 expulsion during TCA cycle. 
Glycolysis The rate of acidification due to the conversion of glucose to pyruvate 
to lactate (anaerobic glycolysis). 
Glycolytic rate will be sensitive to ATP demand, glucose availability, and 
activity of glycolytic enzymes, as well as the metabolic preference cells 
have for ATP production via glycolysis over OXPHOS.  
Maximum glycolytic 
capacity 
The rate of acidification due to glycolysis in the presence of the ATP 
synthase inhibitor oligomycin. Under these conditions, ATP 
production is solely performed by glycolysis, therefore ECAR should 
increase.  
Maximum glycolytic capacity depends strongly on ATP demand of the 
cell, as well as substrate availability and activity of glycolytic enzymes. 
Spare glycolytic capacity The difference between maximum glycolytic capacity and normal 
glycolytic rate gives the spare glycolytic capacity. It is a good measure 
of the cells ability to respond to stress, as well as giving an indication 
as to how much the cell relies on glycolysis under normal conditions. 
Since it is a measure derived from both glycolytic rate as well as 
maximum glycolytic capacity, it is sensitive to both of these parameters 
and the factors affecting them. If normal glycolytic rate is high or 
maximum glycolytic capacity low, then spare glycolytic capacity will be 
low.  
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2.9 Mitochondrial staining 
 
bEnd.3 cells (cultured in either 5mM glucose or 25mM glucose) were plated at a density 
of 250,000/well (6-well plate) on #1.5 (0.16-0.19mm thickness) square gelatin (1%) 
coated-coverslips and allowed to adhere overnight in growth media. The following day, 
media was removed and replaced with media containing either 100μM palmitate or 
vehicle control and incubated overnight. Following this, palmitate/control media was 
removed, and cells were washed once with pre-warmed PBS. The cells were then 
incubated for an optimised incubation time of 30 minutes with an optimised 
concentration of 250nM Mitotracker Red CMXRos (ThermoFisher, M7512) diluted in 
growth media. The media was removed, and the cells were washed twice in pre-warmed 
PBS before being fixed in 1ml 3.7% formalin at 37°C for 15 minutes. Formalin was 
removed and cells were washed twice with pre-warmed PBS. Cells were then incubated 
in 1μM DAPI in PBS (ThermoFisher, D1306) for 5 minutes at room temperature before 
being washed twice in Tris-buffered saline (TBS). Cells were then mounted onto glass 
slides using Prolong™ GOLD Antifade Mountant (ThermoFisher, P36930). Slide 
preparations were kept protected from light at 4°C. The following day, cells were imaged 
using a DeltaVision widefield fluorescent microscope. All images were taken and 
deconvolved by Dr Iain Porter. 
 
2.9 Commonly used lab solutions 
 
Constituent Quantity 
1M Tris-HCl pH 7.4 40mL 
4M NaCl 74mL 
Tween 20 1mL 
dH2O Up to 2L 
Table 2.10 2 litres Tris-buffered saline tween (TBST) 
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Constituent Quantity 
Tris-HCl 150g 
Glycine 720g 
dH2O Up to 5L 
Table 2.11 5 litres 10x stock running buffer 
 
Constituent Quantity 
10 x stock running buffer 200mL 
10% SDS 20mL 
dH2O Up to 2L 
Table 2.12 2 litres 1x running buffer 
 
Constituent Quantity 
Methanol 400mL 
Tris-HCl 11.62g 
Glycine 5.86 
dH2O Up to 2L 
Table 2.13 2 litres transfer buffer 
 
 
Table 2.14 1x stock lysis buffer 
 
Constituent Quantity 
1M Tris-HCl pH 7.4 12.5ml 
750mM NaF  33.5ml 
4M NaCl 12.5ml 
500mM EDTA 10ml 
200mM EGTA 12.5ml 
Triton x-100 5ml 
500mM NaPPi 10ml 
dH2O 400ml 
 111 
 
Constituent Quantity (per 1mL lysis buffer) 
Sucrose 92mg 
β-mercaptoethanol 1μL 
1mM Na3VO4* 1μL 
1mM benzamidine 1μL 
0.1nM PMSF 1μL 
* heat activate at 95°c for 5 minutes immediately prior to use 
Table 2.15 Lysis buffer (immediately prior to use) 
 
Constituent Quantity 
0.5M Tris pH 6.8 4mL 
Glycerol 3.2mL 
20% SDS 3.2mL 
β-mercaptoethanol 1.6mL 
Bromophenol blue Pipette pinch 
Table 2.16 4x sample buffer.
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Chapter 3 
Investigating endothelial 
and hypothalamic 
mitochondrial dynamics in 
mouse models of nutrient 
excess 
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3.1 Introduction 
 
Nutrient excess is associated with many non-communicable diseases, including obesity, 
T2D, CVDs, and dementias3,4. Nutrient excess-associated diseases share common 
pathologies such as hyperglycaemia, dyslipidaemia, ED, and mitochondrial dysfunction.  
 
ED is characterised by an impaired responsiveness to vasodilatory agents, reduced NO 
bioavailability, and decreased eNOS activity/coupling90,94,102,357. Furthermore, ED is 
associated with proinflammatory responses in the EC, termed activation, where ECs 
exhibit increased cell surface expression of cell surface adhesion molecules such as ICAM 
and VCAM102. Proinflammatory signalling molecules such as TNFα and IL-6 will induce 
an increase in the expression of cell-surface adhesion molecules, which facilitate 
leukocyte binding and diapedesis102. ED present in peripheral ECs reduces blood flow 
and promotes atherosclerosis, and reduces insulin transport, contributing to CVD 
development or insulin resistant states respectively. ED present in brain ECs impairs 
cerebral haemodynamics, reduces cerebral blood flow, and damages BBB integrity. 
Investigation into the development of nutrient excess-associated ED is therefore 
warranted. 
 
ED is associated with pathologies linked to nutrient excess, such as hyperglycaemia and 
dyslipidaemia. Indeed, multiple studies investigating both ex vivo138–141,153–156 and in 
vitro154,162–164,171,172 models have reported ED is a direct consequence of nutrient excess.  
However, studies investigating nutrient excess on brain EC function are limited. 
 
Furthermore, it is not clear exactly how nutrient excess leads to ED, but it has been 
proposed that mitochondria may play a role. Indeed, proper mitochondrial function is 
important for EC health127. Nutrient excess has been shown on numerous occasions to 
induce mitochondrial stress, evidenced by increased mROS production198,273,276, reduced 
respiratory capacity268–271,276,280, and dysregulated mitochondrial biogenesis274,278,281–
284. As previously mentioned, chronically upregulated ROS production may be 
detrimental to EC function, as it is known to induce uncoupling of eNOS, inactivate NO 
to form ONOO-, upregulate arginase activity, promote inflammation, and inhibit growth 
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factor signalling357. Furthermore, reduced mitochondrial respiration is associated with 
loss of BBB integrity127. Nutrient excess is also known to impair mitochondrial dynamics, 
with HG and high saturated fats promoting fission over fusion274,278,281–284, resulting in 
dysfunctional and fragmented mitochondria in several cell types. However, the effects 
of nutrient excess on EC mitochondrial dynamics, and how this relates to brain EC 
dysfunction is not well understood.  
 
Therefore, to establish how nutrient excess may affect endothelial mitochondrial 
dynamics, two models of nutrient excess were investigated. The first was a 6-month old 
‘mature adult’ 10-week HFD-fed mouse vs. an age-matched NC-fed control. The reason 
for choosing 10 weeks HFD is that we have observed HFD-dependent vascular 
dysfunction in vivo with only 5 weeks HFD. It should be noted that two other groups – a 
12-week old ‘young adult’ 10-week HFD-fed mouse vs. age-matched NC-fed control – 
were investigated as part of this study in order to determine the two-way effect of both 
age and diet on vascular function. Unfortunately, the weight trajectory of the 12-week 
old young adult HFD-fed mice suggested diet-induced obesity resistance (DIOR) at the 
beginning of the study, or perhaps under eating. At the time the young adult HFD-fed 
mice were on the study, the Medical School Resources Unit (MSRU; the animal unit at 
which the animal work is carried out) was suffering from ongoing structural and 
technical problems. It is assumed that many mice that were undergoing studies during 
this period were experiencing increased levels of stress, which could in turn lead to 
DIOR. For this reason, the in vivo data sets from HFD-fed young mice are not used herein. 
Young adult HFD-fed data sets are shown in Appendix S1, where both the weight 
trajectory and the anxious phenotype of the mice can be seen. The young adult NC-fed 
group is still used herein as a control group for testing the effect of purely aging on 
vascular function.  
 
The other model of nutrient excess used was an 8-week old db/db mouse vs. wt/db and 
wt/wt age-matched controls. The phenotype of the db/db mouse is detailed in Methods 
section 2.2.4 Briefly, db/db mice are obese, hyperinsulinaemic, hyperglycaemia, and 
hyperphagic by 4-5 weeks of age. They are therefore an excellent model of severe 
metabolic syndrome and nutrient excess. 
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Body weight and in vivo endothelial function was assessed in these models, as well as 
expression of proteins involved in mitochondrial dynamics in tissues of interest - aorta, 
VE fraction, and hypothalamus. The aorta and VE fraction were used to investigate 
vascular mitochondrial dynamics. As previously mentioned in section 1.10, capillaries 
comprising the BBB at the ARC are fenestrated and leaky, meaning the hypothalamus is 
vulnerable to the effects of nutrient excess. Therefore, the hypothalamus is an area of 
interest. The hypothesis was that mitochondrial dynamics in these two models of 
nutrient excess would be impaired in the stated tissues and said impairment would be 
associated with ED and body weight gain.  
 
  
3.2 Results 
 
6-month ‘mature adult’ male WT mice were placed on either HFD or NC diet for 10 
weeks to investigate the effect of diet. Mice were randomly assigned to HFD or NC 
groups, but the groups were weight matched. Alongside these groups, a group of 12-
week old ‘young adult’ NC mice were used as a control against ‘mature adult’ NC-fed 
mice to investigate the effect of ageing. MATURE NC mice are compared to YOUNG NC 
mice to investigate the effect of age. The 6-month old groups will be referred to as 
MATURE NC and MATURE HF and the 12-week old group will be referred to as YOUNG 
NC. Therefore, in the in vivo data sets, MATURE HF mice are compared to MATURE NC 
mice to investigate the effect of diet. A timeline of this study can be observed in Fig 3.1. 
3-week old female db/db mice, along with their wt/db and wt/wt littermates were used 
in the second study. A summary of this study timeline is provided in Fig. 3.2. 
 
3.2.1 HFD-feeding increases body weight in 6-month old mice compared to controls 
 
Body weights of mice were measured weekly over 10 weeks. MATURE HF mice gained 
significantly more weight than MATURE NC mice (Fig. 3.3B – MATURE NC 1.05g ± 0.85g 
vs. MATURE HF 8.87g ± 1.59g, p < 0.001, n = 9-11). When expressed as a percentage, 
MATURE HF mice gained significantly more weight than MATURE NC mice (Fig 3.3D – 
MATURE NC 0.73% ± 2.18% vs. MATURE HF 18.45% ± 5.14%, n = 9-11, p < 0.01). MATURE 
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NC mice did not differ from YOUNG NC mice in terms of body weight. From the weight 
trajectories (Fig. 3.3A, C), it is apparent that MATURE NC mice can maintain their weight 
at a steady value. 
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Figure 3.1 Study timeline for young/mature adult mice on NC or HFD 
6-month old male mice were weight matched before undergoing an LDI scan on week 0 (basal scan). 
Following this basal scan, mice were placed on 45% HFD or maintained on NC diet. Microvascular EC 
function was measured again at weeks 5 and 10. At the end of the study mice were fasted overnight and 
culled the following morning. Tissue was harvested for post-mortem biochemical analysis. 
Figure 3.2 Study timeline for db/db mice 
Wt/wt, wt/db, and db/db mice were weighed weekly from 4 until 8 weeks of age. Microvascular EC 
function was measured using LDI, before mice were fasted overnight and culled the following morning. 
Tissue was harvested for post-mortem biochemical analysis. 
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Figure 3.3 HFD-feeding in mature adult mice promotes weight gain 
Young adult mice were fed NC diet for 10 weeks. Mature adult mice were fed either NC or HFD for 10 
weeks. (A) Average weight of the mice over the 10 weeks of the study. (B) Net weight gain at the end of 
the study. (C) Percentage weight gain over the 10 weeks of the study. (D) Percentage weight gain at the 
end of the study.  
 
Data are expressed as mean ± standard error of the mean. 
n = 6-11. (B) and (D) ordinary one-way ANOVA with Bonferroni multiple comparison. ## = p < 0.01, ### 
= p < 0.001. 
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3.2.2 Ageing, but not HFD-feeding, is associated with impaired endothelial function in 
vivo 
 
To measure endothelial function in vivo, mice undergo LDI and iontophoresis of 
vasoactive agents (phenylephrine [PE] to cause vasoconstriction and acetylcholine [ACh] 
to induce endothelium-dependent vasodilation). There are three main outputs that can 
provide information about EC health – 1) baseline flux skin perfusion (AU), 2) % Δ skin 
perfusion in response to ACh compared to PE-induced baseline, and 3) peak flux skin 
perfusion after ACh application (AU).  
 
Pre-diet, the two cohorts of mice did not differ in terms of baseline skin perfusion as 
expected (Fig. 3.4A). Furthermore, mature NC did not differ from young NC mice in 
terms of baseline skin perfusion (Fig. 3.4A). After 5 weeks of dietary intervention, 
mature HF exhibited significantly lower baseline skin perfusion compared to mature NC 
(Fig. 3.4B – mature NC 289.2 ± 13.8 vs. mature HF 232.6 vs. 14.4, n = 9-11, p < 0.05), but 
mature NC mice did not differ from mature NC mice (Fig. 3.4B). At 10 weeks dietary 
intervention, mature HF exhibited a trend toward decreased baseline flux (AU) 
compared to mature NC, but this did not reach significance. Mature HF mice exhibited 
a decline in baseline flux compared to young NC mouse however, suggesting an additive 
effect of HFD-feeding and age on baseline skin perfusion (Fig. 3.4C – young NC 270.6 ± 
16.0 vs. 198.2 ± 14.4, n = 6-9, p < 0.05). When internally normalised and expressed as a 
percentage change in baseline skin perfusion over time (compared to the basal pre-diet 
scan), mature HF mice exhibited a trend toward a decline in % baseline skin perfusion 
compared to the basal scan at 5 and 10 weeks dietary intervention, but this decline was 
not significant compared to mature NC (Fig. 3.4D).  
 
To investigate EC function, the response in skin perfusion to PE application (constriction) 
followed by Ach application (dilation) was measured. This is expressed herein in two 
ways. Fig. 3.4A, C, E express % Δ in skin perfusion (first scan = 100%) against time. The 
time of PE and ACh application is represented by dotted lines. Fig. 3.4B, D, F exhibit % Δ 
skin perfusion in response to ACh where PE-constricted baseline is 100%. At baseline, 
there is no effect of age or diet on endothelial responsiveness to ACh (Fig. 3.5B). After 5 
weeks of diet, ACh response is markedly reduced in both mature groups compared to 
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young NC, but this change is not sensitive to diet (Fig. 3.5D – YOUNG NC 39.18% ± 4.06% 
vs. MATURE NC 8.75% ± 5.05% vs. mature HF 10.39% ± 5.28%, n = 6-11, p < 0.01).  
Similarly, after 10 weeks of diet, ACh response in both mature groups is significantly 
reduced compared to the young NC group, but diet has no affect (Fig. 3.5F – young NC 
40.61% ± 4.44% vs. mature NC 18.6% ± 3.39% vs. mature HF 13.43% ± 6.31%, n = 6-11, 
p < 0.01 mature NC vs. young NC, p < 0.001 mature HF vs. young NC). In terms of PE 
response, no strong effect of age or diet is observed. At the 5-week point, mature groups 
appear to exhibit a larger response to PE with increase vasoconstriction compared to 
young NC mice (Fig. 3.5C), but this effect disappears at the 10-week time point so may 
be a false result. 
 
Peak skin perfusion (AU) was measured in response to ACh. Mature groups did not differ 
from one another or from the young NC group pre-diet (Fig. 3.6A). However, after 5 
weeks of dietary intervention, both mature groups exhibited significantly reduced ACh-
induced peak skin perfusion values (Fig. 3.6B – young NC 342 ± 6.4 vs. mature NC 266.50 
± 17.01, n = 6-11, p < 0.01; young NC 342 ± 6.4 vs. mature HF 216.60 ± 16.95, n = 9-11, 
p < 0.001), suggesting age is having an effect. At 10 weeks of dietary intervention, both 
mature groups exhibited reduced ACh-induced peak skin perfusion compared to young 
NC (Fig. 3.6C – young NC 357.3 ± 9.48 vs. mature NC 230.9 ± 13.34, n = 6-11, p < 0.001; 
young NC 357.3 ± 9.48 vs. mature HF 199.3 ± 8.63, n = 6-9, p < 0.001), suggesting an age-
related effect. When internally normalised and expressed as a percentage of the basal 
scan, at 5 and 10 weeks both mature groups exhibit a significant reduction in peak skin 
perfusion compared to young NC but are not significantly different from one another 
(Fig. 3.6D – 5 weeks – young NC 115.37% ± 8.04% vs. mature NC 80.5% ± 6.89%, n = 6-
11, p < 0.01; young NC 115.37% ± 8.04% vs. mature HF 65.81% ± 6.1% vs., n = 6-9, p < 
0.001; 10 weeks – young NC 121.81% ± 11.95% vs. mature NC 68.85% ± 4.7%, n = 6-11, 
p < 0.001; young NC 121.81% ± 11.95% vs. mature HF 64.08% ± 6.91%, n = 6-9, p < 0.001).  
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Figure 3.4 Effect of age and diet on baseline skin perfusion 
Baseline skin perfusion (AU) was measured using LDI pre-diet (A), after 5 (B), and 10 weeks of dietary 
intervention (C). Data are also expressed as % Δ in baseline skin perfusion over time (weeks) in 
comparison to the basal pre-diet scan (D). 
 
Data are expressed as mean ± standard error of the mean. 
n = 6-11. (A), (B), and (C) – Welch’s ANOVA with Dunnett’s multiple comparison. * = p < 0.05 compared 
to YOUNG NC. # = p < 0.05. (D) – repeated measures with Bonferonni multiple comparison. 
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Figure 3.5 Ageing impairs endothelial response to ACh, but HFD-feeding has no effect 
The effect of ageing and HFD on endothelial function was investigated by measuring endothelial response to 
the vasodilator ACh. PE- and ACh-induced Δ skin perfusion as a percentage of baseline (baseline is 100%) 
against time (minutes) pre diet (A), and after 5 (C) and 10 (E) weeks of dietary intervention. ACh-induced Δ 
skin perfusion as a percentage of the PE-induced normalised baseline pre diet (B), and after 5 (D) and 10 (F) 
weeks of dietary intervention  
Data are expressed as mean ± standard error of the mean 
n = 6-11. (B), (D), and (F) – Welch’s ANOVA with Dunnett’s multiple comparison. * = p < 0.05 in comparison 
to WT NC, ** = p < 0.01 in comparison to YOUNG NC. 
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Figure 3.6 Ageing and diet induce defects in ACh-induced peak skin perfusion 
Peak skin perfusion (AU) in response to the vasodilatory agent ACh was measured pre dietary intervention 
(A), and after 5 (B) and 10 (C) weeks dietary intervention. Data are also expressed as a % Δ in baseline skin 
perfusion in comparison to the basal pre-diet scan (D).  
 
Data are expressed as mean ± standard error of the mean. 
n = 6-11. (A), (B), and (C) – Welch’s ANOVA with Dunnett’s multiple comparison. (D) – repeated measures 
with Bonferonni multiple comparison. ** = p < 0.01, *** = p < 0.001 when compared to YOUNG NC. 
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3.2.3 Db/db mice gain significantly more weight than their wt/db and wt/wt littermates 
 
Wt/wt, wt/db, and db/db mice were weaned at 3 weeks old and weighed weekly from 
4-8 weeks old. By 8 weeks old, db/db mice gained significantly more weight than WT/WT 
(Fig. 3.7B – wt/wt 5.48g ± 0.86g vs. db/db 20.08g ± 1.64g, n = 5-7, p < 0.001) and wt/db 
littermates (Fig. 3.7B – wt/db 4.09g ± 0.64 vs. db/db 20.08g ± 1.64g, n = 6-7, p < 0.001). 
When expressed as percentage weight gain compared to starting weight, by 8 weeks old 
db/db mice exhibited a higher percentage weight gain compared to starting weight than 
wt/wt littermates (Fig. 3.7D – wt/wt 39.94% ± 7.99% vs. db/db 106.9% ± 19.47%, n = 5-
7, p < 0.05) and wt/db littermates (Fig. 3.7D – wt/db 22.59% ± 3.65% vs. db/db 106.9% 
± 19.47%, n = 6-7, p < 0.05).  
 
3.2.4 Db/db mice exhibit severe fasting hyperglycaemia 
 
Fasting blood glucose levels were measured after a 16-hour overnight fast. Db/db mice 
exhibited significantly increased fasting blood glucose levels compared to wt/wt 
littermates (Fig. 3.8 – wt/wt 6.06 mmol/l ± 0.66 mmol/l vs. db/db 22.1 mmol/l ± 1.63 
mmol/l, n = 4-5, p < 0.01) and wt/db littermates (Fig. 3.8 – wt/db 6.93 mmol/l ± 1.86 
mmol/l vs. db/db 22.1 mmol/l ± 1.63 mmol/l, n = 4, p < 0.01).  
 
3.2.5 Db/db mice exhibit endothelial dysfunction in vivo 
 
Endothelial function was measured in wt/wt, wt/db, and db/db mice using LDI and 
iontophoresis of the vasodilator ACh. Db/db mice showed severe blunted 
responsiveness to both the vasoconstrictor PE and the vasodilator ACh (Fig. 3.9A, C, D). 
Interestingly, wt/db mice display a reduced ACh response compared to wt/wt at certain 
time points (Fig 3.9B – 5th scan post ACh – wt/wt 116.35% ± 5.7% vs. wt/db 81.87% ± 
7.4%, n = 5-7, p < 0.05; 10th scan post ACh – wt/wt 112.45% ± 10.24% vs. wt/db 81.89% 
± 7.09%, n = 5-7, p < 0.01). At scans 5, 10, and 11 post ACh, db/db mice exhibited 
significantly reduced % skin perfusion compared to wt/wt (Fig 3.9C – 5th scan post ACh 
– wt/wt 116.35% ± 5.7% vs. db/db 88.91% ± 5.47%, n = 5-8, p < 0.05; 10th scan post ACh 
– wt/wt 112.45% ± 10.24% vs. db/db 86.7% ± 3.84%, n = 5-7, p < 0.05; 11th scan post 
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ACh – wt/wt 113.5% ± 10.2% vs. db/db 88.24% ± 6.05, n = 5-7, p < 0.05), but not wt/db 
littermates (Fig. 3.9D). When expressed as % Δ skin perfusion in response to ACh 
compared to PE-induced normalised baseline, no differences between groups were 
observed. Db/db mice also exhibited significantly reduced baseline flux compared to 
wt/wt (3.10A – wt/wt 352.1 ± 36.63 vs. db/db 217.4 ± 17.91, n = 5-8, p < 0.05) and wt/db 
littermates (3.10A – wt/db 409.3 ± 39.16 vs. db/db 217.4 ± 17.91, p 7-8, p < 0.01). The 
reduced baseline in db/db mice suggests their microvasculature is already very 
constricted and may be a reason why they do not respond well to PE. Furthermore, 
db/db mice display an impaired ACh response, exhibited by a lower peak flux in response 
to ACh compared to wt/wt (3.10B – wt/wt 445.4 ± 49.97 vs. db/db 236.3 ± 15.79, n = 5-
8, p < 0.05) and wt/db littermates (3.10B – wt/db 384.4 ± 37.97 vs. db/db 326.3 ± 15.79, 
n = 7-8, p < 0.05).  
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Figure 3.7 Db/db mice gain significantly more weight than their wt/wt and wt/db littermates 
Wt/wt, wt/db, and db/db mice were weighed weekly from 4 weeks old to 8 weeks old. (A) Average weight of 
the mice from 4 to 8 weeks old. (B) Average body weight gained by 8 weeks old. (C) Weight gain as a % of 
starting weight from 4 to 8 weeks old. (D) Percentage weight gain at 8 weeks old.  
 
Data are expressed as mean ± standard error of the mean. 
n = 5-7. (B) and (D) – Welch’s ANOVA with Dunnett’s multiple comparison. * = p < 0.05, *** = p < 0.001 when 
compared to wt/wt, # = p < 0.05, ### = p < 0.001 when compared to wt/db.  
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Figure 3.8 Db/db mice exhibit severe fasting hyperglycaemia 
Blood glucose levels (mmol/l) were measured after a 16-hour fast in wt/wt, wt/db, and db/db mice.  
 
Data are expressed as mean ± standard error of the mean. 
n = 4-5. Welch’s ANOVA with Dunnett’s multiple comparison. ** = p < 0.01 when compared to wt/wt, ## = 
p < 0.01 when compared to wt/db. 
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Figure 3.9 Db/db mice exhibit reduced responsiveness to vasoactive agents 
To measure endothelial function in vivo, wt/wt, wt/db, and db/db underwent LDI with iontophoresis of 
PE and ACh. (A) ACh-induced skin perfusion as a percentage of baseline (baseline is 100%) over time in 
wt/wt, wt/db, and db/db mice. (B) ACh-induced skin perfusion as a percentage of baseline over time in 
wt/wt and wt/db mice. (C) ACh-induced skin perfusion as a percentage of baseline over time in wt/wt and 
db/db mice. (D) ACh-induced skin perfusion as a percentage of baseline over time in wt/db and db/db 
mice. (E) ACh-induced Δ skin perfusion compared to PE-induced normalised baseline in wt/wt, wt/db and 
db/db mice. The dotted lines represent the induction of the iontophoresis of PE and ACh.  
Data are expressed as mean ± standard error of the mean.n = 5-8. (A), (B), (C), and (D) – repeated 
measures with Bonferroni multiple comparison. (E) – Welch’s ANOVA with Bonferroni multiple 
comparison. * = p < 0.05 when compared to wt/wt, ** = p < 0.01 when compared to wt/wt. 
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Figure 3.10 Db/db exhibit lower baseline and peak fluxes 
Baseline skin perfusion (A) and peak skin perfusion (B) were measured in wt/wt, wt/db, and db/db mice. 
  
Data are expressed as mean ± standard error of the mean. 
n = 5-8, ordinary one-way ANOVA, * = p < 0.05 when compared to wt/wt. ## = p < 0.01 when compared to 
wt/db.  
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3.2.6 Differential effects of age and HFD on aortic expression of proteins controlling 
mitochondrial dynamics 
 
To investigate the effects of age and HFD on aortic mitochondrial dynamics, aortae were 
harvested, and protein was extracted from the four groups of mice: YOUNG NC, YOUNG 
HF, MATURE NC, and MATURE HF. As previously mentioned, the YOUNG HF group 
exhibited resistance to HFD for the first 6 weeks of the study. However, they did 
eventually put on weight from weeks 7-10, and were heavier than their YOUNG NC 
littermates by the end of the study (Appendix S1). Therefore, we decided to use their 
tissues for post-mortem biochemical analysis. The final age of the mice when tissues 
were taken was YOUNG NC/YOUNG HF = 22 weeks old and MATURE NC/MATURE HF = 
32 weeks old. Proteins were separated using SDS-PAGE and proteins of interest were 
probed for using standard Western blotting.  
 
Representative blots for Mfn1, Mfn2, and OPA1 and phospo-Drp1 s637 and total Drp1 
are shown in Fig. 3.11 (A) and (B) respectively. Actin was used as a loading control. 
YOUNG HF mice exhibited a trend toward decreased Mfn1 expression in aorta compared 
to YOUNG NC mice. Power calculations reveal a sample size of 15 is required in order to 
test the null hypothesis adequately. Furthermore, there was a trend toward MATURE-
associated decline in aortic Mfn1 expression (p = 0.08). Mfn2 expression was reduced in 
both MATURE groups when compared to YOUNG HF mice (Fig. 3.11D – YOUNG HF 1.4 ± 
0.26 vs. MATURE HF 0.64 ± 0.11, n = 5-6, p < 0.01; YOUNG HF 1.4 ± 0.26 vs. MATURE NC 
0.56 ± 0.08, n = 5-6, p < 0.01). Indeed, the two-way ANOVA identified a main effect of 
age (p = 0.0049). There was also a trend toward increased Mfn2 expression in YOUNG 
HF mice compared to YOUNG NC mice, with power calculations revealing a sample size 
of 11 is required to test for significance. There was no change in OPA1 expression (Fig. 
3.11E). We observed HFD-associated increased phosphorylation of Drp1 at s637 (Fig. 
3.11F, p = 0.02), as well as age-associated decline in total Drp1 (Fig. 3.11G, p = 0.02). The 
latter may be exacerbated by HFD. Interestingly, when expressed as a ratio of 
phospho/total, there was a significant interactive effect (p = 0.002) in that the additive 
effect of age and diet significantly increased the ratio. Indeed, post-hoc tests reveal the 
MATURE HF group exhibited significantly higher levels compared to MATURE NC (Fig. 
3.11H – MATURE NC 0.61 ± 0.2 vs. MATURE HF 2.74 ± 0.39, n = 5-6, p < 0.001) and 
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YOUNG HF (Fig. 3.11H –YOUNG HF 1.05 ± 0.21 vs. MATURE HF 2.74 ± 0.39, n = 5-6, p < 
0.01), as well as  YOUNG NC (Fig. 3.11H – YOUNG NC 1 ± 0.26 vs. MATURE HF 2.74 ± 
0.39, n = 5-6, p < 0.01), indicating an age- and HFD-associated increase in the phospho 
s637/total Drp1 ratio.  
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Figure 3.11 Aortic expression of mitochondrial dynamics proteins in YOUNG NC, YOUNG HF, 
MATURE NC, and MATURE HF mice 
YOUNG mice were culled at 22 weeks of age and MATURE mice were culled at 34 weeks. Aortae were 
harvested and protein extracted. 20μg of protein was loaded onto acrylamide gels and separated by SDS 
PAGE. (A) and (B) Representative western blots showing expression of proteins regulating mitochondrial 
dynamics in the murine aorta with actin as a loading control. Quantification of western blots normalised to 
actin of (C) Mfn1, (D) Mfn2, (E) OPA1, (F) p-Drp1 s637, (G) total Drp1, and (H) p-Drp1/total Drp1 ratio. 
The molecular weight of (phospho)Drp1 is 81kD. 
 
Data are expressed as mean ± standard error of the mean. 
n = 5-6. (C) – (H) – ordinary two-way ANOVA with Bonferroni multiple comparison. ** = p < 0.01 when 
compared to YOUNG NC, # = p < 0.05 and ## = p < 0.01 when compared to YOUNG HF, $ = p < 0.05 and $$$ 
= p < 0.001 when compared to MATURE NC. 
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3.2.7 Ageing and HFD do not influence VE fraction expression of proteins controlling 
mitochondrial dynamics 
 
Hemi-brains were harvested and VE fractions (NVU) were isolated. Proteins isolated 
from VE fractions were separated using SDS-PAGE and proteins of interest were probed 
for using standard Western blotting. Representative blots for Mfn2 and OPA1 are shown 
in Fig. 3.12 (A). Actin was used as a loading control. In the case of OPA1, the double band 
was quantified to calculate total OPA1 expression, the higher band was quantified to 
calculate long-form OPA1 expression, and the lower band was quantified to calculate 
short-form OPA1 expression.  
 
Interestingly, we observed a trend toward a dietary effect in reducing total OPA1 
expression (p = 0.08). There was also a trend toward reduced total OPA1 (~30%, 3.12C), 
short-form OPA1 (~30%, 3.12D), and long-form OPA1 (~30%, 3.12E), in YOUNG HF vs. 
YOUNG NC. Power calculations suggest sample sizes of 12 to test for significance 
adequately. There was no effect of age or diet on VE fraction Mfn2 expression (Fig. 
3.12B). 
 
3.2.8 Age-related decline in hypothalamic expression of mitochondrial fusion proteins 
 
Hypothalami were harvested from mice. Protein was isolated and separated using SDS-
PAGE and proteins of interest were probed for using standard Western blotting. 
Representative blots for Mfn2 and OPA1 are shown in Fig. 3.13 (A). Actin was used as a 
loading control. In the case of OPA1, the double band was quantified to calculate total 
OPA1 expression, the higher band was quantified to calculate long-form OPA1 
expression, and the lower band was quantified to calculate short-form OPA1 expression.  
 
When performing two-way ANOVA, there was an age-related effect of reduced Mfn2 (p 
< 0.0001), total OPA1 (p < 0.0001), long-form OPA1 (p < 0.0001), and short-form OPA1 
(p < 0.0001).  
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Indeed, MATURE NC and MATURE HF mice exhibited reduced hypothalamic Mfn2 levels 
when compared to YOUNG NC mice (Fig. 3.13B – YOUNG NC 1 ± 0.06 vs. MATURE NC 
0.55 ± 0.06, n = 6-11, p < 0.01; YOUNG NC 1 ± 0.03 vs. MATURE HF 0.44 ± 0.06, n = 6-9, 
p < 0.01) as well as to YOUNG HF mice (Fig. 3.13B – YOUNG HF 1.1 ± 0.04 vs. MATURE 
NC 0.55 ± 0.06, n = 6-11, p < 0.01; YOUNG HF 1.1 ± 0.04 vs. MATURE HF 0.44 ± 0.06, n = 
6-9, p < 0.01).  
 
Both MATURE groups exhibited significant reductions in OPA1 total protein compared 
to YOUNG NC (Fig. 3.31C – YOUNG NC 1 ± 0.03 vs. MATURE NC 0.5 ± 0.03, n = 6-11, p < 
0.001; YOUNG NC 1 ± 0.03 vs. MATURE HF 0.44 ± 0.06, n = 6-11, p < 0.001) and YOUNG 
HF (Fig. 3.31C – YOUNG HF 0.93 ± 0.09 vs. MATURE NC 0.5 ± 0.03, n = 6-11, p < 0.001; 
YOUNG HF 0.93 ± 0.09 vs. MATURE HF 0.44 ± 0.06, n = 6-11, p < 0.001). MATURE groups 
also exhibited reductions in in OPA1 short-form compared to YOUNG NC (Fig. 3.13D – 
YOUNG NC 1 ± 0.13 vs. MATURE NC 0.57 ± 0.05, n = 6-11, p < 0.01; YOUNG NC 1 ± 0.13 
vs. MATURE HF 0.42 ± 0.59, n = 6-11, p < 0.001) and YOUNG HF (Fig. 3.13D – YOUNG HF 
0.92 ± 0.08 vs. MATURE NC 0.57 ± 0.05, n = 6-11, p < 0.05; YOUNG HF 0.92 ± 0.08 vs. 
MATURE HF 0.42 ± 0.59, n = 6-11, p < 0.001).  
 
MATURE groups further showed decreased OPA1 long-form compared to YOUNG NC 
(Fig. 3.13E – YOUNG NC 1 ± 0.12 vs. MATURE NC 0.49 ± 0.08, n = 6-11, p < 0.001; YOUNG 
NC 1 ± 0.12 vs. MATURE HF 0.3 ± 0.03, n = 6-11, p < 0.001) and YOUNG HF (Fig. 3.13E – 
YOUNG HF 0.91 ± 0.07 vs. MATURE NC 0.49 ± 0.08, n = 6-11, p < 0.001; YOUNG HF 0.91 
± 0.07 vs. MATURE HF 0.3 ± 0.03, n = 6-11, p < 0.001). No effect of diet was observed.  
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Figure 3.12 VE fraction expression of mitochondrial fusion proteins in YOUNG NC, YOUNG HF, MATURE 
NC, and MATURE HF mice 
YOUNG mice were culled at 22 weeks of age and MATURE mice were culled at 34 weeks. VE fractions were 
harvested from hemi-brains and protein extracted. 20μg of protein was loaded onto acrylamide gels and 
separated by SDS PAGE. (A) Representative western blots showing expression of proteins regulating 
mitochondrial fusion in the murine NVU with actin as a loading control. Quantification of western blots 
normalised to actin of (B) Mfn2, (C) total OPA1, (D) OPA1 short-form, (E) OPA1 long-form. 
 
Data are expressed as mean ± standard error of the mean. 
n = 6-11. (B) – (E) – ordinary two-way ANOVA with Bonferroni multiple comparison.  
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Figure 3.13 Hypothalamic expression of mitochondrial fusion proteins in YOUNG NC, YOUNG HF, 
MATURE NC, and MATURE HF mice  
YOUNG mice were culled at 22 weeks of age and MATURE mice were culled at 34 weeks of age. Hypothalami 
were harvested and protein extracted. 20μg of protein was loaded onto acrylamide gels and separated by 
SDS PAGE. (A) Representative western blots showing expression of proteins regulating mitochondrial fusion 
in the murine hypothalamus with actin as a loading control. Quantification of western blots normalised to 
actin of (B) Mfn2, (C) total OPA1, (D) OPA1 short-form, (E) OPA1 long-form. 
 
Data are expressed as mean ± standard error of the mean. 
n = 6-11. (B) – (E) – ordinary two-way ANOVA with Bonferroni multiple comparison. ** = p < 0.01 and *** = 
p < 0.001 when compared to YOUNG NC. # = p < 0.05, ## = p < 0.01, and ### = p < 0.001 when compared to 
YOUNG HF. 
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3.2.9 Aortic expression of mitochondrial fusion and fission proteins is not altered in 
db/db mice 
 
Db/db mice and their wt/wt and wt/db littermates were culled at 8 weeks of age. Aortae 
were excised from mice and protein was extracted. Proteins were separated using SDS-
PAGE, and proteins involved in the control of mitochondrial fusion and fission were 
probed for by Western blot. Representative Western blots are shown in Fig. 3.14A. Actin 
was used as a loading control. Db/db mice exhibited no alterations in Mfn1 (3.14B), Mfn 
2 (3.14C), OPA1 (3.14D), or total Drp1 (3.14F). However, there is a trend toward 
decreased phospho-Drp1 s616 expression in db/db mice compared to both wt/wt and 
wt/db (3.14E), with power calculations suggesting a sample size of 12 to accurately 
detect significance. When measuring phospho/total ratio, both wt/db and db/db groups 
exhibit trends toward reduced levels (3.14G) compared to wt/wt. Power calculations 
reveal that sample sizes of only 9 for both wt/db an db/db are required to detect 
significance for the current effect size (compared to wt/wt). 
 
3.2.10 VE fraction expression of mitochondrial fusion and fission proteins is not altered 
in db/db mice 
 
VE fraction was isolated from hemi-brains using a protocol described in Methods 2.6.1. 
Protein was extracted from VE fractions and separated using SDS-PAGE. Proteins 
involved in the control of mitochondrial dynamics were probed for using Western 
blotting. Representative Western blots are shown in Fig 3.15A. Actin was used as a 
loading control. Db/db mice exhibited no alterations in VE fraction expression of Mfn1 
(3.15B), Mfn2 (3.15C), total OPA1 (3.15D), OPA1 short-form (3.15E), OPA1 long-form 
(3.15F), or phospho-Drp1 s616 (3.15G). However, wt/db mice exhibited a trend toward 
increased (~70%) tDrp1 expression compared to wt/wt, an effect that was not present 
in db/db mice (Fig 3.15H). Power calculations reveal a sample size of 8 is required to 
detect significance at this effect size. When expressed as phospho/total, there was no 
change between groups. 
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Figure 3.14 Aortic expression of proteins involved in mitochondrial dynamics in wt/wt, wt/db, and db/db 
mice 
Aortae were harvested and protein extracted. 20μg of protein was loaded onto acrylamide gels and separated by 
SDS PAGE. (A) Representative western blots showing expression of proteins regulating mitochondrial dynamics in 
the murine aorta with actin as a loading control. Quantification of western blots normalised to actin of (B) Mfn1, 
(C) Mfn2, (D) OPA1, (E) p-Drp1 s616, (F) total Drp1, and (G) p-Drp1/total Drp1 ratio. 
 
Data are expressed as mean ± standard error of the mean. 
n = 4-8. (B)-(G) Welch’s ANOVA with Dunnett’s multiple comparison. 
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Figure 3.15 VE fraction expression of proteins controlling mitochondrial dynamics in wt/wt, wt/db, and 
db/db mice 
VE fractions (NVU) and protein extracted. 20μg of protein was loaded onto acrylamide gels and separated by 
SDS PAGE. (A) Representative western blots showing expression of proteins regulating mitochondrial dynamics 
in the murine NVU with actin as a loading control. Quantification of western blots normalised to actin of (B) 
Mfn1, (C) Mfn2, (D) OPA1, (E) OPA1 short-form, (F) OPA1 long-form, (G) p-Drp1 s616, (H) total Drp1, and (I) p-
Drp1/total Drp1 ratio. 
 
n = 4-8. (B)-(I) – Welch’s ANOVA with Dunnett’s multiple comparison.  
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3.2.11 Db/db mice exhibit increased hypothalamic phosphorylation of Drp1 at serine 
616 
 
Hypothalami were harvested and protein was extracted. Proteins were separated using 
SDS-PAGE, and proteins involved in the control of mitochondrial fusion and fission were 
probed for by conventional Western blot. Representative blots are shown in 3.16A. Actin 
was used as a loading control.  
 
Db/db mice did not significantly differ from control groups in terms of hypothalamic 
Mfn1 (Fig. 3.16B) and OPA1 (total Fig. 3.16C, short-form Fig. 3.16D, long-form Fig. 
3.16E). Db/db mice exhibited increased phospho-Drp1 s616 expression compared to 
wt/wt (Fig. 3.16F – wt/wt 1 ± 0.05 vs. db/db 1.63 ± 0.17, n = 4-8, p < 0.05) and a trend 
toward reduced total Drp1 expression (Fig. 3.16G). Power calculations reveal a sample 
size of 9 would be required to test for significance. When expressed as a ratio, db/db 
mice exhibited elevated phospho/total ratio compared to wt/wt (3.16H – WT/WT 1 ± 
0.09 vs db/db 2.16 ± 0.18, n = 4-8, p < 0.001).  
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Figure 3.16 Hypothalamic expression of proteins controlling mitochondria dynamics in WT/WT, WT/db, 
and db/db mice 
Hypothalami were harvested and protein extracted. 20μg of protein was loaded onto acrylamide gels and 
separated by SDS PAGE. (A) Representative western blots showing expression of proteins regulating 
mitochondrial dynamics in the murine hypothalamus with actin as a loading control. Quantification of western 
blots normalised to actin of (B) Mfn1, (C) total OPA1, (D) OPA1 short-form, (E) OPA1 long-form, (F) p-Drp1 s616, 
(G) total Drp1, and (H) p-Drp1/total Drp1 ratio. 
 
Data are expressed as mean ± standard error of the mean. 
n = 4-8. (B)-(H) – Welch’s ANOVA with Dunnett’s multiple comparisons. * = p < 0.05, *** = p < 0.001 when 
compared to wt/wt.  
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3.2.12 Db/db mice do not exhibit aortic or VE fraction endothelial activation 
 
Aortae and VE fractions were isolated and protein extracted. Proteins were separated 
using SDS-page and proteins known to be involved in controlling mitochondrial 
dynamics were probed for using conventional Western blotting. Representative blots of 
aortic and VE fraction ICAM expression are shown in Fig. 3.17A and B respectively. Actin 
was used as a loading control. Db/dbs exhibited no significant difference in ICAM 
expression in aorta (Fig 3.17C) or VE fraction (Fig. 3.17D) compared to control groups.  
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Figure 3.17 Aortic and VE fraction ICAM expression in wt/wt, wt/db, and db/db mice 
Aortae and VE fractions were harvested and protein extracted. 20μg of protein was loaded onto acrylamide 
gels and separated by SDS PAGE. Representative western blots showing expression of ICAM in aorta (A) and 
VE fraction (B) with actin as a loading control. Quantification of western blots normalised to actin of aortic 
ICAM (C) and VE fraction ICAM (D). 
 
Data are expressed as mean ± standard error of the mean. 
n = 4-8. (B)-(H) – Welch’s ANOVA with Dunnett’s multiple comparisons. 
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3.3 Discussion  
3.3.1 Modeling nutrient excess using a mature adult, HFD-fed mouse 
 
The first aim of this study was to establish a mature adult, HFD-fed model of nutrient 
excess. To clarify the effects of HFD-feeding, mice were weighed weekly. As expected, 
mature adult HFD-fed mice gained significantly more weight than their NC-fed 
counterparts. Mature adult mice on NC diets maintained their weights steadily across 
the 10 weeks of the study, not differing in terms of weight gain from the young adult NC 
group. This is likely due to the fact that the mice have reached their stable adult body 
weight by this age. Indeed, human studies suggest fat mass peaks at middle age (40-70 
years)358, and declines thereafter359. It would be of interest to investigate the effect of 
age on susceptibility to HFD; that is compare mature adult HFD-fed mice to young adult 
HFD-fed mice. As previously mentioned in 3.1, this was attempted herein but the weight 
trajectory of the young adult HFD-fed mice was unusual (Appendix S1). HFD-fed mice 
should exhibit rapid increases in weight upon HFD feeding, but in this case young adult 
HFD-fed mice showed remarkably similar weight trajectories to young adult NC-fed 
mice, suggesting DIOR or perhaps under eating. To reiterate, MSRU was experiencing a 
high level of technical and structural issues which was likely to have some kind of impact 
on the mice. We proposed that mice were not putting on weight due to heightened 
anxiety brought on by these issues and tested for such using an open-field test. Young 
adult HFD-fed stayed close to the edges of the open-field box, rarely venturing into the 
middle. These data suggest that mice have an anxious phenotype as opposed to a 
curious or exploratory phenotype. It would have been useful to investigate the anxious 
phenotype of a separate cohort of young adult HFD-fed mice at a time that the MSRU 
was not experiencing these issues for comparison. However, these issues are ongoing, 
and resolution of the problems are unfortunately out with the scope of this PhD project. 
 
3.3.2 Ageing, but not HFD-feeding, is associated with impaired endothelial function in 
vivo 
 
Within this chapter, it was demonstrated that mature adult mice exhibited reduced 
endothelial responsiveness in vivo when compared to young adult mice, but there was 
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no effect of diet. Mature adult mice, both on NC and HF diet, showed impairment in % 
change in vasodilation in response to the potent vasodilator ACh compared to their 
younger counterparts, as well as a lower peak skin perfusion in response to ACh. 
However, mature adult mice did not show any reductions in baseline skin perfusion 
compared to young adult, thus suggesting a clear endothelial-specific dysfunction in this 
case. We did observe a reduction in baseline skin perfusion after 5 weeks of dietary 
intervention in HFD-fed mature adult mice compared to their NC-fed age-matched 
counterparts. Baseline skin perfusion is analogous to resting vessel tone. These data 
suggest that HFD-fed animals may exhibit constricted microvasculature at rest, which 
may indicate ED or VSMC dysfunction. This may be due to a number of factors including 
increased ROS and increased cellular inflammation. 
 
There is a lot of evidence to suggest age-related decline in vascular health. Increasing 
age has been associated with reduced eNOS activity114,360, eNOS uncoupling361, reduced 
NO bioavailability114,360,361, increased endothelial ROS production114,360,361, increased 
endothelial inflammation114,361 and increased ET-1360,361. Human studies investigating 
the effect of age on endothelial function also utilise laser imaging and iontophoresis of 
ACh. Indeed, many studies have reported that peak response to ACh of forearm skin 
perfusion progressively declines with age362–365, and this is a good predictor of CVD 
risk366. In mice, 6 months old is considered a mature adult model, bordering on middle-
aged, rather than an elderly model. There are limited studies looking at the specific 
effect of middle-age on ED, but Celermajer and colleagues found that endothelium-
dependent vasodilation (response to reactive hyperaemia) begins declining as early as 
40 years old in men and 50 years old in women367. Therefore, these data from our mouse 
model corroborate previous studies, in that middle-age is associated with reduced 
endothelial function.  
 
Interestingly, feeding mature adult mice HFD did not exacerbate age-related ED in vivo. 
Previous literature suggests HFD rodent models (6-24 weeks on HFD) exhibit a blunted 
vasodilatory response in ex vivo aortae, indicating ED139–141, findings that our study could 
not corroborate in vivo. Similarly to the study herein, Noronha and colleagues reported 
no effects of HFD (8 week duration) on ACh response in ex vivo aortae138. They attributed 
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this lack of ED to a compensatory mechanism; the hyperpolarising capacity of increased 
H2O2 levels. Indeed, early ED is associated with increased oxidative stress. We did not 
test for the presence of oxidative stress in our model due to time constraints, but it 
would be interesting to investigate whether H2O2 is increased in our HFD model and 
whether this acts as a potential hyperpolarising agent, allowing for vasodilation. 
Furthermore, it is possible that our HFD-fed model exhibits increased NO bioavailability 
due to an increase in iNOS as a result of inflammation in the endothelium.  
 
Although we did not measure oxidative stress in our models, we did attempt to 
investigate endothelial function in a mouse model of oxidative stress – Nrf2 KO mice. 
Nrf2 (NFE2-related factor 2) is a transcription factor known for its role in regulating 
oxidative balance. Nrf2 acts to upregulate the levels of anti-oxidant molecules, leading 
to catabolism of superoxides and other ROS368. Indeed, Nrf2 KO mice exhibit increased 
oxidative stress369 and susceptibility to a range of diseases associated with oxidative 
pathologies, whereas enhancing Nrf2 activity protects animals against oxidative 
damage370. 
Male Nrf2KO mice and WT controls were fed HFD for 10 weeks and we measured 
metabolic parameters including body weight and body composition, as well as vascular 
parameters using LDI. These data can be observed in Appendix S2. Due to the afore-
mentioned issues within the MSRU, HFD-fed Nrf2KO mice, which are known to stay lean, 
were significantly heavier than HFD-fed WT counterparts. Increased weight was 
attributed to a higher fat mass than WTs. As previously mentioned, we presumed that 
the DIOR in the WT mice may be due to increased anxiety and under eating due to the 
ongoing problems in the MSRU. When performing open-field tests, the Nrf2KO mice did 
not exhibit an overt anxious phenotype like the WT mice, suggesting they have a more 
placid nature (Appendix S2). This may indicate why they continued eating in this stress-
inducing environment and thus why they rapidly gain weight and the WT mice did not. 
Due to these reasons we did not continue with the Nrf2KO study so as to properly 
prioritise experiments that were not affected by the MSRU issues.  
 
Other pathologies associated with HFD, such as hyperglycaemia and dyslipidaemia, have 
been shown to lead to ED. Interestingly, Da Silva Rocha and colleagues’ model of obesity 
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(HFD-induced, 20% of calories from fat, 27 weeks), whilst significantly heavier than 
regular chow controls, did not exhibit associated pathologies of obesity including 
dyslipidaemia or hyperglycaemia144. They also observed no impairments in aortic 
dilatory response to ACh, implying HFD-induced ED may be dependent on obesity-
related pathologies, such as those suggested above. We did not measure fasting blood 
glucose levels, nor did we investigate the lipid profile of our HFD-fed mice herein, but 
this is a potential explanation as to why we did not observe HFD-induced ED in vivo. 
Moving forward, fed and fasted blood glucose levels could be measured using a blood 
sample from the tail and a Glucometer and blood lipids can be investigated using a 
simple colorimetric/fluorimetric triglyceride or cholesterol assays. If indeed this 
duration of HFD is not sufficiently long enough to induce hyperglycaemia/dyslipidaemia, 
then a longer exposure to HFD or a higher fat content (65%) may be required. 
Additionally, Western diet, which contains cholesterol and is typically used as an 
atherogenic diet, could be used. The addition of fructose/sucrose to the drinking water 
could also be used to increase calorie intake and encourage a diabetic phenotype, which 
could aid the development of ED.  In order to adequately model human metabolic 
syndrome, Della Vedova and colleagues used an DIO model fed with a diet consisting of 
45% HFD (22% chicken-derived fat), and 10% fructose in the drinking water371. Control 
groups, instead of chow, were fed a diet of similar content but with only 6% fat and 
normal drinking water. Moving forward, we would consider this dietary paradigm in 
order to model human metabolic disease sufficiently. 
 
3.3.3 Db/db mice gain significantly more weight than WT/WT and WT/db mice, and are 
severely hyperglycaemic 
 
The db/db mouse is a well-known and extensively utilised model of obesity and 
diabetes. We report here that female db/db mice gain significantly more weight than 
their wt/wt and wt/db littermates from 4-8 weeks old. Db/db mice were already heavier 
than both their wt/wt and wt/db littermates by 5 weeks old. Kobayashi and colleagues 
were among the first to phenotype the db/db mouse and report that by 6 weeks of age, 
db/db mice develop obesity372, a finding corroborated herein. Other studies have also 
reported the severe obese phenotype of db/db mice373,374.  In terms of glucose 
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tolerance, we report here that female db/db mice develop severe fasting (after 16 
hours) hyperglycaemia, suggesting glucose intolerance and a diabetic phenotype. This 
corroborates previous findings that obesity and hyperglycemia are observed at 8 weeks 
old372–374.  
 
3.3.4 Db/db mice exhibit blunted responses to endothelium-dependent vasoactive 
agents in vivo 
 
We report here that db/db mice exhibit an impaired response to endothelium-
dependent vasoactive agents PE and ACh. The reduced responsiveness to PE indicates 
that the microvasculature of db/db mice is already maximally constricted whereas the 
blunted response to ACh suggests reduced endothelial responsiveness. Together, these 
findings suggest the presence of severe ED. However, it cannot be ignored that the 
contractile responses to PE from ‘true’ baseline are not standardised across groups, 
making it difficult to quantify the PE response. Concentration-response curves could be 
performed, or different vasoconstrictors could be tested in order to understand 
whether the skin microvasculature is already maximally constricted and cannot respond 
to any vasoconstrictor molecule appropriately, or whether it is due to a direct 
irresponsiveness specifically to PE. The latter may involve downregulation of receptors 
for PE, such as adrenergic receptors on the VSMCs. In wt/wt and wt/db mice, we 
observed a reduction in % skin perfusion in response to the vasoconstrictor PE, followed 
by an increase in % skin perfusion in response to the vasodilator ACh. These data suggest 
that wt/wt and wt/db mice have healthy, responsive endothelium in their skin 
microvasculature. As previously mentioned, % skin perfusion response to ACh was 
blunted in db/db mice. This is likely due to impaired NO bioavailability, due to the fact 
that ACh-induced vasodilation depends on NO production375. Reduced NO bioavailability 
occurs due to reduced eNOS activity, increased eNOS uncoupling, increased NO 
degradation secondary to increased ROS presence376, or increased ET-1 expression377. 
Due to time constraints, this has not been measured in our db/db model, but could be 
measured by Western blotting for phosphorylation of eNOS at serine 1177 in the 
vasculature, measuring nitrite (derivative of NO) concentration in the blood using Griess 
assay, and measuring ET-1 expression (mRNA or protein) in the vasculature. Others have 
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reported decreased eNOS expression, increased eNOS uncoupling378,379, reduced 
intracellular NO production380, increased superoxide production379, increased eNOS 
mRNA (due to H2O2 extending mRNA half-life)379, and increased ET-1 expression381 in 
db/db mice. When looking at physiological changes, Solini and colleagues measured ACh 
response in ex vivo mesenteric arteries and reported that arteries from 16-week old 
db/db mice displayed a blunted response to ACh379. To our knowledge, PE and ACh-
induced changes in skin perfusion in vivo have not previously been measured in db/db 
mice. Therefore, this is the first report of reduced endothelial responsiveness in vivo in 
db/db mice. 
 
The severe fasting hyperglycaemia present in db/db mice may be in part responsible for 
the observed ED. Hyperglycaemia has consistently been reported as a potential cause 
of ED. Mice with STZ-induced diabetes exhibit very high fasting blood glucose levels 
(>25mmol/l) and a marked reduction in in vivo ACh-dependent vasodilation183. Others 
have reported STZ mice exhibit reduced ACh-induced vasodilation in ex vivo aortic 
myograph studies153,154, increased eNOS mRNA155, and increased aortic superoxide 
production154. High glucose levels have been proposed to induce ED through increased 
ROS production, which subsequently activates PARP, inhibiting GAPDH and resulting in 
accumulation of glycolysis intermediates.  Several glycolysis intermediates have been 
indicated to be involved in the onset of ED, details of which can be found in 1.8.2. 
 
Due to time constraints, we did not investigate oxidative stress in our db/db model, but 
it is well known that they do display increased O2-379  and this may be a mechanism of 
action in the hyperglycaemia-induced ED seen in db/db mice. If time permitted, we 
could measure O2- and other ROS using one of the many chemiluminescent and 
fluorescent detection methods that exist as simple plate-based assay. However, the 
majority of these assays are not mitochondrial-specific382 and are subject to artifacts. 
However, a commonly used and relatively robust detection method for production of 
mitochondrial O2- is mitoSOX, which is a fluorescent-based probe that can be used as 
stain for microscopy or flow cytometry, or as a plate-based assay383. O2- has an extremely 
short half-life, reported to be between 5-15s384. For this reason, it is not advised to 
investigate O2- levels in stored tissue385. MitoSOX can be used in vitro386 or in fresh 
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tissue385. Other methods that could be utilised to detect increased oxidative stress in 
our model include using Taqman qPCR to investigate NOX mRNA expression, WB to 
measure NOX protein expression, or assays to measure NOX activity387. However, these 
methods are not specific to mitochondrial ROS. Furthermore, assays to detect O2- 
derivatives such as H2O2 are also available388.  
 
Db/db mice are known to exhibit increased plasma TGs and LDL, suggesting 
dyslipidaemia at about 14 weeks of age, which is older than our current model. It is 
unlikely that at 8 weeks the mice are dyslipidaemic, but this was not tested in our model. 
Dyslipidaemia is associated with ED. FFA, which can be produced from TGs, are 
increased in subjects with obesity and T2D186–188, and are a known risk factor in the 
development of CVD188. The FFA palmitate is associated with ED, in that it has been 
shown to induce oxidative stress191–196, activate proinflammatory signalling pathways195 
(including TLR2/NF-κB191,197, IL-6191,197, IL-8197), increase ICAM expression191,192,194,197,198, 
increase monocyte adhesion194,197, increase RAGE expression196, and dysregulate 
mitochondrial bioenergetics194,198; pathologies known to be linked with reduced EC 
responsiveness. The association between high LDL and reduced vascular function is well 
established. Treatment with statins (resulting in lower plasma LDL) shows marked 
improvements in EC function in humans389. LDLR KO have delayed clearance of VLDL and 
LDL390, therefore have elevated plasma levels of these lipids, whilst ApoE mice that have 
impaired lipid uptake, resulting in hypercholesterolaemia390. Both models show severe 
EC dysfunction and atherosclerosis development on NC diets. LDL has been shown to 
enhance monocyte adhesion202 and promote oxidative stress204. It is therefore possible 
that plasma lipids can promote endothelial dysfunction, but the lipid profile of our mice 
would need to be further investigated to elucidate whether dyslipidaemia plays a role 
in the ED seen in our model.  
 
Aside from the observed reduced endothelial responsiveness to the vasodilator ACh in 
db/db mice, they also exhibit a reduced baseline skin perfusion compared to control 
suggesting db/db mice have very constricted microvasculature at rest. It is difficult to 
interpret this outcome, as the extent of basal skin perfusion is likely a result of many 
circulating vasoactive factors, as well as pressure-induced vasoactivation, temperature-
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induced vasoactivation, and the effects of isoflurane anaesthetic391 amongst other 
contributing factors. Therefore, basal skin perfusion is very sensitive to change in every 
individual animal depending on but not limited to the temperature of the animal, the 
last time it ate, how the animal responds to isoflurane, and differing isoflurane % 
inhalation. To combat this, the temperature of the room is maintained at the same value 
and mice are placed on a heat mat which is set to the same temperature. Furthermore, 
isoflurane is kept to 1-1.5% to attempt to control for this. It may be of use to use a rectal 
thermometer to control for body temperature more efficiently. In any case, these 
factors may result in a variation in baseline skin perfusion, especially in treated animals. 
However, we see a large significant reduction in baseline skin perfusion in the db/db 
mice, suggesting further that their endothelium is already, even prior to PE application, 
very constricted. This may be due to a number of issues including reduced NO 
bioavailability or increased ROS. Interestingly, at the age of 8 weeks (the same age of 
the mice used for vascular measurements herein), db/db mice show no difference in 
mean arterial pressure values compared to littermates392, meaning it is not a 
confounding factor in these measurements. Db/db mice begin to exhibit increased mean 
arterial pressure at 11 weeks of age. 
 
3.3.5 Ageing and nutrient excess produce differing effects on aortic mitochondrial 
dynamics 
 
The ED observed in our mature adult mice may be due to impaired mitochondrial 
function, perhaps resulting from dysregulation of mitochondrial dynamics. As previously 
discussed, mitochondria that are ‘stuck’ in either a fused or fragmented state may 
exhibit reduced ATP production, impaired mitochondrial respiration, as well as 
increased ROS production. Impaired mitochondrial dynamics may further lead to 
dysfunctional mitophagic processes. Therefore, we investigated the effects of two 
metabolic stressors, ageing and nutrient excess, on aortic mitochondrial dynamics. We 
did this through conventional Western blot, probing for proteins known to regulate 
mitochondrial dynamics.  
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There was a trend toward an age-related decline in aortic expression of the fusion 
protein Mfn1. Furthermore, in comparison to young adult HFD-fed mice, both groups of 
mature adult mice exhibited a reduction in aortic Mfn2 protein expression, with no 
effect of diet. We did not observe any changes in aortic OPA1 expression. Overall, these 
data suggest an age-associated decline in mitochondrial fusion proteins, perhaps 
indicative of increased mitochondrial fragmentation.  
 
The existing literature on age-associated changes in mitochondrial dynamics is 
contradictory. Some report age-related decline in expression of fusion proteins in 
various tissues, whereas others observe counterintuitive increases in mitochondrial 
fusion. Son and colleagues investigated Mfn1 protein and mRNA expression in normal 
human fibroblasts (NHFs) from donors of varying ages393. They reported that Mfn1 
expression (both protein and mRNA) was significantly increased in donor NHFs from a 
61-year old compared to a 3-day old donor, perhaps suggesting Mfn1 expression 
increases with age. This data was further strengthened when the authors reported that 
Mfn1 mRNA expression increased significantly with age in NHFs from the same donor 
(29 compared to 36 compared to 46 years old). It is possible that we did not see similar 
findings because our mouse model is a mature adult, bordering on middle-aged, at 6 
months, rather than older adult/elderly at 12-24 months of age. The fact that fusion 
proteins appear increased with age in donor NHFs is counterintuitive as one would 
expect that ageing would lead to dysfunctional mitochondria and increased 
fragmentation241. However, mitochondrial hyperfusion may occur for the mitochondria 
to deal with the increasing age-related mtDNA mutations. By undergoing hyperfusion, 
mitochondrial content will be mixed and mtDNA mutations will become diluted and less 
harmful. This is supported by Chen and colleagues who reported that Mfn1 deletion can 
result in mitochondrial dysfunction in mtDNA-mutator genetically altered mice253. 
Highly interconnected, giant mitochondria are also frequently observed in aged 
muscle394 and hyperfused mitochondria can often become dysfunctional, due to the 
inability to target impaired areas for degradation (as this requires mitochondrial 
fragmentation)241.  
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In contrast, another study observed significant reductions in Mfn1 and Mfn2 mRNA 
expression in muscle biopsies from older adult humans (mean age = 69.8) vs. young 
adult humans (mean age = 27.3)395. However, in this study the older group was 
described as ‘sedentary’ meaning there could also be a metabolic factor contributing to 
reduction in mitochondrial fusion proteins. Indeed, when the authors compared Mfn1/2 
mRNA expression in young muscle biopsies with biopsies from senior ‘sportsmen’, they 
observed no differences between groups. Another study investigating muscle biopsies 
from healthy young (mean age = 22.5) and healthy older (mean age = 70.5) adult humans 
corroborates this396. In terms of animal models, Sebastián and colleagues reported a 
reduction in Mfn1 protein expression in gastrocnemius muscle in older mice (22-
months) versus adult younger mice (6-months), suggesting an age-related decline in 
skeletal muscle mitochondrial fusion proteins397, coupled with reductions in Mfn2 
protein expression in soleus muscle, tibialis muscle, gastrocnemius muscle, liver tissue, 
and heart tissue. However, they did not measure protein expression in young adult mice, 
so it is hard to determine whether their 6-month old mouse is comparable to the mouse 
model used herein. Primary myocytes from young vs. older rabbits showed no age-
related decline in Mfn2 protein expression unless further challenged with HFD398.  
 
Although we observed no alterations in OPA1 expression, others have reported age-
associated decline in OPA1 protein expression in murine gastrocnemius muscle399, 
murine tibialis muscle395, and muscle biopsies from sedentary older humans (mean age 
= 69.8 vs young mean age =27.3)395. However, in NHFs, OPA1 mRNA expression followed 
an age-associated increase in cells from the same donor (29 compared to 36 compared 
to 46 years old). Furthermore, this study also reported a significant increase in OPA1 
protein expression in cells from a 61-year old donor compared to cells from a 3-day old 
donor, suggesting an age-associated increase in OPA1. The reported human and animal 
data are somewhat contradictory, and it appears likely that age-associated changes in 
mitochondrial fusion proteins are tissue-dependent and sensitive to lifestyle factors 
such as diet and exercise. 
 
When investigating dietary effects in aortic tissue, we observed trends toward reduced 
aortic Mfn1 expression and increased aortic Mfn2 expression in HFD-fed young adult 
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mice compared to their NC counterparts, suggesting differential effects of HFD on 
mitochondrial fusion proteins. HFD-feeding in mature adult mice did not produce an 
additive nor protective effect on aortic Mfn1/2 expression. Furthermore, diet had no 
effect on aortic OPA1 expression.  
 
The existing literature on HFD-feeding and Mfn1/2 expression in various tissues is 
contradictory. Short-term HFD feeding (2-weeks duration) produced increased mRNA 
expression of Mfn2 in the soleus of rats, whereas protein expression was unaffected400. 
Longer-term HFD exposure in rats (28-weeks duration) led to decreased Mfn2 protein 
and gene expression in myocardium401, whereas HFD-feeding (16-weeks) in mice led to 
reduced Mfn1 protein expression in heart tissue402. It is possible that shorter duration 
of nutrient excess acts as an acute stressor, resulting in an increase in mitochondrial 
fusion processes in order for the mitochondria to deal with the high ATP-demand the 
cell exhibits in times of acute stress403. A longer, more chronic exposure to nutrient 
excess upwards of 16 weeks HFD may result in reduced aortic expression of 
mitochondrial fusion proteins. Indeed, chronic nutrient excess is often associated with 
increased fragmentation. Mitochondrial fission is associated with mitochondrial 
uncoupling from ATP synthesis (due to proton leak), essentially making ATP production 
less efficient, meaning energy from excess nutrients will be lost. This may be a protective 
mechanism by mitochondria in order to keep ROS production to a minimum in times of 
nutrient oversupply403.  
 
We observed an age-associated decline in aortic expression of total Drp1 protein. One 
study that investigated effects of age in murine muscle tissue observed no changes in 
Drp1 expression with age in gastrocnemius397, whereas Tezze and colleagues report a 
reduction in Drp1 protein in muscle biopsies from aged humans (68.9 years old vs. 27.3 
years old). Reduced total Drp1 expression suggests reduced mitochondrial fission, 
depending on the levels of the opposing fusion proteins.  However, activity of Drp1 is 
largely controlled by post-translational modification (PTM). PTM of Drp1 largely consists 
of phosphorylation, acetylation, S-nitrosylation, ubiquitination, SUMOylation, and O-
GlcNAcylaton404, and has varying effects on activity. A diet-associated trend was 
observed herein, where HFD-feeding in both young and mature adult mice produced a 
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slight increase in aortic phosphorylation of serine site 637 of Drp1. Due to an age-
associated trend toward reduced aortic expression of total Drp1, this resulted in a 
significant increase in phospho-Drp1 s637/total Drp1 ratio in mature adult HFD-fed mice 
compared to both young adult HFD-fed mice as well as mature adult NC-fed mice. In 
general, phosphorylation of Drp1 at serine 637 has been reported to reduce Drp1 
activity, by promoting detachment of Drp1 from mitochondria and therefore inhibiting 
mitochondrial fission405,406. However, the effect of phosphorylation on Drp1 activity is 
largely kinase and tissue-dependent. For example, Ca2+/calmodulin-dependent protein 
kinase Iα induces phosphorylation of Drp1 at s637 and acts to promote Drp1 
translocation to mitochondria, allowing for fission to occur407. In contrast, cAMP-
dependent protein kinase phosphorylates Drp1 at s637 to inhibit Drp1 activity408. In a 
cardiomyocyte model of anoxia-reoxygenation injury, an increase in mitochondrial 
fission was observed, but accompanied by a reduction in phosphorylation of s637409. 
Wang and colleagues observed a significant increase in phosphorylation at site s637 on 
Drp1 induced by high glucose (25mM for 36 hours) exposure in immortalised endothelial 
cells, which resulted in increased recruitment of Drp1 to the mitochondria406. These data 
suggest that there are differential effects of phosphorylation of Drp1 in varying disease 
models. In terms of nutrient excess in vivo, HFD-feeding mice for 18 weeks has been 
shown to decrease phosphorylation of Drp1 at s637 and increase phosphorylation at 
s616 in heart tissue410. The authors further observed increased mitochondrial 
fragmentation via electron microcopy in heart tissue, suggesting that reduced 
phosphorylation at s637 in this case contributed toward increased mitochondrial fission.  
This is contradictory to our observations in that the additive metabolic stressors ageing 
and HFD-feeding induced a significant increase in phosphorylation of s637 on Drp1, in 
comparison to young HF-fed mice, as well as in comparison to mature NC-fed mice. Drp1 
phosphorylated at s616 was undetectable in aortic tissue of these mice. It is unclear at 
this time whether the increased phosphorylation at s637 in our model results in 
mitochondrial fragmentation due to contradictory reports in the literature. To 
investigate whether mitochondria are fused or fragmented in response to increased 
Drp1 s637 phosphorylation, electron microscopy could be used to image the 
morphology of mitochondria, or cellular localisation of Drp1 could be investigated to 
observe whether there is increased or decreased Drp1 recruitment to mitochondria. An 
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alternative approach may be to perform a GTPase activity assay, but this would not be 
specific to Drp1 activity. 
 
3.3.6 VE fraction expression of mitochondrial dynamics proteins is unchanged in 
response to ageing and/or HFD 
 
It has been reported that mitochondrial crisis in brain ECs can greatly exacerbate 
inflammation-induced BBB disruption and therefore contribute to cerebrovascular 
pathologies127. Therefore, we chose to investigate alterations in VE fraction expression 
of mitochondrial dynamics proteins in response to the metabolic stressors ageing and 
HFD.  
 
HFD-feeding in young mice produced a trend toward reduced expression of OPA1 (total, 
short, and long forms), but there was no effect of diet on Mfn2. This change in OPA1 
needs to be further investigated by increasing the sample size. Where possible, it is 
important to measure density of OPA1 protein bands in isolation. OPA1 can undergo 
cleavage by the proteases OMA1 and YME1L to form short-form and long-forms of 
OPA1, the functions of which are somewhat distinct. As the OPA1 bands in VE fraction 
Western blots herein were distinguishable from each other, they were densitometrically 
analysed separately to produce short-form, long-form, and total OPA1 protein levels. 
The general consensus in the literature is that long-form OPA1 is fusion competent, in 
that it can perform mitochondrial fusion in the absence of the short-form, whereas this 
is not true of the short-form. On the other hand, the short-form alone has been shown 
to be more capable of maintaining mitochondrial bioenergetics411. However, Del Dotto 
and colleagues report that an intricate balance between long and short-forms is 
required for fully functioning mitochondria247. In any case, we did not observe any 
measured differences between long- and short-forms of OPA1 across our groups, and 
any trends toward changes in OPA1 expression were the same across short-form, long-
form, and total protein.  
 
These data, showing no change in Mfn2 expression upon HFD feeding but trends toward 
reduced OPA1 expression, are not consistent with existing studies. Reductions in Mfn2 
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protein and gene expression were observed in rat myocardium after exposure to HFD 
for 28 weeks401. 16 weeks of HFD in mice led to reduced Mfn1 (which was not detected 
herein) protein expression in heart tissue402, whilst a 40-week HFD intervention in mice 
produced a significant reduction in skeletal muscle protein expression of Mfn1/2, but 
not OPA1412. The potential reduction in mitochondrial fusion with HFD feeding may be 
a protective measure that the mitochondrial undergo to uncouple mitochondrial 
respiration from ATP, meaning energy from excess nutrients (HFD) will be lost as heat 
(proton leak). This would also keep ROS production by the ETC to a minimum and 
therefore prevent oxidative stress413. 
 
Blotting for expression of total Drp1, and phosphorylation of Drp1 at s616 and s637 was 
attempted, but neither were detectable. Due to the low protein content of the VE 
fraction, the number of Western blots that can be attempted are limited. To further 
investigate VE fraction expression and PTM of Drp1, a greater number of animals would 
need to be used and their VE fractions would need to be pooled to produce a higher 
protein concentration.  
 
The role of Drp1 in cerebrovascular integrity and BBB disruption has been investigated 
to an extent in vitro in murine primary brain microvascular ECs. LPS-induced BBB 
disruption was associated with increases in Drp1 phosphorylation at s616, which the 
authors report suggests a shift toward mitochondrial fission414. The authors report an 
increase in endothelial activation (ICAM expression), reduction in mitochondrial 
respiration, increased BBB permeability, and increased cellular ROS production upon 
stimulation with LPS, which were all associated with phosphorylation of Drp1 at s616. 
Interestingly, when cells were treated with LPS in combination with P110 (an inhibitor 
of Drp1 activity), these effects were abrogated. This suggests a role for Drp1-mediated 
mitochondrial fission in cerebrovascular dysfunction, and it would be interesting to 
measure VE fraction Drp1 activity (by phosphorylation status) or Drp1 cellular location 
in our model of HFD and ageing. In a rat model of subarachnoid haemorrhage (SAH), 
BBB disruption is a devastating consequence presenting with reduced whole-brain long-
form OPA1 expression post-SAH. However, when rats are treated with mitoquinone 
(MitoQ; a mitochondrial-targeting drug that has been shown to activate Nrf2 in kidney 
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tissue), BBB disruption was rescued with significant increases in short- and long-form 
OPA1 (Nrf2-dependent) and improved neurological outcome415. These data suggest 
reductions in OPA1 due to insult may mediate BBB disruption and contribute to 
neurological deficits. A similar study from Zhang and colleagues corroborates this. They 
report that intravenous administration of the omega-3 fatty acid docosahexaenoic acid 
(DHA) protected against SAH-induced BBB disruption and cognitive deficits, associated 
with upregulation of OPA1 and downregulation of pDrp1 s616 and improved 
mitochondrial health416. 
 
3.3.7 Hypothalamic expression of Mfn2 and OPA1 is reduced by ageing, but not HFD-
feeding 
 
As previously mentioned, in the ARC of the hypothalamus, AgRP and NPY neurons 
promote orexigenic behaviour and inhibit thermogenesis of brown adipose tissue230, 
whilst POMC neurons exert anorexigenic effects. These well-known control centres 
govern metabolic homeostasis. Impaired hormonal signalling (leptin/insulin/ghrelin) 
and insufficient neuronal firing in the hypothalamus contributes to obesity, 
dysregulation of systemic metabolism, infertility, and obesity-driven hypertension. 
These pathologies are also age-related, and thus the hypothalamus is of interest when 
studying health and unhealthy ageing processes. Neuronal activity of POMC neurons is 
impaired in aged mice, resulting in increased food intake and weight gain417, which is 
reversed when rapamycin is administered due to its activation of POMC signalling 
pathways. Furthermore, adenovirus overexpression of POMC can ameliorate age-
associated metabolic dysfunction418. Paradoxically, NPY expression is reduced in the ARC 
of aged rats419, and its induction in response to fasting is impaired with ageing420. These 
data suggest an age-related dysfunction in hypothalamic metabolic signalling; however, 
it is presently unclear how and when these neurons become dysfunctional.  
 
Hypothalamic mitochondrial function is an attractive target in age-related metabolic 
dysfunction. Ma and colleagues reported an increase in mitochondrial ROS production 
and reduction in mitochondrial function in the hypothalamus of obese mice421, and 
furthermore the association of T2D with mitochondrial dysfunction is beyond doubt. It 
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remains unclear whether alterations to mitochondria are causative or consequential in 
ageing and metabolic disease. ROS production has been shown to be a direct modulator 
of the aforementioned hypothalamic neuronal populations422–425. Therefore, 
hypothalamic mitochondrial function may play a role in regulation of metabolism, and 
furthermore alterations in mitochondrial function during ageing may further exacerbate 
age-related metabolic dysfunction.  
 
We observed age-related reductions in hypothalamic Mfn2 expression and OPA1 
expression (total, long-form and short-form), with no effect of diet. These suggest that 
there is an age-associated reduction in proteins controlling mitochondrial fusion; 
suggesting hypothalamic mitochondria may appear fragmented and dysfunctional. 
Employment of electron or fluorescent microscopy is necessary hereafter to investigate 
ultrastructure of mitochondria. Reductions in these fusion proteins is consistent with 
previously discussed literature; reduced OPA1 protein expression in aged murine 
gastrocnemius muscle399, aged murine tibialis muscle395, and muscle biopsies from 
sedentary (mean age = 68.9 years old) humans395. Mfn2 protein expression was reduced 
in muscle biopsies from aged humans (mean age = 69.8) vs. young humans (mean age = 
27.3)395, as well as muscle biopsies from healthy older (mean age = 70.5) and healthy 
young (mean age = 22.5) adults, with aged human muscle tissue also exhibiting reduced 
Mfn2 mRNA expression396. These studies have focused on the effects of ageing in 
skeletal muscle; there is not a lot of existing literature on how ageing affects 
mitochondrial dynamics in brain tissue. Hypothalamic mitochondrial dynamics has 
however been investigated in relation to metabolic disorders. Studies have investigated 
genetic deletion of Mfn2 in specific hypothalamic neuronal populations, including both 
an AgRP-specific Mfn2 KO, as well as a POMC-specific Mfn2 KO. The POMC-Mfn2-KO 
mouse exhibits obesity, due to increased food intake, reduced energy expenditure, and 
decreased thermogenesis426. These mice exhibit hypothalamic leptin resistance, as well 
as expected mitochondrial dysfunction such as defective mitochondrial respiration and 
increased ROS production. This study closely links Mfn2 with endoplasmic reticulum (ER) 
stress, which is a known causative factor in the development of obesity and 
hypothalamic leptin resistance.  Mfn2 ablation resulted in loss of mitochondria-ER 
contacts, resulting in ER stress and promotion of the unfolded protein response (UPR). 
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Genetic deletion of Mfn2 in AgRP neurons resulted in electrical silencing of these 
neurons due to reduced ATP production, and protected mice against DIO with reduced 
fat mass and significantly lower circulating leptin427. It is possible that in these two 
models lack of Mfn2 and subsequent reduction in mitochondrial fusion results in 
reduced ATP production. Reduced intracellular ATP content would reduce neuronal 
firing428, thus reducing the downstream effects of these neurons on feeding behaviour 
and energy expenditure. These complimentary studies suggest that Mfn2 reduction 
induces differing effects on systemic metabolic physiology depending on the type of 
neuron involved. Since the data herein only investigates whole hypothalamic lysate, to 
move forward with our current data, we would have to investigate how ageing effects 
Mfn2 expression in different neuronal populations of the hypothalamus and whether 
this then exerts any effect of whole-body metabolic homeostasis. If our mature adult 
model exhibited reduction in Mfn2 in POMC neurons alone, this may be a possible 
mechanism in age-associated metabolic dysfunction, due to the potential promotion of 
ER stress and hypothalamic leptin resistance, as well as reduced ATP production and 
neuronal firing. However, the reduction in hypothalamic Mfn2 expression observed in 
our 6-month old mice is not associated with increased body weight.  
 
We did not observe any changes in hypothalamic Mfn2 protein expression with HFD-
feeding for 10 weeks. Schneeburger and colleagues report reductions in Mfn2 mRNA 
expression in hypothalamic lysates in response to as little as 4 days of HFD feeding426, 
before the onset of increased body weight. However, upon longer HFD-feeding 
durations they do not report any further decline in Mfn2 mRNA expression, suggesting 
a plateau. Since they did not measure hypothalamic Mfn2 protein expression in 
response to HFD, and we did not measure Mfn2 mRNA, it is difficult to directly compare 
these data. However, when measuring mitochondrial ultrastructure Schneeburger and 
colleagues observe mitochondrial fission in POMC neurons of DIO mice. Paradoxically, 
Dietrich and colleagues observed increased mitochondrial fusion in AgRP neurons of 
mice fed HFD when employing electron microscopy to investigate mitochondrial 
ultrastructure427. These data further highlight the importance of investigating individual 
hypothalamic neuronal populations in isolation when researching the effects of 
nutrition. Mitochondrial dynamic processes are clearly sensitive to dietary changes, and 
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it is possible that we do not observe any changes in whole hypothalamic lysate in 
response to HFD due to expression of Mfn2 in individual neuronal populations being 
diluted by the presence of other neurons and cell types (astrocytes, microglia etc.). The 
best way to investigate mitochondrial morphology in isolated neuronal populations is 
through electron or fluorescent microscopy with immunohistochemistry.  
 
It should be noted that the differential effects on mitochondrial morphology in these 
neuronal populations may be due to DIO mediated changes in circulating hormones that 
contribute to hypothalamic signalling, or indeed hypothalamic resistance toward these 
hormones. Diseases associated with nutrient excess (obesity in particular) are 
characterised by increased circulating insulin429 and leptin430 and decreased circulating 
ghrelin concentrations431.  
These hormones exert differential effects upon POMC and AgRP neuron. For example, 
leptin activates POMC but inhibits AgRP neurons432. In mice with ablated insulin 
receptors, re-expression of the receptor has been reported to suppress hepatic glucose 
production in AgRP neurons but enhance it in POMC neurons433. Finally, ghrelin can 
enhance the activity of AgRP neurons, but inhibit POMC neurons434. Furthermore, in 
certain pathological situations neurons can become resistance to these circulating 
hormones themselves; hypothalamic leptin resistance is associated with nutrient excess 
and obesity. Hypothalamic leptin resistance would result in reduced POMC neuron 
activity and increased AgRP neuron activity, resulting in hyperphagic behaviour and 
reduced energy expenditure432. Neuronal mitochondrial dysfunction may be a direct 
consequence of this, or indeed may be causal, but this is presently unclear. These data 
suggest these two neuronal populations act differentially in response to DIO mediated 
changes in circulating metabolic hormones and this is a very interesting avenue to 
consider. 
 
 
The role of OPA1 in hypothalamic function is less well studied. A study that aimed to 
investigate the role of OPA1 in pancreatic beta cell function made use of the RIP2-Cre 
mouse to induce a tissue-specific knockout of OPA1 in pancreatic beta cells. However, 
RIP2-Cre is also expressed in hypothalamic tissue. Consequently, the authors 
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investigated metabolic status as well as feeding and locomotor behaviour in these mice 
to determine whether there was any effect of hypothalamic deletion of OPA1 that may 
affect their pancreatic-induced phenotype. They observed no change in body weight, 
food intake, lean mass, or fat mass435. Of note was that these mice were studied when 
they were 2-12 weeks old, when young mice are likely to compensate for genetic 
deletions and fed a NC diet. Therefore, it is presently unknown whether hypothalamic 
OPA1 is important for metabolic homeostasis in older mice, or in nutrient-associated 
diseased models. It is difficult to speculate how the reduction of OPA1 in the 
hypothalamus of our mature adult mice may affect whole-body homeostasis, 
considering we have investigated whole hypothalamic lysate and not individual 
neuronal populations. If fusion was disturbed in either neuronal population it may result 
in reduced intracellular ATP production and reduced neuronal firing, resulting in 
dysregulated hypothalamic control of feeding behaviour and energy expenditure. Global 
OPA1 heterozygous KO mice exhibit increased mitochondrial ROS production in the 
cortex, measured by reduced aconitase activity and reduced SOD expression436. The 
observed reduction in OPA1 in mature adult hypothalamus may be associated with 
increased mitochondrial ROS production, which as previously described is known to 
regulate hypothalamic metabolic signalling422–425. Furthermore, OPA1 governs 
mitochondrial cristae structure, as knockdown of OPA1 results in disorganised cristae, 
which would likely affect the ETC and thus hypothalamic mitochondrial respiration. 
Clearly, this warrants further investigation. 
 
3.3.8 Aortic expression of proteins involved in mitochondrial dynamics remain 
unchanged in db/db mice 
 
To investigate the effects of nutrient excess on mitochondrial dynamics, we also utilised 
a more severe model of obesity – the db/db mouse. As previously discussed, db/db mice 
exhibited extreme vasoconstriction basally, as well as a blunted response to both PE and 
ACh, suggesting severe endothelial dysfunction. They also exhibit increased weight gain 
and severe fasting hyperglycaemia compared to wt/wt and wt/db littermates. To 
elucidate the cause of this ED in db/db mice, and to study the effects of hyperglycaemia 
on vascular mitochondrial function, we looked to further investigate the cause of the 
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observed endothelial dysfunction, by probing for known regulators of mitochondrial 
dynamics in aortic tissue.  
 
Surprisingly, we observed no changes in aortic expression of proteins governing 
mitochondrial dynamics; Mfn1, Mfn2, OPA1, phospho-Drp1 616, and total Drp1. This 
suggests that the ED in this model is not a consequence of dysregulated mitochondrial 
dynamics. There is a slight trend toward reduced phosphorylation of Drp1 at s616 in 
db/db mice; sample size needs to be increased in order to test whether this is a genuine 
result. A reduction in phosphorylation of this site would, as discussed earlier, result in 
reduced Drp1 activity and translocation to mitochondria, resulting in a potential shift 
toward mitochondrial fusion. As mentioned previously, nutrient excess has been 
reported to induce fragmentation of mitochondria, likely resulting in dysfunction, which 
is contradictory to the result we observe herein. However, increased mitochondrial 
fusion has been observed in models of nutrient excess in some cell types400,427, 
suggesting that the effects of nutrient excess on mitochondrial dynamics is both cell-
dependent and situational. Due to the db/db mice being only 8 weeks old, it is possible 
that their hyperglycaemic phenotype acts as an acute stressor, resulting in an increase 
in endothelial mitochondrial fusion processes, in order for the mitochondria to respond 
to high-ATP demand that cells experience during times of acute stress403. Indeed, it 
would be useful to investigate expression of mitochondrial dynamics proteins in db/dbs 
in a time-dependent manner to investigate the effects of a more chronic hyperglycaemic 
stimulus. Indeed, chronic high glucose conditions have been previously reported to 
promote mitochondrial fission in primary cultured β-cells282 and in an immortalised rat 
cardiomycoyte cell line437,438. 
 
3.3.9 VE fraction expression of proteins involved in mitochondrial dynamics are 
unchanged in db/db mice 
 
We thought it important to also investigate VE fraction expression of mitochondrial 
dynamics proteins. Diseases of nutrient excess are associated with impaired BBB 
integrity and dysregulated cerebral haemodynamics111. Furthermore, proper BBB 
integrity is dependent on fully functioning mitochondria127. Therefore, we sought to 
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investigate whether db/db mice exhibited any changes in VE fraction expression of 
proteins governing mitochondrial dynamics.  
 
No changes in VE fraction expression of Mfn1, Mfn2, or OPA1 (total, short-, and long-
form) were observed in db/db mice. Wt/db, but not db/db mice seemed to exhibit a 
trend toward increased Drp1 expression compared to wt/wt. This peculiarality may be 
due to the small size, but also highlights the importance of using not only wt/db as 
controls, but wt/wt littermates as well in studies involving the db/db models. The 
majority of studies usually employ the use of solely the db/db and the wt/db models, 
but it is uncertain at this time whether the wt/db itself may exhibit a phenotype, 
therefore introducing false positives. No change in phosphorylation of Drp1 at s616 was 
observed, nor the phospho/total ratio. Phosphorylation of Drp1 at s637 was attempted 
but could not be detected. 
 
3.3.9 Hypothalamic expression of proteins regulating mitochondrial dynamics remains 
largely unchanged in db/db mice 
 
Due to the known hypothalamic dysfunction associated with models of obesity and 
nutrient excess, we sought to investigate whether db/db mice exhibited any alterations 
in hypothalamic mitochondrial dynamics. No changes in Mfn1, Mfn2, or OPA1 (total, 
short-, or long-form) were observed in the hypothalamus of db/db mice compared to 
controls. Furthermore, no changes in total Drp1 were observed, but phosphorylation at 
site s616 was increased in db/db mice compared to wt/wt mice. When expressing 
phospho/total as a ratio, db/db mice also displayed a significant increase compared to 
wt/wt. An increase in hypothalamic phospho s616/total ratio may suggest a shift toward 
mitochondrial fission, especially since opposing fusion proteins remain unchanged, 
which is in line with existing literature. Although mitochondrial dynamics has not been 
previously studied in the hypothalamus of db/db mice, Huang and colleagues report a 
significant increase in phosphorylation of Drp1 at site s616 in an isolated mitochondrial 
fraction from whole cortex439. As previously mentioned, nutrient excess is proposed to 
induce mitochondrial fission in many cell types. It is possible that the observed severe 
hyperglycaemia in db/db mice induces hypothalamic mitochondrial fission, further 
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exacerbating the metabolic dysfunction exhibited in these mice. It is presently unclear 
whether this is a cause or consequence of mROS production. Hyperglycaemia is a main 
contributor of mROS production, but since we have not measured ROS in our model, the 
mechanism cannot be elucidated at present.  Db/db mice are reported by others to 
exhibit increased ROS production379, but this has not been measured in hypothalamic 
tissue.  
 
As mentioned previously, when investigating hypothalamic tissue, it is important that 
neuronal populations are studied in isolation, due to mitochondrial dynamics behaving 
differently under nutrient stress. Furthermore, other brain cells such as astrocytes and 
microglia may also be affected. Indeed, astrocytes can provide fuel for neurons in times 
of low glucose (in the form of lactate) or in times where neuronal activity is high and 
more ATP is required (lactate or glutamine). Astrocytes may also experience adverse 
effects due to nutrient excess440, impairing intracellular metabolic processes and 
resulting in indirect effects on neurons. Hypothalamic mitochondrial morphology would 
have to be looked at more closely in our db/db model in order to investigate further.  
 
3.3.10 Endothelial dysfunction observed in db/db mice is not associated with endothelial 
activation 
 
Another contributor to impaired endothelial responsiveness is inflammation, termed 
endothelial activation (EA) in ECs. To determine whether the ED observed in db/db mice 
was associated with inflammation, we probed for ICAM protein expression in aortic 
tissue as well as in the NVU, which we hypothesised would be increased in db/db mice. 
We did not observe any changes in ICAM expression in aorta nor NVU. This is particularly 
interesting, as it suggests that ED can develop in the db/db mouse in the absence of an 
inflammatory environment. ICAM is reported to be increased in db/db mice in existing 
studies441–443. However, these studies utilise db/db male mice that are around the ages 
of 12-18 weeks old whereas we employed the use of 8-week old females, so there may 
be some sex- and age-specific differences. We observed severely blunted endothelial 
responsiveness to vasoactive agents in the absence of ICAM overexpression, but we did 
not investigate other inflammatory markers in our models such as VCAM, IL-1β, IL-6, or 
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TNFα, all of which are associated with ED. It would be necessary to investigate other 
markers of inflammation (via Taqman or a cytokine array assay) before coming to a more 
definitive conclusion.  
 
3.3.11 Summary 
 
This chapter aimed to investigate the effects of nutrient excess on in vivo endothelial 
function, as well as elucidate whether any ED observed in the models was associated 
with alterations in mitochondrial dynamics. 
 
We observed an age-associated blunted response in endothelium to the vasodilator 
ACh, suggesting aging is associated with endothelial dysfunction. HFD-feeding did not 
induce ED in young adult mice, nor did it exacerbate ED observed in mature adult mice. 
No stark alterations in proteins governing mitochondrial dynamics were measured in 
vascular tissue (aorta, NVU). These data suggest age-related development of ED is 
independent of changes in mitochondrial dynamics. To further elucidate a mechanism, 
ROS production and blood glucose levels need to be measured in these models. 
Furthermore, it would be interesting to investigate older mice, perhaps at 12 months 
(middle-old aged) or 24 months (old aged) to track ED over time.  
 
Interestingly, reductions in mitochondrial fusion proteins Mfn2 and OPA1 were 
observed in whole hypothalamic tissue of mature adult mice, suggesting age-associated 
reductions in mitochondrial fusion. This may result in reduced ATP production and 
reduced neuronal firing, promoting metabolic dysfunction, or may indeed be due to 
changes in other cell types present in the brain; astrocytes or microglia. Going forward, 
hypothalamic neuronal populations and individual cell types would need to be studied 
in isolation when investigating mitochondrial dynamics due to the opposing responses 
to nutrient excess. This is obviously rather difficult but could be achieved by using 
electron microscopy (EM) to investigating ultrastructure of mitochondria in individual 
cell types, or by isolating primary cells. It would also be interesting to perform single-cell 
RNA seq with technology from 10x Genomics to investigate the effects of nutrient excess 
on the transcript of differing cell populations. 
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Db/db mice gain significantly more weight and are severely hyperglycaemia compared 
to their control littermates. They exhibit a severely blunted response to vasoactive 
agents in vivo but this is independent of changes in vascular mitochondrial dynamics 
(aorta, NVU). ROS levels were not measured herein, but need to be further investigated, 
as the production of which is a potential middleman between the observed 
hyperglycaemia and ED in this model.  
 
Hypothalamic mitochondrial dynamics remain largely unchanged in db/db mice, aside 
from a slight increase in phospho Drp1 s616/total Drp1 ratio in db/db mice compared 
to wt/wt mice, suggesting a potential shift toward mitochondrial fission. This shift 
toward fission is likely a consequence of nutrient excess and may be the result of the 
adaptive nature of mitochondria to uncouple their respiration from ATP synthesis in 
times of nutrient overload (hyperglycaemia seen in db/db mice) to minimise ROS 
production. It may also be a response to altered levels of circulating hormones that act 
hypothalamically, such as leptin, insulin, or ghrelin, or indeed an altered hypothalamic 
response to these signalling hormones. The circulating concentration of these hormones 
could be further investigated, but it has been reported that circulating leptin and insulin 
is increased in db/db mice444 and ghrelin mRNA in the gastric fundus (stomach) is 
reduced445.  
 
In summary, age-associated decline in endothelial response is not associated with 
alterations in proteins governing mitochondria dynamics. Furthermore, 8-week old 
severely hyperglycaemic db/db mice exhibit stark impairments in endothelial response, 
independently of changes in proteins regulating mitochondrial dynamics.
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Chapter 4 
Investigating the effects of 
HFD, BACE1 activity, and 
amyloid beta on vascular 
mitochondrial dynamics 
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4.1 Introduction 
 
BACE1 is an aspartic protease, best known for its role in APP processing (Fig. 1.15). 
Metabolic diseases are associated with increased levels and/or activity of BACE1, and 
thus increased levels of its final cleavage product Aβ. Indeed, BACE1 protein expression 
is increased by exposure to palmitate, and its derivative ceramide in differentiated C2C12 
myotubes306. Additionally, DIO mice (22 weeks 45% HFD) mice express significantly 
increased hypothalamic BACE1 mRNA and protein levels308, and adipose tissue BACE1 
protein levels315. Botteri and colleagues observed a HFD-dependent increase in BACE1 
protein and mRNA in murine muscle tissue307. BACE1 levels are also increased in the 
livers of the diabetic mouse model db/db300. Further to these increases in expression, 
BACE1 activity is also increased with HFD-feeding; DIO mice exhibit increased 
hypothalamic sAPPβ and Aβ42 levels, indicating increased BACE1 activity305 and our most 
recent observations indicate HFD-dependent increases in aorta and plasma Aβ42 in mice 
and plasma Aβ42 in T2D humans316. Botteri and colleagues further report increased 
BACE1 levels in adipose tissue and increased sAPPβ in plasma from people with T2D307. 
Multiple publications indicate a role for BACE1 and Aβ in the development of metabolic 
disorders such as obesity and T2D300,305,307,309,310,317, details of which are reported herein 
(Introduction 1.12.2).   
 
Obesity and T2D are often associated with vascular diseases such as atherosclerosis35–
37. One of the first key events in the development of atherosclerosis is ED, characterised 
by a reduced responsiveness of ECs to vasoactive signals, a low-grade chronic 
inflammatory state, and reduced NO bioavailability. Our recent findings implicate HFD-
driven increases in BACE1 activity and therefore Aβ42 production in the development of 
ED446. Indeed, HFD-driven reduction in endothelial function is rescued by BACE1 
inhibition, whilst increasing circulating Aβ42 levels (using subcutaneous minipump 
infusion) induces ED316. However, it is at present unclear how BACE1 and Aβ42 regulate 
this progression.  
 
BBB disruption is closely linked with obesity and T2D112–122, with the presence of T2D 
systemically contributing to endothelial activation123 and basement membrane 
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thickening124–126. Furthermore, impairments in peripheral EC function is a strong 
predictor of cerebrovascular dysfunction346. Interestingly, BACE1 is expressed in brain 
endothelium319 and others have reported that APP overexpression320 in mice,  as well as 
direct Aβ40 (but not Aβ42) application to the brain reduces CBF320, indicating brain EC 
dysfunction. These data suggest a role for increased Aβ species in the development of 
brain EC dysfunction and therefore perhaps BBB disruption. However, it is very 
important to note that these studies utilise knock-in mouse models with extremely high 
circulating levels of Aβ, or indeed simply apply supraphysiological µM concentrations of 
Aβ peptides directly to the cortex, which is not physiological. 
 
Mitochondrial dysfunction is often observed in diseases of nutrient excess. Indeed, 
animal and cell models of nutrient excess exhibit impaired TCA cycle physiology268–271, 
increased mROS production198,273,276, decreased ATP production272, reduced 
mitochondrial respiratory capacity276,280, impaired mitochondrial biogenesis275, and 
dysregulated mitochondrial dynamics278,281–284. Multiple studies also indicate a role for 
BACE1 and Aβ in initiating mitochondrial dysfunction306,317,331–335, reported in detail in 
section 1.12.3. Mitochondrial crisis in brain ECs has also been shown to exacerbate BBB 
dysfunction in a model of systemic inflammation127. However, it is presently unclear 
whether nutrient access-associated increases in BACE1 activity and Aβ42 production 
contribute to mitochondrial dysfunction in ECs, both peripheral and cerebral, therefore 
contributing to disease pathology.  
 
The aim of this chapter is to confirm a role for BACE1 and Aβ42 in endothelial function in 
vivo, and furthermore elucidate whether any impairments in EC function are associated 
with dysregulated EC mitochondrial dynamics. To do this, we employed the use of 4 
animal models of varied BACE1 activity.  
The first model was a HFD-fed BACE1KO mouse, with HFD-fed WT and HET littermates, 
as well as NC-fed WT controls. These models were used to investigate the effects of a 
10-week HFD on endothelial function in vivo, and the contribution of BACE1 to HFD 
induced endothelial dysfunction  
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The second and third models were HFD-fed WT mouse centrally  or peripherally infused 
with Aβ42 vs. ScrP control, to investigate how raising Aβ42 (as per HFD-induced BACE1 
activity) either centrally or peripherally might affect endothelial function in vivo. 
The final model was a NC-fed APP23 mouse infused with a BACE1 inhibitor vs. vehicle 
control. This model is genetically engineered to harbor pathological levels of Aβ42, so we 
used this mouse to investigate the effects of increased Aβ42 on endothelial function in 
vivo, and whether reducing Aβ42, through BACE1 inhibition, would modulate any 
observed effects. Study timelines can be found in Fig. 4.1-4.3. We investigated EC 
function in vivo and, where possible (BACE1 KO, Aβ42 centrally infused), investigated 
mitochondrial dynamics proteins in tissues of interest (aorta, NVU). We hypothesised 
that, whilst genetic or pharmacological reduction of BACE1 activity would protect mice 
against HFD-induced ED, mice with increased Aβ42 levels (APP23, peripherally/centrally 
infused Aβ42) would exhibit exacerbated ED. Furthermore, this ED may be further 
associated with mitochondrial dysfunction, as measured by dysregulation of proteins 
involved in mitochondrial dynamics. 
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Figure 4.1 Study timeline of BACE1 KO mice 
10-12 week old male BACE1 KO mice and their WT and HET littermates were placed on HFD 
for 10 weeks. A group of age-matched WT mice were maintained on NC diet as a control. 
During the 10th week, mice underwent LDI accompanied with PE and ACh iontophoresis. Mice 
were fasted overnight before being culled the next morning. Plasma, aortae, and hemi-brains 
were harvested for post-mortem biochemical analysis.  
Figure 4.2 Study timeline of chronic Aβ42 infused mice 
10-12 week old male WT mice were placed on HFD for 4 weeks before undergoing surgery to 
fit either a subcutaneous minipump (peripheral infusion) or a subcutaneous minipump 
attached to an icv cannula (central infusion), in order to be infused with either Aβ42 or ScrP 
peptide control. Mice were maintained on HFD during the infusion period. ITT and GTT were 
performed on central Aβ42 mice during weeks 8 and 9 respectively, but not on peripheral Aβ42 
mice. During the 10th week, LDI plus PE and ACh iontophoresis was performed on the mice to 
measure endothelial function. Mice were fasted overnight before being culled the next 
morning. Tissue from centrally infused mice (plasma, aortae, and hemi-brains) was harvested 
for post-mortem biochemical analysis. Peripherally infused mice were perfuse-fixed in order to 
provide tissues for IHC experiments required by a study, separate from the current PhD project. 
0	 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	Week	
LDI	
harvest	
HFD	 surgery	 GTT	ITT	
0	 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	Week	
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harvest	
HFD	
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Figure 4.3 Study timeline of BACE1 inhibitor treated APP23 mice 
8-10 week old NC-fed male and female APP23 mice underwent surgery to fit a subcutaneous 
minipump in order to infuse the BACE1 inhibitor or saline control for 4 weeks. During week 4, 
mice underwent LDI and ACh iontophoresis to measure endothelium-dependent skin 
perfusion. Two days later, mice underwent LDI again, but with SNP iontophoresis to measure 
endothelium-independent skin perfusion. Whilst still under anaesthetic, mice were culled, 
and tissue was harvested in order to provide tissues for experiments required by a study, 
separate from the current PhD project. 
0	 1	 2	 3	 4	Week	
LDI	(SNP),		
harvest	
surgery	
LDI		
(ACh)	
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4.2 Results 
 
4.2.1 Genetically reducing BACE1 protects mice against HFD-induced weight gain 
 
Male BACE1 KO mice, alongside WT and HET littermates, were placed on HFD for 10 
weeks. Age-matched NC-fed WT mice were used as a control. This gave rise to four 
experimental groups: WT NC, WT HF, HET HF, and KO HF. Mice were weighed weekly.  
 
WT HF and HET HF mice gained weight over the course of the 10-week study, whereas 
the weights of KO HF and WT NC mice remained steady (Fig. 4.4A, C). WT HF mice gained 
more weight than WT NC mice (Fig. 4.4B – WT NC 1.53g ± 0.68g vs. WT HF 9.00g ± 1.40g, 
n = 6-10, p < 0.01), whereas HET HF mice exhibited only a trend toward more weight 
gain compared to WT NC. KO HF mice gained a similar amount of weight to WT NC mice 
(Fig. 4.5B – WT NC 1.53g ± 0.68g vs. KO HF 2.23g ± 0.57g) and gained significantly less 
weight than their WT HF counterparts (Fig. 4.5B – WT HF 9g ± 1.4g vs. KO HF 2.23g ± 
0.57g, n = 6-10, p < 0.01). When expressed as percentage weight gain, WT HF mice 
gained significantly more weight than WT NC mice (Fig. 4.5D – WT NC 4.46% ± 2.34% vs. 
WT HF 29.08% ± 4.47%), whereas KO HF exhibited similar weight gain to WT NC mice 
(Fig. 4.5D – WT NC 4.46% ± 2.34% vs. KO HF 6.58% ± 0.86%) and gained significantly less 
weight than WT HF counterparts (Fig. 4.5D WT HF 29.08% ± 4.47% vs. KO HF 6.58% ± 
0.86%).  
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Figure 4.4 Global genetic reduction of BACE1 protects mice against HFD-induced weight gain 
10-12 week old WT (WT HF), BACE1 heterozygous (referred to as HET HF), and BACE1 KO (referred to as KO 
HF) were placed on 45% HFD for 10 weeks. Body weight was measured weekly. WT NC mice were used as 
a control. (A) Average weight of the mice over the 10 weeks of the study. (B) Net weight gain at the end of 
the study. (C) Percentage weight gain over the 10 weeks of the study. (D) Percentage weight gain at the end 
of the study. 
 
Data are expressed as mean ± standard error of the mean. 
n = 6-10. (A) and (C) – Repeated measures ANOVA with Bonferroni’s multiple comparison. (B) and (D) – 
Welch’s ANOVA with Dunnett’s T3 multiple comparison. ** = p < 0.01 when compared to WT NC. ## = p < 
0.01 between WT HF and KO HF.  
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4.2.2 Genetically reducing BACE1 protects mice against HFD-induced endothelial 
dysfunction 
 
To measure endothelial function in vivo, mice underwent LDI and iontophoresis of 
vasoactive agents (PE to induce vasoconstriction and ACh to induce endothelium-
dependent vasodilation). To gather information about endothelial health, three main 
outputs of the above technique were analysed; baseline skin perfusion (AU), % Δ skin 
perfusion in response to ACh compared to PE-induced baseline, and peak skin perfusion 
in response to ACh (AU). A detailed description of this technique can be found in 
Methods. 
 
Fig. 4.5A-E shows percentage change in skin perfusion against time in response to PE 
and ACh (baseline is 100%) in all four groups. These data are split in to two groups per 
graph for clarity. All groups of mice responded to PE with reduced skin perfusion, and 
then exhibited increased skin perfusion in response to ACh application (Fig. 4.5A-E), 
suggesting their cutaneous microvascular ECs are responsive to these vasoactive agents. 
WT HF and HET HF exhibited a slightly blunted response to ACh compared to WT NC 
mice (Fig. 4.5A, C) and compared to KO HF mice (Fig. 4.5B, D), whereas as KO HF 
exhibited a trajectory more comparable to WT NC mice (Fig. 4.5E). Baseline skin 
perfusion did not differ between groups (Fig. 4.5F). WT HF and HET HF displayed 
significantly reduced ACh-induced vasodilation (as a % of PE normalised baseline) 
compared to WT NC (Fig. 4.5G – WT NC 40.61% ± 4.44% vs. WT HF 10.28% ± 3.88%, n = 
6-10, p < 0.01; WT NC 40.61% ± 4.44% vs. HET HF 9.22% ± 3.5%, n = 6-10, p < 0.001). KO 
HF mice exhibited a trend towards improved ACh response compared to WT HF and HET 
HF (Fig. 4.5G). However, KO HF mice also exhibited a trend toward reduced ACh 
response compared to WT NC and power calculations reveal a sample size of at least 10 
is required to test the null hypothesis properly. However, it seems KO HF mice still 
possess healthier vasculature than WT or HET HF mice. WT HF and HET HF mice exhibit 
reduced ACh-induced peak flux compared to WT NC (Fig. 4.5H – WT NC 357.3 ± 9.48 vs. 
WT HF 257.8 ± 17.04, n = 6-10, p < 0.01; WT NC 357.3 ± 9.48 vs. HET HF 212.9 ± 8.6, n = 
6-10, p < 0.001). KO HF displayed a trend toward an increased ACh-induced peak flux 
compared to WT HF and HET HF and similar ACh-induced peak flux to WT NC mice (Fig. 
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4.5H – WT NC 357.3 ± 9.48 vs. KO HF 333.5 ± 33.62). Power calculations reveal that a 
sample size of 13 would be required to detect whether KO HF are significantly different 
from WT HF or HET HF mice in terms of peak flux.  
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Figure 4.5 Global genetic reduction of BACE1 protects mice against HFD-induced endothelial 
dysfunction in vivo  
To measure endothelial function in vivo, NC-fed WT and HFD-fed WT, HET and KO mice underwent LDI 
after 10 weeks of dietary intervention, with iontophoresis of PE and ACh, the application time of which 
are represented by a dotted line. ACh-induced skin perfusion as a percentage of baseline (baseline is 
100%) over time in (A) WT NC and WT HF, (B) WT HF and KO HF, (C) WT NC and HET HF, (D) HET HF and 
KO HF, and (E) WT NC and KO HF. (F) ACh-induced skin perfusion as a percentage of PE baseline in HFD-
fed WT, HET, and KO mice, and NC-fed controls. (G) Baseline skin perfusion in HFD-fed WT, HET, and KO 
mice, and NC-fed controls. (H) ACh-induced peak skin perfusion in HFD-fed WT, HET, and KO mice, and 
NC-fed controls.  
Data are expressed as mean ± standard error of the mean. 
n = 6-10. (F), (G) and (H) - Welch’s ANOVA with Dunnett’s T3 multiple comparison. ** = p < 0.01 and *** 
= p < 0.001 when compared to WT NC. 
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4.2.3 Central chronic infusion of Aβ42 does not affect HFD-induced weight gain 
 
Mice were fed HFD for 4 weeks before undergoing subcutaneous icv minipump surgery 
in order to infuse Aβ42 centrally. ScrP was used as a control. Mice were weighed daily for 
5 weeks following surgery. Percentage weight gain (Fig. 4.6C-D) starts at 7 days post-
surgery, once mice had fully recovered. Although mice are extremely resilient when it 
comes to surgery, they are known to drink and eat less, lose weight, and have difficulty 
regulating their body temperature for up to 9 days after surgery, depending on the 
complexity of the operation and how long they are under anaesthetic447. Therefore, we 
allow our mice one week to recover, after which they have regained their appetite and 
their body weight has stabilised.  
 
Centrally Aβ42 infused mice did not differ from ScrP infused control in terms of average 
body weight across the study (Fig. 4.6A), net weight gain (4.6B), or percentage weight 
gain (Fig. 4.6C-D).  
 
4.2.4 Central chronic infusion of Aβ42 promotes endothelial dysfunction 
 
To investigate effects of centrally infused Aβ42 on endothelial function in vivo, mice 
underwent LDI and iontophoresis of vasoactive agents (PE to induce vasoconstriction 
and ACh to induce endothelium-dependent vasodilation). As previously stated, ACh-
induced percentage change in skin perfusion, baseline skin perfusion, and ACh-induced 
peak skin perfusion were extrapolated for analysis. 
 
When plotted as change in skin perfusion over time, the responsiveness to PE in Aβ42 
appears to be delayed compared to ScrP mice (Fig 4.7A). Aβ42 mice also appear to exhibit 
a  slightly blunted response to ACh (Fig. 4.7A). When expressed as % Δ skin perfusion in 
response to ACh compared to PE-induced normalised baseline, Aβ42 infused mice 
displayed a significantly blunted response to ACh (Fig. 4.7B – ScrP 13.88% ± 1.46% vs. 
2.64% ± 2.66%, n = 7, p < 0.001). Baseline and ACh-induced peak skin perfusion were 
unaffected by Aβ42 infusion.  
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Figure 4.6 Central chronic infusion of Aβ42 has no effect on body weight 
10-12 week old WT mice were placed on HFD for 4 weeks before undergoing surgery to fit a subcutaneous 
minipump with an icv catheter in order to infuse Aβ42 or ScrP control centrally for 4 weeks. Mice were 
maintained on HFD during the infusion period. Body weight was measured daily post-surgery. (A) Average 
daily body weight. (B) Net weight gain at the end of the study. (C) Daily body weight gain as a percentage 
of body weight at 7 days post-surgery. (D) Percentage weight gain at the end of the study.  
 
Data are expressed as mean ± standard error of the mean. 
n = 7. (B) and (D) – Unpaired t-test with Welch’s correction.  
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Figure 4.7 Central chronic infusion of Aβ42 promotes peripheral endothelial dysfunction 
10-12 week old WT mice were placed on HFD for 4 weeks before undergoing surgery to fit a subcutaneous 
minipump with an icv catheter in order to infuse Aβ42 or ScrP control centrally for 4 weeks. Mice were 
maintained on HFD during the infusion period. To measure endothelial function in vivo, ScrP and Aβ42 
infused mice underwent LDI with iontophoresis of PE and ACh. Time of application of PE and ACh are 
represented by dotted lines. (A) ACh-induced skin perfusion as a percentage of baseline (baseline is 100%) 
over time in Aβ42 and ScrP mice. (B) ACh-induced skin perfusion as a percentage of PE baseline in Aβ42 and 
ScrP mice. (C) ACh-induced peak skin perfusion in Aβ42 and ScrP mice. (D) Baseline skin perfusion in Aβ42 
and ScrP mice. 
 
Data are expressed as mean ± standard error of the mean. 
n = 7. (B), (C), and (D) – Unpaired t-test with Welch’s correction. ** = p < 0.01 when compared to ScrP. 
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4.2.5 Central chronic infusion of Aβ42 increases fasting blood glucose levels 
 
To investigate whether the Aβ42-induced ED observed was due to impaired glucose 
homeostasis, we measured systemic glucose tolerance (GTT) and insulin sensitivity (ITT) 
in Aβ42 infused mice. ITT and GTT were completed and fasting blood glucose levels were 
measured after a 4-hour fast and a 16-hour fast.  
 
ITTs and GTT measurements did not differ between Aβ42- and ScrP infused mice (Fig. 
4.8A-C). Blood glucose levels after a 4-hour fast remained unchanged between groups 
(Fig. 4.8D), however after 16 hours of fasting, Aβ42 infused mice exhibited 
hyperglycaemia (Fig. 4.8E – ScrP 6.94mmol/l ± 0.77mmol/l vs. Aβ42 9.97mmol/l ± 
1.09mmol/l, n = 7, p < 0.05). However, this is a small sample size and more experiments 
would have to be performed in order to know whether this is a genuine result. 
Hyperglycaemia at 16 hours fast, but not at shorter timepoints, suggests Aβ42 mice may 
exhibit increased hepatic gluconeogenesis. This is discussed further herein in section 
4.3.3. 
 
3.2.6 Peripheral chronic infusion of Aβ42 does not affect HFD-induced weight gain 
 
Mice were fed HFD for 4 weeks before undergoing subcutaneous minipump surgery in 
order to infuse Aβ42 peripherally. ScrP was used as a control. Mice were weighed daily 
for 5 weeks following surgery. Percentage weight gain given herein (Fig. 4.9C-D) starts 7 
days post-surgery, once mice had fully recovered. Aβ42 infused mice did not differ from 
ScrP infused control in terms of average body weight across the study (Fig. 4.9A), net 
weight gain (4.9B), or percentage weight gain (Fig. 4.9C-D).  
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Figure 4.8 Glucose homeostasis in chronic centrally Aβ42 infused mice 
10-12 week old WT mice were placed on HFD for 4 weeks before undergoing surgery to fit a 
subcutaneous minipump with an icv catheter, in order to infuse Aβ42 or ScrP control centrally for 4 
weeks. Mice were maintained on HFD during the infusion period. Mice underwent various metabolic 
measurements in order to determine the effects of chronic Aβ42 or ScrP infusion of systemic 
metabolism. (A) Insulin tolerance test. (B) Glucose tolerance test. (C) AUC of (B) glucose tolerance 
test. (D) Blood glucose levels after a 4 hour fast and (E) after 16 hour fast.  
Data are expressed as mean ± standard error of the mean. 
n = 7. (A) and (B) – Repeated measures ANOVA with Bonferroni’s multiple comparison. (C), (D), and 
(E) – Unpaired t-test with Welch’s correction. * = p < 0.05 when compared to ScrP control.  
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Figure 4.9 Peripheral chronic infusion of Aβ42 has no effect on body weight 
10-12 week old WT mice were placed on HFD for 4 weeks before undergoing surgery to fit a subcutaneous 
peripheral minipump in order to infuse Aβ42 or ScrP control peripherally for 4 weeks. Mice were 
maintained on HFD during the infusion period. Body weight was measured weekly post-surgery. (A) 
Average daily body weight. (B) Net weight gain at the end of the study. (C) Daily body weight gain as a 
percentage of weight 7 days post-surgery. (D) Percentage weight gain at the end of the study.  
 
Data are expressed as mean ± standard error of the mean. 
n = 4-5 from the datasets shown (B) and (D) – Unpaired t-test with Welch’s correction.  
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3.2.7 Peripheral chronic infusion of Aβ42 produces a trend toward reduced endothelial 
responsiveness to ACh in vivo 
 
To investigate effects of peripherally infused Aβ42 on endothelial function in vivo, mice 
underwent LDI and iontophoresis of vasoactive agents (PE to induce vasoconstriction 
and ACh to induce endothelium-dependent vasodilation). Peripherally infused Aβ42 
mice, similarly to ScrP controls, exhibited reduced % skin perfusion in response to PE. 
However, whilst ScrP exhibited increased % skin perfusion in response to ACh, Aβ42 mice 
displayed a blunted response (Fig. 4.10A). When expressed as ACh-induced change in 
skin perfusion (compared to PE baseline), there was no observed difference between 
Aβ42 and ScrP controls (Fig 4.10B). Furthermore, no change was observed in baseline 
skin perfusion (Fig. 4.10C), or ACh-induced peak skin perfusion (Fig. 4.10D). The sample 
size in this study is very small (n = 4-5). We have observed reduced ACh response in 
peripherally infused Aβ42 previously316 in studies with higher sample sizes and thus less 
variability. It is likely that if we increased experimental numbers, we would observe 
similar findings. 
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Figure 4.10 Peripherally chronically infused Aβ42 mice exhibit a trend toward reduced endothelial 
responsiveness 
10-12 week old WT mice were placed on HFD for 4 weeks before undergoing surgery to fit a 
subcutaneous peripheral minipump in order to infuse Aβ42 or ScrP control peripherally for 4 weeks. Mice 
were maintained on HFD during the infusion period. To measure endothelial function in vivo, ScrP and 
Aβ42 infused mice underwent LDI with iontophoresis of PE and ACh. Application times of PE and ACh are 
represented by the dotted line. (A) ACh-induced skin perfusion as a percentage of baseline (baseline is 
100%) over time, (B) ACh-induced skin perfusion as a percentage of PE baseline, (C) ACh-induced peak 
skin perfusion, and (D) baseline skin perfusion in Aβ42 or ScrP peripherally infused mice. 
Data are expressed as mean ± standard error of the mean. 
n = 4-5. (A) - Repeated measures ANOVA with Bonferroni multiple comparison. (B), (C), and (D) – 
Unpaired t-test with Welch’s correction. 
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3.2.8 Pharmacological inhibition of BACE1 activity improves endothelial and smooth 
muscle cell response in APP23 mice in vivo 
 
To further consolidate the observed outcome of Aβ42 on endothelial function in vivo, we 
investigated how inhibition of BACE1 activity in a model of genetically raised Aβ42 levels 
would influence endothelial and smooth muscle cell responsiveness. NC-fed APP23 mice 
underwent surgery to fit a peripheral subcutaneous minipump to infuse the BACE1 
inhibitor M-3 or a vehicle control. M-3 is a compound produced by Merck that inhibits 
BACE1 enzymatic activity. We have shown previously that infusing the inhibitor leads to 
vast reductions in Aβ42 circulating and tissue concentrations308,316,317. However, it should 
be noted that the there is no peer-reviewed published data on the selectivity or the off-
target effects of this compound. Mice underwent LDI and iontophoresis of vasoactive 
agents (PE to induce vasoconstriction, ACh to induce endothelium-dependent 
vasodilation, and SNP to induce endothelium-independent vasodilation). Baseline skin 
perfusion, ACh-induced and SNP-induced percentage change in skin perfusion, and ACh-
induced or SNP-induced peak skin perfusion were extrapolated for analysis.  
 
As mentioned in Methods 2.2.6, 16 APP23 mice were purchased in order to obtain a 
sample size of 8 per group. However, several mice were found dead within the first 
couple of weeks of arriving and further mice were found dead/had to be euthanised 
following minipump surgery. It should be noted that peripheral minipump surgery is 
very non-invasive. Mice are under anaesthetic for no longer than 10-15 minutes and 
there is a very high success rate. In our experience, there is roughly <5% death rate after 
minipump surgery. However, with APP23 mice, there was ~50% death rate. This was 
concerning and Jax Labs were informed regarding these issues. For these reasons, 
sample size for this study is very small. 
 
To confirm BACE1 activity inhibition, we measured plasma Aβ42 and observed a trend 
toward reduced levels of Aβ42 in M-3 infused APP23 mice compared to vehicle controls 
(Fig. 4.11), but sample size is very low (n = 2). 
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There was no observed change in baseline skin perfusion (Fig. 4.12A) or peak skin 
perfusion in response to ACh (4.12D) or SNP (4.12E). APP23 mice did not respond to ACh 
application in terms of skin perfusion (Fig. 4.12B). There were slight trends toward 
increased ACh- and SNP-induced change in skin perfusion in M-3 infused APP23 mice 
compared to vehicle infused (Fig. 4.12F and G). Our power calculations prior to the 
experiment suggested a sample size of 6-8 for this study, but as previously mentioned, 
many of the mice that were purchased died or had to be euthanized.  
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Figure 4.11 Plasma Aβ42 is reduced in M3 infused APP23 mice 
8-10 week old APP23 mice underwent surgery to peripherally infuse the BACE1 inhibitor M-3 
vs. saline vehicle for 4 weeks. At the end of the study, blood was harvested and plasma 
extracted. Aβ42 concentration was measured using an ELISA.  
 
Data are expressed as mean ± standard error of the mean. 
n = 2. Sample size too small to perform statistical analysis. 
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Figure 4.12 Inhibition of BACE1 activity in APP23 mice improves endothelial and smooth muscle 
responsiveness in vivo 
8-10 weeks old APP23 mice underwent surgery to infuse the BACE1 inhibitor M-3 vs. saline vehicle for 4 
weeks. To measure endothelial function in vivo, mice underwent LDI with iontophoresis of PE and ACh. In 
order to measure endothelium-independent vasodilation, mice underwent LDI and iontophoresis of PE 
and SNP.  Times point of ACh and SNP application are labeled. (A) Baseline skin perfusion. (B) ACh-induced 
skin perfusion as a percentage of baseline (baseline is 100%) over time in minutes. (C) SNP-induced skin 
perfusion as a percentage of baseline (baseline is 100%) over time in minutes. (D) ACh-induce peak skin 
perfusion. (E) SNP-induced peak skin perfusion. (F) ACh-induced skin perfusion as a percentage of PE 
baseline. (G) SNP-induced skin perfusion as a percentage of PE baseline. 
Data are expressed as mean ± standard error of the mean. 
n = 4. (B) and (C) – repeated measures ANOVA with Bonferroni’s multiple comparison. (A), (D), (E), (F), (G) 
– Unpaired t-test with Welch’s correction.  
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3.2.9 Effects of varying Aβ42 levels on nitric oxide bioavailability 
 
We measured plasma nitrite concentration (direct metabolite of NO) as well as plasma 
ET-1 concentration to investigate whether Aβ42 was promoting the observed ED in vivo 
through reduced NO bioavailability. Plasma nitrite remained unchanged in centrally 
infused Aβ42 mice compared to ScrP controls (Fig. 4.13A) or in M-3 infused APP23 mice 
compared to vehicle controls (Fig. 4.13B). We observed a strong trend in reduced ET-1 
levels upon M-3 infusion in APP23 mice compared to controls (4.13C – vehicle 4.63pg/ml 
± 0.14pg/ml vs. M-3 2.9pg/ml ± 0.67pg/ml, n = 4, p = 0.07). ET-1 levels were not 
measured in Aβ42 mice in the current study due to financial constraints. 
 
3.2.9 Genetically reducing BACE1 does not affect aortic or VE fraction expression of 
proteins governing mitochondrial dynamics 
 
Aortae and hemi brains were harvested from NC-fed WT mice, as well as HFD-fed BACE1 
KO mice and their WT and HET littermates. VE fractions were isolated from hemi-brains. 
Protein was extracted from tissues and separated using SDS-PAGE. Proteins of interest 
were probed for using conventional Western blotting methods.  
 
Representative blots showing aortic Mfn2 and OPA1 expression are shown in Fig. 4.14A. 
Actin was used as a loading control. HFD-feeding and genetic reduction of BACE1 did not 
induce any changes in aortic OPA1 expression (Fig. 4.14C). However, BACE1 KO mice did 
exhibit a trend toward increased Mfn2 expression compared to all three groups (Fig. 
4.14B). Power calculations reveal a sample size of around 12 is needed to test the null 
hypothesis accurately. Blotting for total Drp1 and phosphorylation status of Drp1 (s616 
and s637) was attempted in the aortae of these mice, but proteins were undetectable. 
Due to lack of sample, blots could only be attempted once. We were also not able to 
probe for Mfn1 in these tissues due to lack of sample. More mice would need to be 
harvested in order to further investigate aortic expression of Drp1 and Mfn1 protein.  
 
Representative blots showing VE fraction expression of Mfn1, Mfn2, OPA1, and Drp1 
protein is shown in Fig. 4.15A. Actin was used as a loading control. VE fraction expression 
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of Mfn1 (Fig. 4.15B), Mfn2 (Fig. 4.15C), and total Drp1 (Fig. 4.15G) was unchanged by 
HFD feeding or BACE1 reduction.  BACE1 HET and BACE1 KO mice exhibit a trend toward 
reduced VE fraction protein expression of the short form of OPA1 (Fig. 4.15E). Power 
calculations reveal a sample size of at least 7 is required to test significance sufficiently. 
Again, phosphorylation status of Drp1 (s616 and s637) was attempted but could not be 
detected herein. 
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Figure 4.13 Effects of differing Aβ42 levels on nitric oxide bioavailability 
10-12 week old WT mice were placed on HFD for 4 weeks before undergoing surgery to fit a subcutaneous 
peripheral minipump, in order to infuse Aβ42 or ScrP control peripherally for 4 weeks. Mice were maintained 
on HFD during the infusion period. 8-10 weeks old APP23 mice underwent surgery to infuse the BACE1 
inhibitor M-3 vs. saline vehicle for 4 weeks. (A) Plasma nitrite concentration in Aβ42 and ScrP mice. (B) Plasma 
nitrite concentration in APP23 ± M-3. (C) Plasma endothelin-1 concentration in APP23 ± M-3. (D) Plasma Aβ42 
concentration in APP23 ± M-3. 
 
Data are expressed as mean ± standard error of the mean. 
Aβ42 vs. ScrP, n = 7. APP23 ± M-3, n = 3-4. Unpaired t-test with Welch’s correction. 
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Figure 4.14 Aortic expression of proteins governing mitochondrial fusion are unchanged by genetically 
reducing BACE1 
10-12 week old WT, BACE1 heterozygous (referred to as HET), and BACE1 KO (referred to as KO) were 
placed on 45% HFD for 10 weeks. At the end of the study, aortae were harvested and protein extracted. 
20μg of protein was loaded onto acrylamide gels and separated by SDS PAGE. (A) Representative western blots 
showing expression of proteins regulating mitochondrial fusion in the murine aorta with actin as a loading 
control. Quantification of western blots normalised to actin of (B) Mfn2 and (C) OPA1. 
 
Data are expressed as mean ± standard error of the mean. 
n = 6. (B) and (C) – Welch’s ANOVA with Dunnett’s multiple comparison.  
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Figure 4.15 VE fraction expression of proteins governing mitochondrial dynamics remain unchanged by 
genetically reducing BACE1 
10-12 week old WT, BACE1 heterozygous (referred to as HET), and BACE1 KO (referred to as KO) were placed on 
45% HFD for 10 weeks. At the end of the study, hemi-brains were harvested, VE enriched fractions were isolated, 
and protein extracted. 20μg of protein was loaded onto acrylamide gels and separated by SDS PAGE. (A) 
Representative western blots showing expression of proteins regulating mitochondrial fusion in the murine NVU with 
actin as a loading control. Quantification of western blots normalised to actin of (B) Mfn1, (C) Mfn2, (D) total OPA1, (E) 
short-form OPA1, (F) long-form OPA1, and (G) total Drp1. 
 
Data are expressed as mean ± standard error of the mean. 
n = 6. (B) - (G) – Welch’s ANOVA with Dunnett’s multiple comparison.  
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3.2.10 Central Aβ42 infusion increases VE fraction expression and phosphorylation of 
Drp1, but other proteins remain unchanged 
 
Hemi-brains were harvested from Aβ42 infused mice and their controls, and VE fractions 
were isolated. Protein was extracted from VE fractions and separated using SDS-PAGE. 
Proteins of interest were probed for using conventional Western blotting. 
Representative western blots are shown in Fig. 4.16A. Actin was used as a loading 
control. In the case of OPA1, the double band was quantified together to give total 
OPA1, the lower band was quantified separately to give short-form OPA1, and the higher 
band was quantified separately to give long-form OPA1.  
 
VE fraction expression of Mfn2, total OPA1, short-form OPA1, and long-form OPA1 
remained unchanged by central Aβ42 infusion (Fig. 4.16B and C) Interestingly, 
phosphorylation of Drp1 at site s616 was increased in Aβ42 infused mice compared to 
vehicle control (Fig. 4.16D – vehicle 1 ± 0.1 vs. Aβ42 1.44 ± 0.15, n = 7, p < 0.05) and total 
Drp1 protein was also increased by ~2-fold upon Aβ42 infusion (Fig. 4.16E – vehicle 1 ± 
0.25 vs. Aβ42 2.11 ± 0.41, n = 7, p < 0.05). When expressed as phospho/total ratio, Aβ42 
did not promote any changes in the NVU compared to vehicle controls. Due to lack of 
sample, Mfn1 was not probed for herein, but would be interesting to investigate in 
relation to Aβ42 infusion. 
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Figure 4.16 VE fraction expression of Drp1 is increased upon Aβ42 central infusion 
10-12 week old WT mice were placed on HFD for 4 weeks before undergoing surgery to fit a 
subcutaneous peripheral minipump with a central catheter, in order to infuse Aβ42 or ScrP control 
icvly for 4 weeks. Mice were maintained on HFD during the infusion period. At the end of the study, 
hemi-brains were harvested, VE enriched fractions were isolated, and protein extracted. 20μg of 
protein was loaded onto acrylamide gels and separated by SDS PAGE. (A) Representative western blots 
showing expression of proteins regulating mitochondrial fusion in the murine NVU with actin as a loading 
control. Quantification of western blots normalised to actin of (B) Mfn2 (D) total, short, and long-form 
OPA1, (D) phospho-Drp1 s616, (E) total Drp1, and (F) phospho/total. 
 
Data are expressed as mean ± standard error of the mean. 
n=7. (B) – (F) Unpaired t-test with Welch’s correction. 
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3.2.11 Genetically reducing BACE1 does not affect VE fraction of aortic ICAM expression 
 
Aortae and hemi-brains were harvested and VE fractions were isolated from hemi-
brains. Protein was extracted from aortae and VE fractions and separated using SDS-
PAGE. ICAM was probed for using conventional Western blotting as a marker for 
endothelial activation – an inflammatory pathology associated with ED. Actin was used 
as a loading control. Representative blots can be found in Fig. 4.17A (VE fraction 
expression) and B (aortic expression).  
 
A trend towards reduced VE fraction ICAM expression was observed in all three HFD-fed 
groups (WT HF, HET HF, KO HF) compared to WT NC controls. Indeed, the reduction in 
VE fraction ICAM was close to significance in WT HF mice compared to WT NC mice (Fig. 
4.17C – WT NC 1 ± 0.16 vs. WT HF 0.54 ± 0.11, n = 6, p = 0.07). No effect of diet was 
observed on aortic ICAM expression (Fig. 4.17D). Furthermore, genetic reduction of 
BACE1 (as in HET HF and KO HF) groups did not produce any observable difference in 
neither VE fraction nor aortic ICAM expression (Fig. 4.17C and D). Due to lack of tissue, 
ICAM was not probed for in Aβ42 mice, but it would be of value to investigate this. 
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Figure 4.17 HFD feeding and genetically reducing BACE1 has no effect on ICAM expression 
10-12 week old WT, BACE1 heterozygous (referred to as HET), and BACE1 KO (referred to as KO) were 
placed on 45% HFD for 10 weeks. At the end of the study aortae and hemi-brains were harvested. VE 
enriched fractions were isolated, and protein extracted. 20μg of protein from aortic and VE fraction lysate 
was loaded onto acrylamide gels and separated by SDS PAGE. (A) Representative western blots showing 
expression of ICAM in the murine NVU and (B) aorta with actin as a loading control. (C) Quantification of NVU 
ICAM normalised to actin. (D) Quantification of aortic ICAM normalised to actin.  
 
Data are expressed as mean ± standard error of the mean. 
n = 6. (B) and (C) – Welch’s ANOVA with Dunnett’s multiple comparison. 
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Discussion 
 
4.3.1 Genetically reducing BACE1 protects against diet-induced weight gain 
 
In order to confirm the previously observed protective metabolic phenotype of BACE1 
KO mice, we fed 45% HFD to BACE1 KO mice (KO HF), as well as their heterozygous and 
WT littermates (HET HF and WT HF), for 10 weeks and measured body weight weekly. 
In line with our existing publications, we observed that globally reducing BACE1 levels  
protects against diet-induced weight gain317. Although body composition was not 
measured in the present study, the reduced weight gain is likely due to reduced fat mass 
as previously observed317. Body composition was not measured herein as in vivo 
measurements in mice can be stress inducing and can result in weight loss. We expected 
that this potential weight loss might interfere with our in vivo vascular measurements, 
which we deemed more important as the main in vivo experimental output of this study. 
The reduced weight gain in these mice could also be due to increased energy 
expenditure and metabolic inefficiency, as we have previously observed increased in 
expression of uncoupling proteins (UCPs) in BACE1 KO mice317. UCP1 protein was 
upregulated in brown adipose tissue (BAT) in BACE1KO mice (both NC-fed and HFD-fed) 
compared to WT mice, as well as increased Ucp2 and Ucp3 mRNA in skeletal muscle. 
HET HF mice do not exhibit the same protective phenotype, suggesting the remaining 
copy of the BACE1 gene is sufficient to contribute to HFD-induced weight gain. Indeed, 
we have shown that chronic HFD feeding induces upregulation of BACE1 protein levels 
in BACE1 HET mice in skeletal muscle317. 
 
4.3.2 Genetically reducing BACE1 protects against diet-induced endothelial dysfunction 
in vivo 
 
Due to the known association between nutrient excess and vascular disease, we 
investigated the effects of HFD and BACE1 genetic reduction on endothelial function in 
vivo. 
 
 
 
 
201 
ACh-induced percentage change in vasodilation as well as ACh-induced peak skin 
perfusion was reduced in WT HF and HET HF mice compared to WT NC, suggesting HFD-
induced ED. However, BACE1 KO mice did not differ from WT NC mice, and exhibited a 
trend toward improved endothelial response compared to WT HF and HET HF, indicating 
protection against diet-induced ED. The data herein suggest a role for BACE1 in the 
development of ED and subsequent vascular complications. 
 
It must be considered that the reduced response to ACh may in fact was not due to 
endothelial unresponsiveness, but due to VSMC dysfunction. When NO diffuses into 
neighbouring VSMCs, it activates a cGMP-PKG-dependent mechanism to induce muscle 
relaxation. This signalling pathway has been implicated in the development of vascular 
dysfunction, and we have reported that animals challenged with HFD for 20 weeks 
exhibit reduced cGMP and PKG expression in aortic tissue316. We did not measure VSMC 
function in vivo, but this can be done by applying the NO donor SNP to the skin and 
measuring the skin perfusion response.  
 
As previously discussed, ED may result from reduced NO bioavailability, increased EA, 
increased ROS production, and/or mitochondrial dysfunction. Although not measured 
herein due to lack of tissue and time constraints, we have previously observed increased 
NO bioavailability in HFD-fed (10 weeks) BACE1 KO mice compared to WT littermates, 
reporting increased plasma nitrite and reduced ET-1316. Furthermore, HFD-fed BACE1 
KO mice exhibit increased aortic phosphorylation of eNOS at s1177 compared to WT 
littermates, indicating increased eNOS activity. They also display increased aortic 
phosphorylation of PKB at s473, a potent activator of eNOS. These data suggest that 
BACE1 KO mice are protected against HFD-induced ED due to their retention of eNOS 
activity and thus NO bioavailability. 
 
HFD-fed (20-weeks) BACE1 KO mice exhibit reduced fasting blood glucose levels 
compared to WT littermates, improved glucose tolerance, and a preference for 
carbohydrate oxidation rather than fatty acid oxidation317. These results indicate that 
BACE1 KO mice harbor an enhanced ability to dispose of glucose. As previously 
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mentioned, hyperglycaemia has on numerous occasions been closely linked with ED. To 
briefly recap, mice with very high fasting blood glucose levels (>25mmol/l) exhibit a 
marked reduction in in vivo ACh-dependent vasodilation183. Others have reported 
diabetic mice exhibit reduced ACh-induced vasodilation in ex vivo aortic myograph 
studies153,154, increased eNOS mRNA155, and increased aortic superoxide expression154. 
Hyperglycaemia is linked with increased ROS production287,290, leading to inhibition of 
GAPDH, an important glycolysis enzyme. The inhibition of GAPDH results in the 
accumulation of glycolysis intermediates (G6P, F6P), which, through several diverging 
pathways, can result in ED. For example, G6P can lead to DAG accumulation174 and 
increased methylglyoxal levels, which is known to forms AGEs176. F6P can enter the 
hexosamine pathway, forming UDP-GlcNAc and upregulating O-linked GlcNAcylation. 
Glucose can be converted to sorbitol, increasing uric acid accumulation. This model is 
described in more detail in section 1.8.2. Due to the increased capacity for glucose 
disposal in BACE1 KO mice, it may be that the resulting reduction in blood glucose per 
se contributes to the improved endothelial function in these mice. Due to time 
constraints, ROS production was not measured in these mice, but this would be an 
important future step in this study. Section 3.3.4 indicates several assays that we would 
consider performing in order to measure ROS in this model.  
 
It is possible that BACE1 KO mice also possess greater mitochondrial flexibility, as 
indicated by the fact they express increased uncoupling protein expression (UCP1 
protein in brown adipose tissue, Ucp2 and Ucp3 mRNA in skeletal muscle)317. These data 
suggest that energy from excess nutrients can be lost due to enhanced proton leak (by 
UCPs) in BACE1 KO mice, protecting mitochondria from nutrient-excess induced 
dysfunction. Due to the known deleterious effects of nutrient excess on endothelial 
function, enhanced endothelial proton leak may protect against ED. This is because 
excessive nutrient supply can lead to enhanced ETC activity and increased MMP, which 
overwhelms mitochondria leading to RET and superoxide production. This is discussed 
in greater detail in section 1.12.4. Uncoupling mitochondria from ATP production 
(through increased UCP expression) and dissipating MMP may protect against mROS 
production by nutrient excess-induced RET and superoxide production.286–288. UCP 
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expression has not been investigated in the vasculature from BACE1 KO mice, but it 
would be interesting to perform qPCR or conventional WB for UCP mRNA/protein 
expression in aortic or VE fraction tissue.  
 
 
4.3.3 Chronic infusion of Aβ42 promotes endothelial dysfunction independently of 
metabolic impairments 
 
Due to the observed role of BACE1 in protecting against HFD-induced ED, we decided to 
investigate the products of increased BACE1 enzymatic activity. Indeed, infusion of a 
BACE1 inhibitor protects against ED in DIO mice (20 weeks HFD; manuscript in review). 
To study the effects of increased BACE1 activity in relation to its most well-known 
substrate APP, we investigated the vascular consequences of chronically infusing of Aβ42 
vs. ScrP both centrally and peripherally using surgical minipumps.  
 
Chronic central infusion of Aβ42 produced a blunted response to ACh-induced 
vasodilation compared to ScrP infused controls, indicating central infusion of Aβ42 
causes ED. Due to the strong link between metabolic dysfunction and vascular 
impairments, we also investigated whether metabolic parameters were changed by 
central Aβ42 infusion. Interestingly, Aβ42 did not induce any changes in body weight, 
insulin sensitivity, or glucose tolerance. This indicates the vascular impairments 
observed in Aβ42 infused mice are not due to metabolic dysfunction. However, central 
Aβ42 mice did exhibit higher fasting blood glucose levels, but only after 16 hours of 
fasting, potentially suggesting dysregulation of gluconeogenesis. Sample size is small 
however, and more experiments would need to be performed in order to be sure. It is 
possible that the observed fasting hyperglycaemia may contribute to the reduced 
response to ACh. As previously mentioned, hyperglycaemia can result in decreased NO 
bioavailability and consequently ED153–155,183,287,290.  
 
It is interesting that central infusion of Aβ42 can induce systemic effects. There is an 
emerging role for the hypothalamus in controlling peripheral metabolic homeostasis 
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outside of appetite regulation. It is possible that central Aβ42 infusion can regulate 
glucose homeostasis through a hypothalamic mechanism. Indeed, we have shown 
central infusion of Aβ42 can promote hypothalamic leptin resistance305 and perhaps 
contribute to the development of obesity. The hypothalamus is home to glucose-sensing 
neurons, which are known to respond to varying levels of blood glucose and result in 
altered autonomic output. The autonomic nervous system (ANS) transmits efferent 
signals through nerves to the pancreas, skeletal muscle, and liver in order to control 
blood glucose levels. It is possible that Aβ42 can regulate the action of the neurons that 
govern the autonomic output to increase fasting blood glucose levels. This would need 
to be further investigated. Firstly, we would have to measure Aβ42 concentration in the 
plasma and brain tissue of Aβ42 and ScrP mice to elucidate whether the centrally infused 
Aβ42 is entering the systemic circulation, which would shed some light on whether Aβ42 
is exerting its effects centrally or systemically. We did attempt to measure Aβ42 levels in 
these mice, but they were undetectable. The low pM concentrations of Aβ42 that we 
infuse may be difficult to detect using simple MSD ELISAs. A better ELISA-like method 
for measuring Aβ42 would be the Simoa, which employs an ultra-sensitive bead 
technology and is reportedly 1000 times more sensitive than traditional methods. An in-
house assay for Aβ42 is set up and is currently being used for other studies within the 
School of Medicine. It is possible that we could use this technique to measure Aβ42 levels 
in the plasma and brain tissue of our mice. If the Aβ42 is indeed acting centrally (likely in 
the hypothalamus) we could employ several techniques to further investigate the 
effects of raised hypothalamic BACE1 activity on peripheral glucose homeostasis. 
Indeed, we could specifically raise BACE1 levels in the hypothalamus by stereotaxically 
injecting a BACE1-overexpressing adenovirus into this part of the brain and investigate 
the effects on glucose homeostasis. Coupling this model with infusion of a BACE1 
inhibitor would give insight into role of hypothalamic BACE1 enzymatic activity in this 
process. A model of increased Aβ42 could be used. One such model is the called BRI-
Aβ42, which overexpresses Aβ42 without overexpressing APP. BRI-Aβ42 mice exhibit 
amyloid pathology in brain tissue as well as cerebral vessels as early as 3 months of 
age448. This model could be investigated alongside the BRI-Aβ40 mouse which 
interestingly does not exhibit overt amyloid pathology448. An existing model of raised 
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pyroglutamate Aβ (Aβ3(pE)) exists, whereby Aβ3(pE) is produced under the Thy-1 promoter 
(which is thought to be mainly neuronal specific)449. It would be possible to employ a 
similar technique using Aβ42 and a specific promoter of interest present in cells known 
to be involved in regulating systemic metabolism, such as POMC/CART or AgRP/NPY 
neurons, or astrocytes, which are now recognised for their role in sensing nutrients450. 
The ANS has been also been reported to control vascular tone. The ANS, the control of 
which is governed by the hypothalamus and brain stem, can be further split into 
parasympathetic and sympathetic nervous systems. Both the parasympathetic and 
sympathetic nervous systems can regulate vascular tone and have been reported to 
induce vasodilation and vasoconstriction through β- and α-adrenoreceptors (ARs) 
present on the vasculature respectively451. For example, β1-, β2-, and β3-ARs expressed 
on endothelium mediate vasodilation through an NO-dependent mechanism452–454, and 
are likely activated by circulating adrenaline produced by the adrenal gland. α1-ARs 
present on VSMCs respond to noradrenaline released from postganglionic neurons by 
inducing VSMC contraction and thus vasoconstriction455. Central infusion of Aβ42 may 
modulate central pathways that control ANS output to contribute to regulation of 
vascular tone. It is possible that this could result in a blunted response to ACh, but not 
much is known about the cross talk between ANS- and ACh-dependent regulations of 
vascular tone. It has been reported that NO itself can be released from sympathetic 
nerve fibres to act on the vasculature, so this could also be a mechanism by which Aβ42 
modulates peripheral vasculature through central mechanisms. Furthermore, we have 
only measured endothelium-dependent vasodilation in our Aβ42 centrally infused 
model. It would also be useful to measure endothelium-independent vasodilation to 
elucidate whether central Aβ42 infusion is affecting only the sympathetic regulation of 
AR signalling on ECs, or also contributes to impairment in VSMC function. To investigate 
this, iontophoresis of SNP can be used in conjunction with LDI technology. SNP can 
surpass the endothelium, acting directly on VSMCs to induce vasodilation456. Using this 
agent would elucidate whether the effects Aβ42 are due specifically to ED, or due to an 
impairment in the response VSMC response to NO. SNP iontophoresis was not 
completed in these mice. A derivative of SNP is cyanide, meaning that when applied to 
mice they must be culled immediately after. This prevents tissue from being harvested 
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after a fasting period, which is required when investigating protein changes in tissues of 
HFD-fed mice. We prioritised overnight fasting and tissue harvested over LDI and SNP 
iontophoresis, with the intention of using a separate batch of central Aβ42 vs. ScrP mice 
for SNP at a later date. Due to financial and time constraints this was not completed. 
It should be noted that the infused Aβ42 may be sequestered out of the brain into the 
circulation through Aβ42 transporters at the BBB such as LRP1457. As previously 
mentioned, to shed light on this an MSD ELISA was performed to measure Aβ42 
concentration in the hypothalamus vs. plasma of these mice. Unfortunately, Aβ42 was 
completely undetectable in both tissues. This left us hesitant about the validity of our 
centrally infused Aβ42 mouse and is the reason why tissue processing from this Aβ42 
study was not prioritized. Therefore, it can be observed in this chapter that only the VE 
fraction tissue was processed for subsequent Western blot. Due to the nature of the 
minipumps the maximum infusion time is 4 weeks, meaning there is a week at the end 
of the study during which Aβ42 is no longer being infused, but we still observe the 
reduced endothelial response. Of course, there is the possibility of Aβ42 being degraded 
by one of its catabolic enzymes, such as insulin degrading enzyme (IDE), gelatinase A/B, 
or cathepsin D458, and the reduced endothelial response may be due to lasting 
regulatory effects of Aβ42 on endothelial function. Indeed, we cannot be certain that the 
ED observed in this model is due to central effects, or whether Aβ42 is leaking into the 
plasma and exerting direct effects on the endothelium, similarly to a chronic systemic 
infusion.  
 
Chronic peripheral infusion of Aβ42 produced a trend toward reduced vasodilatory 
response to ACh, indicating ED. The sample size would have to be increased in order to 
reach significance. Using datasets from centrally infused Aβ42 mice, power calculations 
indicate that if a similar effect size were observed, a minimum sample size of 7 would 
be required to reach significance. The observed trend in reduced response to ACh in 
peripherally infused Aβ42 mice was independent of any changes in weight gain compared 
to ScrP. Further descriptive metabolic parameters were not investigated, such as body 
composition (echoMRI) or a glucose stimulated insulin secretion test (GSIS). This 
minimised the amount of stress the animals had to endure in order to obtain the best 
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experimental results from the in vivo vascular imaging. Furthermore, tissue from these 
peripherally infused Aβ42 was required for postmortem pathological staining procedures 
and therefore we thought it best to minimise procedures involving large boluses of 
glucose/insulin that can produce lasting transcriptional effects. 
These results agree with our existing data currently in review. Here, we reported that 
chronic peripheral infusion of Aβ42 on NC background causes blunted vasodilatory to 
ACh in vivo. When animals are on HFD, this effect is exacerbated. Aβ42 resulted in a 
blunted response to ACh due to reduced NO bioavailability, suggesting ED. The existing 
data indicate that Aβ42 infusion in HFD-fed mice could reduce plasma nitrite and increase 
plasma ET-1 concentration, as well as reduce aortic phosphorylation of PKB (s473), and 
eNOS (s1177). This corroborates previous work, where others have reported that Aβ42 
application results in reduced phosphorylation of eNOS at s1177459,460. The finding that 
raised Aβ42 was associated with reduced PKB (as detected through phosphorylation of 
PKB at s473), indicates Aβ42 may interfere with PKB signalling to reduce PTM of eNOS. 
This is supported by a previous in vitro study on cultured ECs, which showed that μM 
application of soluble Aβ peptides of varying lengths inhibited PKB phosphorylation and 
p-eNOS461. This may occur through the interference of Aβ peptides with the formation 
of the activation complex of PKB with PDK1460. As previously mentioned, we reported 
previously that raising circulating Aβ42 levels increased plasma ET-1 concentration on 
HFD background. However, it should be noted that raising circulating Aβ42 levels on a NC 
background failed to increase ET-1 levels, suggesting that upregulating of ET-1 in this 
case requires a metabolic stressor as well as increased Aβ42. 
 
In the study herein, our centrally infused Aβ42 mouse did not exhibit reduced plasma 
nitrite concentrations. This could be a genuine finding, in that the measured ED caused 
by central Aβ42 infusion is independent of reduced NO bioavailability. However, this 
could equally be due to issues with reproducibility due to nature of nitrite 
measurements. To measure nitrite, the Griess assay is used. The Griess assay is simple 
absorbance assay, meaning it is sensitive to changes in the existing absorbance of 
plasma itself. If plasma samples are slightly haemolysed, this can introduce false 
positives. There is also the possibility of nitrite degradation in frozen plasma samples, as 
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well as degradation of the nitrite standard, and other reagents involved in the assay. We 
did not measure nitrite in the plasma of the peripherally infused mice herein as they 
underwent perfuse-fixation, meaning blood could not be harvested.  
 
Overall, the data collected herein on Aβ42 infused mice (both central and peripheral) 
point toward a role for HFD-induced raised Aβ42 levels in the development of nutrient 
excess-associated ED. The peripheral microvascular ED measured in vivo is a good 
predictor of potential dysfunction in brain ECs, suggesting that Aβ42 may impair cerebral 
haemodynamics, further contributing to nutrient excess-associated disease. It would be 
useful to measure CBF in vivo, in order to confirm this. CBF in vivo can be measured using 
laser technology, but the laser needs to be powerful enough to penetrate bone. This 
was attempted using the laser speckle moorFLPI-1. Unfortunately, the signal produced 
from this laser was not strong enough to measure CBF through the skull. It is possible 
that this laser is outdated. Other groups have employed the use of the newer model, 
the moorFLPI-2, and it seems a useful method to measure changes in CBF in real 
time462,463.  
 
4.3.4 APP23 mice exhibit vascular dysfunction, which is rescued by BACE1 inhibition 
 
To further consolidate the role of raised Aβ42 in the development of ED, we investigated 
the vascular profile of APP23 in vivo, and whether inhibiting BACE1 activity had a 
protective effect. 
 
Firstly, to confirm BACE1 inhibition, we measured plasma Aβ42 levels in APP23 that had 
undergone 4 weeks of infusion of the BACE1 inhibitor M-3 or saline control. Although 
sample size is small (n=2), M-3 treated mice exhibited reduced plasma Aβ42 levels, 
suggesting the treatment had successfully lowered BACE1 activity. Power calculations 
on this data set reveal that in order for statistical significance to be reached, a sample 
size of only 3 is needed for this effect size. This is because the effect size is very large. If 
possible, the Aβ42 levels of every mouse receiving M-3 or control would have been 
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measured, and any outliers (any APP23 M3 mice that did not exhibit reduced Aβ42) 
would be removed from each dataset.  
 
Although we observed no differences between groups in resting vascular tone (baseline 
skin perfusion), NC-fed APP23 mice of around 12 weeks of age did exhibit a trend toward 
a blunted response to vasodilator compounds which was rescued upon M-3 infusion. 
However, sample size is very small and further experiments would have to be done. In 
agreement with the aforementioned studies, these data suggest raised Aβ levels 
contribute to ED. However, we cannot be certain from this particular study that it is Aβ42 
that is taking effect. APP23 mice have a 7-fold overexpression of the human APP gene 
harboring the Swedish mutation464, and thus possess higher than normal levels of 
soluble Aβ40 as well as Aβ42465. As they age, soluble levels decrease and Aβ begins to 
deposit as plaques465. It is likely that M-3 infusion will reduce the levels of both Aβ40 and 
Aβ42 in the APP23 mouse. Therefore we cannot be certain at present which peptide is 
affecting EC function in the APP23 mouse, or whether it is a combined effort. Again, the 
use of amyloid overexpressing mice, BRI-Aβ42 and BRI-Aβ40, could be employed to 
better understand this.  A number of studies indicate a role for Aβ40, Aβ42, or both, in 
mediating vasoactivity in the brain320,466,467, and the periphery468. However, it should be 
noted that previous experiments on mice conducted in our lab indicate that only Aβ42 
levels are sensitive to HFD-feeding and that Aβ40 levels do not change, thus HFD-
associated ED in mice may be due to Aβ42 alone. Furthermore, we found that plasma of 
T2D humans exhibited increased Aβ42 levels compared to controls, but Aβ40 was 
unchanged.  Contradictory to this, recent analysis of human datasets from Professor 
Faisel Khan’s group suggests that it is plasma Aβ40 in humans that possesses a stronger 
link with vascular dysfunction. Indeed, circulating Aβ40, and to a lesser extent Aβ42 levels, 
were found to be strongly correlated with reduced cutaneous microvascular 
responsiveness to ACh and SNP, and arterial stiffness (unpublished data). These data 
suggest there may be species variation when it comes to Aβ and the development of ED.  
 
Aside from ACh-induced vasodilation, we also investigated SNP-mediated vasodilation 
in the APP23 mouse with and without BACE1 inhibition. SNP application will induce 
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endothelium-independent vasodilation, as SNP is a NO donor that can act directly on 
VSMCs. APP23 mice exhibited a delayed and somewhat blunted vasodilatory response 
to SNP, which was rescued by M-3. The change in percentage vasodilation due to SNP 
was almost significantly different between groups (n = 4, p = 0.05) and power 
calculations reveal that a larger sample size of 5 is required to properly test for 
significance. A blunted SNP response suggests that APP23 mice have dysfunctional 
VSMCs, potentially due to downregulation of proteins involved in NO-induced 
vasodilation, such as PKG and cGMP. Although these proteins were not measured 
herein, previous studies from our lab indicate that Aβ42 infusion can reduce PKG 
expression and cGMP activity in aortic tissue (manuscript in review).  
 
Postmortem biochemical analysis in plasma from these mice was performed in an 
attempt to investigate a potential mechanism. Plasma nitrite was found to be 
unaffected by BACE1 inhibition in APP23 mice. However, when compared to WT NC 
levels316, APP23 mice seem to exhibit overall lower levels of nitrite (WT NC ~70μmol/l 
vs. APP23 ~ 30μmol/l), suggesting reduced NO bioavailability. A trend toward reduced 
plasma ET-1 levels was observed upon BACE1 inhibition in APP23 mice (n = 4, p = 0.07). 
Power calculations suggest a sample size of 9 to accurately test statistical significance 
for the proposed effect size. The trend toward decreased ET-1 upon BACE1 inhibition, 
independently of any change in plasma nitrite, suggests a more direct effect of raised 
BACE1 activity on ET-1 expression. Indeed, it has been reported that ET-1 mRNA is 
increased in the temporal cortex469 and leptomeningeal vessels470 of AD patients and 
that Aβ42 incubation can increase ET-1 protein expression in the neuroblastoma cell line 
SH-SY5Ys469 and primary human brain ECs470.  
 
It is unclear at this time whether the raised Aβ found in the APP23 mouse is promoting 
vascular dysfunction due to upstream impairments in the EC (decreased NO 
bioavailability through reduced PKB or eNOS activity, or increased ET-1), or downstream 
damage in NO-mediated VSMC signalling (through reduced PKG or cGMP activity), or 
perhaps a combination of both. Further postmortem biochemical analysis is required in 
order to understand this mechanism.  
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4.3.5 Genetically reducing BACE1 may increase aortic Mfn2 expression, but has no effect 
on OPA1 
 
Mitochondrial dysfunction is a direct consequence of nutrient excess burden. HFD-
feeding can contribute to the development of ED and genetically reducing BACE1 levels 
is protective. For these reasons, we decided to investigate whether proteins governing 
mitochondrial dynamics (Mfn2 and OPA1) were affected in aortae from HFD-fed BACE1 
KO mice (alongside WT and HET littermates, and WT NC controls).  
 
We report here that HFD-feeding and genetically reducing BACE1 levels does not affect 
aortic OPA1 expression. However, HFD-fed BACE1 KO mice seemed to exhibit a trend 
toward ~45% increase in Mfn2 levels compared to WT littermates.  Power calculations 
reveal that a sample size of 12 is to test for significance, but the current sample size is 
only 6. Therefore, more mice would need to be investigated to clarify whether this was 
a genuine result.  
 
If it did transpire that BACE1 KO mice do indeed express higher aortic Mfn2 levels, this 
could be due to increased EC Mfn2, or VSMC Mfn2, or both. This is because harvested 
aortic tissue will contain both of these cell types. Primary isolation of these cells could 
be performed to clarify which cell type is affected. 
 
BACE1 KO exhibit improved endothelial responsiveness to ACh. It is possible that this is 
due to improved mitochondrial function. Indeed, as discussed in section 1.12.3, APP 
processing, and thus BACE1, has been implicated in regulating mitochondrial function. 
Aβ has been shown to accumulate in mitochondria prior to plaque deposition245,330,331, 
several APP mutant mouse models have exhibited mitochondrial dysfunction331–333, and 
immortalised neuronal cells overexpressing APPswe possess reduced OPA1 and Mfn1/2 
protein expression, a higher percentage of fragmented mitochondria, and reduced ATP 
production334. This is in line with our BACE1 KO model, which possesses very low or non-
detectable Aβ, potentially expressing increased Mfn2 levels in aortic tissue. 
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If Mfn2 levels were increased, this could potentially mean a shift toward mitochondrial 
fusion, however expression of opposing mitochondrial fission proteins would have to be 
investigated (Drp1). Furthermore, mitochondrial morphology would need to be studied 
to clarify whether any observed changes in expression of proteins governing 
mitochondrial dynamics actually resulted in changes in ultrastructure. Morphological 
studies can performed using electron microscopy471, or immunofluorescence coupled 
with fluorescent microscopy. Common antibodies for investigating mitochondrial 
morphology in fixed tissue include TOM20, cytochrome c oxidase IV (COX IV), or 
manganese superoxide dismutase (MnSOD). A more recently developed method for 
staining mitochondria in fixed tissue is using an iridium coordination complex called 
IraSolve-Mito, an inorganic fluorophore that is highly specific for mitochondria472. 
Iridium and other transition metal complexes are particularly attractive as imaging 
agents as their mechanism of action does not depend on membrane potential, they can 
be used for mitochondrial detection in fixed tissue, they have superior photostability, 
and large Stokes’ shifts473. Fluorescent imaging relies on the principles of Stokes’ shift, 
which is described as the change in wavelength light undergoes when it is absorbed by 
a fluorophore vs. when it is omitted. A small Stokes’ shift can result in reabsorption of 
the emitted light, resulting in high background and inaccurate signal. Large Stokes’ shifts 
are thus preferred as they minimise this issue.   
 
Altered mitochondrial dynamics in the endothelium has been linked with cellular 
dysfunction. Mitochondrial fragmentation is observed in the endothelium following 
exposure to stressors such as H202474, HG475,476, and ischaemia477. Furthermore, diabetic 
patients exhibit increased expression of the fission protein Fis1 in isolated venous ECs476. 
Human aortic ECs exposed to HG exhibit increased Fis1 and Drp1 expression, as well as 
increased mitochondrial fragmentation, increased ROS production, and inactivation of 
eNOS. Silencing of Fis1 or Drp1 expression prevents these glucose-induced changes476. 
Of particular interest, silencing Mfn1 or Mfn2 in cultured ECs reduces PKB-dependent 
activation of eNOS4. Thus it is possible that the trend toward increased Mfn2 in BACE1 
KO mice is enhancing activation of eNOS. Although not measured herein, data that are 
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currently in review from our lab indicate that BACE1 KO mice do exhibit increased 
phosphorylation of eNOS at serine s1177316, suggesting enhanced activation.  
 
4.3.6 Genetically reducing BACE1 does not affect VE fraction expression of proteins 
governing mitochondrial dynamics 
 
In this chapter we have shown that HFD-associated increases in BACE1 may promote EC 
dysfunction and genetic reduction of BACE1 may be protective, as measured by LDI of 
peripheral microvascular skin perfusion. It has been suggested that peripheral 
microvascular dysfunction is a good predictor of and may precede cerebrovascular 
dysfunction346. This suggests that BACE1 KO mice may also be protected against brain 
EC dysfunction.  
 
We do not presently have the ability to measure CBF in vivo. This is unfortunate as it 
would give us a direct read of brain EC responsiveness to several stimuli including, but 
not limited to, reactive hyperaemia, or topical application of vasoactive agents (ACh, 
SNP, bradykinin)320–324,466. We decided to investigate brain EC function instead by 
measuring mitochondrial function. To do this we set out to detect any changes in VE 
fraction protein expression of mitochondrial dynamics proteins, due to the known 
importance of maintaining mitochondrial health at the BBB127. We measured VE fraction 
expression of these proteins in WT NC, WT HF, HET HF, and KO HF groups to investigate 
whether HFD-feeding or genetically reducing BACE1 could induce any changes. We did 
not observe any changes in VE fraction expression of proteins governing mitochondrial 
dynamics with HFD feeding, or with genetic BACE1 reduction.  
 
It should be noted that the sample size is small (n=6) and the variability for some 
proteins is high in certain groups. The VE fraction (NVU) that is obtained from the hemi-
brain is reported to contain different cell types. The majority of the fraction is made up 
of microvessels, but any cell that is present at the NVU may have been pulled down with 
the vessel. This means that the VE fraction likely contains ECs, pericytes, astrocytic end-
feet, microglia, and neurons. This may account for some of the variability that is 
observed in some proteins, as no two isolated fractions will be identical in terms of cell 
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type. It would be more useful to isolate primary brain ECs in order to detect purely 
endothelial changes. Indeed, this was attempted extensively using the Miltenyi Biotec 
gentleMACS™ Tissue Dissociator followed by CD31+ selection of endothelial cells using 
magnetic microbead technology. Although the yield of ECs was pure, the number of cells 
obtained (and therefore protein and mRNA content) was not sufficient for the nature of 
the experiments we wished to perform (Western blots, qPCR). In order to obtain 
confluent monolayers in 2-3 wells of a 6-well plate, 12 4-6 week old mice had to be 
sacrificed and then cells were passaged 2-3 times. We thought this an inefficient method 
and decided to use immortalised cell lines instead (more information in Chapter 5).  
 
BACE1 HET and BACE1 KO mice exhibit a trend toward reduced VE fraction protein 
expression of the short-form of OPA1. Power calculations on this data suggest a sample 
size of 7 is required in order to detect significance (current n = 6). This is not in line with 
the literature, where Wang and colleague report that neuronal cells overexpressing 
APPswe exhibit reduced OPA1 expression334. It should be noted however, when 
observing the OPA1 Western blots in this publication, it seems they did not separate the 
proteins sufficiently during the electrophoresis step, leaving them with two 
indistinguishable bands. Therefore it is difficult to know whether APPswe 
overexpression leads to a reduction in long-, or short-form OPA1, or both, as they have 
measured both bands as one. There is a resulting increase in mitochondrial 
fragmentation observed in APPswe overexpressing cells, which is blocked when BACE1 
is inhibited, suggesting that these changes in mitochondrial dynamics are mediated 
through an APP cleavage product such as Aβ. From this information, one would expect 
BACE1 KO mice, that have reduced Aβ levels, would exhibit increased OPA1 levels. There 
is a noticeable lack of information regarding mitochondrial dynamics in brain ECs. The 
reason we are not seeing similar results to the literature regarding OPA1 could be 
because brain ECs may act differently in response to stressors than other cell types. 
Indeed, brain ECs are structurally dissimilar to peripheral ECs in that they express high 
levels of tight junction proteins, making them less permeable than the latter. Brain ECs 
are ultimately the main line of protection that the brain has from systemic insults and, 
for this reason, are perhaps more robust. Indeed, some reports suggest cerebral ECs 
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harbor more mitochondria than peripheral ECs, indicating the potential for a higher 
capacity to deal with metabolic stress225–227. 
 
4.3.7 Chronic central infusion upregulates VE fraction expression phosphorylation and 
expression of Drp1 
 
Within this chapter, we reported that chronic central infusion of Aβ42 resulted in a 
reduced response of ECs to ACh, as measured in the skin microvasculature. As previously 
mentioned, we do not have the technology to measure cerebral microvasculature in 
vivo, but we can isolate cerebral vessels and extract protein to study expression of 
mitochondrial dynamics proteins. We did not observe any changes in Mfn2 or OPA1 
(short-form, long-form, or total) in the NVU of Aβ42 compared to ScrP controls. However, 
we did see an increase in phosphorylation of Drp1 at s616 and an increase in total Drp1 
expression in the NVU of Aβ42 mice compared to ScrP controls. When expressed as a 
ratio of phospho/total, this change is lost, suggesting the true change is in total Drp1 
expression.  
 
Drp1 governs the fission component of mitochondrial dynamics. An increase in its 
expression, without any accompanying increase in fusion proteins (Mfn1/2 or OPA1), 
may indicate a shift toward mitochondria fission and fragmentation. Under normal 
conditions mitochondrial fission is likely an adaptive response to cellular stressors and 
may occur to remove damaged areas of mitochondria from the network and target them 
for mitophagy239. Chronically unopposed fragmentation may lead to reduced capacity 
to produce ATP, increased heterogeneity of mitochondria, increased mitophagy, 
alteration in Ca2+ signalling, and/or increased ROS production239. Therefore, the Aβ42 
dependent increase in VE fraction Drp1 expression observed herein may result in 
mitochondrial crisis and contribute to damage at the NVU127. Interestingly, this is not in 
line with previous literature. Wang and colleagues, who overexpressed APPswe in a 
neuronal cell line, observed reductions in Drp1 expression334. However, when 
investigating overall mitochondrial morphology, they did observe that APPswe 
overexpression led to mitochondrial fragmentation. This is likely because they observed 
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reductions in Mfn1/2 and OPA1 and an accompanying increase in the fission protein 
Fis1. The actual morphology in fixed tissue in our Aβ42 mice would have to be 
investigated to ensure that the observed increase Drp1 truly resulted in upregulated 
fragmentation. This can be done using mitochondrial stains following by microscopy, 
details of which are given in section 4.3.5.  
 
It has been reported that nutrient rich environments, such as that in HFD-feeding, tend 
to lead to more fragmented mitochondria281,282. High saturated fat (HSD) feeding in rats 
promoted fission over fusion by increasing Drp1 hepatic protein expression276, whilst 
skeletal muscle myotubes exhibit a higher percentage of fragmented mitochondria 
following exposure to nutrient excess in vitro (glucose and palmitate)278. This was 
accompanied by a modest increase in Drp1, a finding that has been corroborated by 
others283,284. Due to the fact that nutrient excess promotes BACE1 activity305–309,317,335, it 
may be that nutrient excess-associated Aβ42 is partly responsible for the observed 
increase in mitochondria fragmentation in these environments. This warrants further 
investigation.  
 
If unregulated mitochondrial fragmentation is indeed occurring in the NVU in our Aβ42 
mice, this may contribute to BBB disruption127 and impaired cerebral 
haemodynamics478, contributing to known cerebrovascular diseases.  
 
4.3.8 VE fraction and aortic ICAM expression is unchanged by genetically reducing BACE1 
 
ED is associated with increased inflammatory markers (endothelial activation), including 
ICAM expression. Therefore, we investigated whether ICAM expression was changed 
with HFD-feeding or genetically reducing BACE1 in the aortae and NVUs of mice. Aortic 
expression of ICAM remained unchanged in all groups, which is not in line with our 
previous data currently in review, that exhibited decreases in aortic ICAM expression in 
HFD-fed BACE1 mice compared to WT controls.  VE fraction ICAM expression trended 
toward a reduction in all three HFD groups (WT HF, HET HF, KO HF) compared to WT NC. 
Indeed, the reduction in VE fraction ICAM was close to significance in WT HF mice 
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compared to WT NC mice (~45% decrease, n = 6, p = 0.07). There was no effect of varying 
BACE1 levels on VE fraction ICAM expression.  
 
This is an interesting finding as nutrient excess is often associated with increased ICAM 
expression both in peripheral and central vasculature. Indeed, exposure to HG162, 
palmitate191,192,194,197,198, and oxLDL206,209 results in increased ICAM expression in 
peripheral cultured ECs. Furthermore, brain ECs incubated in oxLDL also exhibit 
increased ICAM expression213, and T2Ds exhibit increased CSF ICAM levels123. There is 
no existing literature to explain why HFD-feeding in this case is resulting in a trend 
toward reduce ICAM expression. There may be a compensatory mechanism involved 
and perhaps 10 weeks of HFD feeding is not a lengthy enough duration to observe 
endothelial inflammation. It should be noted that WT NC mice are from our WT-only 
line, whereas WT HF, HET HF, and KO HF mice are littermates from the BACE1 KO line. 
Although these mice are both on a C57Bl6/J background, and the BACE1 KO line is 
backcrossed regularly with “true WT mice” from Charles River, there may be some 
discrepancies in genetics. WT littermates fed NC-diet would to be investigated to 
provide more clarity. 
 
4.3.9 Summary 
 
This chapter aimed to further confirm our previous findings that raised Aβ42 levels are 
associated with the development of ED, as observed in vivo in cutaneous 
microvasculature. We also aimed to investigate whether any ED observed in the models 
of reduced Aβ42 (BACE1 KO) and increased Aβ42 (Aβ42 central infusion) was associated 
with alterations in mitochondrial dynamics. 
 
We observed a trend toward improved EC vasodilatory response to ACh in cutaneous 
microvasculature of HFD-fed BACE1 KO mice compared to WT and HET littermates, as 
well as a blunted EC vasodilatory response to ACh in Aβ42 centrally infused mice. 
Furthermore, a trend toward reduced ACh dependent vasodilation was observed in 
peripherally infused Aβ42 mice. We also observed blunted vasodilation to both ACh and 
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SNP in APP23 mice, which was rescued by BACE1 inhibition. These data suggest a role 
for BACE1 and Aβ42 in the development of ED and is in line with our previous data that 
is currently in review. Neither Aβ42 central infusion to WT HFD-fed mice, nor M-3 
infusion to APP23 mice induced any changes in plasma nitrite concentration. M-3 
infusion to APP23 mice did however produce a trend toward reduced circulating ET-1 
levels. These data suggest a direct role for Aβ peptides in modulating ET-1 levels, which 
could contribute to ED onset. 
 
Expression of proteins involved in mitochondrial dynamics in aortae and NVUs remained 
largely unchanged by HFD-feeding or BACE1 genetic reduction. Of note was an increase 
in aortic expression of Mfn2 in BACE1 KO mice, which may be involved in the observed 
protection these mice exhibit against ED. Further studies would need to be performed 
to investigate mitochondrial ultrastructure in vascular tissues. 
 
Aβ42 central infusion produced an increase in VE fraction expression of Drp1 levels, 
without accompanying increases in OPA1 or Mfn2, indicating a shift toward 
mitochondrial fission. This may contribute to the cerebrovascular dysfunction that is 
observed in APP overexpressing mice320,324,466. Furthermore, due to the similarities 
between cutaneous and cerebral mirovasculature346, changes observed in the NVU may 
reflect the status of microvascular mitochondrial dynamics in the periphery, and 
therefore may contribute to the cutaneous ED observed in vivo.  
 
In summary, there is a role for HFD-associated BACE1 and Aβ42 in the development of 
microvascular ED, which may be linked to slight alterations in mitochondrial dynamics 
proteins. Sample sizes would need to be increased in order to clarify this. Future 
experiments could involve investigating brain EC function in vivo using laser speckle and 
studying mitochondrial ultrastructure to link observed changes in proteins with changes 
in morphology.  
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Chapter 5 
Investigating the effects of 
nutrient excess on 
mitochondrial function in a 
cerebral endothelial cell line 
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5.1 Introduction 
 
The BBB is an “interface” barrier between the blood and the interstitial fluid of the brain. 
It plays an important role in restricting the movement of potentially damaging particles 
from the blood, delivering essential nutrients to the brain, removing waste products, 
and is involved in haemodynamics and regulation of CBF. The integrity of the BBB is 
crucial to proper brain function and dysfunction in brain ECs is linked to impaired 
cerebral blood flow and BBB opening110. If the BBB becomes leaky, this will allow entry 
of potentially toxic blood-derived molecules into the brain and has been largely linked 
to neuroinflammation111 and neurodegenerative disease479.  
 
BBB dysfunction is observed in many disease such as obesity and T2D, as well as CVD, 
and cerebrovascular integrity is altered during aging and age-related disorders112–114. 
HFD-fed rats exhibit increased BBB leakiness115 and T2D induces downregulation of TJ 
proteins including claudin-5 and occludin, as well as the TJ-associated protein ZO-1116–
120, which could lead to BBB opening121,122. Inflammation is also observed in brain 
endothelium in T2D, with upregulated protein expression of ICAM and VCAM123 and 
increased basement membrane (BM) thickening124–126, which can result in cell 
detachment from the BM as well as BBB opening. Systemic inflammation, which is 
observed in multiple metabolic disorders, has also been shown to induce BBB 
opening127. 
 
Mitochondrial function is important for EC health. A study by Doll and colleagues 
suggests BBB breakdown may in fact be secondary to mitochondrial dysfunction127. 
Peripheral ECs exposed to nutrient excess (HG, palmitate, cholesterol) exhibit impaired 
mitochondrial bioenergetics165,166,194,198,208, but there is limited research into how 
disorders of nutrient excess may lead to mitochondrial dysfunction in brain ECs. We 
attempted to answer this question in chapters 3 and 4, by investigating mitochondrial 
dynamic protein expression at the BBB in mice that were subjected to nutrient excess 
by HFD-feeding. However, few convincing results were obtained due to low sample size, 
and also potentially because the several cell types present in the VE fraction may dilute 
signals from individual cells. Jin and colleagues investigated the brain endothelial cell 
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line bEnd.3 and reported that HG exposure induced EC injury by promoting mPTP 
opening, reducing MMP, inducing mitochondrial Ca2+ overload, increasing Drp1 levels, 
and decreasing PGC1-α mRNA expression173. However, this study failed to investigate 
mitochondrial respiration in real-time, did not extensively investigate mitochondrial 
dynamics, and only studied the effects of HG, and not the effects of other potentially 
damaging nutrient such as fatty acids. Nevertheless, these data do imply that nutrient 
excess may result in mitochondrial dysfunction in brain ECs. Considering the absolute 
importance of healthy brain EC function to multiple processes (including cerebral 
haemodynamics, BBB integrity, nutrient transport), the contribution mitochondria make 
to maintain brain EC health127, and furthermore that neurological complications are 
secondary to many metabolic diseases, it is imperative that further research into 
nutrient excess and brain ECs is undertaken. As previously discussed, brain ECs have 
more mitochondria than peripheral ECs; mitochondrial volume in brain ECs accounts for 
2-4 times the mitochondrial volume of peripheral ECs. The higher mitochondrial volume 
may act as an advantage in brain ECs, increasing their capacity to deal with nutrient 
excess. However, this needs further investigation. Nutrient excess is also associated with 
increased BACE1 activity300,305–307,309–311,317,335 and our previous findings suggest a role 
for increased Aβ42 (due to nutrient excess) in the development of ED in peripheral 
vasculature142 Furthermore, Aβ has been reported to induce mitochondrial 
dysfunction306,317,331–335.  
 
The aim of this chapter was to find a suitable cell culture model of brain ECs and use this 
model to investigate how nutrient excess (glucose and palmitate) affects endothelial 
mitochondrial function. In order to investigate mitochondrial physiology and respiration 
in real time, we employed the use of the Seahorse extracellular flux analyser. 
Furthermore, due to the known connection between metabolic syndrome, ED, and 
BACE1 and Aβ, we also investigated the effects of palmitate exposure on brain EC BACE1 
levels and studied the effects of exogenous aged Aβ42 dimer application on 
mitochondrial respiration. Due to the existing data that suggest a role for nutrient excess 
in mitochondrial dysfunction in brain ECs173 and peripheral ECs198,280,475, we 
hypothesised that HG and palmitate exposures would reduce the oxidative capacity of 
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bEnd.3 cells, suggesting mitochondrial dysfunction. We further hypothesised that Aβ42 
would exacerbate the effects of HG/palmitate exposure on mitochondrial respiration. 
 
 
 
5.2 Results 
 
5.2.1 Optimising a brain endothelial cell model 
 
The first aim of this chapter was to optimise a suitable cell culture model for 
investigating brain EC function. We aimed to find an immortalised cell line that could be 
used to study 1) NO bioavailability (phosphorylation of PKB and eNOS, media nitrite 
concentration), 2) endothelial activation (exhibits an inflammatory response), and 3) 
mitochondrial function (possessed sufficient mitochondrial respiration that could be 
altered using known mitochondrial modulators). We obtained two potential 
immortalised cell lines, a rat brain endothelial cell line called RBE4 and a mouse brain 
endothelial cell line called bEnd.3. 
 
In order to investigate NO bioavailability, the cells had to express eNOS and PKB, and 
the phosphorylation of which had to be sensitive to stimulation by known inducers of 
eNOS activity (insulin). Therefore, we investigated eNOS and PKB phosphorylation in 
response to insulin post-serum starve in RBE4 cells (Fig. 5.1). PKB exhibited a 
concentration-dependent increase in phosphorylation at s473 in response to insulin, 
which was also increased with duration of exposure to insulin.  However, 
phosphorylation of eNOS at s1177 (~133 kDa) was undetectable in these cells in 
response to insulin. We then investigated insulin dependent phosphorylation of eNOS 
and PKB in bEnd.3 cells (Fig. 5.2). Interestingly, even after several durations of serum 
starvation (stated in figure legend), bEnd.3 cells exhibited high levels of phosphorylation 
of both eNOS (s1177) and PKB (s473), which was totally insensitive to insulin 
concentrations. bEnd.3 cells seemed to possess consistently activated PKB, and thus 
eNOS. Following this, we confirmed the absence of phosphorylation of eNOS in RBE4 
cells (Fig. 5.3) by using bEnd.3 cells as a positive control, whilst simultaneously 
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confirming the unresponsiveness of bEnd.3 cells to both serum starvation and 
supraphysiological concentrations of insulin (Fig. 5.3). Following this finding, an 
extensive search through the literature revealed that RBE4 cells do not express eNOS 
mRNA480. Considering this, we decided that RBE4 cells should not be used in any further 
studies. bEnd.3 cells do express eNOS, meaning they are capable of producing NO, and 
thus are a better model of brain ECs. We moved forward with the bEnd.3 cell line and 
decided to investigate another parameter; mitochondrial function. 
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Figure 5.1 Insulin dependent phosphorylation of eNOS in RBE4 cells 
RBE4 cells were serum-starved before being stimulated with insulin at the concentrations stated. 
Protein was extracted from cell lysates. 20μg of protein was loaded on to an acrylamide gel and 
separated using SDS-PAGE. Representative western blots showing phosphorylation of eNOS (s1177) 
and PKB (s473) in RBE4 cells in response to insulin stimulation for a duration of (A) 5 minutes, (B) 
15 minutes, and (C) 30 minutes. Red arrows depict where eNOS (~133kDa) would be expected. 
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Figure 5.2 Insulin dependent phosphorylation of eNOS in bEnd.3 cells 
bEnd.3 cells were stimulated with insulin at the stated concentrations for 30 minutes after being serum 
starved for (A) 0 hours, (B) 2 hours, (C) 8 hours, (D) 16 hours. Protein was extracted from cell lysates. 
20μg of protein was loaded on to acrylamide gels and separated using SDS-PAGE. Representative 
western blots showing phosphorylation of eNOS (s1177) and PKB (s473) in bEnd.3 cells in response to 
insulin stimulation.  
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Figure 5.3 Insulin dependent phosphorylation of eNOS in RBE4 and bEnd.3 cells 
RBE4 and bEnd.3 cells were stimulated with 0 or 100nM insulin for 30 minutes after being serum 
starved for 2 hours. Protein was extracted from cell lysates. 20μg of protein was loaded on to 
acrylamide gels and separated using SDS-PAGE. Representative western blots are shown 
depicting phosphorylation of eNOS (s1177) and PKB (s473) in RBE4 and bEnd3 cells in response 
to insulin stimulation. 
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5.2.3 Acute and chronic palmitate exposures increase ICAM mRNA expression  
 
To confirm that the acute and chronic treatments were able to mimic previously 
published effects of palmitate198,277,278, we measured ICAM mRNA expression in 
response to acute (400μM, 6 hours) and chronic (100μM, 24 hours) palmitate exposure 
with appropriate controls (Fig. 5.4). Acute palmitate treatment significantly increased 
ICAM mRNA expression (Fig. 5.4 – control 1 ± 0.04 vs. 400μM 1.68 ± 0.1, n = 4, p < 0.05) 
as did chronic palmitate exposure (Fig. 5.4 – control 1 ± 0.05 vs. 100μM 1.98 ± 0.1, n = 
4-6, p < 0.001). These data confirm the validity of the concentrations and durations of 
the palmitate treatments. Further validation can be observed by MitoTracker staining in 
Appendix S3, where large cell vesicles can be depicted in cells that have been exposed 
to palmitate. Although this would need to be confirmed by BODIPY or oil red O lipid 
staining, it is possible that these are lipid droplets. Together, these data indicate that 
the palmitate/BSA conjugate used for the studies herein is capable of entering the cell 
and exerting effects. 
 
5.2.6 Bioenergetic profile of untreated bEnd.3 cells 
 
We investigated the oxidative and glycolytic profiles of bEnd.3 cells by performing Mito 
Stress Tests and Glycolysis Stress Tests respectively. OCR values for the oxidative profile 
and ECAR values for the glycolytic profile were internally normalised as a fold change of 
the first baseline. Presenting the data in this way allows observation of how hard the 
cells are working oxidatively/glycolytically at basal compared to their maximum and 
allows comparison of the data to previously published data on other cell types. 
 
Figure 5.5A depicts the fold change in OCR compared to the first basal reading against 
time during a Mito Stress Test. Figure 5.5B shows the average of each of the four 
readings per treatment (basal, oligomycin, FCCP, and rotenone/antimycin). Fig. 5.5C 
depicts fold change in ECAR compared to the first basal reading against time during a 
Glycolysis Stress Test, and 5.5D shows the average of the four readings per treatment 
(basal, glucose, oligomycin, 2-DG). 
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Upon oligomycin application in the Mito Stress Test, OCR values were reduced by half 
and the subsequent FCCP injection caused OCR values to increase to about 1.7-fold 
higher than basal (Fig. 5.5A, B). The final injection, a combination of rotenone and 
antimycin A, caused OCR values to reduce by approximately 70% (Fig. 5.5A, B).  
 
During the Glycolysis Stress Test, application of glucose caused ECAR to increase by 70%, 
but inhibition of ATP synthase by oligomycin in the second injection induced an increase 
in ECAR to approximately 3.7-fold higher than basal (Fig. 5.5C, D). 2-DG application, 
which inhibits glycolysis, reverted ECAR values to the same levels as basal (Fig. 5.5C, D).  
 
The implications of the observed metabolic profiles are discussed in detail in the 
discussion of this chapter. Briefly, the Mito Stress Test profile indicates that, compared 
to other cell types356, bEnd.3 cells have a low capacity for OXPHOS at 70% higher than 
basal. For example, differentiated cells such as neurons and adipocytes are reported to 
have high spare capacities for undertaking OXPHOS. bEnd.3 cells exhibit a much lower 
capacity for OXPHOS and were similar in nature to other undifferentiated cell lines such 
as L6 myoblasts. Furthermore bEnd.3 cells were using approximately 35% of their 
maximum oxidative capacity to drive ATP-synthesis, suggesting a high ATP turnover, 
similar to other proliferating cell types356. The Glycolysis Stress Test suggests bEnd.3 cells 
are capable of increasing glycolytic flux to produce ATP upon the addition of glucose, 
and further increase their glycolytic flux by almost 4-fold upon the addition of 
oligomycin. Together these data indicate that bEnd.3 cells have a high ATP drive, but are 
metabolically flexible with a large glycolytic capacity.  
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Figure 5.4 Palmitate exposure increases ICAM mRNA expression  
bEnd.3 cells cultured at 25mM glucose were exposed to either 400μM palmitate (6 hours) or 100μM 
palmitate (24 hours), or the appropriate controls. mRNA was extracted and cDNA synthesised. ICAM 
expression was measured using Taqman qPCR. ICAM was normalised to actin and is expressed as a 
fold change of the control treatments (0μM for 6 or 24 hours).  
 
Data are expressed as mean ± standard error of the mean. 
n = 4-6. Welch’s ANOVA with Dunnett’s multiple comparison. * = p < 0.05 when compared to 0μM 
6 hours. ### = p < 0.001 when compared to 0μM 24 hours. 
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Figure 5.5 Bioenergetic profile of bEnd.3 cells 
bEnd.3 cells cultured at 5mM glucose were subjected to a Mito Stress Test (A, B) to investigate 
functionality of different mitochondrial parameters or a Glycolysis Stress Test (C, D) to measure glycolytic 
parameters. Changes in OCR (Mito Stress Test) and ECAR (Glycolysis Stress Test) are given as fold change 
of the first baseline reading. 
 
Data are expressed as mean ± standard error of the mean. 
Technical replicates = 20, n = 4. 
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5.2.5 Effects of high glucose and acute palmitate exposure on mitochondrial function in 
bEnd.3 cells 
 
bEnd.3 cells were exposed to four treatments (5mM glu. 0μM pal., 5mM glu. 400μM 
pal., 25mM glu. 0μM pal., and 25mM glu. 400μM pal.). For ease, these groups will be 
referred to as 1) low glucose control (LG control), low glucose palmitate (LG pal.), high 
glucose control (HG control), and high glucose palmitate (HG pal.). Cells were then 
subjected to a Mito Stress Test comprising injections of 1) ATP synthase inhibitor 
oligomycin, 2) mitochondrial uncoupler FCCP, and 3) mitochondrial respiration 
inhibitors rotenone and antimycin A. A detailed description of Mito Stress Tests, and the 
information they can provide regarding mitochondrial parameters, is given in sections 
2.7.2-2.7.4.  
 
Fig. 5.6 shows OCR normalised to protein content against time. The data are not 
internally normalised here as it is important to observe any changes in basal oxygen 
consumption, which would not be detected if the data were internally normalised. The 
four treatment groups are split into separate graphs for clarity. LG pal. did not induce 
any changes in OCR/μg protein over time compared to LG control in response to the 
Mito Stress Test (Fig. 5.6A). The same was true for HG pal. compared to HG control (Fig. 
5.6C). There was an observed trend toward increased baseline OCR/μg protein in bEnd.3 
cells cultured in HG control compared to LG control (Fig. 5.6B), and as were the OCR/μg 
protein readings in response to FCCP (Fig. 5.6B). Fig. 5.6D shows the effects of glucose 
levels on the acute palmitate exposure. bEnd.3 cells cultured in HG pal. had increased 
basal OCR/μg protein readings compared to LG equivalent (Fig. 5.6D – row 1 LG pal. 9.09 
± 0.85 pmol/min/μg protein vs. HG pal. 11.65 ± 0.65pmol/min/μg protein; row 2 LG pal. 
9.15 ± 0.85 pmol/min/μg protein vs. HG pal. 11.95 ± 0.0.78 pmol/min/μg protein; row 3 
LG pal. 0.16 ± 0.82 pmol/min/μg protein vs. HG pal. 12.13 ± 0.85 pmol/min/μg protein; 
row 4 LG pal. 9.09 ± 0.71 pmol/min/μg protein vs. HG pal. 12.15 ± 0.94 pmol/min/μg 
protein, n = 4, p < 0.05). HG pal. also showed a trend toward increased FCCP readings 
compared to LG pal. (Fig. 5.6D). 
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Fig. 5.7 shows OCR as a percentage of the first baseline reading, which is 100%. No 
changes were observed herein in any of the treatment groups.  
 
Interesting information regarding different parameters of mitochondrial function can be 
extrapolated from the XY OCR/μg protein against time graphs. These data are shown in 
Fig. 5.8. bEnd.3 cells cultured at HG control/HG pal. exhibited increased basal respiration 
compared to the LG pal. group (Fig. 5.8A – LG pal. 6.07 ± 0.53 pmol/min/μg protein vs. 
HG control 7.84 ± 0.29 pmol/min/μg protein, n = 4, p < 0.05; LG pal. 6.07 ± 0.53 control 
group as well, but this did not reach significance presumably due to variation in the 
latter. According to power calculations, larger sample sizes of at least 7 are likely to be 
required to detect significance with the current effect sizes. Aside from basal 
respiration, no other parameters of mitochondrial function were significantly changed 
with the experimental conditions, but a couple of trends of interest were observed. HG 
control exhibited a trend towards increased ATP-linked respiration (Fig. 5.8C) and 
palmitate exposure was associated with trends toward increased proton leak (Fig. 5.8D) 
that is potentially further exacerbated by HG. Power calculations reveal sample sizes of 
9 and 7 may be required to detect statistical significance in ATP-linked and proton leak 
respectively.  
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Figure 5.6 Effect of high glucose and acute palmitate exposure on mitochondrial respiration in bEnd.3 
cells  
bEnd.3 cells cultured at either 5 or 25mM glucose were exposed to 400μM palmitate (or control) for 6 
hours before being subjected to a Mito Stress Test to investigate functionality of different mitochondrial 
parameters. Changes in OCR are normalised to protein concentration. (A) Effect of palmitate exposure at 
5mM glucose. (B) Effect of high glucose. (C) Effect of palmitate at 25mM glucose. (D) Effects of glucose 
concentration on palmitate exposure. 
 
Data are expressed as mean ± standard error of the mean. 
Technical replicates = 20, n = 4. Repeated measures ANOVA with Bonferroni multiple comparison. * = p < 
0.05.  
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Figure 5.7 Effects of high glucose and acute palmitate exposure on mitochondrial respiration in 
bEnd.3 cells 
bEnd.3 cells cultured at either 5 or 25mM glucose were exposed to 400μM palmitate (or control) for 
6 hours before being subjected to a Mito Stress Test. Changes in OCR were internally normalised as a 
% of the baseline reading (baseline = 100%). (A) Effect of palmitate exposure at 5mM glucose. (B) 
Effect of high glucose. (C) Effect of palmitate at 25mM glucose. (D) Effects of palmitate at 5mM vs. 
25mM glucose. 
 
Data are expressed as mean ± standard error of the mean. 
Technical replicates = 20, n = 4. Repeated measures ANOVA with Bonferroni multiple comparison. 
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Figure 5.8 Effect of high glucose and acute palmitate exposure on mitochondrial respiration in 
bEnd.3 cells 
bEnd.3 cells cultured at either 5 or 25mM glucose were exposed to 400μM palmitate (or control) 
for 6 hours before being subjected to a Mito Stress Test to investigate functionality of different 
mitochondrial parameters. The OCR corresponding to each parameter was calculated as described 
in Methods. (A) Basal respiration, (B) non-mitochondrial oxygen consumption, (C) ATP-linked 
respiration, (D) proton leak, (E) spare respiratory capacity, (F) maximum respiratory capacity, (G) 
coupling efficiency, and (H) respiratory control ratio. 
Data are expressed as mean ± standard error of the mean. 
Technical replicates = 20, n = 4. Welch’s ANOVA with Dunnett’s multiple comparison. # = p < 0.05 
and ## = p < 0.01 when compared to 5mM glucose + 400μM palmitate group. 
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5.2.5 Effects of high glucose and chronic low-level palmitate exposure on mitochondrial 
function in bEnd.3 cells 
 
To investigate the effects of high glucose and chronic low-level palmitate on bEnd.3 
cells, cultures were exposed to four treatments (5mM glu. 0μM pal., 5mM glu. 100μM 
pal., 25mM glu. 0μM pal., and 25mM glu. 100μM pal.). bEnd.3 cells were exposed to the 
aforementioned experimental treatments before being subjected to Mito Stress Tests. 
Groups are referred to as 1) LG chronic control, 2) LG chronic pal., (3) HG chronic control, 
and (4) HG chronic pal.  
 
Fig. 5.9 shows OCR over time during Mito Stress Tests of bEnd.3 cells normalised to 
protein content, whilst Fig. 5.10 depicts OCR as a percentage of the first baseline reading 
(baseline = 100%). We observed no changes in OCR/μg protein or %OCR in any of the 
four treatment groups. 
 
Extrapolated data from Mito Stress Tests are shown in Fig. 5.11. No statistically 
significant changes were observed in any of the mitochondrial parameters. Proton leak 
exhibited an increased trend in palmitate treated groups (Fig. 5.11D). Sample size is low 
(n = 4) and variability is very high in these treatments. More experiments would have to 
be conducted to increase sample size and reduce standard deviation to investigate 
whether this was a genuine result. If this trend holds, it may be that palmitate exposure 
is inducing proton leak through increased activity of UCPs. This is discussed in more 
detail in section 5.3.4. 
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Figure 5.9 Effect of high glucose and chronic palmitate exposure on mitochondrial respiration in bEnd3 
cells  
bEnd.3 cells cultured at either 5 or 25mM glucose were exposed to 100μM palmitate (or control) for 24 
hours before being subjected to a Mito Stress. OCR is normalised to protein concentration. (A) Effect of 
palmitate exposure at 5mM glucose. (B) Effect of high glucose. (C) Effect of palmitate at 25mM glucose. 
(D) Effects of glucose concentration on palmitate exposure. 
 
Data are expressed as mean ± standard error of the mean. 
Technical replicates = 20, n = 4. Repeated measures ANOVA with Bonferroni multiple comparison. 
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Figure 5.10 Effects of high glucose and chronic palmitate exposure on mitochondrial respiration in 
bEnd.3 cells 
bEnd.3 cells cultured at either 5 or 25mM glucose were exposed to 100μM palmitate (or control) for 24 
hours before being subjected to a Mito Stress Test to investigate functionality of different mitochondrial 
parameters. Changes in OCR were internally normalised as a % of the baseline reading. (A) Effect of 
palmitate exposure at 5mM glucose. (B) Effect of high glucose. (C) Effect of palmitate at 25mM glucose. 
(D) Effects of palmitate at 5mM vs. 25mM glucose. 
 
Data are expressed as mean ± standard error of the mean. 
Technical replicates = 20, n = 4. Repeated measures ANOVA with Bonferroni multiple comparison. 
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Figure 5.11 Effect of high glucose and chronic palmitate exposure on mitochondrial respiration in bEnd.3 
cells 
 
bEnd.3 cells cultured at either 5 or 25mM glucose were exposed to 100μM palmitate (or control) for 24 
hours before being subjected to a Mito Stress Test to investigate functionality of different mitochondrial 
parameters. The OCR corresponding to each parameter was calculated as described in Methods. (A) Basal 
respiration, (B) non-mitochondrial oxygen consumption, (C) ATP-linked respiration, (D) proton leak, (E) 
spare respiratory capacity, (F) maximum respiratory capacity, (G) coupling efficiency, and (H) respiratory 
control ratio. 
Data are expressed as mean ± standard error of the mean. 
Technical replicates = 20, n = 4. Welch’s ANOVA with Dunnett’s multiple comparison.  
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5.2.7 Chronic, but not acute, palmitate exposure increases BACE1 mRNA and protein 
expression in bEnd.3 cells 
 
Palmitate exposure has been shown to increase BACE1 expression and activity in 
cells306,307, so we investigated whether acute (400μM 6 hours) and chronic (100μM 24 
hours) palmitate exposure could influence BACE1 expression (protein and mRNA) in 
bEnd.3 cells cultured at 25mM glucose. We also investigated the effect of palmitate 
exposure on App mRNA levels. 
 
Whilst there were no changes in App levels, Bace1 expression was significantly increased 
with chronic exposure to 100μM palmitate compared to control (Fig. 5.12B - 0μM pal. 
24 hours 1 ± 0.14 vs. 100μM pal. 24 hours 2.46 ± 0.44, n = 8, p < 0.05). Acute exposure 
to 400μM did not influence Bace1 expression. bEnd.3 cells exposed to 100μM for 24 
hours expressed significantly higher Bace1 levels compared to cells exposed to 400μM 
palmitate for 6 hours (Fig. 5.12B - 400μM pal. 6 hours 0.76 ± 0.22 vs. 100μM pal. 24 
hours 2.46 ± 0.44, n = 8-10, p < 0.001). Changes in mRNA expression were complimented 
by similar findings in BACE1 protein expression. BACE1 protein expression was increased 
by approximately 80% with chronic exposure to 100μM palmitate (Fig. 5.12C, E – 0μM 
pal. 24 hours 1 ± 0.16 vs. 100μM pal. 24 hours 1.8 ± 0.18, n = 5-6, p < 0.01). However, 
acute palmitate exposure of 400μM did not influence BACE1 protein expression (Fig. 
5.12D, F).  
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Figure 5.12 Chronic low-level palmitate exposure increases BACE1 mRNA and protein expression, 
whereas acute treatment does not 
bEnd3 cells cultured at 25mM glucose were exposed to either 400μM or 100μM palmitate for 6 and 24 
hours respectively, or appropriate controls. mRNA was extracted and cDNA synthesised. App (A) and 
Bace1 (B) expression was measured using Taqman qPCR. Genes were normalised to actin and are 
expressed as a fold change of the control treatments (0μM for 6 or 24 hours). Protein was extracted from 
cell lysates.  20μg was loaded on to an acrylamide gel and separated using SDS-PAGE. Representative 
western blots for BACE1 expression in response to acute 400μM palmitate exposure (C) and chronic 
100μM palmitate exposure (D). Actin was used as a loading control. Quantification of BACE1 blots 
normalised to actin for acute 400μM palmitate exposure (E) and chronic 100μM palmitate exposure (F). 
Data are expressed as mean ± standard error of the mean. 
n = 4-10. (A) and (B) - Welch’s ANOVA with Dunnett’s multiple comparison. * = p < 0.05 when compared 
to 0μM 6 hours. ## = p < 0.01 when compared to 0μM 24 hours. (C) and (D) – Unpaired t-test with Welch’s 
correction. ** = p < 0.01 when compared to control.  
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5.2.7 Effects of exogenous Aβ42 and chronic palmitate exposure on mitochondrial 
function in bEnd.3 cells 
 
There is a known link between nutrient excess, Aβ, and ED321,324,466,481, and Aβ peptides 
have been reported to influence mitochondrial function306,317,331–335. These reports, 
together with the finding herein that chronic palmitate exposure can increase BACE1 
expression, led us to investigate the effects of exogenous Aβ42 accompanied by chronic 
palmitate exposure on mitochondrial function in bEnd.3 cells. bEnd.3 cells cultured in 
25mM glucose were exposed to 1nM aged (5 days) Aβ42 peptides (shown previously to 
be in dimeric form354) or aged ScrP peptide control for 24 hours in addition to 100μM 
palmitate or control. This gave rise to four experimental groups: ScrP 0μM pal., ScrP 
100μM pal, Aβ42 0μM pal., and Aβ42 100μM pal, which will be referred to as ScrP control, 
ScrP pal., Aβ42 control, and Aβ42 pal. for ease.  
 
Fig. 5.13 depicts OCR over time during Mito Stress Tests of bEnd.3 cells normalised to 
protein content. Data from the four experimental groups are split into separate graphs 
for clarity. Application of exogenous Aβ42 for 24 hours with and without palmitate did 
not result in any statistical changes or trends. Fig. 5.14 exhibits OCR against time as a % 
of the first baseline reading, which is 100%. Again, %OCR was unchanged in the presence 
of Aβ42 and/or palmitate. 
 
Fig. 5.15 comprises the extrapolated data from the Mito Stress Tests. Overall, the 
variability in these data sets is very high, making it difficult to obtain conclusive results. 
However, proton leak was again observed to be increased upon palmitate treatment 
(~30% increase in Aβ42 pal. group), which is potentially exacerbated by the presence of 
Aβ42 (Fig. 5.15D). However, sample size is low and data are extremely variable, meaning 
that when power calculations are performed on these pilot data, the suggested sample 
size is 15.  
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Figure 5.13 Effect of Aβ42 and chronic palmitate exposure on mitochondrial respiration in bEnd.3 cells  
bEnd.3 cells cultured in 25mM glucose were exposed to either 1nM ScrP or Aβ42 as well as 100μM 
palmitate (or control) for 24 hours before being subjected to a Mito Stress Test to investigate 
functionality of different mitochondrial parameters. Changes in OCR are normalised to protein 
concentration. (A) Effect of Aβ42. (B) Effect of Aβ42 on palmitate exposure. (C) Effect of palmitate with 
ScrP exposure. (D) Effect of palmitate with Aβ42 exposure. 
 
Data are expressed as mean ± standard error of the mean. 
Technical replicates = 20, n = 4. Repeated measures ANOVA with Bonferroni multiple comparison. 
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Figure 5.14 Effect of Aβ42 and chronic palmitate exposure on mitochondrial respiration in bEnd3 cells  
bEnd.3 cells bEnd.3 cells cultured in 25mM glucose were exposed to either 1nM ScrP or Aβ42 as well as 100μM 
palmitate (or control) for 24 hours before being subjected to a Mito Stress Test to investigate functionality 
of different mitochondrial parameters. Changes in OCR internally normalised to the first baseline reading. 
(A) Effect of Aβ42. (B) Effect of Aβ42 on palmitate exposure. (C) Effect of palmitate with ScrP exposure. (D) 
Effect of palmitate with Aβ42 exposure. 
 
Data are expressed as mean ± standard error of the mean. 
Technical replicates = 20, n = 4. Repeated measures ANOVA with Bonferroni multiple comparison. 
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Figure 5.15 Effects of Aβ42 and chronic palmitate exposure on mitochondrial respiration in bEnd3 
cells 
bEnd.3 cells cultured in 25mM glucose were exposed to either 1nM ScrP or Aβ42 as well as 100μM 
palmitate (or control) for 24 hours before being subjected to a Mito Stress Test to investigate 
functionality of different mitochondrial parameters. The OCR corresponding to each parameter was 
calculated as described in Methods. (A) Basal respiration, (B) non-mitochondrial oxygen consumption, 
(C) ATP-linked respiration, (D) proton leak, (E) spare respiratory capacity, (F) maximum respiratory 
capacity, (G) coupling efficiency, and (H) respiratory control ratio. 
Data are expressed as mean ± standard error of the mean. 
Technical replicates = 20, n = 4. Welch’s ANOVA with Dunnett’s multiple comparison.  
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5.3 Discussion 
 
5.3.1 Optimising a cell culture model of brain endothelial cells 
 
We investigated the possibility of using either RBE4 cells or bEnd.3 cells. It was 
determined that it was important for the cell line to express eNOS, as well as have the 
ability to phosphorylate and activate it and thus produce NO, as this is a crucial function 
that all healthy ECs possess. Furthermore, we have observed that modulation of BACE1 
activity and thus Aβ42 levels in vivo resulted in reduced eNOS activity and thus aimed to 
able to test this parameter in vitro. To test this in RBE4 cells, cultures were serum-
starved and stimulated with insulin; a known vasodilatory agent that can induce 
phosphorylation of eNOS at s1177 through a phospho-PKB (s473) dependent 
mechanism. Cells were stimulated with 0-100nM insulin for 3 different durations; 5 
minutes, 15 minutes and 30 minutes. RBE4 cells exhibited a concentration- and time-
dependent increase in phosphorylation of PKB at s473. However, they did not exhibit 
phosphorylation of eNOS under any of these conditions. In the representative western 
blot of phospho-eNOS there are detectable bands. However, these bands are not the 
correct size and are likely to be non-specific binding of the primary or secondary 
antibody. To confirm this, bEnd.3 cells were used as a positive control as they express 
sustained high levels of eNOS482. Indeed, we determined that RBE4 cells did not exhibit 
any phosphorylation of eNOS at s1177, which is in line with data from another group 
who could not detect eNOS mRNA in these cells480. However, contradictory to this, 
another group did detect eNOS in this cell line483. After several attempt in trying to 
detect eNOS with no success, it was decided that these cells would not be utilised for 
further studies modelling brain ECs. bEnd.3 cells were subsequently investigated to 
determine their suitability as a brain EC model. Cultures were serum-starved and 
stimulated with varying insulin concentrations for 30 minutes. In response to serum-
starving, cells will exhibit reduced activation of the PI3K signalling pathway due to the 
fact that there are no growth factors present in their culture medium during starves. 
This means that when cells are stimulated with insulin, for example, it should produce 
an increase in PI3K signalling (measured here by phosphorylation of PKB at s473). 
Interestingly, bEnd.3 cells do not exhibit reduced PI3K signalling in response to the 4 
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different serum starve durations, indicated by their constitutive phosphorylation of PKB 
(s473) and eNOS (s1177). bEnd.3 cells were created by isolating primary brain ECs from 
BALB/c mice and infecting these cultures with a middle T antigen-expressing retrovirus, 
thereby transforming these cells352. Middle T antigen is an oncogenic protein that has 
been shown to activate PKB in a PI3K-dependent manner. This constant activation of 
PI3K and PKB may result in the constitutively high phosphorylation of PKB exhibited in 
bEnd.3 cells. This meant we were unable to investigate modulation of eNOS 
phosphorylation in our model. Despite this fact, we continued with the bEnd.3 cell line 
for mitochondrial studies due to the fact they 1) express endothelial-specific markers 
such as eNOS, von Willebrand factor484, and TJ proteins484,485; 2) are commonly used as 
a model of the BBB as they exhibit low permeability relative to other immortalised cell 
lines485; and 3) have previously been used to measure mitochondrial function using 
Seahorse technology486. 
 
5.3.2 Validating the palmitate exposures using the inflammatory marker ICAM 
 
We opted to model nutrient excess in bEnd.3 culture by altering glucose levels in the 
media and exposing cells to both acute (6 hours) and chronic (24 hours) palmitate 
incubations. Indeed, palmitate is commonly used in vitro as a model of elevated FFA190. 
From the literature it is apparent that researchers utilise varying concentrations of 
palmitate ranging from 100-750μM195,198,277,278,306,335. We opted for an acute palmitate 
incubation of  400μM as this has been shown to induce mitochondrial dysfunction in a 
skeletal muscle cell line278. It should be noted that we attempted longer exposure 
durations (16 and 24 hours) using 200 and 400μM palmitate, but these concentrations 
induced cell death. Therefore, chronic exposures were completed using 100μM 
palmitate. It should be noted that ‘cell death’ was measured herein simply by visualising 
live cultures before and after palmitate treatments using a cell culture microscope, 
during which extensive cell death was observed in 200/400μM 24-hour exposures. The 
experimenter can assume bEnd.3 cells are dead if they are small, floating, and circular 
in shape. Furthermore, when protein and mRNA was extracted from the remaining live 
cells in these treated cultures, the protein content and mRNA yield were too low to be 
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used for Western blot or Taqman respectively, suggesting extensive cell death. In order 
to quantify cell viability, an MTT assay could be performed, or cleaved caspase-3 or 
caspases-8/9 could be measured. 
 
To validate the palmitate treatments, we investigated a common cellular response to 
palmitate; inflammation. Inflammation in ECs is termed endothelial activation (EA), and 
is characterised by, amongst other markers, an increased expression of the adhesion 
molecule ICAM. Changes in expression of ICAM mRNA in response to 400μM palmitate 
(6 hours) and 100μM (24 hours) was measured. ICAM mRNA expression was significantly 
increased by both palmitate exposures in bEnd.3 cells, which is line with the literature 
on peripheral ECs. Indeed, ICAM has been reported to be upregulated in peripheral ECs 
in response to 400-500μM palmitate 24 hours192,198, 100μM for 24 hours487, 200μM for 
18 hours197, 150μM for 24 hours488, and 150μM for a much longer chronic incubation 
period of 6 days198. To the best of our knowledge this is the first report of the effects of 
palmitate treatment on ICAM expression on cultured brain ECs. An inflammatory 
environment induced by fatty acids in brain endothelium may result in ED by reducing 
eNOS mRNA half-life, as well as by reducing NO bioavailablity through induction of 
ROS102. It would have been interesting to investigate the effects of palmitate treatment 
on eNOS mRNA expression as well as ROS production in bEnd.3 cells if time permitted. 
ED in brain ECs can lead to impairments in barrier function or reduced control of cerebral 
haemodynamics. Inflammation can also increase the permeability of the BBB127489, 
reduce mitochondrial function of brain ECs, and decrease expression of TJ proteins490. 
Prolonged expression of adhesion molecules such as ICAM can result in infiltration of 
peripheral inflammatory cells into the brain, promoting neuroinflammation which can 
be detrimental to brain function491. These data suggest a role for palmitate and nutrient 
excess in impairing brain EC function. This is in line with existing literature reporting that 
HFD-fed rats exhibit BBB dysfunction as early as 24-days post diet induction115 and 
downregulation of TJ proteins including claudin-5, ZO-1, occludin, and caveolin116–120 is 
observed in rodent models of T2D, leading to BBB opening121,122. T2D rodent models also 
exhibit upregulated protein expression of ICAM and VCAM123 at the brain endothelium 
as well as increased basement membrane (BM) thickening124–126. 
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ICAM gene transcription is mainly under the control of nuclear factor-kappa B (NFκB). 
Palmitate is capable of inducing NFκB signalling278 and can do so through a number of 
mechanisms such as activation of toll-like receptors492, induction of MAP kinase 
pathways493, ROS generation494, or promotion of inflammatory cytokines495. Indeed, if 
time permitted, the mechanism by which palmitate promotes ICAM mRNA expression 
in bEnd.3s could be further investigated by measuring whether IκB kinase (IKK) or NFκB 
expression is increased or whether IκBα is reduced by palmitate, or whether palmitate 
induced ICAM expression is prevented by an NFκB inhibitor. Interestingly, palmitate has 
been reported to increase NADPH oxidase activity, and thus ROS generation, through a 
toll-like receptor 4 (TLR4) dependent mechanism191, which is also associated with 
increased ICAM expression. Furthermore, ROS generation could be measured in bEnd.3s 
in response to palmitate using one of the many existing chemiluminescent and 
fluorescent detection methods382,383,388, or by measuring NADPH oxidase expression 
(mRNA or protein) or activity387. MAP kinase signalling could be investigated using 
conventional western blotting for phosphorylation of proteins involved in these 
pathways (p38 MAPK, JNK, ERK) or by using inhibitors toward the afore-mentioned 
pathways. Inflammatory cytokine expression could be measured by using Taqman to 
probe for markers such as TNFα and IL-6.  
 
5.3.3 Bioenergetic profile of bEnd.3s cells 
 
Metabolism of cerebral ECs has been largely overlooked for many years. Historically, ECs 
were thought of as only an inert lining of blood vessels, but it is becoming more apparent 
that ECs are a complex, metabolically active cell with important functions in health and 
disease.  
 
Most research into EC fuel utilisation has been in the field of angiogenesis and tumor 
vascularization, so very little is known about brain EC metabolism. It is largely accepted 
that peripheral ECs prefer not to utilise OXPHOS for energy, but rely instead on glycolysis 
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for the vast majority of their ATP216,218,220. Mitochondrial content is significantly lower in 
ECs compared to other cell types; 5% in liver-derived ECs vs. 28% in hepatocytes219. 
 
Studies reporting on fuel utilisation in cerebral ECs is lacking. There is some information 
to suggest that cerebral ECs may harbor more mitochondria than peripheral ECs. 
Mitochondrial volume in brain ECs accounted for 8-11% of total cytoplasmic volume in 
rat brain capillary ECs, which is 2-4 times the mitochondrial volume of peripheral ECs227, 
indicating a higher capacity for OXPHOS225,226. However, mitochondria possess many 
functions other than OXPHOS. They are important for ROS production and redox 
signalling, as well as modulating cell proliferation and growth496. Therefore, just because 
a cell possesses a larger volume of mitochondria, it does not necessarily mean it will 
perform OXPHOS to a higher capacity. Two studies by Xuefeng Ren’s group investigated 
the role of mitochondria in brain EC function, particularly BBB permeability and effects 
on stroke127,486. Both the cultured cell model (bEnd.3) and their primary cell model of 
ECs indeed seemed to exhibit a relatively low spare respiratory capacity. As previously 
mentioned, FCCP application to cells will uncouple mitochondria and dissipate the 
proton gradient. In order to maintain MMP, mitochondria must compete with the 
uncoupling agent and increase ETC activity (respiration) to pump protons across the 
membrane. If the mitochondria of the cell in question have a high capacity for OXPHOS, 
spare capacity will be high. bEnd.3 cells exhibited a 1.75-fold increase in FCCP induced 
OCR compared to resting OCR, whereas primary cerebral ECs exhibited only a 1.6-fold 
increase. For comparison, terminally differentiated neurons, myotubes, and white 
adipocytes exhibit 3.5-, 3-, and 3.3-fold changes respectively in response to FCCP356. 
These data suggest that brain ECs may be metabolically similar to peripheral ECs, which 
have been reported to possess around a 1.75-fold increase in response to FCCP497. 
However it has also been reported that inhibiting various parts of the ETC rapidly 
increased cell permeability in bEnd3 cells, but did not induce cell death, indicating that 
mitochondrial respiration is key to healthy brain EC function127. 
 
We observed a similar oxidative phenotype in bEnd.3 cells when performing a Mito 
Stress Test. At rest, untreated bEnd.3 cells were working at approximately 59% of their 
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maximum oxidative capacity, as when stimulated with FCCP, a 1.7-fold increase in OCR 
was observed. In comparison to other cell types, such as the afore-mentioned neurons, 
this indicates a low capacity for OXPHOS. bEnd.3 cells were using approximately 35% of 
their maximum oxidative capacity to drive ATP-synthesis. This is unsurprisingly higher 
when comparing bEnd.3s to terminally differentiated primary cultured cells such as 
neurons (18%) and adipocytes (16%)356, as immortalised cells are constantly 
proliferating and have a high ATP turnover. This high ATP drive is similar to other 
proliferating cell types including C2C12 myoblasts (34%) and lung epithelial cells (50%)356. 
The findings herein regarding the oxidative profile of bEnd.3s are similar to information 
gathered on a peripheral EC cell line, HUVECs. HUVECs exhibited a 1.75-fold increase in 
OCR when stimulated with FCCP, suggesting a low spare capacity for OXPHOS, and 
around 45% of their basal respiration was being used for ATP synthesis497. It is difficult 
to deduce whether this is due to inherent metabolic and physiological similarities 
between peripheral and brain ECS, or whether it is because bEnd.3 and HUVEC cells are 
proliferative cell types and are maximising ATP production in order to create daughter 
cells.  
 
We also investigated the glycolytic profile of untreated bEnd.3 cells using a Glycolysis 
Stress Test. Upon the application of 10mM glucose, bEnd.3 cells exhibited a 1.7-fold 
increase in ECAR, indicating they are able to increase glycolytic flux to produce ATP in 
the presence of glucose. Peripheral ECs were shown to increase their glycolytic flux by 
2.5-fold in response to 10mM glucose, suggesting peripheral ECs are more glycolytic 
than cerebral ECs. Interestingly, when ATP synthase is inhibited upon oligomycin 
application, ECAR increases by almost 4-fold compared to basal, indicating bEnd.3 cells 
have a high ATP drive, but are metabolically flexible. A study investigating the glycolytic 
capacity of different types of ECs from sprouting vessels found that non-tip cells were 
significantly more glycolytic than tip cells in vitro498. Tip cells are described as the leading 
cells of a sprouting blood vessels and non-tip cells are described as either stalk cells, 
which directly follow the tip cell. Specifically, upon 10mM glucose application, non-tip 
cells exhibited a 2.75-fold increase in ECAR, which did not increase further upon 
oligomycin application, suggesting non-tip cells rely heavily on glycolysis for ATP 
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synthesis. However, tip cells responded remarkably similar to bEnd.3 cells, where they 
exhibited a 1.5-fold increase in ECAR following glucose application, and a 2.5-fold 
increase following ATP synthase inhibition. These data suggest that tip cells are 
metabolically flexible, relying on both OXPHOS and glycolysis for ATP synthesis. bEnd.3 
cells responded in a similar manner, suggesting that brain ECs may be metabolically 
similar to endothelial tip cells. However, it cannot be ignored that bEnd.3 cells are an 
immortalised cell line, and this could explain their metabolic flexibility and high ATP 
drive. Indeed, these intrinsic mechanisms may not be shared between peripheral tip 
cells and brain ECs in vivo. Furthermore, we did not compare peripheral ECs and brain 
ECs (bEnd.3 cells) herein, so this would need to be further investigated. 
 
5.3.4 Effects of nutrient excess on mitochondrial bioenergetics in bEnd.3 cells 
 
We modelled nutrient excess in bEnd.3 culture by altering glucose levels in the media 
(5mM vs. 25mM) and exposing cells to both acute (400μM, 6 hours) and chronic 
(100μM, 24 hours) palmitate treatments. 
 
It should firstly be noted that sample size was very small for Seahorse experiments. Five 
replicates per treatment were performed on the same plate in hopes to reduce 
variability, but unfortunately, inter-plate variability was still present. This makes the 
data herein difficult to interpret and, to be sure of any genuine results, more 
experiments would need to be performed to add to the sample size. This issue is 
discussed in detail in section 5.3.7. 
 
Overall, nutrient excess had very little effect on mitochondrial function in bEnd.3 cells. 
Basal respiration was significantly increased in cells cultured in HG vs. LG, with no change 
when exposed to palmitate for 6 hours. Basal respiration is composed of two main 
mitochondrial processes, ATP-linked respiration and mitochondrial proton leak, and is 
driven by substrate availability and ATP demand. In the other set of experiments 
investigating the effects of chronic palmitate exposure, this increase in basal respiration 
in HG-treated groups was not observed. This is likely due the experimental design being 
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slightly different between these two sets of experiments. Palmitate exposures are 
performed by aspirating previous media and adding fresh media that contains palmitate 
(or control), meaning cells are given fresh glucose in the media as well. This is the most 
accurate way to add palmitate to the cultures. In acute palmitate experiments fresh 
media is given 6-7 hours pre-assay, more recently than in chronic palmitate 
experiments. This particular limitation of experimental design is commented upon 
further later in this chapter (section 5.3.7.2). The fresh glucose provides the cell with 
more substrate, presumably in the form of pyruvate that will drive mitochondrial 
respiration in this proliferating cell line with a high ATP demand, leading to an observed 
higher basal respiration. In the case of the HG treated group without palmitate, there is 
a trend toward increased ATP-linked respiration, which is presumably driving the high 
basal respiration. In the case of the HG treated group with palmitate, the combination 
of the slightly increased ATP-linked respiration, alongside the palmitate induced trend 
toward increase in proton leak is driving the higher basal respiration. However, if the 
availability of nutrients is determining the rate of respiration here, then the addition of 
palmitate should also result in higher basal respiration compared to cultures without 
palmitate. This suggests that bEnd.3 cells have a preference for glucose oxidation rather 
than FAO. It would be interesting to investigate the oxidation of palmitate in the absence 
of glucose by these cells, by performing a Mito Fuel Flex Test. This test adds different 
substrate to cultures and measures mitochondrial oxygen consumption in response to 
substrate, determining the preferred fuel. It would also be useful to investigate fuel 
preference in normal conditions vs. stress conditions, such as an inflammatory stress or 
oxidative stress (TNFα or H202).  
 
An interesting outcome was the trend toward increased proton leak in response to 
palmitate exposure, present with both acute and chronic treatments and in combination 
with both glucose concentrations. These trends are of a relatively small effect size, but 
they are consistent across different concentrations and durations of palmitate 
exposures and are in line with the literature (discussed below). If higher palmitate 
concentrations were used, there may have been a larger effect size, increasing the 
likelihood of a significant outcome. However, there is the issue of palmitate induced cell 
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death in this cell line. Perhaps very low-level chronic treatments whereby the palmitate 
is in the culture media for upwards 6 days would be a more useful avenue to consider. 
Chronic, low-level high glucose/palmitate treated cultures could then be treated with 
an added stressor, such as TNFα or H202, followed by Seahorse analysis. To recap, 
protons that are pumped across the IMM, generate the protonmotive force. Not all of 
these protons are used to drive ATP synthesis and some of them leak back across the 
membrane, dissipating the MMP and thus stimulating ETC activity to compete to 
maintain MMP235. The nature of proton leak is not fully understood, but it is thought 
that there are two types; basal and inducible proton leak. A small fraction of basal 
proton leak is attributable to physical leakiness of the lipid bilayer499, whereas a larger 
portion is thought to be under control of the adenine nucleotide translocase (ANT), 
which exchanges ADP for ATP at the IMM500. The mechanism of ANT regulated basal 
proton leak is unknown at this time. A group of anion carriers known as uncoupling 
proteins (UCP1, 2, 3) partly regulate inducible proton leak. They are activated by fatty 
acids and may serve as an explanation for why we observed palmitate dependent 
increases in proton leak herein. The protonophoretic model of FA-mediated UCP activity 
dictates that protonised FAs carry protons across the bilayer of the IMM from the inter-
membrane space (IMS) to the matrix, owing to their ability to flip-flop in the lipid-bilayer. 
Once the FA has flipped and the proton is released into the matrix, the proton-less FA 
can no longer readily flop back across the membrane. The proposed role of UCPs is to 
aid the FA in flopping back across the membrane in order for it to bind another proton 
from the IMS to carry back to the matrix501. Palmitate treatment has previously been 
reported to increase UCP2 and UCP3 expression502,503, and thus it would be useful to 
investigate UCP expression in palmitate treated bEnd.3s, either via Western blot for 
protein expression or Taqman for mRNA expression. Increased proton leak is linked to 
mitochondrial uncoupling of respiration to ATP, meaning that potential energy created 
from substrate oxidation is instead lost as heat rather than ATP generation. Increased 
flow of electrons through the ETC due to enhanced substrate oxidation (during times of 
nutrient excess without a parallel increase in ATP demand) increases mROS production 
and contribute to mitochondrial dysfunction. Uncoupling mitochondrial respiration 
from ATP synthesis (potentially through increased UCP expression) has been linked to 
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reduced mROS production and could therefore be a protective mechanism against 
nutrient excess induced mitochondrial dysfunction. 
 
Another interesting trend was the increase in spare and maximum capacity in HG 
groups. This was again only observed in the acute experiments and not the chronic 
experiments due to flaws in the experimental design. As previously mentioned, spare 
capacity and maximum capacity are calculated from FCCP response. FCCP application to 
cells uncouples mitochondria, dissipates the proton gradient, and drives OXPHOS to 
pump protons across the membrane to maintain the gradient. This process is inherently 
dependent on substrate availability. Mitochondria in HG cultures have more access to 
substrate, hence the higher spare and maximum capacities. Indeed, there is a starvation 
step during which cells from all treatment groups are placed in assay medium (Methods 
section) comprised of the same glucose concentration for one hour prior to the 
beginning of the assay. However, it is possible that cultures previously treated with HG 
may still possess more carbon intermediates than those treated with LG and can use 
these substrates for the TCA cycle and OXPHOS, thus resulting in higher basal 
respiration. To confirm this, a set of experiments could be undertaken on HG vs. LG 
cultures to investigate whether, after a one hour starve, HG cultures exhibit a higher 
pyruvate, malate, succinate, etc. content using basic fluorometric or colorimetric assays 
for these molecules. 
 
The data we observed herein, whereby nutrient excess does not induce mitochondrial 
dysfunction in brain ECs, is not in line with the literature on peripheral ECs. A study by 
Koziel and colleagues investigated the effects of culturing the peripheral EC line 
EA.hy926, which are derived from HUVECs, at HG (25mM) vs. LG (5mM) on 
mitochondrial respiration280. They measured basal oxygen uptake (substrate = 5mM 
glucose) after culturing cells in HG for 3, 6, or 9 days and compared this to cells at LG. 
Culturing cells in HG for 6 days or more significantly reduced basal oxygen uptake. 
Additionally, maximal oxygen uptake (in response to FCCP) was markedly reduced in ECs 
exposed to HG compared to LG. These data suggest that exposure of peripheral ECs to 
HG for 6 or more days induces mitochondrial dysfunction, accompanied by increased 
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mROS production. We may not have observed similar findings as we utilised a different 
experimental set up, whereby bEnd.3 cells were constantly maintained in LG or HG for 
over 2 weeks. This may have allowed cells time to become used to the glucose levels 
and adapt accordingly. If performing the experiment again, bEnd.3 cells would only be 
cultured in HG for between 6-10 days, similar to the afore-mentioned study. This 
experimental set up would perhaps produce similar effects on mitochondrial respiration 
in bEnd.3 cells. When investigating the effects of chronic palmitate treatment, another 
study reported that a 6-day incubation with 100μM or 150μM palmitate produced 
reductions in basal respiration and maximal respiration in EA.hy926 cells. These effects 
were accompanied by upregulation of ICAM expression and increased mROS and non-
mitochondrial ROS production. We did not observe similar findings in bEnd.3 cells with 
palmitate exposures, but again different experimental designs were used. The 
experimental design whereby cells are cultured in palmitate chronically for 6 days is 
more physiological when modelling nutrient excess and is therefore a desired approach. 
The current study did not attempt this but moving forward this avenue should be 
considered. A study investigating the effects of LG (5.5mM) vs. HG (25mM) overnight 
exposure on bovine aortic ECs (BAEs) observed similar findings to the data herein, in 
that mitochondrial bioenergetics (measured by Seahorse) remained unchanged in 
response to HG504. The authors also reported no change in superoxide production. 
Although the authors did not investigate palmitate, they incubated BAEs with another 
saturated FA stearate (150μM, 18 hours) and observed no alterations to mitochondrial 
function. These data suggest that nutrient excess in BAEs does not induce mitochondrial 
function. These conflicting data on nutrient excess and ECs suggests strongly that 
bioenergetic response to nutrient excess is sensitive to different experimental designs 
and is cell line dependent. Our findings did not align with previous studies investigating 
nutrient excess in a differentiated immortalised myotube cell line. Nisr and colleagues 
investigated the effects of glucose (5mM) and palmitate (400μM, 16 hours) alone, or 
glucose and palmitate together, on mitochondrial function. Glucose and palmitate alone 
had no effect, but together acted as a nutrient burden and overwhelmed mitochondria, 
resulting in reduced basal respiration and reduced maximum capacity278. Taken 
together these data suggest that nutrient excess can, in some scenarios, induce 
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dysfunction in mitochondrial bioenergetics. This may be either due to ROS production 
or can itself promote ROS production, eventually leading to overall cellular dysfunction. 
These mechanisms may underlie pathologies associated with metabolic syndrome 
including ED and skeletal muscle insulin resistance.  
  
5.3.5 Exposure to chronic, but not acute, palmitate upregulates BACE1 mRNA and 
protein expression 
 
Palmitate exposure has been shown to increase BACE1 expression and activity in 
vitro306,307,505,506, so we investigated whether acute (400μM, 6 hours) and chronic 
(100μM, 24 hours) palmitate exposure could influence BACE1 expression (protein and 
mRNA) in bEnd.3 cells cultured at 25mM glucose. We also investigated the effect of 
palmitate exposure on APP mRNA levels. 
 
Both acute and chronic palmitate exposure produced a trend toward a slight increase in 
APP mRNA expression. According to power calculations, a sample size of between 10-
20 is required in order to reach statistical significance with these effect sizes. It would 
be interesting to investigate whether protein expression was also increased in response 
to palmitate incubation, as previous data from our lab suggests palmitate incubation can 
increase APP protein expression in a differentiated C2C12 myotube cell line306. This could 
be investigated by performing western blot and probing for APP protein. 
 
Interestingly, in bEnd.3 cells BACE1 mRNA and protein expression was increased in 
response to chronic exposure to 100μM palmitate, but not by acute exposure to 400μM 
palmitate, indicating a time-dependent increase in palmitate induced Bace1 
transcription. Indeed, a previous study in differentiated C2C12 cells corroborates this 
data, reporting that palmitate (750μM) did not increase BACE1 protein levels after 2, 6, 
and 8-hour incubations and only did so after 16 and 24 hours306. BACE1 is in part under 
transcriptional regulation by NFκB signalling. Indeed, treating cells with an IKK inhibitor, 
knocking down IKK expression using shRNA, or by overexpression of IκBα attenuated 
palmitate (100μM, 24 hours) induced increases in BACE1 mRNA and protein levels505. 
This is of particular interest as colleagues in the BACE1 field have noted that there are 
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few instances where increased transcript levels of Bace1 are detected in response to 
treatments. As previously mentioned, palmitate activates NFκB pathways in peripheral 
ECs494. It would be interesting to investigate whether palmitate induced BACE1 mRNA 
and protein expression is dependent on NFκB signalling in bEnd.3 cells using afore-
mentioned inhibitor or knockdown methods.  
 
These data also align with our in vivo data that show that HFD-feeding in mice increases 
Aβ42 levels in aorta316. Although BACE1 has been shown to be present in brain 
endothelium319, we ourselves have not investigated whether BACE1 activity or 
expression is increased upon HFD-feeding in cerebral vasculature. It is important that 
this avenue is investigated, because brain vasculature and peripheral vasculature might 
respond differently to HFD in terms of BACE1 expression and activity. However, the fact 
that we have observed increased BACE1 mRNA and protein expression in bEnd.3 cells is 
promising. Increased BACE1 expression does not necessarily mean increased activity. To 
confirm increased BACE1 enzymatic activity in the bEnd.3 cells in response to palmitate, 
we could perform western blot and probe for sAPPβ, or measure Aβ42 levels via ELISA.  
 
5.3.6 The effects of palmitate and Aβ42 exposure on mitochondrial respiration in bEnd.3 
cells 
 
Palmitate exposure increased BACE1 expression in bEnd.3 cells, indicating that Aβ42 is 
potentially also increased, but this would need further investigation. If Aβ42 is increased 
in bEnd.3 cells in response to palmitate, Aβ42 could be secreted and act in a paracrine 
fashion on neighbouring ECs, or indeed in an autocrine fashion on the EC itself. It is also 
possible that, in vivo, Aβ42 derived other sources (HFD-induced increase in BACE1 activity 
in adipose tissue307,315, skeletal muscle307, hypothalamus308) can act on endothelium. In 
support of this, we know that HFD increases plasma Aβ42 concentration316. Of particular 
interest when studying the BBB, palmitate has been shown to activate (i.e. increase 
inflammatory phenotype) of astrocytes, which in turn can upregulate BACE1 levels in 
neurons by secreting TNFα and IL-1β507. Neurons can then secrete Aβ to act on other 
cell types.  
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We observed no alterations in mitochondrial function upon nutrient excess in ECs, but 
perhaps dysfunction that occurs in ECs in metabolic syndromes is dependent on 
alternative factors such as Aβ42 derived from other tissues. Aβ peptides have previously 
been implicated in the development of mitochondrial dysfunction306,317,331–335. For these 
reasons, we investigated the effects of exogenously applied Aβ42 (vs. ScrP control) on 
mitochondrial bioenergetics using Seahorse in bEnd.3 cells cultured in HG conditions. 
We also introduced chronic palmitate exposure (100uM, 24 hours) as an additional 
factor to investigate the cumulative effects of high FA and Aβ42 together on EC 
mitochondria. Once again it should be noted that sample size was also very small for 
Aβ42 Seahorse experiments. Similarly, to other Seahorse experiments, five replicates per 
treatment were performed on the same plate to reduce variability, but inter-plate 
variability was still present. The data herein may therefore not reflect what is truly 
occurring energetically in these cells, but the data do provide a preliminary look. 
 
Overall, exposure of bEnd.3 cells to palmitate, Aβ42, or both together did not induce 
changes to mitochondrial bioenergetics. Consistent with precluding nutrient excess 
experiments, proton leak was again observed in response to palmitate treatment. 
Respiratory control ratio also appeared reduced; expectedly by palmitate due to the 
increase in proton leak, but also by Aβ42 alone, suggesting the presence of mitochondrial 
dysfunction. Due to proton leak not being affected by Aβ42 incubation, the observed 
trend toward reduced respiratory control ratio may be due to a dysfunctional OXPHOS 
system, potentially due to changes in respiratory complexes286. This could be further 
investigated by measuring protein or mRNA expression of ETC complexes I-V. Indeed, 
spare and respiratory capacity may also be reduced in Aβ42 treated cells, but data are 
variable and sample size is small. More experiments need to be performed to determine 
whether these results are genuine. 
 
There is not a vast amount of research into Aβ peptides and mitochondrial 
bioenergetics, but some studies do indicate a role for increased amyloidogenic APP 
processing (and reduced non-amyloidogenic processing) in the modulation of 
mitochondrial function. Accumulation of Aβ in and around the mitochondria has been 
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observed in both human and murine brain tissue245,329,330 and APP transgenic mice do 
exhibit varying parameters of mitochondrial dysfunction including reduced 
respiration331,332 due to diminished activity of respiratory complexes331, reduced 
MMP332333, reduced ATP production332,333. APP overexpression in vitro is also associated 
with diminished respiratory capacity, reduced MMP, and impaired ATP production, 
effects that were abolished upon application of a BACE1 inhibitor334.  BACE1 
overexpression in C2C12 myotubes impairs glucose metabolism and reduces 
mitochondrial oxygen consumption, an effect that can be rescued by BACE1 
inhibition306. BACE1 overexpression in neuronal SH-SY5Y cells also altered glucose 
metabolism, by inhibiting glucose oxidation, and compensating by increasing 
glycolysis335. BACE1 overexpressing SH-SY5Ys also exhibited reduced enzymatic activity 
of alpha-ketoglutarate dehydrogenase, isocitrate dehydrogenase, and pyruvate 
dehydrogenase indicating lesions in TCA cycle activity. This resulted in reduced substrate 
delivery to the mitochondria, leading to reduced OXPHOS. Interestingly, Aβ42 incubation 
at 10μM for 3 hours in SH-SY5Ys induced apoptosis, reduced MMP, promoted oxidative 
stress, and reduced mitochondrial Ca2+336. Perhaps most relevant to the study herein is 
an investigation undertaken by Solesio and colleagues looking at the effects of Aβ40-Q22 
(a form of Aβ peptide produced with the Dutch mutation) on a human brain EC line, 
hCMEC/D3. Aβ40-Q22 incubation at 50μM for 3 hours induced apoptosis, reduced 
MMP, promoted oxidative stress, and reduced mitochondrial Ca2+ concentrations336. 
However, this study did not investigate mitochondrial bioenergetics in real-time and the 
authors utilise a very high concentration of Aβ peptide for a very short incubation time, 
so it is not particularly physiologically or pathologically relevant. For example, if we are 
generous and suggest AD patients may exhibit plasma Aβ42 concentrations of 
0.5ng/ml508, this equates to ~100pM when a molecular weight of 4514.08g/l is used. 
Thus, the aforementioned studies use concentrations 100,000-500,000 times the 
pathophysiological plasma concentrations. For these reasons it is difficult to compare 
these two studies. It remains unclear at present whether Aβ peptides can induce 
mitochondrial dysfunction. Our data, suggesting Aβ does not promote mitochondrial 
dysfunction in brain ECs, does not align with existing literature. The afore-mentioned 
study does however employ a different brain EC line (which is human), a different form 
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of Aβ peptide, and their experimental set up uses supraphysiological levels of Aβ. These 
factors may account for discrepancies between these two investigations. 
 
5.3.7 Limitations associated with the current experimental paradigms 
 
5.3.7.1 Sample size 
 
As mentioned earlier in the chapter, the sample size for Seahorse experiments is very 
low, resulting in high variability. This made it difficult to interpret the findings. The 
sample size would have to be increased in order to be certain of any experimental 
results. In the literature, most studies use a sample size of 6 (6 plates, with technical 
replicates within each plate), but our power calculations reveal that in some instances a 
sample size of 10 would be required. Furthermore, these experiments were performed 
using the Seahorse XF24 analyser, which uses a 24-well culture plate. This allows for five 
replicates per treatment when four treatments are being investigated, as well as 4 
background wells. A far more useful machine for these types of experiments is the 
Seahorse XF96 analyser, which uses a 96-well culture plate. Agilent, the company that 
manufacture Seahorse analysers, recommend only 4 background wells still, leaving 92 
assay wells that can be used for experimentation. The vast majority of studies in the 
literature utilise the XF96 for cell cultures because it is a high throughput system and 
experimenters can perform many technical replicates, leading to more accurate and less 
varied data sets. However, the XF24 analyser is very useful for tissue explants, as the 
well size is larger. Where possible, for experiments using cell cultures, the XF96 analyser 
should be utilised, but unfortunately the School of Medicine at the University of Dundee 
does not possess one. 
 
5.3.7.2 Immortalised cell lines 
 
The use of immortalised cell lines clearly carries several advantages, such as they are 
easy to use, cost effective, essentially provide an unlimited supply of experimental 
material, and researchers do not need ethical approval to use them.  The key aspect of 
immortalised cell lines is they are constantly proliferating, meaning they have a high 
biosynthetic demand for ATP356,509. In retrospect, we believe this makes it particularly 
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difficult to study nutrient excess in immortalised cell lines, as it may be that any excess 
substrates will simply be oxidised to meet the ATP demand. This means that nutrient 
excess isn’t acting as a burden on mitochondria. Some studies investigating nutrient 
excess using immortalised cell lines have bypassed this issue by differentiating their cell 
lines, thus producing cells that do not proliferate and that possess more specialised 
functions278. It would be more useful to isolate primary differentiated brain ECs. As 
previously mentioned, this was attempted extensively with mouse brain using CD31+ 
selection of ECs using magnetic microbead technology. The yield of ECs was pure, but 
the number of cells obtained was not enough for the experiments we wished to 
perform. It is possible to purchase human primary brain ECs, which can be cultivated. 
This may be an option in the future, as well as perhaps attempting to isolate brain ECs 
from rats, whose brains are larger.  
 
As previously mentioned, bEnd.3 cells have a constitutively active PI3K pathway, due to 
the manner in which they are immortalised. PI3K signalling, particularly the 
phosphorylation of PKB, has been linked to increased OXPHOS. Indeed, PTEN-/- 
(endogenous inhibitor of PKB) immortalised hepatocytes exhibit significantly increased 
mitochondrial respiration (measured using Seahorse Mito Stress Tests)510. The authors 
report that this is due to PKB-mediated inactivation of GSK3β and subsequent activation 
of pyruvate dehydrogenase (PDH) through reduced phosphorylation of the E1 α subunit 
at ser293, a key metabolic enzyme that couples glycolysis to OXPHOS. PTEN-/- cells also 
exhibited increased ATP synthase activity. Thus, PKB activation enhances mitochondrial 
electron transfer capacity. A similar mechanism may be present in bEnd.3 cells, but this 
would have to be investigated by western blotting for phospho-GSKβ at ser9 (inhibitory 
site) and phospho-PDH (E1 α subunit) at ser293 (inhibitory site) or by investigating PDH 
activity and ATP synthase activity. If this mechanism is present, it may explain why 
nutrient excess is not inducing any reductions in mitochondrial respiration, when it does 
in other EC lines198,280 as well as other cell types277,278.  
 
5.3.7.3 Flawed experimental paradigms 
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The studies herein regarding nutrient excess are limited by the experimental design. As 
described in Methods (seahorse section), many parameters of extracellular flux analysis 
are dependent on substrate availability. For many immortalised cells, more substrate = 
more ATP generation and thus increased OXPHOS. In retrospect we understand that 
differing substrate availability, due to culturing bEnd.3 cells in 5 vs. 25mM glucose and 
giving them fresh media 6 hours before the assay (as in acute palmitate exposures), will 
result in increased OXPHOS and false positives. It may have been useful to perform a 
glucose starvation step prior to the 45 minutes to an hour degassing step, allowing cells 
to use up any excess substrate, before reintroducing physiological glucose 
concentrations for the assay to take place. This could potentially eliminate any false 
positives, and any observed changes in mitochondrial respiration would be due to the 
lasting effects of glucose and palmitate incubations (i.e. inflammatory effects, increased 
BACE1 levels, ROS production etc.) 
 
Another issue with the cell culture experimental set-up is that bEnd.3 cells were sub-
cultured at their associated glucose concentrations at all times, 5 and 25mM. Around 
one month before the Seahorse experiments were performed, cells were transferred 
into these culturing conditions and kept at these concentrations. Immortalised cell lines 
are assumed to be able to adapt to their conditions easily since they are essentially 
cancerous. It is possible that cultures of bend.3 cells have adapted to their respective 
glucose conditions. It would perhaps be more useful to sub-culture cells in LG levels 
(5mM) and perform a single incubation in HG vs. LG levels for a set number of days. For 
example, Koziel and colleagues used a 6-day incubation in HG when they observed 
mitochondrial dysfunction in a peripheral cell line280. Similarly, we did not observe any 
convincing findings with palmitate exposures, but if we extended the incubation time 
and sub-cultured cells for 6 days in low palmitate (100-150μM), in line with Broniarek 
and colleagues198, the cells may exhibit mitochondrial dysfunction.  
 
5.3.8 Summary 
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The first aim of this chapter was to develop a suitable cell culture model for brain ECs to 
investigate endothelial function. Following this, it aimed to investigate the effects of 
nutrient excess on brain EC mitochondrial function. It also investigated whether 
incubation with Aβ42 in the presence of nutrient excess had any effects on mitochondrial 
function in the brain EC model. After testing both RBE4 cells and bend.3 cells on their 
suitability as a model for brain ECs, we opted to use bEnd.3 cells as RBE4s did not express 
eNOS. bEnd.3 cells were not without their disadvantages however, and we realized that 
investigating NO bioavailability in the model was not possible. We continued with the 
bEnd.3 cells and sought to investigate another aspect of EC health – mitochondrial 
function. 
 
To measure mitochondrial function, we employed the use of extracellular flux analysis, 
specifically using the Seahorse XF24 to measure oxygen consumption and thus 
mitochondrial respiration. bEnd.3 cells appeared to have a high ATP demand and 
exhibited metabolic flexibility, with both oxidative and glycolytic capacities. Their 
bioenergetic profile appeared similar to peripheral endothelial tip cells. We observed no 
convincing alterations in mitochondrial respiration in response to HG or palmitate 
exposures (both acute and chronic) or in response to Aβ42 incubations. Trends toward 
increased proton leak were observed with palmitate exposure (both acute and chronic), 
which may be attributed to increased activation of UCPs. This would need to be further 
investigated by blotting for UCP2/3 protein expression or probing for mRNA expression.  
 
The lack of mitochondrial dysfunction upon nutrient excess in these cells, when it has 
been observed in other cell lines, may be attributed to 1) the flaws in the experimental 
design herein, 2) the fact that they are an immortalised cell line with a high ATP demand, 
or 3) the constitutively active PI3K pathway present in these cells. Of course, it may be 
due to the inherent nature of brain ECs as well, in that they are more robust in order to 
protect the brain from injury. In hindsight, the experimental paradigm used herein for 
glucose and palmitate exposures is not the best method. Existing studies in the literature 
use HG exposures ranging from 8-72 hours to 6-9 days, rather than sub-culturing the 
cells in HG at all times. Indeed, constantly maintaining the cell line in HG conditions may 
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allow for metabolic adaptation. Furthermore, short and low-level palmitate exposures 
may not be enough to induce mitochondrial dysfunction. Previous studies sub-culture 
peripheral ECs in palmitate for up to 6 days. This take on chronic exposure is more 
physiological and should be adapted moving forward. Cells with high ATP demand like 
bEnd.3s may have a high capacity for substrate utilisation, meaning that nutrient excess 
does not pose a burden nor act as a detriment to mitochondrial function. Furthermore, 
the constitutively active PI3K pathway observed in bEnd.3 cells may result in decreased 
GSK3β activity and increased PDH activity. This would lead to increased coupling of 
glycolysis to OXPHOS, resulting in constant shuttling of pyruvate into the TCA cycle 
creating substrate for OXPHOS. Activated PKB has also been shown to induce ATP 
synthase activity, leading to increased ETC activity. This means that no matter the effect 
of glucose and palmitate on mitochondrial function (i.e. through increase inflammation 
or ROS production), the ETC will remain active due to constant PKB activity. For these 
reasons, we conclude that bEnd.3 cells are not a good model for measuring endothelial 
function or mitochondrial respiration.  
 
However, in this chapter we did manage to confirm our previous data that palmitate can 
indeed increase BACE1 protein and mRNA expression, and, for the first time, report that 
palmitate can upregulate ICAM mRNA expression in cultured brain ECs. These data are 
in line with previously existing in vivo studies that suggest a role for nutrient excess in 
BBB dysfunction. 
 
In summary, these data suggest that nutrient excess may still be a valid avenue to 
consider when investigating brain EC injury and thus cerebrovascular dysfunction that is 
present in metabolic disorders. Immediate future directions should focus on seeking a 
more physiological culture model. As previously mentioned, primary cells that are 
differentiated with their own specialised functions are the best model when 
investigating mitochondrial respiration in cultures. Human primary brain ECs are 
commercially available, but costly. Isolation of primary rat brain ECs is another method 
to consider. The Seahorse 24XF is also capable of measuring mitochondrial from tissue 
explants. Moving forward we would consider isolating cerebral vessels such as the 
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middle cerebral artery for example and measure ex vivo mitochondrial respiration. We 
would also consider culturing the vessel enriched fraction from the brain (section 
methods) measuring mitochondrial function ex vivo here. Indeed, using these methods 
would allow investigation of tissue explants from mice fed HFD, high sugar/fructose diet, 
high cholesterol diet, mice infused with amyloid, or genetically manipulated models. 
More long-term future directions should continue investigating nutrient excess and 
mitochondrial respiration, but with a reevaluated and more physiological experimental 
design. 
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Chapter 6 
Final discussion 
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6.1 The role of nutrient excess in the development of endothelial dysfunction 
 
6.1.1 Background summary 
 
Excessive consumption of food that is not complimented by increased energy 
expenditure can result in numerous adverse health complications, such as obesity, T2D, 
and CVD. Nutrient excess and sedentary lifestyles are becoming increasingly 
problematic in the 21st century as the global diet transitions towards refined foods, 
simple carbohydrates, and high levels of saturated fat. It is imperative that the 
underlying mechanisms of these diseases are investigated if an effective prevention or 
treatment strategy is to be developed. 
 
There are several pathologies associated with nutrient excess that are of particular 
interest to our lab; hyperglycaemia, dyslipidaemia, ED (in both peripheral and central 
microvasculature), and mitochondrial dysfunction. Hyperglycaemia has been strongly 
linked to ED in humans151,158, and ex vivo myograph studies153–155 and multiple in vitro 
studies indicate a role for high glucose levels in inducing peripheral and cerebral EC 
injury154,162–164. Regarding dyslipidaemia, high circulating FFA are a known risk factor for 
CVD188, and in vitro exposure of peripheral ECs to palmitate has been shown to impair 
EC health191–198.  
 
It is widely accepted that nutrient excess in these forms is related to ED, but it is unclear 
exactly how these pathologies are linked. An attractive mechanism is that of 
mitochondrial dysfunction. Mitochondrial dysfunction is a common pathology of 
metabolic and cardiovascular disorders, as well as ageing. Nutrient excess may lead to 
mitochondrial dysfunction by saturating ETC activity, elevating the MMP, increasing RET, 
and producing pathological levels of mROS287. Oxidative stress is strongly linked to ED, 
due to its role in eNOS uncoupling, NO inactivity, inflammation, and mitochondrial 
dysfunction, amongst other pathologies. Furthermore, mitochondria are key to healthy 
brain EC health, as mitochondrial crisis in brain ECs is linked to BBB opening127,486.  
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Aside from impaired respiration, alterations in dynamics may also act as an indicator of 
unhealthy mitochondria. Indeed, in order for the organelle function properly, 
mitochondrial morphology must be tightly regulated by fission and fusion processes. 
Imbalance in the proteins that govern these processes (Mfn1/2, OPA1, Drp1) may lead 
to reduced ability to produce ATP, heterogenous populations of mitochondria with 
differing mtDNA distribution, increased mROS, and apoptosis. Nutrient excess has been 
reported to alter mitochondrial dynamics; the general consensus being that nutrient 
overload results in increased mitochondrial fission, which may then reduce 
mitochondrial respiratory function and increases mROS production278,281–284 
 
It is presently unclear whether nutrient overload induces alterations in endothelial 
mitochondrial dynamics, and whether this process is associated with ED, both peripheral 
and central. To investigate this, we employed the use of two animal models of nutrient 
excess and measured in vivo microvascular function and expression of proteins 
regulating mitochondrial dynamics in the aorta, VE fraction unit, and hypothalamus. To 
further elucidate the role of nutrient excess in EC function, an in vitro study investigating 
bEnd.3 cells was initiated whereby cells were exposed to nutrient excess (high glucose 
and high palmitate alone or in combination) and mitochondrial respiration was 
measured.  
 
6.1.1 Db/db mice exhibit severe hyperglycaemia and endothelial dysfunction in vivo 
 
We report here for the first time that 8-week old female db/db mice exhibit ED in vivo 
as measured by reduced responsiveness in skin perfusion to iontophoresis of the 
vasoconstrictor PE and the vasodilator ACh. Indeed, the cutaneous microcirculation was 
already so constricted in db/db mice, that application of PE did not induce 
vasoconstriction, yet it did in wt/wt and wt/db littermates.  Furthermore, ACh 
application did not result in vasodilation in db/db mice, whereas wt/wt and wt/db mice 
exhibited increased skin perfusion.  
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Importantly, we only investigated 8-week old female db/db mice in the study herein and 
there may be sex and age differences in this model. Other members of the lab have 
studies underway that are investigating vascular and metabolic parameters in male 
db/db, db/wt, and wt/wt mice, and at different time points. Preliminary data indicate 
that male db/db mice at 14 weeks also show reduced ACh response. 
 
Moving forward, it is essential to investigate the mechanism underlying this. It would be 
important to measure endothelium-independent vasodilation in vivo to elucidate 
whether this is an issue specific to ECs or whether it is a downstream impairment in the 
VSM. This can be performed by measuring cutaneous microvascular perfusion in 
response to the endothelium-independent NO donor, SNP. This was not measured 
herein because following SNP iontophoresis, mice need to be culled immediately after 
the LDI scan meaning tissue would be harvested without an overnight fast. We decided 
to prioritise tissue processing in this case, but more db/db mice are available to perform 
further experiments. Another important aspect to consider is NO bioavailability in db/db 
mice. This can be investigated by measuring plasma nitrite, as well as phosphorylation 
and thus activity of eNOS, eNOS mRNA, and ET-1 expression in vascular tissues. These 
are all fairly straight forward measurements, but unfortunately time and financial 
constraints did not allow for these parameters to be measured herein. Others have 
however reported decreased eNOS expression, increased eNOS uncoupling378,379, 
reduced intracellular NO production380, increased eNOS mRNA379, and increased ET-1 
expression381 in db/db mice. Furthermore, impaired VSMC signalling can be investigated 
using cGMP assays and PKG expression. It should also be noted that in early stage 
disease, ED is likely to be present in the microcirculation, but not yet present in larger 
vessels such as the aorta. Therefore, investigating the above signalling molecules in 
aortic tissue at such an early time point may not be the best option. Studying the 
microvasculature, such as that in the VE fraction of the brain or in highly vascularised 
tissues such as lung or kidney, is more physiologically relevant. Harvesting pieces of skin 
where cutaneous microvasculature is present for IHC or IF is also an option.  
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It is interesting that db/db mice exhibit such severe impairments in EC responsiveness 
at such a young age. It has been previously reported that db/db mice exhibit 
hyperglycaemia at 8 weeks old372–374, findings corroborated by our study herein (fasting 
blood glucose 22.1mmol/l). As previously discussed, high blood glucose levels are 
associated with the onset of ED. It would be of use to measure in vivo endothelial 
function and blood glucose levels at earlier timepoints to decipher when each of these 
pathologies first appear, and whether high blood glucose precedes ED in this model. This 
would provide a greater understanding of the development of ED in relation to nutrient 
excess, allowing for more prevention and treatment options.  
 
The key mediator in this hyperglycaemic ED model is oxidative stress, an aspect we did 
not measure in our db/db mice. However, measuring ROS in our model is very important 
moving forward, since others have reported increased superoxide production379. mROS 
production can be measured using MitoSox in fresh tissue385. NOX mRNA and protein 
expression or activity387 could be investigated, specifically Nox2 in the endothelium. 
Although we could not successfully investigate Nrf2KO mice herein, using this mouse 
model is still of interest when considering the role of oxidative stress in the development 
of ED. Using this model alongside a further stressor such as a dietary intervention or 
ageing may be useful, or indeed attempt to reduce Nrf2 in a model of severe 
hyperglycaemia (db/db, STZ). However, perhaps more interesting would be an attempt 
to relieve oxidative stress in the db/db mouse. This could be done by overexpressing 
Nrf2 or using Nrf2 activators such as sulforaphane. Another method of increasing Nrf2 
is to reduce the expression or activity of an interacting protein Keap1. Keap1 binds to 
Nrf2 and keeps it in the cytoplasm, making it vulnerable to ubiquitination and 
degradation. Keap1 KO mice are available and are a model of increased Nrf2 antioxidant 
activity, which should be considered in this context. Mitoquinone mesylate (MitoQ) is a 
targeted mitochondrial anti-oxidant with a ubiquinone moiety that has been shown to 
relieve mitochondrial oxidative stress and protect against metabolic and vascular 
disorders511 and AD512. Mice can be exposed to MitoQ simply by adding it to drinking 
water513. Another potent antioxidant is the manganese superoxide dismutase (MnSOD 
or SOD2) that is found in mitochondria. MnSOD neutralises superoxide into the less 
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reactive H2O2. MnSOD overexpressing mice, or Nox2 KO mice, are available and could 
be crossed with db/db mice to investigate whether endothelial function in db/db mice 
is completely, or partly, rescued by relieving oxidative stress. Indeed, Thompson et al. 
have investigated the effects of deletion of Nox1, which is also expressed in ECs as well 
as VSMCs. They found through ex vivo myograph studies that genetic reduction of Nox1 
on a db/db background significantly improved macrovascular function in these mice514. 
However, it would be interesting to repeat similar studies using in vivo techniques to 
measure microvasculature. MnSOD (or SOD2) KO mice are also available, but they 
exhibit very premature death (3 weeks of age). A heterozygous mouse model of MnSOD 
deficiency (MnSOD+/-) has been investigated on an ApoE background, to investigate 
whether increased mROS levels can worsen ED in ApoE mice in both carotid vessels and 
aorta515. In carotid artery, ex vivo responses to acetylcholine were significantly reduced 
in ApoE mice with MnSOD deficiency compared with ApoE mice with full MnSOD 
function, suggesting elevated mROS can act as a further detriment in the development 
of ED. This heterozygous MnSOD mouse, or indeed a tet-inducible/reversible MnSOD 
knockdown mouse, would be interesting to investigate, either alone or alongside dietary 
and ageing stressors. 
 
To focus on ECs specifically, a conditional knockout mouse may prove useful. As 
mentioned, MnSOD KO mice are not suitable herein, but the Cre/loxP system could be 
utilised in order to create a cell-specific conditional knock out of MnSOD only in ECs. This 
can be done by crossing a mouse expressing a Cre recombinase under an EC-specific 
promoter such as VE-Cadherin with a mouse with the MnSOD gene flanked by two loxP 
sites (floxed), meaning that in cells that express VE-Cadherin the Cre recombinase will 
cut the gene at the loxP sites, resulting in genetic deletion of MnSOD from EC cells. This 
would result in high levels of superoxide in the endothelium, and we could use this 
model to investigate the role of ROS production in ED. Furthermore, this model could 
be stressed further using dietary intervention or ageing.  
 
Aside from hyperglycaemia, db/db mice are reported to exhibit hyperleptinaemia, likely 
due to increased fat mass516. High leptin levels are thought to adversely affect vascular 
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health, inducing oxidative stress517, increasing blood pressure518, impairing arterial 
distensibility in humans519, and inducing vascular permeability520. However, chronic 
leptin treatment has also been shown to reduce atherogenic lesions in leptin deficient 
atherosclerosis-prone mice (LDLRKO;ob/ob, ApoEKO;ApoB48KO;ob/ob, 
LDLRKO;ApoB48KO;ob/ob)521,522, likely mediated by improvements in metabolic 
parameters. Others report that leptin possesses vasodilatory action, by enhancing NO 
production through a PI3K-independent PKB/eNOS-dependent mechanism523. Leptin 
clearly plays a role in mediating vascular tone, but it is presently uncertain whether it 
does so via the leptin receptor or a different receptor entirely. In support of this, isolated 
mesenteric arteries from ob/ob mice exhibit severely blunted responses to ACh and this 
was improved upon leptin therapy (14 days minipump infusion)524. However, this rescue 
is likely to be due to improved metabolic status. A synergistic relationship between ACh 
and leptin action on the endothelium may exist. Indeed, our preliminary data from 14-
week old wt/db male mice suggests that mice heterozygous for faulty Ob-Rb may also 
exhibit reduced ACh responsiveness in vivo, independently of any metabolic 
impairments (data not shown). These data, along with the information from relevant 
literature cited above, warrant further investigation into leptin and Ob-Rb regulators of 
endothelial function. Conditional (VE Cadherin-Cre) Ob-Rb KO/mutant models could be 
utilised to investigate this, as well as using in vitro endothelial cultures. EC-specific Ob-
R KO exist, but every isoform of the leptin receptor is absent in ECs in these mice525. The 
authors report that EC-specific Ob-R KO mice exhibit impaired vascular remodelling and 
increased VSMC proliferation, findings similar to that seen in obese, hyperleptinemic 
WT animals, suggesting obesity induced leptin resistance may influence vascular 
remodelling. However, the authors did not investigate microvascular perfusion in 
response to vasodilators and thus this avenue is worth exploring. 
 
6.1.2 A mature adult 10-week HFD model of nutrient excess does not exhibit endothelial 
dysfunction in vivo 
 
Db/db mice are genetically modified and are therefore an imperfect model of nutrient 
excess. Thus, we fed HFD to a mature adult (6 months old) mice for 10 weeks, in order 
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to investigate the effects of short-term nutrient excess on endothelial function in vivo. 
We chose this length of diet because we have previously observed reduced endothelial 
responsiveness to ACh in vivo as early as 5 weeks of HFD feeding316. However, we did 
not observe any vascular impairments in HFD-fed mice compared to age-matched NC 
controls, which was not in line with our previous findings. Indeed, these studies were 
performed approximately 2 years apart, so the observed discrepancies may be due to 
batch differences in the diet or genetic variability in the mice. Furthermore, experiments 
were completed by two separate experimenters, which could account for this variance.  
 
Moving forward, it may be useful to use a more severe diet (65% HFD), an atherogenic 
diet (Western diet, contains cholesterol), sucrose/fructose in the drinking water, or a 
longer duration of diet (16-22 weeks). Furthermore, blood samples should be taken at 
varying time points throughout the study alongside vascular scans to investigate blood 
glucose, lipid levels, and circulating hormone levels. This method would ensure 
pathological signs of nutrient excess were present alongside any changes in endothelial 
responsiveness.  
 
Further to hyperglycaemia and dyslipidaemia, nutrient excess is also associated with 
increased circulating leptin. As previously mentioned, hyperleptinaemia can enhance 
oxidative stress and increase vascular permeability, and leptin has also been shown to 
elevate ET-1 levels526. Additionally, ex vivo aortae from female protein tyrosine 
phosphatase 1B (PTP1B) KO mice, which have an increased sensitivity to leptin, display 
reduced ACh-response compared to WT which is rescued by treatment with the 
designer leptin receptor antagonist Allo-Aca527. Increased circulating leptin is associated 
with increased sympathetic tone. Indeed, leptin treatment in male mice reduced ACh 
response in isolated mesenteric arteries, an effect that was abolished by sympathetic 
denervation528. The effect was also abolished by treating mice with a superoxide 
scavenger. These data suggest that, through increased sympathetic tone, 
hyperleptinaemia may impair EC function through increased oxidative stress. We did not 
measure circulating leptin levels in our HFD mature adult model (10 weeks HFD), but 
others have reported that hyperleptinaemia is present at 16 weeks HFD. Contradictory 
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to this, aortae from ob/ob mice which are deficient in leptin exhibited enhanced 
vasoconstriction in response to PE and impaired vasodilation in response to ACh which 
was rescued when leptin was infused524. These data suggest an intricate balance of 
leptin levels is required for proper endothelial function and responsiveness, and these 
actions may be mediated both centrally and locally. 
 
Another important hormone when considering nutrient excess and obesity is ghrelin. 
Ghrelin is primarily released from endocrine cells found in the gastric fundus (upper part 
of the stomach) and exerts orexigenic effects through the growth hormone 
secretagogue receptor (GHSR) present on hypothalamic neuronal populations529. 
Circulating ghrelin exists as two forms in the plasma – acylated ghrelin and des-acylated 
ghrelin. It is acylated ghrelin that is known to be involved in meal initiation. Perhaps 
paradoxically, obese people exhibit reduced circulating ghrelin530. However, obesity is 
associated with impairments in postprandial reductions in ghrelin, whereby circulating 
ghrelin is still high after eating, continuing to stimulate orexigenic behaviours529. Obesity 
is also linked with ghrelin resistance. Transport of ghrelin across the BBB is impaired in 
obese mice531. For example, in a 12-week HFD model, central and peripheral injections 
of ghrelin fail to induce ARC neuronal activity, measured by c-Fos immunoreactivity532. 
Interestingly, ghrelin is reported to be expressed in peripheral ECs, but not brain ECs533,  
and has been shown to increase NO production534,535 as well as protect ECs from 
apoptosis536. Furthermore, whole-body infusion of ghrelin into humans reduces blood 
pressure537. Therefore, reduced circulating ghrelin levels in obesity may contribute to 
disorders related to CVD. Ghrelin has also been shown to act on cerebral ECs. Ghrelin 
must pass through the BBB to exert its effects on brain tissue; thus, it can enter ECs and 
potentiate intracellular effects. However BBB transport of ghrelin does not rely on its 
signalling receptor GHSR538 and GHSR protein is not expressed in cerebral vessels533. 
Using ex vivo intact middle cerebral arteries, Ku and colleagues observed no dilatory 
response to acylated ghrelin application (binds GHSR), but increased vasodilation in 
response to des-acylated ghrelin (does not bind GHSR)533. The authors also show that 
this is a NO-dependent mechanism, which is not present in GHSR knockout mice. 
Furthermore, des-acylated ghrelin application protected against superoxide production 
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in MCAs and ghrelin-deficient mice exhibit increased superoxide compared to WT mice. 
These data suggest that des-acylated ghrelin possesses vasodilatory capacity in cerebral 
arteries through a receptor that is yet to be identified and is also cardioprotective. 
However, this peptide did not produce similar effects in systemic arteries539. It is clear 
that ghrelin plays a role in modulating vascular tone and function and, given its role in 
regulating metabolism, this avenue would be interesting to further investigate in regard 
to nutrient excess. For example, it may prove useful to investigate in vivo endothelial 
function in the ghrelin deficient mouse with and without oxidative stress relievers 
(MitoQ, sulforaphane, mild mitochondrial uncoupler), or with and without dietary 
interventions. Chronically infusing differing forms of ghrelin in to DIO animals or models 
of atherosclerosis (ApoE KO, LDLR KO), or indeed modulating ghrelin O-acyltransferase 
(the enzyme responsible for producing acyl-ghrelin), and subsequently studying 
endothelial function in response to this may also be interesting. Of course, ghrelin 
resistance occurs in the hypothalamus of DIO models, but ghrelin resistance in vascular 
tissue requires further investigation. 
 
As previously discussed, ROS production is an important measure to investigate herein. 
Superoxide production can be measured with MitoSox in fresh tissue (aortic tissue, 
cutaneous microcirculation), or through investigating activity or protein/mRNA 
expression of markers associated with ROS production (NOX). Furthermore, enhanced 
chemiluminescence methods exist for measuring NOX-dependent ROS production in 
vivo, ex vivo or in vitro. Beyond measuring ROS production in models of nutrient excess, 
models of increased and reduced oxidative stress (as described earlier in 6.1.1) can be 
considered in combination with dietary intervention.  
 
6.1.3 Ageing is associated with endothelial dysfunction in vivo  
 
We observed reduced endothelial responsiveness to ACh in mature adult mice (6 
months old at start of study) vs. young adult mice (3 months old at start of study), 
suggesting age-related decline in EC function. This is in line with previous literature; 
increasing age has been associated with reduced eNOS activity114,360, elevated eNOS 
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uncoupling361, reduced NO bioavailability114,360,361, increased endothelial ROS 
production114,360,361, enhanced endothelial activation114,361, and increased ET-1360,361. 
Similar to our findings herein, human studies have reported that peak response to ACh 
of forearm skin perfusion progressively declines with age362–365, and this is a good 
predictor of CVD risk366. Of note is that our 6-month old model is not considered elderly, 
and rather considered mature adult/borderline middle aged. Indeed, it has been 
reported that endothelium-dependent vasodilation (response to reactive hyperaemia) 
begins declining as early as 40 years old in men and 50 years old in women367.  
 
Ageing is often associated with metabolic dysfunction and increased oxidative stress, so 
moving forward it would be of use to measure blood glucose levels, ROS production, 
circulating insulin/leptin/ghrelin in our mature adult mice compared to our young adult 
mice in association with in vivo vascular data.  
 
A useful future study would be to measure endothelial function in WT mice 
‘longitudinally’ over 3-24 months, investigating how EC health declines over this time, 
when it begins to decline, markers (glucose, lipids, hormones, ROS) it is associated with, 
and whether it plateaus at a certain age. This would provide more information about 
the nature of ageing and vascular health. Furthermore, metabolic and oxidative 
stressors could be introduced. For example, we attempted herein to measure HFD and 
age as two factors that may affect vascular health. Oxidative stress could also be 
introduced by using aforementioned models (Nrf2 KO, conditional Nrf2KO, conditional 
MnSOD KO), or relieved (MnSOD overexpressor, MitoQ, sulforophane, Keap1 KO, 
conditional Keap1KO, modulate Keap1/Nrf2 binding) and investigating their vascular 
health as they age.  
 
Many rapid ageing mouse models exist, of which several exhibit impaired cardiovascular 
phenotypes. It would be interesting to employ the use of one of these models such as 
the Bub1b deficient mouse which displays reduced aortic ACh response and arterial wall 
thickening540, the SAMP8 mouse which exhibits endothelial senescence and cognitive 
decline541, or the LMNA mouse which suffers from progressive VSMC dysfunction542. 
 
 
 
278 
Investigating these mice with or without oxidative or dietary interventions would 
provide useful information on the relationship between healthy and unhealthy ageing, 
in regard to nutrient excess, oxidative stress, and vascular dysfunction.  
 
6.1.4 Endothelial function in vivo is not associated with changes in mitochondrial 
dynamics proteins 
 
In an attempt to understand how ED develops, proteins governing mitochondrial 
dynamics were investigated in vascular tissue (peripheral = aorta, central = NVU), as well 
as tissues that may be vulnerable to BBB breakdown (hypothalamus). The reason for 
investigating this particular process is dysregulation of mitochondrial dynamics is caused 
by imbalances in fusion and fission proteins and may result in mitochondrial dysfunction 
(reduced ATP production and respiration, increased mROS, increased mitophagy, 
increased apoptosis). 
 
The HFD-fed model and the db/db mice did not exhibit a relationship between nutrient 
excess and changes in mitochondrial dynamics proteins in any tissue. Furthermore, no 
association between in vivo measurements of endothelial function and expression of 
mitochondrial dynamics proteins was observed. This was surprising, as nutrient excess 
has been reported to promote mitochondrial fission previously in several tissues and 
cell types274,278,281–284, providing a potential mechanism behind nutrient excess-induced 
mitochondrial dysfunction. Perhaps no changes were observed herein due to the mild 
10-week HFD model not being long enough to induce severe mitochondrial dysfunction. 
However, db/db mice exhibited endothelial dysfunction in vivo, but no alterations in 
mitochondrial dynamics proteins in aortic or VE fraction tissue, suggesting that the onset 
of ED may be independent of impairments in mitochondrial dynamics entirely. 
 
In hindsight, probing for proteins involved in mitochondrial dynamics via Western blot 
is not the most efficient or accurate method. Fission and fusion processes are fleeting. 
Changes in expression of these proteins is only half the story; cellular localisation is of 
great importance when considering their activity and functionality. Herein, our lysates 
contained both cytosolic and mitochondrial fractions due to the nature of sonification 
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lysis. Moving forward, it would be of use to separate these fractions and measure fission 
and fusion protein content in each of these fractions in order to gain a better 
understanding of cellular localisation. Indeed, an increase in mitochondrial fraction 
expression accompanied by a decrease in cytosolic content may indicate an increase in 
activity. Cellular localisation could also be investigated using staining 
immunofluorescence methods in tissues. Ideally, the best method is to visualise 
mitochondria in tissue using electron microscopy (EM) as this is more accurate and far 
more coherent. Using this method, the mitochondria can be observed in great detail, 
and it can be deduced whether mitochondria are more prone to fission (higher presence 
of fragmented, circular mitochondria) or fusion (hypertubular, elongated mitochondria). 
Aside from dynamics and morphology, mitochondrial respiration could be taken as a 
measure of function. Tissues (aorta, cerebral vessels) from our models could be excised 
and processed as tissue explants, whereby they can be put through a Mito Stress Test 
protocol using a Seahorse Analyser XF24. Similarly, mitochondria can be isolated from 
tissues of interest and investigated using Seahorse technology. These avenues should 
be considered in the future. Furthermore, although mitochondrial dynamic proteins 
were unchanged in these models, mitochondrial dysfunction may still be present. mROS 
production should be measured herein, or studies could be initiated where db/db mice 
are treated with agents to reduce ROS production, or indeed scavenge superoxide, such 
as sulforaphane, mild mitochondrial uncouplers, or MitoQ.  
6.1.5 Exposure to nutrient excess in vivo did not induce mitochondrial dysfunction in 
immortalised brain endothelial cells 
 
As previously discussed, one of the better methods for measuring mitochondrial 
dysfunction is through extracellular flux analysis using a Seahorse machine. We 
employed this method to investigate how nutrient excess (glucose, palmitate) could 
influence mitochondrial respiration in the brain endothelial cell line, bEnd.3s. Others 
have shown previously that nutrient excess can induce mitochondrial dysfunction (as 
measured by impaired oxygen uptake) in cultured myotubes277,278, and peripheral 
ECs165,166,194,198,208. Furthermore, exposure to high glucose has been shown previously to 
reduce MMP, induce mitochondrial Ca2+ overload, increase Drp1 levels, and decrease 
PGC1-α mRNA expression173, suggesting mitochondrial dysfunction. This study did not 
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investigate mitochondrial respiration in real-time however, so we set out to perform 
these experiments. 
 
We did not observe any changes in mitochondrial respiration in cells exposed to high 
glucose (25mM) levels vs. normal glucose levels (5mM). Furthermore, acute and chronic 
exposure to palmitate alongside these two glucose concentrations did not result in any 
alterations in mitochondrial respiration. One observation was increased mitochondrial 
oxygen consumption in relation to proton leak upon palmitate exposure. However, 
sample size for these experiments was small and the effect size was not large enough to 
produce significance. It was surprising that we did not observe any mitochondrial 
impairments resulting from nutrient excess. We suggested several reasons for this, 
highlighted in section 5.3.7.2. It may be because brain ECs are inherently more robust 
than other cell types, due to their functional barrier properties or their intrinsically 
higher mitochondrial volume. Brain ECs act as a barrier to protect the brain from 
systemic insults. Hypothetically, this could mean they are more resilient to stressors 
such as nutrient excess. It cannot be ignored that immortalised cell lines are not truly 
physiological models. Immortalised cell lines are cancerous with a very high ATP drive, 
making it particularly difficult to study the effects of nutrient excess on their 
functionality. Indeed, excess substrates may simply be oxidised to meet the ATP 
demand, meaning that nutrient excess does not act as a burden on mitochondria. 
Additionally, bEnd.3 cells exhibit constantly active PI3K signalling and thus enhanced 
phosphorylation of PKB, which has been linked to increased OXPHOS. Immortalised 
hepatocytes that have had PTEN knocked out (an endogenous inhibitor of PKB activity) 
exhibit significantly increased mitochondrial respiration (measured using Seahorse Mito 
Stress Tests)510. This is due to PKB-dependent inactivation of GSK3β (enhanced 
phosphorylation at ser9) and subsequent activation of PDH (reduced phosphorylation 
of the E1 α subunit at ser293). PTEN-/- hepatocytes also exhibited increased ATP 
synthase activity, indicating that enhanced PKB activity promotes electron transfer 
capacity and a similar mechanism may be present in bEnd.3 cells with constantly active 
ATP synthase. If this is true, it may explain why nutrient excess has no effect on 
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mitochondrial respiration, when it does in other EC lines198,280 as well as other cell 
types277,278.  
 
In retrospect, bEnd.3 cells are not an appropriate model for investigating mitochondrial 
function due to these downfalls and next steps should focus on developing a working 
model. The cell line hCMEC/d3 is a human brain EC model utilised mainly for BBB 
research. This could be an avenue to consider, but it should be noted that these cells are 
also immortalised using SV40 large T antigen, meaning they likely also have constantly 
active PI3K signalling. However, it may be that it is not as highly active as in bEnd.3 cells. 
Ideally, primary brain ECs would be the best avenue to consider. Human primary brain 
ECs are commercially available, or rodent brain ECs can be isolated in the lab. Another 
possible model is human iPSCs, which could be differentiated into human brain ECs. 
 
Increased hyperglycaemia and circulating FAs are, as previously mentioned, not the only 
pathologies associated with nutrient excess. Indeed, systemic inflammation and 
enhanced circulating cytokines is present in metabolic syndrome543 as well as increased 
oxidative stress544. These pathologies are strongly associated with the onset of ED. 
Inflammation can be modelled in cell culture by exposing cultures to inflammatory 
cytokines (TNFa, interleukins), c-reactive peptide (CRP), LPS, and oxLDL amongst others. 
It would be interesting to investigate mitochondrial respiration in brain ECs (hCMEC/d3s, 
primaries) in response to inflammatory stimuli with and without a further nutrient 
stressor (glucose, palmitate). Similarly, oxidative stress can be induced easily in cultures 
simply by applying H2O2, using hypoxic chambers (stroke model), phorbol-12,13 
dibutyrate (PDBu), or angiotensin II amongst others. This may induce impairments in 
mitochondrial function in cultured brain ECs. After which, the response to palmitate 
and/or glucose could be investigated – not only as stressors to induce mitochondrial 
dysfunction but also as a fuel source to study whether brain EC fuel preference changes 
under stress. This would give further insight into how brain EC mitochondria are affected 
by several stressors that are associated with metabolic and vascular disease. Indeed, it 
may be that brain ECs are robust and need to be ‘hit’ several times with multiple 
stressors in order to become dysfunctional.  
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6.2 The role of APP processing, BACE1, and Aβ in endothelial dysfunction  
 
6.2.1 Background summary 
 
BACE1 and APP are associated with metabolic305–307,309–311,317,545 and vascular 
disorders320,321,324,466. The activity of BACE1, and thus amyloidogenic APP processing, is 
upregulated under a number of cellular stressors, in particular HFD308,317, 
hyperglycaemia546,547, and fatty acid exposure306,548. More recently, we have shown that 
Aβ42 is upregulated in aorta and plasma from DIO mice446, as well as in plasma from T2D 
humans545, whilst Bace1 mRNA is increased in mammary arteries of obese women 
(manuscript in review). Furthermore, chronic infusion of Aβ42 into WT mice on both a 
NC and HFD background induced ED. These data suggest a role for BACE1 and Aβ42 in 
the development of ED, however the mechanisms by which this occurs are unclear. 
Furthermore, it is unknown whether BACE1 and Aβ42 play a role in ED in brain ECs and 
thus BBB breakdown. Therefore, part of this PhD project aimed to further confirm the 
role of BACE1 and Aβ42 in the development of ED, whilst investigating the potential 
mechanism of mitochondrial dysfunction and dysregulated mitochondrial dynamics in 
vascular tissues (aorta, NVU). Using the bEnd.3 cell line, the effects of Aβ42 exposure 
(with and without palmitate) on mitochondrial respiration were also investigated. 
 
6.2.2 Increased BACE1 activity is associated with the development of endothelial 
dysfunction 
 
In line with previous data, models of reduced Aβ42 (BACE1 KO mice) as well as 
normalising Aβ42 in a model of increased Aβ42 (APP23 + M3), exhibited improved 
endothelial responsiveness in vivo compared to their controls, whilst models of 
increased Aβ42 (peripherally and centrally infused, APP23 + vehicle), displayed impaired 
responsiveness. These data suggest Aβ42 plays a role in the development of ED. It is 
known that HFD upregulates the production of Aβ42, meaning this may be a potential 
link between nutrient excess and the development of vascular disorders.  
 
 
 
 
283 
Importantly, BACE1 possesses substrates other than APP, and it may be that the 
improved endothelial response in BACE1 KO mice is due to reduced BACE1 interaction 
with another substrate. Potential identified substrates which may be involved in the 
improved endothelial response include LRP, a protein involved in lipid metabolism, and 
IL-1 type II receptor and PSGL-1, proteins that are both involved in inflammatory 
responses. Furthermore, our collaborators identified the insulin receptor as a potential 
substrate for BACE1, whereby cleavage of the insulin receptor by BACE1 results in 
reduced downstream insulin action300. Insulin resistance in ECs may be associated with 
reduced functionality549. We have previously considered the use of insulin to investigate 
vasodilation in vivo with iontophoresis. Transdermal iontophoresis of insulin has been 
shown to be possible, but may prove difficult due to the size of the peptide550. Dr Paul 
Meakin (University of Leeds) continues this work, employing the use of an endothelial-
specific BACE1 KO mouse. In relation to this work, our lab and Dr Meakin’s lab are 
currently collaborating to further investigate BACE1s role in EC function using a BACE1-
BirA construct that was validated by Dr Jennie Gabriel354. This construct is part of what 
is called a BioID assay. The construct is transiently transfected into cells of interest and 
cells are loaded with biotin. The BirA protein that is joined to BACE1 will biotinylate any 
proteins that come into contact with BACE1. A biotin pull-down is then performed 
followed by proteomics to identify biotinylated proteins. This assay will give insight into 
the physiological role of BACE1 under normal conditions, and pathophysiological 
conditions upon application of stressors, in whichever cells are of interest. The current 
project, funded by Alzheimer’s Research UK, attempts to identify differences in the 
BACE1 interactome in brain ECs vs. peripheral ECs.  
 
We have recently shown that the mechanism behind Aβ42 induced ED may be reduced 
NO bioavailability, with Aβ42 infusion resulting in reduced PKB and eNOS 
phosphorylation, cGMP activity, and PKG expression in the aorta compared to controls. 
Aβ42 infused mice on HFD also exhibited reduced plasma nitrite and enhanced plasma 
ET-1. We did not measure these parameters herein, but it would be interesting to do so. 
An aspect we had considered but did not measure in relation to Aβ42 induced ED is 
oxidative stress. Aβ42 peptides are strongly linked to the production of ROS and it may 
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be that this is a key mechanism in this model as well. It would be possible to infuse both 
Aβ42 alongside an oxidative stress-relieving agent, to study whether the adverse vascular 
effects are rescued. Furthermore, infusing Aβ42 into a model of reduced oxidative stress 
(Nrf2 overexpressor, MnSOD overexpressor, Keap1KO) would be useful. Indeed, the 
group led by Iadecola have reported topical application of Aβ40 onto the cerebrum 
results in vasoconstriction and reduced resting CBF, but this can be rescued by perfusing 
superoxide scavengers SOD and MnTBAP551. They also corroborated these data in an 
SOD1 x APP Tg mouse model552. It would be interesting to perform similar experiments 
in regard to peripheral vasculature using Aβ42/APP23 mouse and superoxide scavenging.  
 
It has been reported that impaired peripheral microcirculation does indicate impaired 
cerebral microvasculature346, but it would be important to investigate the effects of Aβ42 
on cerebral haemodynamics in vivo. This could be done using a laser speckle through 
the intact skull and can provide information about perfusion of whole cerebrum or 
certain areas. However perhaps the best approach for investigating CBF in vivo is 
through the use of 2-/3-photon microscopy. Photon microscopy is a state-of-the-art 
deep brain imaging tool that is capable of mapping complex angioarchitecture of the 
brain, whilst also measuring moving RBCs (blood flow) and neurovascular coupling553. 
Dilation capacity of larger vessels could be investigated by isolating cerebral arteries and 
performing wire myography. 
 
In the study herein, we have only investigated the effects of Aβ42, not Aβ40, infusion in 
mice. The reason for this is because when measuring Aβ42 and Aβ40 levels in response to 
HFD, only Aβ42 was increased in mouse plasma and hypothalamus. Furthermore, we 
showed that T2D plasma contains a high Aβ42 content than controls, but Aβ40 was 
unchanged. More recently however, preliminary data suggest that Aβ40 is more strongly 
associated with impaired vasodilatory responses and arterial stiffness in humans (data 
not shown). These data are in line with studies investigating Aβ40 and cerebral 
haemodynamics in mice320,323,466. We have not yet performed studies in which mice are 
infused with Aβ40 and their vascular responses are measured but moving forward this 
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must be considered. Additionally, infusing Aβ40 and Aβ42 together may prove to further 
exacerbate vascular defects. 
 
6.2.2 Endothelial dysfunction caused by increased BACE1 activity is not associated with 
alterations in mitochondrial dynamics  
 
We investigated the avenue of the involvement of BACE1 and Aβ42 in mitochondrial 
dysfunction. Indeed, the literature does suggest a role for altered APP processing in 
certain mitochondrial pathologies including reduced MMP332–334, increased mROS334, 
altered bioenergetics306,317,331,335, and impaired regulation of mitochondrial dynamics334. 
Particularly, exposure of cultured brain ECs to the Aβ peptide Aβ40-Q22 at a 
concentration of 50μM resulted in mitochondrial injury336. To investigate mitochondrial 
dysfunction in vascular tissues, we probed for proteins regulating mitochondrial 
dynamics in aorta from BACE1 KO mice and in NVU from BACE1 and centrally infused 
Aβ42 mice. Minimal alterations in fission and fusion proteins were observed in these 
models, suggesting the development of Aβ42 induced ED is not dependent on a 
mechanism related to mitochondrial dynamics. Of note was the potential increase in VE 
fraction expression of Drp1 protein in Aβ42 mice compared to controls. Since fusion 
proteins remained unchanged, this change may indicate an increase in mitochondrial 
fission in the NVU. This would have to be confirmed by using either EM or fluorescent 
microscopy (with MitoSox).  It would be interesting to investigate this further by 
isolating which cell type this change may stem from or whether it is a change observed 
in all cells of the NVU. Drp1 activity has previously been associated with BBB breakdown 
in response to LPS challenge414. The authors observed an increase in brain endothelial 
activation (ICAM expression), reduction in mitochondrial respiration, increased BBB 
permeability, and increased cellular ROS production in cultured ECs upon stimulation 
with LPS, which were all associated with phosphorylation of Drp1 at s616. When cells 
were treated with LPS in combination with P110 (an inhibitor of Drp1 activity), these 
effects were abrogated. This suggests a role for Drp1-mediated mitochondrial fission in 
cerebrovascular dysfunction, and it would be interesting to investigate this further in 
Aβ42 infused mice by measuring Drp1 phosphorylation, as this may be a potential link 
between nutrient excess, Aβ42, and vascular neurodegeneration.  
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6.2.3 Exposure of bEnd.3 cells to Aβ42 does not alter mitochondrial respiration 
 
To compliment in vivo studies, we investigated the effects of Aβ42 exposure on 
mitochondrial respiration in bEnd.3 cells with and without palmitate and observed no 
changes. The potential issues associated with these cells are described earlier in this 
chapter.  
 
Aβ42 peptides are ‘aged’ herein; incubated at 37°c for 5 days in order to allow peptides 
to dimerise and oligomerise. A previous PhD project in the lab completed by Dr Jennie 
Gabriel optimised this ‘ageing’ time period and found that Aβ42 is present mostly in 
dimers, with some oligomerisation, after 5 days354. Purified Aβ from human CSF has 
revealed that dimers are indeed associated with neurodegeneration, but oligomers of 
Aβ42 are classically known to be the most toxic355. It would be interesting to repeat this 
study using a longer ‘ageing’ period with the Aβ42 peptides. We unfortunately are not 
aware of the form (monomers/dimers/oligomers) of the Aβ42 that we have detected in 
the DIO models, as the MSD ELISA does not distinguish between forms. The cells 
themselves are only exposed to Aβ42 dimers for 24 hours, and it may be that this 
duration is not severe enough. It should be noted however that existing literature on 
synthetic Aβ peptides and vascular impairments involves vastly supraphysiological 
concentrations of amyloid (50μM-500μM)336, whilst we have used a near-physiological 
concentration of 1nM. This may further explain why we have not observed similar 
findings to the literature. We should also consider investigating Aβ40, considering this 
peptide is also involved in neurodegeneration and has indeed been reported to impair 
cerebral haemodynamics320,322,323,466. The reason we did not investigate Aβ40 herein is 
that we did not observe increased plasma Aβ40 levels in response to HFD or in plasma 
from T2Ds compared to controls. It may be that Aβ40 and Aβ42 need to be present 
together to exert effects, so this is worth exploring.  
 
In the current study, we studied the effects of Aβ42 in association with high glucose levels 
(25mM) as well as chronic low-level palmitate (100μM 24 hours), but we did not 
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investigate inflammatory or oxidative stimuli. Since these pathologies are associated 
with metabolic and vascular dysfunction, as well as neurodegeneration, it would be of 
interest to investigate the accumulative effects of inflammation, oxidative stress, 
nutrient excess, and Aβ42 on mitochondrial respiration in cells. However, measuring so 
many parameters may prove difficult, especially with the Seahorse XF24 which only 
allows 20 wells for experimentation. To investigate as many aspects as this, the XF96 
would be far better suited. 
 
Raising BACE1 expression and activity in cells would also be of interest. We have 
previously been successful in overexpressing BACE1 by transfecting a plasmid into SH-
SY5Ys335, C2C12s306, RAW cells and 3T3-L1s (data not published). This was attempted in 
bEnd.3 cells using several transfection agents (lipofectamine 2000, lipofectamine 3000, 
FUGENE). Using a GFP-tagged vector as a transfection control, transfection efficiency of 
these cells was deemed to be very low (< 1%), thus other experiments were prioritised. 
It would be interesting to further pursue this idea however, perhaps using a different 
cell line. BACE1-overexpressing endothelial cell cultures could be used to investigate 
mitochondrial respiration, endothelial activation (inflammation) and monocyte 
adhesion, ROS production, barrier permeability, and transepithelial resistance, amongst 
others. Cells could also be used in co-cultures with neurons, astrocytes, and other cell 
types, to model a functional BBB. For example, BACE1-overexpressing RAW cells 
(macrophages) may be of interest in investigating how raised BACE1 activity in systemic 
immune cells (perhaps as a result of nutrient excess, metabolic disorders) may inflict 
damage on the BBB (inflammation, barrier permeability, migration). Similarly, BACE1-
overexpressing neuron-like cells (SH-SY5Ys) could also be considered when investigating 
raised BACE1 activity and the effects this might have on brain ECs. 
 
 
6.3 Final comments 
 
The studies presented herein set out to 1) establish whether ED due to nutrient excess 
was associated with impaired mitochondrial dynamics, 2) further confirm the role of 
raised BACE1 activity in the development of ED, and 3) develop a cultured EC model with 
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which mitochondrial respiration could be investigated in real-time. Although the use of 
the db/db model did indeed strengthen the knowledge that pathologies associated with 
nutrient excess (obesity, hyperglycaemia) promote the development of ED, the HFD-fed 
model did not. Furthermore, both these models of nutrient excess did not exhibit 
changes in vascular mitochondrial dynamic proteins, indicating ED develops 
independently of this process. The second study was successful in further confirming 
the role of increased BACE1 activity in the development of ED but did not shed further 
light on whether ED in the brain endothelium and BBB breakdown is also associated with 
this protein. However, we did observe that improved EC health in BACE1KO and APP23 
+ M3 mice, and impaired EC health in Aβ42 infused and APP23 mice was not associated 
with alterations in mitochondrial dynamics proteins. Finally, we report herein that 
mitochondrial respiration in bEnd.3 cells was not affected by nutrient excess or Aβ42 
exposure, but also that bEnd.3 cells are not an appropriate model for investigating these 
parameters. In conclusion, this thesis provides further valuable information about the 
development of ED in relation to nutrient excess and raised BACE1 activity. Indeed, the 
findings presented herein, taken together with the existing literature, suggest that it 
could be useful to repurpose BACE1 inhibitors for the treatment of metabolic and 
vascular disorders relating to nutrient excess. 
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Appendix S1 Weight gain trajectory and open-field phenotype of YOUNG HF mice 
(A) 12-week old male mice were placed on NC or HFD for 10 weeks and their body weights were measured 
weekly. Weights are expressed as % weight gain from starting weight. Representative trace (B) and heat 
map (C) images from an open-field anxiety test in YOUNG HF mice. YOUNG HF mice exhibit an anxious 
phenotype as evidenced by the mouse keeping to the outside of the box, close to the sides and rarely 
venturing into the middle.  
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Appendix S2 Weight trajectories and open-field phenotype tests of WT HF and Nrf2 KO HF 
mice 
(A) 12-week old male WT and Nrf2 KO mice were placed on HFD for 10 weeks and weighed 
weekly. Weights are expressed as % weight gain from starting weight. Representative traces (B, 
D) and heat-map images (C, E) of open-field anxiety tests from WT mice and Nrf2KO mice 
respectively. Nrf2KO mice are less anxious than WT mice and exhibit an exploratory phenotype, 
evidenced by their frequent ventures into the middle of the box. 
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Appendix S3 bEnd.3 cells exposed to palmitate exhibit large cellular vesicles that may be lipid 
droplets 
 
bEnd.3 cells were exposed to control (A) or 100μM palmitate for 24 hours. Mitochondria (red) were 
stained using MitoTracker (Methods section 2.8), cells were fixed using formalin, and then nuclei 
(blue) were stained using DAPI. Slides were imaged by Dr Iain Porter using a DeltaVision Widefield 
Fluorescent microscope. White arrows depict potential lipid droplets.  
A B
